The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses (v12)

David Simons, Lion Shahab, Jamie Brown and Olga Perski

Tuesday 27 July 2021

## Abstract

**Aims:** To estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-2/COVID-19 disease.

**Design:** Living rapid review of observational and experimental studies with random-effects hierarchical Bayesian meta-analyses. Published articles and pre-prints were identified via MEDLINE and medRxiv.

**Setting:** Community or hospital. No restrictions on location.

**Participants:** Adults who received a SARS-CoV-2 test or a COVID-19 diagnosis.

**Measurements:** Outcomes were SARS-CoV-2 infection, hospitalisation, disease severity and mortality stratified by smoking status. Study quality was assessed (i.e. ‘good,’ ‘fair’ and ‘poor’).

**Findings:** v12 (searches up to 2021-07-18) included 547 studies with 87 ‘good’ and ‘fair’ quality studies included in unadjusted meta-analyses. 171 studies (31.3%) reported current, former and never smoking status with the remainder using broader categories. Recorded smoking prevalence among people with COVID-19 was generally lower than national prevalence. Current compared with never smokers were at reduced risk of SARS-CoV-2 infection (RR = 0.67, 95% Credible Interval (CrI) = 0.6-0.75, τ = 0.27). Data for former smokers were inconclusive (RR = 0.99, 95% CrI = 0.94-1.05, τ = 0.12) but favoured there being no important association (0% probability of RR ≥1.1). Former compared with never smokers were at increased risk of hospitalisation (RR = 1.27, CrI = 1.15-1.4, τ = 0.2), greater disease severity (RR = 1.69, CrI = 1.3-2.22, τ = 0.43) and mortality (RR = 1.59, CrI = 1.34-1.89, τ = 0.37). Current compared with never smokers were at increased risk of greater disease severity (RR 1.3, 95% CrI = 1.01-1.71, τ = 0.32). Data for current smokers on hospitalisation and mortality were inconclusive (RR = 1.1, 95% CrI = 0.97-1.24, τ = 0.23; RR = 1.13, 95% CrI = 0.9-1.4, τ = 0.41, respectively) but favoured there being no important associations (50% and 60% probability of RR ≥1.1, respectively).

**Conclusions:** Compared with never smokers, current smokers appear to be at reduced risk of SARS-CoV-2 infection and increased risk of greater disease severity, while former smokers appear to be at increased risk of hospitalisation, greater disease severity and mortality from COVID-19. However, it is uncertain whether these associations are causal.

v7 of this living review article has been published in [*Addiction*](https://doi-org.libproxy.ucl.ac.uk/10.1111/add.15276)

## Introduction

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Large age and gender differences in case severity and mortality have been observed in the ongoing COVID-19 pandemic (Guan, Ni, et al., 2020); however, these differences are currently unexplained. SARS-CoV-2 enters epithelial cells through the angiotensin-converting enzyme 2 (ACE-2) receptor (Hoffmann et al., 2020). Some evidence suggests that gene expression and subsequent receptor levels are elevated in the airway and oral epithelium of current smokers (Brake et al., 2020; G. Cai, 2020), which could put smokers at higher risk of contracting SARS-CoV-2. Other studies, however, suggest that nicotine downregulates the ACE-2 receptor (Oakes et al., 2018). These uncertainties notwithstanding, both former and current smoking is known to increase the risk of respiratory viral (Abadom et al., 2016; Denholm et al., 2010) and bacterial (Almirall et al., 1999; Feldman & Anderson, 2013) infections and is associated with worse outcomes once infected. Cigarette smoke reduces the respiratory immune defence through peri-bronchiolar inflammation and fibrosis, impaired mucociliary clearance and disruption of the respiratory epithelium (Dye & Adler, 1994). There is also reason to believe that behavioural factors (e.g. regular hand-to-mouth movements) involved in smoking may increase SARS-CoV-2 infection and transmission in current smokers. However, early data from the COVID-19 pandemic have not provided clear evidence for a negative impact of current or former smoking on SARS-CoV-2 infection or COVID-19 disease outcomes, such as hospitalisation or mortality (Vardavas & Nikitara, 2020). It has also been hypothesised that nicotine might protect against a hyper-inflammatory response to SARS-CoV-2 infection, which may lead to adverse outcomes in patients with COVID-19 disease (Farsalinos, Niaura, et al., 2020).

There are several reviews that fall within the scope of smoking and COVID-19 (Alqahtani et al., 2020; Berlin et al., 2020; Emami et al., 2020; Farsalinos, Barbouni, et al., 2020; Grundy\* et al., 2020; Patanavanich & Glantz, 2020; Vardavas & Nikitara, 2020). We aimed to produce a rapid synthesis of available evidence pertaining to the rates of infection, hospitalisation, disease severity and mortality from SARS-CoV-2/COVID-19 stratified by smoking status. Given the increasing availability of data on this topic, this is a living review with regular updates. As evidence accumulates, the review will be expanded to include studies reporting COVID-19 outcomes by alternative nicotine use (e.g., nicotine replacement therapy or e-cigarettes).

## Methods

*Study design*

This is a living evidence review which is updated as new evidence becomes available (Elliott et al., 2014). We adopted recommended best practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract the data and another verify (Tricco et al., 2015). This study was not pre-registered but evolved from a report written for a UK medical society (Simons, Brown, et al., 2020). The most recent version of this living review is available [here](https://www.qeios.com/read/latest-UJR2AW). Version 7 of this living review has been published in a peer-reviewed journal (Simons, Shahab, et al., 2020). A completed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist is included in Supplementary file 1.

*Eligibility criteria*

Studies were included if they:

1. Were primary research studies using experimental (e.g. randomised controlled trial), quasi-experimental (e.g. pre- and post-test) or observational (e.g. case-control, retrospective cohort, prospective cohort) study designs;
2. Included adults aged 16+ years;
3. Recorded as outcome i) results of a SARS-CoV-2 diagnostic test (including antibody assays), ii) clinical diagnosis of COVID-19, iii) hospitalisation with COVID-19, iv) severity of COVID-19 disease in those hospitalised or v) mortality from COVID-19; Reported any of the outcomes of interest by self-reported or biochemically verified smoking status (e.g. current smoker, former smoker, never smoker) or current vaping and nicotine replacement therapy (NRT) use;
4. Were available in English;
5. Were published in a peer-reviewed journal, as a pre-print or a public health report by reputable bodies (e.g. governments, scientific societies).

*Search strategy*

The following terms were searched for in Ovid MEDLINE (2019-search date) as free text or Medical Subject Headings:

1. Tobacco Smoking/ or Smoking Cessation/ or Water Pipe Smoking/ or Smoking/ or Smoking Pipes/ or Cigar Smoking/ or Smoking Prevention/ or Cigarette Smoking/ or smoking.mp. or Pipe Smoking/ or Smoking, Non-Tobacco Products/ or Smoking Water Pipes/
2. Nicotine/ or nicotine.mp. or Electronic Nicotine Delivery Systems/ or Nicotine Chewing Gum/
3. vaping.mp. or Vaping/
4. 1 or 2 or 3
5. Coronavirus/ or Severe Acute Respiratory Syndrome/ or Coronavirus Infections/ or covid.mp.
6. 4 and 5

The following terms were searched for in titles, abstracts and full texts in medRxiv (no time limitations):

1. covid (this term captures both covid and SARS-CoV-2) AND smoking
2. covid AND nicotine
3. covid AND vaping

Additional articles/reports of interest were identified through mailing lists, Twitter, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) and the US Centers for Disease Control and Prevention (CDC). Where updated versions of pre-prints or public health reports were available, old versions were superseded.

*Selection of studies*

One reviewer screened titles, abstracts and full texts against the inclusion criteria.

*Data extraction*

Data were extracted by one reviewer and verified (i.e. independently checked against pre-prints and published reports) by another on i) author (year); ii) date published; iii) country; iv) study design; v) study setting; vi) sample size; vii) sex; viii) age; ix) smoking status (e.g. current, former, never, not stated, missing) and whether it was biochemically verified; x) use of alternative nicotine products (e.g. e-cigarettes); xi) SARS-CoV-2 testing; xii) SARS-CoV-2 infection; xiii) diagnosis of COVID-19; xiv) hospitalisation with COVID-19; xv) disease severity in those hospitalised with COVID-19; xvi) mortality; xvii) adjustment of smoking specific risk estimates for relevant covariates (e.g. age, sex); and xviii) whether a representative or random sampling method was used.

*Quality appraisal*

The quality of included studies was assessed to determine suitability for inclusion in meta-analyses. Studies were judged as ‘good’ quality if they: i) had <20% missing data on smoking status and used a reliable self-report measure that distinguished between current, former and never smoking status; AND ii) used biochemical verification of smoking status and reported results from adjusted analyses; OR reported data from a representative/random sample. Studies were rated as ‘fair’ if they fulfilled only criterion i) and were otherwise rated as ‘poor.’ The quality appraisal was conducted by one reviewer and verified by a second.

*Evidence synthesis*


A narrative synthesis was conducted. Data from ‘good’ and ‘fair’ quality studies were pooled in R v.3.6.3 (Team, 2013). In a living review where new data are regularly added to the analyses, it may be more appropriate to use a Bayesian (as opposed to frequentist) approach where prior knowledge is used in combination with new data to estimate a posterior risk distribution. A Bayesian approach mitigates the issue of performing multiple statistical tests, which can inflate family-wise error. A series of random-effects hierarchical Bayesian meta-analyses were performed with the brms (Bürkner, 2017) package to estimate the relative risk for each comparison with accompanying 95% credible intervals (CrIs). We first defined prior distributions for the true pooled effect size (µ) and the between-study heterogeneity (τ), with µ specified as a normal distribution with a mean equal to the derived point estimate from each comparison of interest in the immediately preceding version of this living review, and τ specified as a half-Cauchy distribution with a mean of 0 and standard deviation of 1. The half-Cauchy distribution was selected to reflect prior knowledge that high levels of between-study heterogeneity are more likely than lower levels. Markov Chain Monte Carlo methods (20,000 burn-ins followed by 80,000 iterations) were then used to generate a risk distribution for each study, in addition to a pooled effect for the posterior risk distribution. We report forest plots with the pooled effect for the posterior risk distribution displayed as the median relative risk with an accompanying 95% CrIs. We used the empirical cumulative distribution function (ECDF) to estimate the probability of there being a 10% reduction or 10% increase in relative risk (RR) (i.e. RR ≥1.1 or RR ≤0.9). Due to a lack of indication as to what constitutes a clinically or epidemiologically meaningful effect (e.g. with regards to onward disease transmission or requirements for intensive care beds), we deemed a 10% change in risk as small but important. Where data were inconclusive (as indicated by CrIs crossing RR = 1.0), to disambiguate whether data favoured no effect or there being a small but important association, we estimated whether there was ≥75% probability of RR ≥1.1 or RR ≤0.9.

Two sensitivity analyses were performed. First, a minimally informative prior for µ was specified as a normal distribution with a mean of 0 and standard deviation of 1 and τ as described above. Second, an informative prior as described above for µ was used with τ specified as a half-Cauchy distribution with a mean of 0.3 and standard deviation of 1 to reflect greater between-study heterogeneity.

To aid in the visualisation of smoking prevalence in the included studies, the weighted mean prevalence of current and former smoking was calculated for countries with ≥3 studies and plotted for comparison with national prevalence estimates. It should be noted that prevalence estimates in the included studies were not adjusted for age, sex, socioeconomic position, or geographic region within countries.

## Results

In the current review version (v12) with searches up to 2021-07-18, a total of 1940 records were identified, with 547 studies included in a narrative synthesis and 87 studies included in meta-analyses (see [Figure 1](#fig-1)).



*Figure 1.* PRISMA flow diagram of included studies.

Characteristics of included studies are presented in [Table 1](#table-1). Studies were conducted across 51 countries. 139 studies were conducted in the USA, 76 in China, 63 in the UK, 32 in Spain, 26 in Italy, 25 in France, 21 in Mexico, 18 in multiple countries, 12 in Switzerland, 11 in Iran, 10 in Turkey, 9 in Brazil, with 8 in India and 97 studies from 39 further countries. The majority of studies used observational designs (see [Supplementary table S1](#supplementary-t1)). 326 (59.6%) were conducted in hospital settings, 129 studies (23.6%) included individuals from community and hospital settings, 88 studies (16.1%) were conducted exclusively in the community, with one study each conducted in a homeless shelter and a quarantine centre, and one study that did not state the study setting. Studies had a median of 576 (interquartile range = 170-2810) participants. The majority of studies (58.1%) used reverse transcriptase polymerase chain reaction (RT-PCR) for confirmation of SARS-CoV-2 infection, 9.7% used an antibody test to confirm prior infection and 4.4% of studies relied on a combination of RT-PCR, antigen or antibody assays.

### Smoking status

Categorisation of smoking status was heterogeneous (see [Table 1](#table-1)). 296 (54.1%) studies collected data on smoking status through routine electronic health records (EHRs), 211 (38.6%) studies used a bespoke case report form for COVID-19 and 40 (7.3%) studies did not state the source for information on smoking status. None of the studies verified smoking status biochemically. Notably, only 171 (31.3%) studies reported current, former and never smoking status (see [Supplementary table S2a](#supplementary-t2a)), with a further 26 studies reporting only ever and never smoking status (see [Supplementary table S2b](#supplementary-t2b)). The remaining 336 studies reported current, current/former or current and former smoking status but did not explicitly state whether remaining participants were never smokers or if data were missing on smoking status (see [Supplementary table S2c](#supplementary-t2c)). 188 studies explicitly reported the proportion with missing data on smoking status, which ranged from 0% to 97.6%.

### Use of alternative nicotine products

Fifteen studies recorded the use of alternative nicotine products in current and/or former smokers but did not report COVID-19 outcomes stratified by alternative nicotine use (see [Table 1](#table-1)).

### Quality appraisal


Nine studies were performed in random or representative population samples and were rated as ‘good’ quality, and 131 studies were rated as ‘fair’ quality, of which 87 studies reported results stratified by smoking status for the outcomes of interest and could be included in meta-analyses. The remaining 407 studies were rated as ‘poor’ quality (see [Table 1](#table-1)).

#### *Table 1.* All studies included in narrative review and meta-analysis

| ref | Lead author | Date published | Country | Sample size | Study setting | Median (IQR) | Female % | Current smoker % | Current vaper % | Current smoker, current vaper % | Current smoker, former vaper % | Former smoker % | Former smoker, current vaper % | Former smoker, former vaper % | Current/former smokers % | Never smokers % | Never smoker, current vaper % | Never smoker, former vaper % | Never/unknown smokers % | Missing % | Study quality |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C. Huang et al. (2020) | Huang, Wang | 2020-01-24 | China | 41 | Hospital | 49 (41-58) | 27.0 | 7.3 | - | - | - | - | - | - | - | - | - | - | - | 92.7 | poor |
| Jie Li et al. (2020) | Li | 2020-02-12 | China | 17 | Hospital | 45 (33-57) | 47.1 | 17.6 | - | - | - | - | - | - | - | - | - | - | - | 82.3 | poor |
| Jin-jin Zhang et al. (2020) | Zhang, Dong | 2020-02-19 | China | 140 | Hospital | 57^ (25-87) | 46.3 | 1.4 | - | - | - | 5.0 | - | - | - | - | - | - | - | 93.6 | poor |
| Yang et al. (2020) | Yang, Yu | 2020-02-24 | China | 52 | Hospital | 60 (47-73) | 37.0 | 3.8 | - | - | - | - | - | - | - | - | - | - | - | 96.2 | poor |
| Guan, Ni, et al. (2020) | Guan, Ni | 2020-02-28 | China | 1,099 | Hospital | 47 (35-58) | 41.9 | 12.5 | - | - | - | 1.9 | - | - | - | 84.3 | - | - | - | 1.3 | fair |
| W. Liu et al. (2020) | Liu, Tao | 2020-02-28 | China | 78 | Hospital | 38 (33-57) | 50.0 | - | - | - | - | - | - | - | 6.4 | - | - | - | - | 93.6 | poor |
| Qi et al. (2020) | Qi | 2020-03-03 | China | 267 | Hospital | 48 (35-65) | 45.2 | 19.9 | - | - | - | - | - | - | - | - | - | - | 80.1 | 0.0 | poor |
| Y. Huang et al. (2020) | Huang, Yang | 2020-03-05 | China | 36 | Hospital | 69 (60-78) | 30.6 | - | - | - | - | - | - | - | 11.1 | - | - | - | - | 88.9 | poor |
| Xu et al. (2020) | Xu | 2020-03-08 | China | 53 | Hospital | NA | 47.2 | 11.3 | - | - | - | - | - | - | - | - | - | - | - | 88.7 | poor |
| F. Zhou et al. (2020) | Zhou, Yu | 2020-03-11 | China | 191 | Hospital | 56 (46-67) | 38.0 | 5.8 | - | - | - | - | - | - | - | - | - | - | - | 94.2 | poor |
| R. Liu et al. (2020) | Liu, Ming | 2020-03-12 | China | 41 | Hospital | 39 (30-48) | 58.5 | 9.8 | - | - | - | - | - | - | - | - | - | - | - | 90.2 | poor |
| Mo et al. (n.d.) | Mo | 2020-03-16 | China | 155 | Hospital | 54 (53-66) | 44.5 | 3.9 | - | - | - | - | - | - | - | - | - | - | - | 96.1 | poor |
| Y. Shi et al. (2020) | Shi, Yu | 2020-03-18 | China | 487 | Hospital | 46 (27-65) | 46.8 | - | - | - | - | - | - | - | 8.2 | - | - | - | - | 91.8 | poor |
| Xiaoli Zhang et al. (2020) | Zhang, Cai | 2020-03-20 | China | 645 | Hospital | NA | 49.1 | 6.4 | - | - | - | - | - | - | - | - | - | - | - | 93.6 | poor |
| Dong et al. (2020) | Dong, Cao | 2020-03-20 | China | 9 | Hospital | 44 (30-46) | 66.7 | 11.1 | - | - | - | - | - | - | - | - | - | - | - | 88.9 | poor |
| S. Wan et al. (2020) | Wan | 2020-03-21 | China | 135 | Hospital | 47 (36-55) | 46.7 | 6.7 | - | - | - | - | - | - | - | - | - | - | - | 93.3 | poor |
| X. Jin et al. (2020) | Jin | 2020-03-24 | China | 651 | Hospital | 46 (32-60) | 49.2 | 6.3 | - | - | - | - | - | - | - | - | - | - | - | 93.7 | poor |
| R. Wang et al. (2020) | Wang, Pan | 2020-03-24 | China | 125 | Hospital | 41 (26-66) | 43.2 | - | - | - | - | - | - | - | 12.8 | - | - | - | - | 87.2 | poor |
| Lian et al. (n.d.) | Lian | 2020-03-25 | China | 788 | Hospital | NA | 38.5 | 6.9 | - | - | - | - | - | - | - | - | - | - | - | 93.2 | poor |
| Hu et al. (2020) | Hu | 2020-03-25 | China | 323 | Hospital | 61^ (23-91) | 48.6 | - | - | - | - | - | - | - | 11.8 | - | - | - | - | 88.2 | poor |
| Guan, Liang, et al. (2020) | Guan, Liang | 2020-03-26 | China | 1,590 | Hospital | 49 (33-64) | 42.7 | - | - | - | - | - | - | - | 7.0 | 93.0 | - | - | - | 0.0 | poor |
| T. Chen et al. (2020) | Chen | 2020-03-26 | China | 548 | Hospital | 62 (44-70) | 37.6 | 4.4 | - | - | - | 2.6 | - | - | - | - | - | - | - | 93.1 | poor |
| Guo et al. (2020) | Guo | 2020-03-27 | China | 187 | Hospital | 59 (45-73) | 51.3 | 9.6 | - | - | - | - | - | - | - | - | - | - | - | 90.4 | poor |
| CDCMMWR (2020) | Chow (US CDC) | 2020-03-31 | USA | 7,162 | Community and Hospital | NA | - | 1.3 | - | - | - | 2.3 | - | - | - | - | - | - | - | 96.4 | poor |
| E. S. Kim et al. (2020) | Kim | 2020-04-01 | South Korea | 28 | Hospital | 43 (30-56) | 46.4 | 17.9 | - | - | - | - | - | - | - | - | - | - | - | 82.1 | poor |
| Feng et al. (2020) | Feng | 2020-04-10 | China | 476 | Hospital | 53 (40-64) | 43.1 | 9.2 | - | - | - | - | - | - | - | - | - | - | - | 90.8 | poor |
| C. Rentsch et al. (2020) | Rentsch | 2020-04-14 | USA | 3,528 | Community and Hospital | 66 (60-70) | 4.6 | 27.2 | - | - | - | 30.6 | - | - | - | 36.9 | - | - | - | 5.3 | fair |
| Goyal et al. (2020) | Goyal | 2020-04-17 | USA | 393 | Hospital | 62.2 (49-74) | 39.3 | 5.1 | - | - | - | - | - | - | - | - | - | - | - | 94.9 | poor |
| K. I. Zheng et al. (2020) | Zheng, Gao | 2020-04-19 | China | 66 | Hospital | 47^ (NA) | 25.8 | 12.1 | - | - | - | - | - | - | - | - | - | - | - | 87.9 | poor |
| Gold et al. (2020) | Gold (US CDC) | 2020-04-20 | USA | 305 | Hospital | NA | 50.5 | 5.2 | - | - | - | - | - | - | - | - | - | - | - | 94.8 | poor |
| Argenziano et al. (2020) | Argenziano | 2020-04-22 | USA | 1,000 | Hospital | 63 (50-75) | 40.4 | 4.9 | - | - | - | 17.9 | - | - | - | 77.2 | - | - | - | 0.0 | fair |
| Richardson et al. (2020) | Richardson | 2020-04-22 | USA | 5,700 | Hospital | 63 (52-75) | 39.7 | - | - | - | - | - | - | - | 9.8 | 52.8 | - | - | - | 37.4 | poor |
| Fontanet et al. (2020) | Fontanet | 2020-04-23 | France | 661 | Community and Hospital | 37 (16-47) | 62.0 | 10.4 | - | - | - | - | - | - | - | - | - | - | 89.6 | 0.0 | poor |
| P. Shi et al. (2020) | Shi, Ren | 2020-04-23 | China | 134 | Hospital | 46 (34-58) | 51.5 | - | - | - | - | - | - | - | 10.4 | - | - | - | - | 89.5 | poor |
| Hadjadj et al. (2020) | Hadjadj | 2020-04-23 | France | 50 | Hospital | 55 (50-63) | 22.0 | 2.0 | - | - | - | 18.0 | - | - | - | 80.0 | - | - | - | 0.0 | fair |
| Liao et al. (2020) | Liao, Feng | 2020-04-24 | China | 1,848 | Hospital | 55 (48-61) | 54.7 | - | - | - | - | - | - | - | 0.4 | - | - | - | - | 99.6 | poor |
| Gil-Agudo et al. (2020) | Gil-Agudo | 2020-04-24 | Spain | 7 | Hospital | 68 (34-75) | 28.6 | - | - | - | - | - | - | - | 42.9 | 57.1 | - | - | - | 0.0 | poor |
| Q. Yao et al. (n.d.) | Yao | 2020-04-24 | China | 108 | Hospital | 52 (37-58) | 60.2 | 3.7 | - | - | - | - | - | - | - | - | - | - | - | 96.3 | poor |
| Zuo, Yalavarthi, et al. (2020) | Zuo, Yalavarthi | 2020-04-24 | USA | 50 | Hospital | 61 (46-76) | 34.0 | - | - | - | - | - | - | - | 36.0 | - | - | - | - | 64.0 | poor |
| Solís & Carreño (2020) | Solis | 2020-04-25 | Mexico | 650 | Hospital | 46 (NA) | 42.1 | 9.4 | - | - | - | - | - | - | - | - | - | - | - | 90.6 | poor |
| Yu et al. (2020) | Yu, Cai | 2020-04-27 | China | 95 | Hospital | NA | 44.2 | 8.4 | - | - | - | - | - | - | - | - | - | - | - | 91.6 | poor |
| Ziehr et al. (2020) | Ziehr | 2020-04-29 | USA | 66 | Hospital | 58 (23-87) | 35.0 | - | - | - | - | - | - | - | 33.3 | 63.6 | - | - | - | 3.0 | poor |
| Yi Zheng et al. (2020) | Zheng, Xiong | 2020-04-30 | China | 73 | Hospital | 43^ (NA) | 45.2 | - | - | - | - | - | - | - | 11.0 | 89.0 | - | - | - | 0.0 | poor |
| Kalan et al. (2020) | Kalan | 2020-05-01 | Iran | 193 | Hospital | 52.6^ (37-67) | 36.3 | 7.3 | - | - | - | - | - | - | - | 85.0 | - | - | - | 7.8 | poor |
| Kolin et al. (2020) | Kolin | 2020-05-05 | UK | 1,474 | Community and Hospital | 58 (49-67) | 46.6 | 14.5 | - | - | - | 40.2 | - | - | - | 44.6 | - | - | - | 0.8 | fair |
| Borobia et al. (2020) | Borobia | 2020-05-06 | Spain | 2,226 | Hospital | 61 (46-78) | 52.0 | 7.1 | - | - | - | - | - | - | - | - | - | - | - | 93.0 | poor |
| Giacomelli et al. (2020) | Giacomelli | 2020-05-06 | Italy | 233 | Hospital | 61 (50-72) | 31.9 | - | - | - | - | - | - | - | 30.0 | 70.0 | - | - | - | 0.0 | poor |
| Shah et al. (2020) | Shah | 2020-05-06 | USA | 316 | Hospital | 63 (43-72) | 48.1 | 16.5 | - | - | - | 17.7 | - | - | - | 42.1 | - | - | - | 23.7 | poor |
| Williamson et al. (2020) | The OpenSAFELY Collaborative | 2020-05-07 | UK | 17,425,445 | Community and Hospital | NA | 50.1 | 17.0 | - | - | - | 32.9 | - | - | - | 45.9 | - | - | - | 4.2 | fair |
| Allenbach et al. (2020) | Allenbach | 2020-05-08 | France | 152 | Hospital | 77 (60-83) | 31.1 | - | - | - | - | - | - | - | 6.6 | - | - | - | - | 93.4 | poor |
| Robilotti et al. (2020) | Robilotti | 2020-05-08 | USA | 423 | Hospital | NA | 50.0 | 2.1 | - | - | - | 37.6 | - | - | - | 58.6 | - | - | - | 1.6 | fair |
| Lubetzky et al. (2020) | Lubetzky | 2020-05-08 | USA | 54 | Hospital | 57 (29-83) | 62.0 | - | - | - | - | - | - | - | 22.2 | - | - | - | - | 77.8 | poor |
| Yin et al. (2020) | Yin, Yang | 2020-05-10 | China | 106 | Hospital | 73 (61-85) | 39.6 | - | - | - | - | - | - | - | 17.0 | - | - | - | - | 83.0 | poor |
| Rica et al. (2020) | de la Rica | 2020-05-11 | Spain | 48 | Hospital | 66^ (33-88) | 33.0 | - | - | - | - | - | - | - | 20.8 | - | - | - | - | 79.2 | poor |
| Cho et al. (2020) | Cho | 2020-05-11 | UK | 1,331 | Community and Hospital | NA | 49.2 | 19.0 | - | - | - | 27.0 | - | - | - | 54.0 | - | - | - | 0.0 | fair |
| Yanover et al. (2020) | Yanover | 2020-05-13 | Israel | 4,353 | Community and Hospital | 35 (22-54) | 44.5 | 11.8 | - | - | - | 3.0 | - | - | - | 85.2 | - | - | - | 0.0 | fair |
| Hamer et al. (2020) | Hamer | 2020-05-13 | UK | 387,109 | Hospital | 56.2 (48-64) | 55.1 | 9.7 | - | - | - | 34.8 | - | - | - | 55.5 | - | - | - | 0.0 | fair |
| Targher et al. (2020) | Targher | 2020-05-13 | China | 339 | Hospital | 48.4^ (NA) | 52.8 | 8.3 | - | - | - | - | - | - | - | - | - | - | - | 91.7 | poor |
| Carrillo-Vega et al. (2020) | Carillo-Vega | 2020-05-14 | Mexico | 10,544 | Community and Hospital | 46.5^ (30-62) | 42.3 | 8.9 | - | - | - | - | - | - | - | - | - | - | - | 91.1 | poor |
| Regina et al. (2020) | Regina | 2020-05-14 | Switzerland | 200 | Hospital | 70 (55-81) | 40.0 | 4.5 | - | - | - | - | - | - | - | - | - | - | - | 95.5 | poor |
| Almazeedi et al. (2020) | Almazeedi | 2020-05-15 | Kuwait | 1,096 | Hospital | 41 (25-57) | 19.0 | 4.0 | - | - | - | - | - | - | - | - | - | - | 96.0 | 0.0 | poor |
| Lusignan et al. (2020) | de Lusignan | 2020-05-15 | UK | 3,802 | Community | 58 (34-73) | 57.6 | 10.9 | - | - | - | 46.1 | - | - | - | 29.6 | - | - | - | 13.4 | fair |
| Palaiodimos et al. (2020) | Palaiodimos | 2020-05-15 | USA | 200 | Hospital | 64 (50-73.5) | 51.0 | - | - | - | - | - | - | - | 32.5 | 67.5 | - | - | - | 0.0 | poor |
| Mejia-Vilet et al. (2020) | Mejia-Vilet | 2020-05-16 | Mexico | 329 | Hospital | 49 (41-60) | 36.0 | - | - | - | - | - | - | - | 7.0 | - | - | - | - | 93.0 | poor |
| C. Chen et al. (2020) | Chen, Jiang | 2020-05-16 | China | 135 | Hospital | NA | 42.2 | - | - | - | - | - | - | - | 9.6 | - | - | - | - | 90.4 | poor |
| Jiong Li et al. (2020) | Li, Chen | 2020-05-16 | China | 1,008 | Hospital | 55 (44-65) | 43.6 | 5.7 | - | - | - | - | - | - | - | - | - | - | - | 94.3 | poor |
| Valenti et al. (2020) | Valenti | 2020-05-18 | Italy | 789 | Community | 40.7^ (NA) | 35.0 | 25.9 | - | - | - | - | - | - | - | - | - | - | - | 74.1 | poor |
| Feuth et al. (2020) | Feuth | 2020-05-18 | Finland | 28 | Hospital | 56 (47-72) | 46.0 | 10.7 | - | - | - | 28.6 | - | - | - | 60.7 | - | - | - | 0.0 | fair |
| Ge et al. (2020) | Ge | 2020-05-18 | China | 51 | Hospital | 70 (58-79) | 27.5 | 13.7 | - | - | - | - | - | - | - | - | - | - | - | 86.3 | poor |
| Parrotta et al. (2020) | Parrotta | 2020-05-18 | USA | 76 | Community and Hospital | 44.9 (13-71) | 61.8 | 2.6 | - | - | - | 26.3 | - | - | - | 68.4 | - | - | - | 2.6 | fair |
| Shekhar et al. (2020) | Shekhar | 2020-05-18 | USA | 50 | Hospital | 55.5 (20-85) | 54.0 | 48.0 | - | - | - | - | - | - | - | - | - | - | - | 52.0 | poor |
| Rimland et al. (2020) | Rimland | 2020-05-19 | USA | 11 | Hospital | 59 (48-65) | 18.2 | 9.1 | 9.1 | - | - | - | - | - | - | - | - | - | - | 81.8 | poor |
| Basse et al. (2020) | Basse | 2020-05-19 | France | 141 | Hospital | 62 (52-72) | 72.0 | 17.7 | - | - | - | - | - | - | - | - | - | - | - | 82.3 | poor |
| Freites et al. (2020) | Freites | 2020-05-19 | Spain | 123 | Hospital | 59.88^ (44-74) | 69.9 | 3.3 | - | - | - | - | - | - | - | - | - | - | - | 96.8 | poor |
| Alshami et al. (2020) | Alshami | 2020-05-19 | Saudi Arabia | 128 | Quarantine Centre | 39.6^ (24-55) | 53.9 | 15.6 | - | - | - | 2.3 | - | - | - | - | - | - | - | 82.0 | poor |
| Q. Shi et al. (2020) | Shi, Zhao | 2020-05-20 | China | 101 | Hospital | 71 (59-80) | 40.6 | - | - | - | - | - | - | - | 5.0 | - | - | - | - | 95.0 | poor |
| Al-Hindawi et al. (2020) | Al-Hindawi | 2020-05-20 | UK | 31 | Hospital | 61 (NA) | 12.9 | 3.2 | - | - | - | 71.0 | - | - | - | 25.8 | - | - | - | 0.0 | fair |
| M. A. Wu et al. (2020) | Wu | 2020-05-21 | Italy | 174 | Hospital | 61.2^ (50-71) | 30.5 | - | - | - | - | - | - | - | 33.3 | - | - | - | - | 66.7 | poor |
| L. Kim et al. (2020) | Kim, Garg | 2020-05-22 | USA | 2,491 | Hospital | 62 (50-75) | 46.8 | 6.0 | - | - | - | 25.8 | - | - | - | - | - | - | 68.1 | 0.1 | poor |
| Docherty et al. (2020) | Docherty | 2020-05-22 | Multiple | 20,133 | Hospital | 72.9 (58-82) | 40.0 | 4.2 | - | - | - | 21.7 | - | - | - | 44.5 | - | - | - | 29.6 | poor |
| Petrilli et al. (2020) | Petrilli | 2020-05-22 | USA | 5,279 | Community and Hospital | 54 (38-66) | 51.5 | 5.5 | - | - | - | 17.1 | - | - | - | 61.9 | - | - | - | 15.6 | fair |
| Klang et al. (n.d.) | Klang | 2020-05-23 | USA | 3,406 | Hospital | NA | 61.8 | - | - | - | - | - | - | - | 23.3 | - | - | - | - | 76.7 | poor |
| Vaquero et al. (2020) | Vaquero-Roncero | 2020-05-24 | Spain | 146 | Hospital | 66^ (59-72) | 32.2 | - | - | - | - | - | - | - | 6.8 | - | - | - | - | 93.2 | poor |
| Ip et al. (2020) | Ip | 2020-05-25 | USA | 2,512 | Hospital | 64 (52-76) | 37.6 | 3.1 | - | - | - | 17.8 | - | - | - | 64.5 | - | - | - | 14.6 | fair |
| Heili-Frades (n.d.) | Heili-Frades | 2020-05-25 | Spain | 4,712 | Hospital | 62 (47-77) | 50.5 | 4.9 | - | - | - | 17.4 | - | - | - | - | - | - | 66.5 | 11.2 | poor |
| Berumen et al. (2020) | Berumen | 2020-05-26 | Mexico | 102,875 | Hospital | NA | 49.1 | - | - | - | - | - | - | - | 9.6 | - | - | - | 90.4 | 0.0 | poor |
| Garibaldi et al. (2020) | Garibaldi | 2020-05-26 | USA | 832 | Hospital | 63 (49-75) | 47.0 | 5.5 | - | - | - | 22.6 | - | - | - | - | - | - | - | 71.9 | poor |
| Soto-Mota et al. (2020) | Soto-Mota | 2020-05-27 | Mexico | 400 | Hospital | NA | 30.0 | - | - | - | - | - | - | - | 12.0 | - | - | - | - | 88.0 | poor |
| Jingwen Li et al. (n.d.) | Li, Long | 2020-05-28 | China | 145 | Not Stated | 49^ (13-80) | 61.0 | - | - | - | - | - | - | - | 5.5 | - | - | - | - | 94.5 | poor |
| Louis et al. (2020) | Louis | 2020-05-28 | USA | 22 | Hospital | 66.5^ (55-77) | 36.4 | - | - | - | - | - | - | - | 45.5 | - | - | - | - | 54.5 | poor |
| Kuderer et al. (2020) | Kuderer | 2020-05-28 | Multiple | 928 | Community and Hospital | 66 (57-76) | 50.0 | 4.6 | - | - | - | 35.1 | - | - | - | 50.5 | - | - | - | 9.7 | fair |
| M. Gianfrancesco et al. (2020) | Gianfrancesco | 2020-05-29 | Multiple | 600 | Community and Hospital | 56 (45-67) | 71.0 | - | - | - | - | - | - | - | 21.5 | 64.8 | - | - | - | 13.7 | poor |
| Chaudhry et al. (2020) | Chaudhry | 2020-05-29 | USA | 40 | Community and Hospital | 52 (45.5-61) | 60.0 | - | - | - | - | - | - | - | 15.0 | - | - | - | - | 85.0 | poor |
| Niedzwiedz et al. (2020) | Niedzwiedz | 2020-05-29 | UK | 392,116 | Community and Hospital | NA | 54.9 | 9.8 | - | - | - | 34.8 | - | - | - | 55.4 | - | - | - | 0.0 | fair |
| Valle et al. (2020) | del Valle | 2020-05-30 | USA | 1,484 | Hospital | 62 (52-72) | 40.6 | 5.5 | - | - | - | 23.3 | - | - | - | - | - | - | - | 71.2 | poor |
| Bello-Chavolla, Bahena-López, et al. (2020) | Bello-Chavolla | 2020-05-31 | Mexico | 177,133 | Community and Hospital | 42.6 (26-59) | 48.9 | - | - | - | - | - | - | - | 9.3 | - | - | - | - | 90.7 | poor |
| Batty et al. (2020) | Batty | 2020-06-01 | UK | 908 | Hospital | 57.27^ (48-66) | 44.3 | 11.2 | - | - | - | - | - | - | - | - | - | - | - | 88.8 | poor |
| Israel, Feldhamer, et al. (2020) | Israel | 2020-06-01 | Israel | 24,906 | Community and Hospital | 40 (27-59) | 48.7 | 16.8 | - | - | - | 12.7 | - | - | - | 70.5 | - | - | - | 0.0 | fair |
| Hao et al. (2020) | Hao | 2020-06-01 | China | 788 | Hospital | 46 (35-56) | 48.4 | 6.9 | - | - | - | - | - | - | - | - | - | - | - | 93.2 | poor |
| Lassale et al. (2020) | Lassale | 2020-06-01 | UK | 900 | Hospital | 57.2^ (48-66) | 44.4 | 11.4 | - | - | - | 41.9 | - | - | - | 46.7 | - | - | - | 0.0 | fair |
| Eugen-Olsen et al. (2020) | Eugen-Olsen | 2020-06-02 | Denmark | 407 | Hospital | 64 (47-77) | 57.7 | 20.6 | - | - | - | 36.9 | - | - | - | 39.6 | - | - | - | 3.0 | fair |
| Martinez-Portilla et al. (2020) | Martinez-Portilla | 2020-06-02 | Mexico | 224 | Community and Hospital | 29 (26-33) | 100.0 | - | - | - | - | - | - | - | 3.1 | - | - | - | - | 96.9 | poor |
| Raisi-Estabragh et al. (n.d.) | Raisi-Estabragh | 2020-06-02 | UK | 4,510 | Hospital | NA | 48.8 | - | - | - | - | - | - | - | 51.8 | - | - | - | - | 48.2 | poor |
| H. Luo et al. (2020) | Luo | 2020-06-02 | China | 625 | Hospital | 46 (NA) | 47.7 | 3.0 | - | - | - | - | - | - | - | - | - | - | - | 97.0 | poor |
| Boulware et al. (2020) | Boulware | 2020-06-03 | Multiple | 821 | Community | 40 (33-50) | 51.6 | 3.3 | - | - | - | - | - | - | - | - | - | - | - | 96.7 | poor |
| Ikitimur et al. (n.d.) | Ikitimur | 2020-06-03 | Turkey | 81 | Hospital | 55^ (38-72) | 44.0 | - | - | - | - | - | - | - | 28.4 | - | - | - | - | 71.6 | poor |
| Sierpiński et al. (2020) | Sierpinski | 2020-06-03 | Poland | 1,942 | Community | 50 (NA) | 60.0 | 6.3 | - | - | - | - | - | - | - | - | - | - | 49.7 | 44.0 | poor |
| B. Wang et al. (2020) | Wang, Oekelen | 2020-06-05 | USA | 58 | Community and Hospital | 67 (NA) | 48.0 | - | - | - | - | - | - | - | 36.2 | - | - | - | - | 63.8 | poor |
| Perrone et al. (2020) | Perrone | 2020-06-05 | Italy | 1,189 | Hospital | NA | 21.2 | - | - | - | - | - | - | - | 21.9 | - | - | - | - | 78.1 | poor |
| Sharma et al. (2020) | Sharma | 2020-06-05 | India | 501 | Hospital | 35.1^ (18-51) | 36.0 | - | - | - | - | - | - | - | 4.2 | - | - | - | - | 95.8 | poor |
| Magagnoli et al. (2020) | Magagnoli | 2020-06-05 | USA | 807 | Hospital | 70 (60-75) | 4.3 | - | - | - | - | - | - | - | 15.9 | - | - | - | - | 84.1 | poor |
| Ramlall et al. (2020) | Ramlall | 2020-06-06 | USA | 11,116 | Community and Hospital | 52 (34.7-69.5) | 55.2 | - | - | - | - | - | - | - | 26.8 | 73.2 | - | - | - | 0.0 | poor |
| Giannouchos et al. (2020) | Giannouchos | 2020-06-07 | Mexico | 236,439 | Community and Hospital | 42.5^ (25-59) | 49.1 | 9.1 | - | - | - | - | - | - | - | - | - | - | 90.9 | 0.0 | poor |
| Romão et al. (2020) | Romao | 2020-06-08 | Portugal | 34 | Community | 41^ (26-66) | 67.7 | - | - | - | - | - | - | - | 26.5 | - | - | - | - | 73.5 | poor |
| Cen et al. (2020) | Cen | 2020-06-08 | China | 1,007 | Hospital | 61 (49-68) | 51.0 | - | - | - | - | - | - | - | 8.7 | - | - | - | - | 91.3 | poor |
| Houlihan et al. (2020) | Houlihan | 2020-06-09 | UK | 200 | Community | 34 (29-44) | 61.0 | 11.0 | - | - | - | 16.5 | - | - | - | 66.5 | - | - | - | 6.0 | fair |
| Lan et al. (2020) | Lan | 2020-06-09 | USA | 104 | Community | 49^ (34-63) | 47.1 | - | - | - | - | - | - | - | 24.0 | - | - | - | - | 76.0 | poor |
| Russell et al. (2020) | Russell | 2020-06-09 | UK | 156 | Community and Hospital | 65.18^ (50-79) | 42.3 | 7.1 | - | - | - | 25.0 | - | - | - | 37.8 | - | - | - | 30.1 | poor |
| Veras et al. (2020) | Veras | 2020-06-09 | Brazil | 32 | Hospital | 58.9^ (40-77) | 47.0 | - | - | - | - | - | - | - | 25.0 | - | - | - | - | 75.0 | poor |
| Rossi et al. (2020) | Rossi | 2020-06-09 | France | 246 | Hospital | 68^ (53-83) | 39.0 | - | - | - | - | - | - | - | 25.2 | - | - | - | - | 74.8 | poor |
| Martin-Jimenez et al. (2020) | Martin-Jiminez | 2020-06-09 | Spain | 339 | Hospital | 81.6 (72-87) | 39.5 | - | - | - | - | - | - | - | 30.7 | - | - | - | - | 69.3 | poor |
| Rajter et al. (2020) | Rajter | 2020-06-10 | USA | 280 | Hospital | 59.6^ (41-77) | 45.5 | 5.7 | - | - | - | 10.7 | - | - | - | 74.6 | - | - | - | 8.9 | fair |
| Yaya Zhou et al. (2020) | Zhou, He | 2020-06-10 | China | 238 | Hospital | 55.5 (35-67) | 57.0 | 2.9 | - | - | - | - | - | - | - | - | - | - | - | 97.1 | poor |
| Woolford et al. (2020) | Woolford | 2020-06-11 | UK | 4,510 | Community and Hospital | 70.5 (NA) | 51.2 | 13.0 | - | - | - | 38.1 | - | - | - | 48.1 | - | - | - | 0.8 | fair |
| Hultcrantz et al. (2020) | Hultcrantz | 2020-06-11 | USA | 127 | Community and Hospital | 68 (41-91) | 46.0 | - | - | - | - | - | - | - | 26.8 | 72.4 | - | - | - | 0.8 | poor |
| Hernández-Garduño (2020) | Hernandez, Garduno | 2020-06-11 | Mexico | 32,583 | Community and Hospital | 45 (34-56) | 48.7 | - | - | - | - | - | - | - | 11.0 | - | - | - | 88.8 | 0.1 | poor |
| Sterlin et al. (2020) | Sterlin | 2020-06-11 | France | 135 | Hospital | 61 (50-72) | 41.0 | 3.7 | - | - | - | 38.5 | - | - | - | 57.8 | - | - | - | 0.0 | fair |
| Maraschini et al. (2020) | Maraschini | 2020-06-12 | Italy | 146 | Hospital | 32.5^ (27-38) | 100.0 | - | - | - | - | 9.6 | - | - | - | 80.8 | - | - | - | 9.6 | poor |
| A.-L. Wang et al. (2020) | Wang, Zhong | 2020-06-12 | USA | 7,592 | Community and Hospital | NA | 45.1 | 3.6 | - | - | - | 17.1 | - | - | - | 51.9 | - | - | - | 27.4 | poor |
| McQueenie et al. (2020) | McQueenie | 2020-06-12 | UK | 428,199 | Community and Hospital | NA | 54.9 | - | - | - | - | - | - | - | 44.4 | 55.0 | - | - | - | 0.6 | poor |
| Miyara et al. (2020) | Miyara | 2020-06-12 | France | 479 | Community and Hospital | NA | 44.7 | 6.7 | 0.4 | - | - | 31.6 | - | - | - | 59.5 | - | - | - | 1.9 | fair |
| Apea et al. (2021) | Apea | 2020-06-12 | UK | 1,737 | Hospital | 63.4^ (NA) | 30.4 | - | - | - | - | - | - | - | 10.0 | - | - | - | - | 90.0 | poor |
| Garassino et al. (2020) | Garassino | 2020-06-12 | Multiple | 200 | Community and Hospital | 68 (61.8-75) | 30.0 | 24.0 | - | - | - | 55.5 | - | - | - | 18.5 | - | - | - | 2.0 | fair |
| Zeng et al. (2020) | Zeng | 2020-06-16 | China | 1,031 | Hospital | 60.3^ (46-74) | 47.8 | - | - | - | - | - | - | - | 10.2 | - | - | - | - | 89.8 | poor |
| Suleyman et al. (2020) | Suleyman | 2020-06-16 | USA | 463 | Hospital | 57.5^ (40-74) | 55.9 | - | - | - | - | - | - | - | 34.6 | - | - | - | - | 65.4 | poor |
| L. Chen et al. (2020) | Chen, Yu | 2020-06-16 | China | 1,859 | Hospital | 59 (45-68) | 50.0 | 2.4 | - | - | - | 3.6 | - | - | - | 94.0 | - | - | - | 0.0 | fair |
| Kibler et al. (2020) | Kibler | 2020-06-16 | France | 702 | Community and Hospital | 82^ (75-88) | 56.0 | 3.7 | - | - | - | - | - | - | - | - | - | - | - | 96.3 | poor |
| Olivares et al. (2020) | Olivares | 2020-06-16 | Chile | 21 | Hospital | 61^ (26-85) | 76.2 | - | - | - | - | - | - | - | 9.5 | - | - | - | - | 90.5 | poor |
| Elezkurtaj et al. (2020) | Elezkurtaj | 2020-06-17 | Germany | 26 | Hospital | 70 (61.8-78.3) | 34.6 | - | - | - | - | - | - | - | 19.2 | - | - | - | - | 80.8 | poor |
| Zuo, Estes, et al. (2020) | Zuo, Estes | 2020-06-17 | China | 172 | Hospital | 61^ (25-95) | 44.0 | - | - | - | - | - | - | - | 26.2 | - | - | - | - | 73.8 | poor |
| Killerby (2020) | Killerby | 2020-06-17 | USA | 531 | Community and Hospital | 51.6 (38-62) | 57.1 | - | - | - | - | - | - | - | 17.1 | 71.4 | - | - | - | 11.5 | poor |
| Gu et al. (2020) | Gu | 2020-06-18 | USA | 5,698 | Community and Hospital | 47^ (26-67) | 62.0 | 7.0 | - | - | - | 24.7 | - | - | - | 50.8 | - | - | - | 17.5 | fair |
| Wei et al. (2020) | Wei | 2020-06-18 | USA | 147 | Hospital | 52^ (34-70) | 41.0 | 14.3 | - | - | - | - | - | - | - | - | - | - | - | 85.7 | poor |
| Crovetto et al. (2020) | Crovetto | 2020-06-19 | Spain | 874 | Community and Hospital | 33.7^ (28-38) | 100.0 | 1.1 | - | - | - | - | - | - | - | - | - | - | 13.2 | 85.7 | poor |
| Govind et al. (2020) | Govind | 2020-06-20 | UK | 6,309 | Community and Hospital | 46.5^ (31-61) | 38.3 | 66.3 | - | - | - | 26.8 | - | - | - | 5.5 | - | - | - | 1.5 | fair |
| Sisó-Almirall et al. (2020) | Siso-Almirall | 2020-06-20 | Spain | 322 | Community and Hospital | 56.7^ (38-74) | 50.0 | - | - | - | - | - | - | - | 25.2 | - | - | - | - | 74.8 | poor |
| Salton et al. (2020) | Salton | 2020-06-20 | Italy | 173 | Hospital | 64.4^ (NA) | 34.9 | - | - | - | - | - | - | - | 29.5 | - | - | - | - | 70.5 | poor |
| Duan et al. (2020) | Duan | 2020-06-22 | China | 616 | Hospital | 64 (53-70) | 57.5 | 3.7 | - | - | - | - | - | - | - | - | - | - | - | 96.3 | poor |
| Lenka et al. (2020) | Lenka | 2020-06-22 | USA | 32 | Hospital | 62.2^ (51-73) | 37.5 | - | - | - | - | - | - | - | 50.0 | - | - | - | - | 50.0 | poor |
| Fisman et al. (2020) | Fisman | 2020-06-23 | Canada | 21,922 | Community and Hospital | NA | 57.0 | - | - | - | - | - | - | - | 2.3 | - | - | - | - | 97.7 | poor |
| Madariaga et al. (2020) | Madariaga | 2020-06-23 | USA | 103 | Community and Hospital | 41.8^ (27-55) | 48.5 | - | - | - | - | - | - | - | 25.2 | 74.8 | - | - | - | 0.0 | poor |
| C. Jin et al. (2020) | Jin, Gu | 2020-06-25 | China | 6 | Hospital | 60.5^ (51-75) | 33.3 | 33.3 | - | - | - | - | - | - | - | - | - | - | - | 66.7 | poor |
| Mendy et al. (2020) | Mendy | 2020-06-27 | USA | 689 | Community and Hospital | 49.5 (35.2-67.5) | 47.0 | - | - | - | - | - | - | - | 24.7 | - | - | - | - | 75.3 | poor |
| Sigel et al. (n.d.) | Sigel | 2020-06-28 | USA | 493 | Hospital | 60 (55-67) | 24.1 | - | - | - | - | - | - | - | 28.6 | - | - | - | - | 71.4 | poor |
| Souza et al. (2020) | de Souza | 2020-06-28 | Brazil | 8,443 | Hospital | NA | 53.0 | - | - | - | - | - | - | - | 1.7 | - | - | - | 96.3 | 2.0 | poor |
| Nguyen et al. (2020) | Nguyen | 2020-06-29 | USA | 689 | Community and Hospital | 55 (40-68) | 57.0 | - | - | - | - | - | - | - | 24.8 | - | - | - | - | 75.2 | poor |
| Melo et al. (2020) | de Melo | 2020-06-29 | Brazil | 181 | Hospital | 55.3^ (34-76) | 60.8 | 9.9 | - | - | - | 12.2 | - | - | - | 38.1 | - | - | - | 39.8 | poor |
| Auvinen et al. (2020) | Auvinen | 2020-06-29 | Finland | 61 | Hospital | 53 (41-67) | 36.0 | 18.0 | - | - | - | 27.9 | - | - | - | 54.1 | - | - | - | 0.0 | fair |
| Magleby et al. (n.d.) | Magleby | 2020-06-30 | USA | 678 | Hospital | 68 (50-81) | 38.9 | - | - | - | - | - | - | - | 28.6 | - | - | - | - | 71.4 | poor |
| Hewitt et al. (2020) | Hewitt | 2020-06-30 | Multiple | 1,564 | Hospital | 74 (61-83) | 42.3 | 7.7 | - | - | - | 38.6 | - | - | - | 52.0 | - | - | - | 1.7 | fair |
| Mohamud et al. (2020) | Mohamud | 2020-07-02 | USA | 6 | Hospital | 65.8^ (55-78) | 16.7 | - | - | - | - | - | - | - | 16.7 | - | - | - | - | 83.3 | poor |
| Trubiano et al. (2020) | Trubiano | 2020-07-02 | Australia | 2,935 | Community and Hospital | 39 (29-53) | 63.5 | - | - | - | - | - | - | - | 8.8 | - | - | - | - | 91.2 | poor |
| Patel et al. (2020) | Patel | 2020-07-03 | USA | 129 | Hospital | 60.8^ (47-74) | 45.0 | 37.2 | - | - | - | - | - | - | - | - | - | - | 55.8 | 7.0 | poor |
| Merzon et al. (2020) | Merzon | 2020-07-03 | Israel | 7,807 | Community and Hospital | 46.2^ (NA) | 58.6 | - | - | - | - | - | - | - | 16.2 | - | - | - | - | 83.8 | poor |
| Bello-Chavolla, Antonio-Villa, et al. (2020) | Bello-Chavolla, Antonio-Villa | 2020-07-04 | Mexico | 60,121 | Community and Hospital | 45.5^ (29-61) | 47.0 | - | - | - | - | - | - | - | 10.5 | - | - | - | - | 89.5 | poor |
| Zacharioudakis et al. (2020) | Zacharioudakis | 2020-07-04 | USA | 314 | Hospital | 64 (54-72) | 34.7 | - | - | - | - | - | - | - | 22.8 | - | - | - | - | 77.2 | poor |
| Antonio-Villa et al. (2020) | Antonio-Villa | 2020-07-04 | Mexico | 34,263 | Community and Hospital | 40^ (29-50) | 62.9 | 9.7 | - | - | - | - | - | - | - | - | - | - | - | 90.3 | poor |
| Kimmig et al. (2020) | Kimmig | 2020-07-06 | USA | 111 | Hospital | 63^ (48-78) | 44.1 | 7.2 | - | - | - | 36.0 | - | - | - | 56.8 | - | - | - | 0.0 | fair |
| Senkal (2020) | Senkal | 2020-07-07 | Turkey | 611 | Hospital | 57^ (18-98) | 40.6 | 11.3 | - | - | - | - | - | - | - | - | - | - | - | 88.7 | poor |
| Xie et al. (2020) | Xie | 2020-07-07 | China | 619 | Hospital | NA | 52.0 | - | - | - | - | - | - | - | 8.2 | - | - | - | - | 91.8 | poor |
| Elmunzer et al. (2020) | Elmunzer | 2020-07-09 | Multiple | 1,992 | Hospital | 60^ (43-76) | 43.0 | 6.3 | - | - | - | 28.6 | - | - | - | 59.0 | - | - | - | 6.1 | fair |
| Alizadehsani et al. (2020) | Alizadehsani | 2020-07-09 | Iran | 319 | Hospital | 45.48^ (26-63) | 55.5 | - | - | - | - | - | - | - | 0.3 | - | - | - | - | 99.7 | poor |
| Maucourant et al. (2020) | Maucourant | 2020-07-10 | Sweden | 27 | Hospital | 57 (18-78) | 22.2 | 11.1 | - | - | - | 25.9 | - | - | - | 40.7 | - | - | - | 22.2 | poor |
| Fan et al. (2020) | Fan | 2020-07-11 | UK | 1,425 | Community and Hospital | NA | 46.7 | 12.2 | - | - | - | 40.1 | - | - | - | 46.9 | - | - | - | 0.8 | fair |
| Z. Shi et al. (2020) | Shi, Resurreccion | 2020-07-11 | UK | 1,521 | Community and Hospital | 61.5^ (57-66.8) | 45.9 | - | - | - | - | - | - | - | 54.9 | - | - | - | - | 45.1 | poor |
| Riley et al. (2020) | Riley | 2020-07-11 | UK | 120,620 | Community and Hospital | NA | 54.0 | 2.2 | - | - | - | - | - | - | - | - | - | - | 16.5 | 81.3 | poor |
| Hippisley-Cox et al. (2020) | Hippisley-Cox | 2020-07-13 | UK | 8,275,949 | Community and Hospital | 48.5^ (30-66) | 50.3 | 17.2 | - | - | - | 21.4 | - | - | - | 57.3 | - | - | - | 4.0 | fair |
| Jin‐jin Zhang et al. (2020) | Zhang, Cao | 2020-07-14 | China | 289 | Hospital | 57 (22-88) | 46.6 | 3.5 | - | - | - | 6.2 | - | - | - | - | - | - | - | 90.3 | poor |
| Eiros et al. (2020) | Eiros | 2020-07-14 | Spain | 139 | Community and Hospital | 52 (41-57) | 72.0 | 4.3 | - | - | - | 50.4 | - | - | - | - | - | - | - | 45.3 | poor |
| Marcos et al. (2020) | Marcos | 2020-07-14 | Spain | 918 | Hospital | 72.8^ (58-87) | 42.2 | 6.1 | - | - | - | - | - | - | 15.3 | - | - | - | - | 78.7 | poor |
| Hoertel, Rico, Vernet, Beeker, et al. (2020) | Hoertel, Sanchez, Rico | 2020-07-14 | France | 7,345 | Hospital | NA | 49.3 | 8.5 | - | - | - | - | - | - | - | - | - | - | - | 91.5 | poor |
| H. Shi et al. (2020) | Shi, Zuo | 2020-07-15 | USA | 172 | Hospital | 61.48^ (25-96) | 44.0 | - | - | - | - | - | - | - | 26.2 | - | - | - | - | 73.8 | poor |
| Hussein et al. (2020) | Hussein | 2020-07-15 | USA | 502 | Hospital | 60.9^ (45-76) | 52.0 | 9.0 | - | - | - | 22.1 | - | - | - | - | - | - | 68.9 | 0.0 | poor |
| Bian et al. (2020) | Bian | 2020-07-15 | China | 28 | Hospital | 56^ (42-67) | 42.9 | 7.1 | - | - | - | - | - | - | - | - | - | - | - | 92.9 | poor |
| Z. Zhan et al. (2020) | Zhan | 2020-07-16 | China | 75 | Hospital | 57 (25-75) | 48.0 | - | - | - | - | - | - | - | 12.0 | - | - | - | - | 88.0 | poor |
| Omrani et al. (2020) | Omrani | 2020-07-16 | Qatar | 1,409 | Community and Hospital | 39 (30-50) | 17.2 | - | - | - | - | - | - | - | 9.2 | - | - | - | - | 90.8 | poor |
| Gupta et al. (2020) | Gupta | 2020-07-16 | USA | 496 | Hospital | 70 (60-78) | 46.0 | - | - | - | - | - | - | - | 7.3 | - | - | - | 31.7 | 61.1 | poor |
| Soares et al. (2020) | Soares | 2020-07-16 | Brazil | 10,713 | Community and Hospital | NA | 55.0 | 2.0 | - | - | - | - | - | - | - | - | - | - | 98.0 | 0.0 | poor |
| Abolghasemi et al. (n.d.) | Abolghasemi | 2020-07-17 | Iran | 24 | Hospital | 49^ (29-64) | 37.5 | - | - | - | - | - | - | - | 4.2 | - | - | - | - | 95.8 | poor |
| Merkely et al. (2020) | Merkely | 2020-07-17 | Hungary | 10,474 | Community | 48.7^ (30-66) | 53.6 | 28.0 | - | - | - | 20.5 | - | - | - | 51.4 | - | - | - | 0.2 | good |
| Fox et al. (n.d.) | Fox | 2020-07-17 | UK | 55 | Community and Hospital | 63 (23-88) | 31.0 | 1.8 | - | - | - | 10.9 | - | - | - | 56.4 | - | - | - | 30.9 | poor |
| Pandolfi et al. (2020) | Pandolfi | 2020-07-17 | Italy | 33 | Hospital | 62 (52-65) | 21.1 | 3.0 | - | - | - | 24.2 | - | - | - | 72.7 | - | - | - | 0.0 | fair |
| Girardeau et al. (2020) | Girardeau | 2020-07-17 | France | 10 | Community | 30 (29-33) | 50.0 | 40.0 | 10.0 | - | - | 10.0 | - | - | - | - | - | - | - | 40.0 | poor |
| Kurashima et al. (2020) | Kurashima | 2020-07-17 | Japan | 53 | Hospital | 62.9^ (49-76) | 35.8 | - | - | - | - | - | - | - | 50.9 | - | - | - | - | 49.1 | poor |
| McGrail & Edwards (2020) | Edwards | 2020-07-19 | USA | 209 | Hospital | 62.5 (NA) | 38.8 | - | - | - | - | - | - | - | 18.7 | - | - | - | - | 81.3 | poor |
| Martinez-Resendez et al. (2020) | Martinez-Resendez | 2020-07-20 | Mexico | 8 | Hospital | 57 (48-69) | 25.0 | - | - | - | - | - | - | - | 12.5 | - | - | - | - | 87.5 | poor |
| Hoertel, Rico, Vernet, Jannot, et al. (2020) | Hoertel | 2020-07-20 | France | 12,612 | Hospital | 58.7^ (39-77) | 49.6 | - | - | - | - | - | - | - | 9.3 | - | - | - | - | 90.7 | poor |
| Z.-H. Wang et al. (2020) | Wang, Shu | 2020-07-20 | China | 59 | Hospital | 67.4^ (56-78) | 35.6 | - | - | - | - | - | - | - | 15.3 | - | - | - | - | 84.8 | poor |
| Bernaola et al. (2020) | Bernaola | 2020-07-21 | Spain | 1,645 | Hospital | NA | 38.5 | 2.5 | - | - | - | 10.9 | - | - | - | 86.6 | - | - | - | 0.0 | fair |
| Schneeweiss et al. (2020) | Schneeweiss | 2020-07-22 | USA | 24,313 | Community and Hospital | 67^ (53-80) | 53.0 | - | - | - | - | - | - | - | 2.9 | - | - | - | - | 97.1 | poor |
| Concha-Mejia & Rincon-Sanchez (2020) | Mejia | 2020-07-24 | Colombia | 72 | Community and Hospital | 46 (28-64) | 47.0 | 8.3 | - | - | - | 11.1 | - | - | - | - | - | - | - | 80.6 | poor |
| Izquierdo et al. (2020) | Izquierdo | 2020-07-24 | Spain | 71,192 | Community and Hospital | 42^ (18-66) | 59.0 | 10.0 | - | - | - | - | - | - | - | - | - | - | 90.0 | 0.0 | poor |
| Santos et al. (2020) | Santos | 2020-07-25 | USA | 23 | Community and Hospital | NA | - | - | - | - | - | - | - | - | 8.7 | - | - | - | - | 91.3 | poor |
| Reiter et al. (2020) | Reiter | 2020-07-26 | Austria | 235 | Community | 44.2^ (32-55) | 70.0 | 22.6 | - | - | - | 22.6 | - | - | - | 54.5 | - | - | - | 0.4 | fair |
| Motta et al. (2020) | Motta | 2020-07-26 | USA | 374 | Hospital | 64.7^ (46-82) | 41.4 | - | - | - | - | - | - | - | 33.2 | 66.8 | - | - | - | 0.0 | poor |
| Altamimi et al. (2020) | Altamimi | 2020-07-27 | Qatar | 68 | Hospital | 49^ (40-58) | 2.0 | 16.2 | - | - | - | - | - | - | - | - | - | - | 83.8 | 0.0 | poor |
| Thompson et al. (2020) | Thompson | 2020-07-27 | UK | 470 | Hospital | 71 (57-82) | 46.0 | 14.0 | - | - | - | 27.2 | - | - | - | 58.7 | - | - | - | 0.0 | fair |
| Zobairy et al. (2020) | Zobairy | 2020-07-28 | Iran | 203 | Community and Hospital | 49.2^ (32-65) | 44.8 | 5.9 | - | - | - | - | - | - | - | - | - | - | 94.1 | 0.0 | poor |
| K. Zhou et al. (2020) | Zhou, Sun | 2020-07-29 | China | 144 | Hospital | 47 (38-56) | 46.5 | 9.0 | - | - | - | - | - | - | - | - | - | - | 91.0 | 0.0 | poor |
| Kumar et al. (2020) | Kumar | 2020-07-29 | India | 91 | Hospital | 47^ (41-52) | 21.0 | 44.0 | - | - | - | - | - | - | - | - | - | - | - | 56.0 | poor |
| Qu et al. (2020) | Qu | 2020-07-29 | China | 246 | Hospital | 53.6^ (38-68) | 53.3 | 42.3 | - | - | - | - | - | - | - | - | - | - | - | 57.7 | poor |
| Higuchi et al. (2020) | Higuchi | 2020-07-30 | Japan | 57 | Hospital | 52 (35-70) | 43.9 | 12.3 | - | - | - | 29.8 | - | - | - | 57.9 | - | - | - | 0.0 | fair |
| Zhao et al. (2020) | Zhao, Chen | 2020-07-30 | USA | 641 | Hospital | 60 (NA) | 40.1 | 21.7 | - | - | - | - | - | - | - | - | - | - | - | 78.3 | poor |
| Fond et al. (2020) | Fond | 2020-07-30 | France | 1,092 | Hospital | 62.5 (51-76) | 45.7 | 11.4 | - | - | - | - | - | - | - | - | - | - | 88.6 | 0.0 | poor |
| Jun et al. (2020) | Jun | 2020-08-01 | USA | 3,086 | Hospital | 66 (56-77) | 40.9 | 3.7 | - | - | - | 21.3 | - | - | - | 52.8 | - | - | - | 22.2 | poor |
| Morshed et al. (2020) | Morshed | 2020-08-02 | Bangladesh | 103 | Community | 37 (31-53) | 28.2 | 31.1 | - | - | - | - | - | - | - | - | - | - | 68.9 | 0.0 | poor |
| Iversen et al. (2020) | Iversen | 2020-08-03 | Denmark | 28,792 | Community and Hospital | 44.4^ (31-57) | 78.9 | 16.0 | - | - | - | 6.5 | - | - | - | 76.8 | - | - | - | 0.7 | fair |
| Ebinger et al. (2020) | Ebinger | 2020-08-04 | USA | 6,062 | Community | 41.5^ (29-53) | 67.8 | 1.7 | 1.4 | - | - | - | - | - | - | - | - | - | - | 96.9 | poor |
| Hadi et al. (2020) | Hadi | 2020-08-05 | USA | 370 | Community and Hospital | 48.2^ (34-62) | 29.5 | - | - | - | - | - | - | - | 15.1 | 84.9 | - | - | - | 0.0 | poor |
| Tao et al. (2020) | Tao | 2020-08-06 | China | 70 | Community | 33.2^ (12-53) | 48.6 | - | - | - | - | - | - | - | 15.7 | - | - | - | 84.3 | 0.0 | poor |
| Klang et al. (2020) | Klang, Soffer | 2020-08-09 | USA | 1,320 | Hospital | NA | 41.5 | - | - | - | - | - | - | - | 24.7 | - | - | - | - | 75.3 | poor |
| J. Zhou et al. (2021) | Zhou, Ma | 2020-08-10 | China | 429 | Hospital | 58.3^ (42-74) | 50.6 | - | - | - | - | - | - | - | 8.4 | - | - | - | 91.6 | 0.0 | poor |
| Altibi et al. (2020) | Altibi | 2020-08-11 | USA | 706 | Hospital | 66.7^ (51-81) | 43.0 | 4.0 | - | - | - | 37.3 | - | - | - | 58.8 | - | - | - | 0.0 | fair |
| Izzi-Engbeaya et al. (2020) | Izzi-Engbeaya | 2020-08-11 | UK | 889 | Hospital | 65.8^ (48-83) | 40.0 | - | - | - | - | - | - | - | 21.3 | 33.2 | - | - | - | 45.6 | poor |
| Rizzo et al. (2020) | Rizzo | 2020-08-11 | USA | 76,819 | Hospital | 54 (38-67) | 55.2 | 6.7 | - | - | - | 20.8 | - | - | - | 50.4 | - | - | - | 22.1 | poor |
| Jehi et al. (2020) | Jehi | 2020-08-11 | USA | 4,536 | Community and Hospital | NA | - | 7.3 | - | - | - | 28.5 | - | - | - | 49.9 | - | - | - | 14.4 | fair |
| Holman et al. (2020) | Holman | 2020-08-13 | UK | 10,989 | Community and Hospital | NA | 38.8 | 5.5 | - | - | - | 42.6 | - | - | - | 49.0 | - | - | - | 2.8 | fair |
| Ouyang et al. (2020) | Ouyang | 2020-08-14 | China | 217 | Hospital | 46.5^ (30-62) | 53.5 | 16.6 | - | - | - | - | - | - | - | - | - | - | - | 83.4 | poor |
| Valenzuela et al. (2020) | Valenzuela | 2020-08-14 | Chile | 29 | Hospital | 56.9^ (43-70) | 6.9 | 17.2 | - | - | - | - | - | - | - | - | - | - | 82.8 | 0.0 | poor |
| Monteiro et al. (2020) | Monteiro | 2020-08-14 | USA | 112 | Hospital | 61 (45-74) | 34.0 | 6.2 | - | - | - | 17.9 | - | - | - | 68.8 | - | - | - | 7.1 | fair |
| Philipose et al. (2020) | Philipose | 2020-08-14 | UK | 466 | Hospital | 67 (6-97) | 41.8 | 6.0 | - | - | - | 73.2 | - | - | - | 16.5 | - | - | - | 4.3 | fair |
| Weerahandi et al. (2020) | Weerahandi | 2020-08-14 | USA | 394 | Community | 63 (55-70) | 37.0 | 5.3 | - | - | - | 25.9 | - | - | - | 55.8 | - | - | - | 12.9 | fair |
| Parra-Bracamonte et al. (2020) | Parra-Bracamonte | 2020-08-14 | Mexico | 331,298 | Community and Hospital | 44 (33-56) | 46.2 | - | - | - | - | - | - | - | 7.4 | - | - | - | - | 92.6 | poor |
| Peters et al. (2020) | Peters | 2020-08-15 | Netherlands | 1,893 | Hospital | 66.8^ (52-81) | 39.4 | 4.9 | - | - | - | - | - | - | - | - | - | - | - | 95.1 | poor |
| Islam et al. (2020) | Islam | 2020-08-18 | Bangladesh | 1,016 | Community and Hospital | 37 (28-49) | 35.9 | 18.2 | - | - | - | - | - | - | - | - | - | - | - | 77.8 | poor |
| Chand et al. (2020) | Chand | 2020-08-19 | USA | 300 | Hospital | 58.2^ (45-70) | 39.3 | 22.3 | - | - | - | - | - | - | - | - | - | - | - | 77.7 | poor |
| Aksu et al. (2020) | Aksu | 2020-08-19 | Turkey | 123 | Community and Hospital | 49.7^ (36-63) | 33.3 | 11.4 | - | - | - | - | - | - | - | - | - | - | 88.6 | 0.0 | poor |
| Alkurt et al. (2020) | Alkurt | 2020-08-20 | Turkey | 932 | Community and Hospital | 34.8^ (25-44) | 64.4 | 24.5 | - | - | - | - | - | - | - | - | - | - | - | 75.5 | poor |
| Ward et al. (2020) | Ward | 2020-08-21 | UK | 99,908 | Community | NA | 56.1 | 10.6 | - | - | - | - | - | - | - | - | - | - | 88.4 | 1.0 | poor |
| Salerno et al. (2020) | Salerno | 2020-08-22 | USA | 15,920 | Hospital | 49 (30-65) | 57.0 | - | - | - | - | - | - | - | 36.8 | 55.9 | - | - | - | 7.3 | poor |
| M. Rashid et al. (2020) | Rashid | 2020-08-22 | UK | 517 | Hospital | 72.8^ (59-86) | 31.9 | 9.9 | - | - | - | 29.0 | - | - | - | 29.4 | - | - | - | 31.7 | poor |
| Pan et al. (2020) | Pan | 2020-08-22 | USA | 12,084 | Community and Hospital | 45.5^ (27-63) | 54.3 | - | - | - | - | - | - | - | 17.5 | - | - | - | - | 82.5 | poor |
| Fillmore et al. (2020) | Fillmore | 2020-08-24 | USA | 22,914 | Community and Hospital | NA | - | 37.5 | - | - | - | 40.7 | - | - | - | 15.5 | - | - | - | 6.4 | fair |
| Wei Zhou et al. (2020) | Zhou, Qin | 2020-08-25 | China | 51 | Hospital | 57.37^ (42-72) | 29.4 | - | - | - | - | - | - | - | 78.4 | 21.6 | - | - | - | 0.0 | poor |
| Ibrahim et al. (2020) | Ibrahim | 2020-08-27 | USA | 38 | Hospital | 63^ (51-75) | 47.0 | 10.5 | - | - | - | - | - | - | - | - | - | - | - | 89.5 | poor |
| Oliveira et al. (2020) | Oliveira | 2020-08-31 | USA | 131 | Hospital | 61 (49.5-71.5) | 64.9 | - | - | - | - | - | - | - | 17.6 | 26.7 | - | - | - | 55.7 | poor |
| Yoo et al. (2020) | Yoo | 2020-08-31 | USA | 4,840 | Hospital | 66.4 (54.9-77.8) | 43.5 | 4.4 | - | - | - | 21.4 | - | - | - | 53.3 | - | - | - | 20.9 | poor |
| T. Zhan et al. (2020) | Zhan, Liu | 2020-08-31 | China | 405 | Hospital | 56^ (17-95) | 54.1 | - | - | - | - | - | - | - | 11.4 | 88.6 | - | - | - | 0.0 | poor |
| Mohamed-Hussein et al. (2020) | Hussein, Galal | 2020-09-01 | Egypt | 444 | Community | 33.1^ (21-45) | 56.8 | 13.1 | - | - | - | 9.0 | - | - | - | 77.9 | - | - | - | 0.0 | fair |
| Villar-Garcia et al. (2020) | Vilar-Garcia | 2020-09-01 | Spain | 7,699,568 | Community and Hospital | 43 (24-59) | 50.9 | 17.1 | - | - | - | - | - | - | - | - | - | - | - | 82.9 | poor |
| Ibarra-Nava et al. (2020) | Ibarra-Nava | 2020-09-01 | Mexico | 416,546 | Community and Hospital | NA | 46.9 | 7.4 | - | - | - | - | - | - | - | - | - | - | - | 92.6 | poor |
| Rubio-Rivas et al. (2020) | Rubio-Rivas | 2020-09-01 | Spain | 186 | Hospital | 64.3^ (51-77) | 30.6 | 4.3 | - | - | - | 20.4 | - | - | - | 75.3 | - | - | - | 0.0 | fair |
| Mamtani et al. (2020) | Mamtani | 2020-09-02 | USA | 403 | Hospital | 55^ (41-68) | 32.3 | 9.7 | - | - | - | 12.7 | - | - | - | 68.5 | - | - | - | 9.2 | fair |
| Ren, Guo, Blighe, et al. (2020) | Ren | 2020-09-02 | China | 432 | Hospital | NA | 57.9 | 10.0 | - | - | - | - | - | - | - | 90.0 | - | - | - | 0.0 | poor |
| Mutambudzi et al. (2020) | Mutambudzi | 2020-09-03 | UK | 120,075 | Community and Hospital | NA | 54.2 | 11.7 | - | - | - | 26.4 | - | - | - | 61.9 | - | - | - | 0.0 | fair |
| Yan et al. (2020) | Yan | 2020-09-07 | China | 578 | Hospital | 49.2^ (35-63) | 49.3 | 9.2 | - | - | - | - | - | - | - | - | - | - | - | 90.8 | poor |
| Mancilla-Galindo et al. (2020) | Mancilla-Galindo | 2020-09-08 | Mexico | 183,779 | Community and Hospital | 45^ (28-61) | 46.0 | 7.6 | - | - | - | - | - | - | - | - | - | - | - | 92.4 | poor |
| Ullah et al. (2020) | Ullah | 2020-09-08 | UK | 212 | Community and Hospital | 66.7 (54.2-80.5) | 44.8 | 11.3 | - | - | - | 48.1 | - | - | - | 37.7 | - | - | - | 2.8 | fair |
| Hamadah et al. (2020) | Hamadah | 2020-09-10 | Kuwait | 1,123 | Hospital | 40 (1-93) | 18.7 | 3.9 | - | - | - | - | - | - | - | - | - | - | 96.1 | 0.0 | poor |
| Sami et al. (2020) | Sami | 2020-09-14 | Iran | 490 | Community and Hospital | 56.6^ (41-71) | 39.0 | 14.1 | - | - | - | - | - | - | - | - | - | - | - | 85.9 | poor |
| Pongpirul et al. (2020) | Pongpirul | 2020-09-16 | Thailand | 193 | Community and Hospital | 37 (29-53) | 41.5 | - | - | - | - | - | - | - | 15.0 | 66.3 | - | - | - | 18.6 | poor |
| Burrell et al. (2020) | Burrell | 2020-09-16 | Australia | 204 | Hospital | 63.5 (53-72) | 31.4 | - | - | - | - | - | - | - | 13.2 | - | - | - | 82.8 | 3.9 | poor |
| Nicholson et al. (2020) | Nicholson | 2020-09-17 | USA | 1,042 | Hospital | 64 (53-75) | 43.2 | 8.3 | - | - | - | 22.2 | - | - | - | 37.1 | - | - | - | 32.4 | poor |
| Ariza et al. (2020) | Ariza | 2020-09-18 | Colombia | 351 | Community and Hospital | 30.5 (NA) | 54.0 | 6.8 | - | - | - | - | - | - | - | - | - | - | 93.2 | 0.0 | poor |
| Carrat et al. (2020) | Carrat | 2020-09-18 | France | 14,628 | Community | NA | 60.3 | 12.0 | - | - | - | 40.8 | - | - | - | 45.6 | - | - | - | 1.6 | good |
| Favara et al. (2020a) | Favara | 2020-09-20 | UK | 434 | Community | 40 (19-66) | 82.0 | 8.5 | - | - | - | - | - | - | - | - | - | - | 91.5 | 0.0 | poor |
| Favara et al. (2020b) | Favara | 2020-09-20 | UK | 434 | Community | 40 (19-66) | 82.0 | 8.5 | - | - | - | - | - | - | - | - | - | - | 91.5 | 0.0 | poor |
| Invernizzi et al. (2020) | Invernizzi | 2020-09-20 | Italy | 54 | Hospital | 49.9^ (34-65) | 29.7 | - | - | - | - | - | - | - | 24.1 | - | - | - | - | 75.9 | poor |
| Zhu et al. (2020) | Zhu | 2020-09-21 | China | 432 | Community and Hospital | 49 (35-60) | 47.9 | 14.4 | - | - | - | - | - | - | - | - | - | - | - | 85.7 | poor |
| O’Reilly et al. (2020) | O'Reilly | 2020-09-21 | Australia | 1,334 | Hospital | NA | - | - | - | - | - | - | - | - | 28.5 | - | - | - | - | 71.5 | poor |
| Meini et al. (n.d.) | Meini | 2020-09-23 | Italy | 461 | Hospital | NA | 51.2 | 10.4 | - | - | - | 25.8 | - | - | - | 63.8 | - | - | - | 0.0 | fair |
| Silva Neto et al. (2020) | da Silva Neto | 2020-09-23 | Brazil | 91 | Community and Hospital | 49^ (29-68) | 49.4 | - | - | - | - | - | - | - | 19.8 | - | - | - | 80.2 | 0.0 | poor |
| Ioannou et al. (2020) | Ioannou | 2020-09-23 | USA | 88,747 | Community and Hospital | NA | 9.0 | 20.6 | - | - | - | 37.5 | - | - | - | 29.3 | - | - | - | 12.6 | fair |
| Torres-Macho et al. (2020) | Torres-Macho | 2020-09-23 | Spain | 1,968 | Hospital | NA | 44.0 | - | - | - | - | - | - | - | 23.4 | - | - | - | - | 76.6 | poor |
| F. Li et al. (2020) | Li, Cai | 2020-09-28 | China | 98 | Hospital | 68.5 (63-75) | 58.2 | - | - | - | - | - | - | - | 11.2 | - | - | - | 88.8 | 0.0 | poor |
| J. G. Wang et al. (2020) | Wang | 2020-09-29 | USA | 1,078 | Hospital | NA | 38.2 | 3.7 | - | - | - | 24.9 | - | - | - | 49.0 | - | - | - | 22.4 | poor |
| Lopez-Medrano et al. (2020) | Lopez-Medrano | 2020-09-30 | Spain | 261 | Hospital | NA | 43.7 | - | - | - | - | - | - | - | 37.2 | - | - | - | 62.8 | 0.0 | poor |
| Collard et al. (2020) | Collard | 2020-10-01 | Netherlands | 1,604 | Hospital | 65.7^ (50-80) | 39.5 | 4.9 | - | - | - | - | - | - | - | - | - | - | - | 95.1 | poor |
| Makaronidis et al. (2020) | Makaronidis | 2020-10-01 | UK | 567 | Community | 39.4^ (27-51) | 69.1 | 9.3 | - | - | - | - | - | - | - | - | - | - | 90.7 | 0.0 | poor |
| Yadaw et al. (2020) | Yadaw | 2020-10-01 | USA | 5,051 | Community and Hospital | NA | - | 3.6 | - | - | - | 15.9 | - | - | - | 51.4 | - | - | - | 29.1 | poor |
| Talavera et al. (2020) | Talavera | 2020-10-01 | Spain | 576 | Hospital | 67.2^ (52-81) | 43.4 | - | - | - | - | - | - | - | 20.5 | - | - | - | - | 79.5 | poor |
| Jakob et al. (2020) | Jakob | 2020-10-01 | Multiple | 2,155 | Community and Hospital | NA | 40.3 | 6.6 | - | - | - | 7.3 | - | - | - | 34.3 | - | - | - | 51.7 | poor |
| Incerti et al. (2020) | Incerti | 2020-10-02 | USA | 13,658 | Hospital | 62 (49-75) | 48.1 | 6.3 | - | - | - | 22.6 | - | - | - | 45.4 | - | - | - | 25.6 | poor |
| J. Luo et al. (2020) | Luo, Rizvi | 2020-10-03 | USA | 102 | Hospital | 68 (61-75) | 52.0 | - | - | - | - | - | - | - | 26.5 | - | - | - | 73.5 | 0.0 | poor |
| Alharthy et al. (2020) | Alharthy | 2020-10-03 | Saudi Arabia | 352 | Hospital | 50.6^ (37-63) | 12.8 | 49.4 | - | - | - | - | - | - | - | - | - | - | 50.6 | 0.0 | poor |
| Robinson et al. (2021) | Robinson | 2020-10-05 | USA | 3,248 | Hospital | 51^ (34-68) | 72.0 | 4.0 | - | - | - | 17.6 | - | - | - | 61.8 | - | - | - | 16.6 | fair |
| Adrish et al. (2020) | Adrish | 2020-10-05 | USA | 1,173 | Hospital | NA | 38.6 | 14.0 | - | - | - | 14.7 | - | - | - | 71.4 | - | - | - | 0.0 | fair |
| Erber et al. (2020) | Erber | 2020-10-06 | Germany | 4,554 | Community | 38.5^ (NA) | 70.4 | - | - | - | - | - | - | - | 18.0 | - | - | - | 82.0 | 0.0 | poor |
| Chaudhary et al. (2020) | Chaudhary | 2020-10-06 | Nepal | 220 | Hospital | 31.5 (25-37) | 17.7 | 11.4 | - | - | - | 7.7 | - | - | - | 80.0 | - | - | - | 0.9 | fair |
| Raines et al. (2021) | Raines | 2020-10-07 | USA | 453 | Community and Hospital | 60.8^ (46-74) | 10.7 | - | - | - | - | - | - | - | 53.0 | 41.9 | - | - | - | 5.1 | poor |
| Roederer et al. (2021) | Roederer | 2020-10-09 | France | 818 | Community | NA | 20.4 | 36.9 | - | - | - | 8.8 | - | - | - | 53.9 | - | - | - | 0.4 | fair |
| Zinellu et al. (2021) | Zinellu | 2020-10-11 | Italy | 105 | Hospital | 72 (59.5-80) | 33.3 | 30.5 | - | - | - | 10.5 | - | - | - | 59.0 | - | - | - | 0.0 | fair |
| Ramachandran et al. (2020) | Ramachandran | 2020-10-12 | USA | 188 | Hospital | NA | - | 18.6 | - | - | - | - | - | - | - | - | - | - | - | 81.4 | poor |
| Lamure et al. (2020) | Lamure | 2020-10-12 | France | 89 | Hospital | 67 (19-92) | 34.0 | 5.6 | - | - | - | 32.6 | - | - | - | 48.3 | - | - | - | 13.5 | fair |
| Ghinai et al. (2020) | Ghinai | 2020-10-12 | USA | 1,435 | Homeless Shelters | NA | 27.6 | 36.6 | - | - | - | 17.5 | - | - | - | 33.2 | - | - | - | 12.8 | fair |
| Best et al. (2020) | Best | 2020-10-12 | USA | 3,471 | Hospital | 63.5^ (47-79) | 51.2 | - | - | - | - | - | - | - | 28.6 | - | - | - | 71.4 | 0.0 | poor |
| Savarraj et al. (n.d.) | Savarraj | 2020-10-18 | USA | 48 | Hospital | 50^ (33-67) | 48.0 | 10.4 | - | - | - | - | - | - | - | - | - | - | - | 89.6 | poor |
| Israel, Schäffer, et al. (2020) | Israel, Schaffer | 2020-10-18 | Israel | 26,959 | Hospital | NA | 50.6 | 6.8 | - | - | - | 15.2 | - | - | - | 77.0 | - | - | - | 1.1 | fair |
| El-Solh et al. (2020) | El-Solh | 2020-10-20 | USA | 7,816 | Hospital | 69 (60-74) | 5.5 | - | - | - | - | - | - | - | 45.3 | - | - | - | 54.7 | 0.0 | poor |
| Perico et al. (2020) | Perico | 2020-10-22 | Italy | 423 | Community | 44.3^ (34-54) | 36.4 | 21.7 | - | - | - | 18.0 | - | - | - | 60.3 | - | - | - | 0.0 | fair |
| Wenqian Zhou et al. (2020) | Zhou, Song | 2020-10-22 | China | 124 | Hospital | 67 (30-86) | 48.0 | 19.1 | - | - | - | - | - | - | - | - | - | - | - | 80.9 | poor |
| Chudasama et al. (2020) | Chudasama | 2020-10-23 | UK | 1,706 | Community and Hospital | 68 (48-85) | 42.5 | 13.8 | - | - | - | 41.0 | - | - | - | 45.3 | - | - | - | 0.0 | fair |
| Salama et al. (2021) | Salama | 2020-10-23 | Multiple | 377 | Hospital | 55.9^ (41-70) | 40.8 | 5.8 | - | - | - | 17.0 | - | - | - | 77.2 | - | - | - | 0.0 | fair |
| Z. Wang et al. (2020) | Wang, Zheutlin | 2020-10-26 | USA | 3,273 | Hospital | 65 (53-77) | 42.7 | 3.5 | - | - | - | 20.7 | - | - | - | 53.2 | - | - | - | 22.6 | poor |
| Yiwu Zhou et al. (2020) | Zhou, He, Yang | 2020-10-27 | China | 1,087 | Hospital | NA | 51.7 | - | - | - | - | - | - | - | 85.0 | 15.0 | - | - | - | 0.0 | poor |
| Hoertel, Sánchez, et al. (2020) | Hoertel, Sanchez, Vernet | 2020-10-27 | France | 12,210 | Hospital | NA | 50.1 | 9.0 | - | - | - | - | - | - | - | - | - | - | - | 91.0 | poor |
| Arleo et al. (2020) | Arleo | 2020-10-27 | USA | 70 | Community and Hospital | 56.6^ (48-65) | 80.0 | 1.4 | - | - | - | 28.6 | - | - | - | 70.0 | - | - | - | 0.0 | fair |
| Bermejo-Martin et al. (2020) | Bermejo-Martin | 2020-10-27 | Spain | 250 | Community and Hospital | NA | 64.0 | 6.0 | - | - | - | - | - | - | - | - | - | - | - | 94.0 | poor |
| Joubert et al. (2020) | Joubert | 2020-10-29 | France | 74 | Community and Hospital | NA | - | 5.4 | - | - | - | - | - | - | - | - | - | - | - | 94.6 | poor |
| Kortela et al. (2020) | Kortela | 2020-11-01 | Finland | 3,008 | Community and Hospital | 51 (36-69) | 59.6 | 11.0 | - | - | - | 14.0 | - | - | - | 29.2 | - | - | - | 45.8 | poor |
| M. A. Gianfrancesco et al. (2020) | Gianfrancesco, Leykina | 2020-11-03 | USA | 1,324 | Community and Hospital | NA | 75.9 | - | - | - | - | - | - | - | 26.7 | 68.2 | - | - | - | 5.1 | poor |
| Colaneri et al. (2021) | Colaneri | 2020-11-03 | Italy | 1,447 | Community | 45 (33.2-53.4) | 69.6 | 17.1 | - | - | - | 9.5 | - | - | - | 49.8 | - | - | - | 23.6 | poor |
| Gallichotte et al. (2020) | Gallichotte | 2020-11-05 | USA | 239 | Community | 41^ (16-76) | - | 20.1 | 5.9 | - | - | 16.7 | - | - | - | 57.3 | - | - | - | 0.0 | fair |
| Lin et al. (2020) | Lin | 2020-11-05 | USA | 2,821 | Hospital | 62.7^ (NA) | 45.0 | 2.9 | - | - | - | 12.5 | - | - | - | 3.3 | - | - | - | 81.3 | poor |
| (**kim\_easy?**)–use\_2020 | Kim, Han | 2020-11-09 | South Korea | 4,787 | Hospital | 55 (38-68) | 60.1 | 5.5 | - | - | - | 2.8 | - | - | - | 91.7 | - | - | - | 0.0 | fair |
| Galal et al. (2020) | Galal | 2020-11-12 | Egypt | 430 | Community | 37.4^ (24-50) | 63.7 | 6.0 | - | - | - | 7.7 | - | - | - | 86.3 | - | - | - | 0.0 | fair |
| Riou et al. (2021) | Riou | 2020-11-12 | France | 124 | Hospital | 62 (54-72) | 40.0 | - | - | - | - | - | - | - | 41.1 | - | - | - | - | 58.9 | poor |
| Sourij et al. (2020) | Sourij | 2020-11-16 | Austria | 238 | Hospital | 71.1^ (58-83) | 36.1 | 1.7 | - | - | - | 16.0 | - | - | - | 82.4 | - | - | - | 0.0 | fair |
| Clavario et al. (2020) | Clavario | 2020-11-16 | Italy | 110 | Community | 61.7 (53.5-69.2) | 40.9 | 40.9 | - | - | - | - | - | - | - | - | - | - | - | 59.1 | poor |
| Saeed et al. (2020) | Saeed | 2020-11-16 | United Arab Emirates | 173 | Hospital | NA | 34.1 | 6.4 | - | - | - | - | - | - | - | - | - | - | - | 93.6 | poor |
| Mansour et al. (2020) | Mansour | 2020-11-16 | Iran | 353 | Hospital | 61.7^ (45-78) | 42.5 | 7.1 | - | - | - | - | - | - | - | - | - | - | - | 92.9 | poor |
| Cadegiani et al. (2020) | Cadegiani | 2020-11-18 | Brazil | 130 | Community | 42^ (NA) | 0.0 | 7.7 | - | - | - | - | - | - | - | - | - | - | - | 92.3 | poor |
| Ilic et al. (2021) | Ilic | 2020-11-19 | Serbia | 107 | Community and Hospital | 39.1^ (27-50) | - | 29.9 | - | - | - | - | - | - | - | - | - | - | - | 70.1 | poor |
| Benaim et al. (2020) | Benaim | 2020-11-19 | Israel | 693 | Hospital | 59.8 (NA) | 47.9 | - | - | - | - | - | - | - | 5.1 | - | - | - | - | 95.0 | poor |
| F. K. Ho et al. (2020) | Ho | 2020-11-19 | UK | 235,928 | Community and Hospital | NA | - | - | - | - | - | - | - | - | 45.4 | - | - | - | 54.6 | 0.0 | poor |
| Singh et al. (2020) | Singh | 2020-11-20 | UK | 930 | Hospital | 71.4^ (54-87) | 44.8 | - | - | - | - | - | - | - | 19.0 | - | - | - | 81.0 | 0.0 | poor |
| Márquez-Salinas et al. (2020) | Marquez-Salinas | 2020-11-24 | Mexico | 1,068 | Hospital | 53 (44-63) | 36.8 | - | - | - | - | - | - | - | 15.0 | - | - | - | - | 85.0 | poor |
| Díez-Manglano et al. (2020) | Diez-Manglanas | 2020-11-24 | Spain | 4,393 | Hospital | 53^ (NA) | 40.8 | 6.6 | - | - | - | - | - | - | - | - | - | - | - | 93.4 | poor |
| Bellan et al. (2020) | Bellan | 2020-11-26 | Italy | 1,697 | Hospital | 71 (58-80) | 41.0 | 3.2 | - | - | - | - | - | - | - | - | - | - | 15.2 | 81.6 | poor |
| Woolcott & Castilla-Bancayán (2021a) | Woolcott | 2020-11-26 | Mexico | 1,636,050 | Community and Hospital | 42 (34-54) | 51.9 | - | - | - | - | - | - | - | 8.8 | - | - | - | - | 91.2 | poor |
| Woolcott & Castilla-Bancayán (2021b) | Woolcott | 2020-11-26 | Mexico | 1,636,050 | Community and Hospital | 42 (34-54) | 51.9 | - | - | - | - | - | - | - | 8.8 | - | - | - | - | 91.2 | poor |
| K. Yao et al. (2021) | Yao, Hasegawa | 2020-11-26 | Japan | 101 | Hospital | 60^ (17-97) | 39.6 | - | - | - | - | - | - | - | 28.7 | - | - | - | 71.3 | 0.0 | poor |
| H. Chen et al. (2020) | Chen, Varathraja | 2020-11-29 | USA | 10,123 | Community and Hospital | 40 (28-54) | 53.6 | 4.4 | - | - | - | 9.7 | - | - | - | 45.9 | - | - | - | 40.0 | poor |
| Serling-Boyd et al. (2020) | Serling-Boyd | 2020-11-30 | USA | 831 | Hospital | NA | 76.0 | 3.0 | - | - | - | 23.2 | - | - | - | 50.1 | - | - | - | 23.7 | poor |
| Simons et al. (2020) | Simons | 2020-11-30 | UK | 446 | Hospital | 64.9 (52.4-76.2) | 35.9 | 9.4 | - | - | - | 38.6 | - | - | - | 52.0 | - | - | - | 0.0 | fair |
| Dupraz et al. (2020) | Dupraz | 2020-11-30 | Switzerland | 219 | Community | NA | 54.8 | 11.0 | - | - | - | - | - | - | - | - | - | - | - | 89.0 | poor |
| Barasa et al. (2020) | Barasa | 2020-11-30 | USA | 394 | Hospital | NA | 47.7 | 14.7 | - | - | - | 36.0 | - | - | - | 41.6 | - | - | - | 7.6 | fair |
| Ren, Guo, Tu, et al. (2020) | Ren, Guo | 2020-11-30 | China | 481 | Hospital | NA | 45.7 | 7.7 | - | - | - | 0.6 | - | - | - | 91.7 | - | - | - | 0.0 | fair |
| J. Li et al. (2020) | Li, Long, Zhang | 2020-12-03 | China | 954 | Hospital | NA | - | - | - | - | - | - | - | - | 5.9 | 94.1 | - | - | - | 0.0 | poor |
| Martini et al. (2020) | Martini | 2020-12-04 | Italy | 146 | Hospital | NA | 49.0 | - | - | - | - | - | - | - | 46.6 | 53.4 | - | - | - | 0.0 | poor |
| O’Gallagher et al. (2020) | O'Gallagher | 2020-12-04 | UK | 1,721 | Hospital | 71 (56-83) | 43.4 | 6.6 | - | - | - | 18.5 | - | - | - | 74.9 | - | - | - | 0.0 | fair |
| Alguwaihes et al. (2020) | Alguwaihes | 2020-12-05 | Saudi Arabia | 439 | Hospital | 55 (19-101) | 31.7 | 2.1 | - | - | - | - | - | - | - | - | - | - | 97.9 | 0.0 | poor |
| Zuo, Warnock, et al. (2020) | Zuo, Warnock | 2020-12-05 | USA | 118 | Hospital | 61^ (44-78) | 46.0 | - | - | - | - | - | - | - | 23.7 | - | - | - | - | 76.3 | poor |
| Xiaomeng Zhang et al. (2020) | Zhang, Li | 2020-12-06 | UK | 1,746 | Community and Hospital | 68.8^ (59-78) | 47.1 | 10.1 | - | - | - | 35.1 | - | - | - | 44.2 | - | - | - | 10.5 | fair |
| Dai et al. (2020) | Dai | 2020-12-09 | China | 1,574 | Hospital | 57.3^ (41-73) | 48.2 | - | - | - | - | - | - | - | 9.2 | 90.8 | - | - | - | 0.0 | poor |
| Vila-Córcoles et al. (2020) | Vila-Corcoles | 2020-12-10 | Spain | 79,083 | Community | NA | 52.4 | - | - | - | - | - | - | - | 16.1 | - | - | - | - | 83.9 | poor |
| Bisso et al. (2020) | Bisso | 2020-12-11 | Argentina | 168 | Hospital | 67 (58-75) | 34.0 | 10.7 | - | - | - | - | - | - | - | - | - | - | - | 89.3 | poor |
| C. T. Rentsch et al. (2020) | Rentsch, Beckman | 2020-12-11 | USA | 4,297 | Hospital | 68 (58-75) | 6.6 | 36.8 | - | - | - | 39.3 | - | - | - | 1.9 | - | - | - | 22.1 | poor |
| Thiabaud et al. (2020) | Thiabaud | 2020-12-11 | Switzerland | 3,582 | Hospital | 68 (54-79) | 40.5 | - | - | - | - | - | - | - | 6.6 | - | - | - | 50.5 | 42.9 | poor |
| Vila-Corcoles et al. (2020) | Vila-Corcoles, Satue-Gracia | 2020-12-11 | Spain | 282 | Community and Hospital | 65.9^ (53-78) | 50.3 | 8.9 | - | - | - | - | - | - | - | - | - | - | - | 91.1 | poor |
| Lévy et al. (2020) | Levy | 2020-12-12 | France | 61 | Hospital | 60 (50-69) | 20.0 | 8.2 | - | - | - | - | - | - | - | - | - | - | - | 91.8 | poor |
| Kantele et al. (2020) | Kantele | 2020-12-13 | Finland | 1,095 | Community and Hospital | 38 (31-48) | 82.7 | 16.0 | 0.2 | - | - | 25.3 | - | - | - | 55.3 | - | - | - | 0.0 | fair |
| Iftime et al. (2020) | Iftimie | 2020-12-14 | Spain | 468 | Hospital | NA | 44.9 | - | - | - | - | - | - | - | 7.9 | - | - | - | - | 92.1 | poor |
| K. S. Ho et al. (2020) | Ho, Narasimhan | 2020-12-15 | USA | 9,991 | Community and Hospital | 58^ (39-76) | 45.9 | 4.1 | - | - | - | 18.1 | - | - | - | 77.9 | - | - | - | 0.0 | fair |
| Caliskan & Saylan (2020) | Caliskan | 2020-12-16 | Turkey | 565 | Hospital | 48 (38-58) | - | 20.9 | - | - | - | 14.0 | - | - | - | 65.1 | - | - | - | 0.0 | fair |
| Muñoz et al. (2020) | Munoz | 2020-12-16 | Spain | 314 | Community | 45 (40-53) | 52.5 | 6.7 | - | - | - | - | - | - | - | - | - | - | - | 93.3 | poor |
| Crooks et al. (2020) | Crooks | 2020-12-16 | UK | 2,964 | Hospital | NA | 52.6 | 11.7 | 5.1 | - | - | - | - | - | - | - | - | - | - | 83.2 | poor |
| Nunez-Gil et al. (2020) | Nunez-Gil | 2020-12-17 | Multiple | 2,798 | Hospital | 67 (53-78) | 40.0 | 6.2 | - | - | - | - | - | - | - | - | - | - | - | 93.8 | poor |
| Núñez-Gil et al. (2021) | Nunez-Gil | 2020-12-17 | Multiple | 2,798 | Hospital | 67 (53-78) | 40.0 | 6.2 | - | - | - | - | - | - | - | - | - | - | - | 93.8 | poor |
| Gori et al. (2020) | Gori | 2020-12-17 | Italy | 1,352 | Hospital | 68 (58-77) | 28.4 | 3.6 | - | - | - | 18.4 | - | - | - | 66.6 | - | - | - | 11.4 | fair |
| Rowlands et al. (2020) | Rowlands | 2020-12-18 | UK | 580 | Community | 63.8^ (56-70) | 52.2 | 10.2 | - | - | - | 38.1 | - | - | - | 51.7 | - | - | - | 0.0 | fair |
| Richard et al. (2020) | Richard | 2020-12-18 | Switzerland | 8,344 | Community | 46.9^ (NA) | 53.5 | 15.2 | - | - | - | 17.1 | - | - | - | 66.2 | - | - | - | 1.5 | good |
| Schubl et al. (2020) | Schuble\* | 2020-12-19 | USA | 1,557 | Community | NA | 68.9 | 2.4 | - | - | - | - | - | - | - | - | - | - | - | 97.6 | poor |
| Ugur Chousein et al. (2020) | Chousein | 2020-12-21 | Turkey | 114 | Hospital | 51.1^ (36-66) | 32.5 | 16.7 | - | - | - | 20.2 | - | - | - | 63.2 | - | - | - | 0.0 | fair |
| Modrák et al. (2020) | Modrak | 2020-12-22 | Czechia | 213 | Hospital | 69 (58-80) | 51.0 | - | - | - | - | - | - | - | 13.1 | - | - | - | - | 86.8 | poor |
| Kara Polat et al. (2020) | Polat | 2020-12-22 | Turkey | 1,322 | Community | NA | 47.6 | 35.6 | - | - | - | 15.6 | - | - | - | 48.8 | - | - | - | 0.0 | fair |
| Kjetland et al. (2020) | Kjetland | 2020-12-24 | Norway | 7,839 | Community and Hospital | 45.3^ (33-56) | 77.0 | - | - | - | - | - | - | - | 41.0 | - | - | - | - | 59.0 | poor |
| Lewnard et al. (2021) | Lewnard | 2021-01-02 | USA | 1,115 | Community | NA | 52.6 | 4.4 | - | - | - | 14.2 | - | - | - | 81.3 | - | - | - | 0.1 | fair |
| Nezhadmoghadam & Tamez-Peña (2021) | Nezhadmoghadam | 2021-01-04 | Mexico | 33,325 | Hospital | NA | - | 10.2 | - | - | - | - | - | - | - | - | - | - | - | 89.8 | poor |
| Covid-19 in pregnancy et al. (2021) | Vousden | 2021-01-05 | UK | 1,148 | Community and Hospital | NA | 100.0 | 8.6 | - | - | - | - | - | - | - | - | - | - | - | 91.4 | poor |
| Boyd & Martin-Loeches (2021) | Boyd | 2021-01-07 | Ireland | 38 | Hospital | NA | 26.3 | - | - | - | - | - | - | - | 5.3 | - | - | - | - | 94.7 | poor |
| Paleiron et al. (2021) | Paleiron | 2021-01-09 | France | 1,688 | Community | 28 (23-35) | 13.0 | 42.1 | 12.9 | - | - | 19.9 | - | - | - | 25.1 | - | - | - | 0.0 | fair |
| Ader et al. (2021) | Ader | 2021-01-09 | Multiple | 583 | Hospital | 63 (54-71) | 28.3 | 3.1 | - | - | - | - | - | - | - | - | - | - | - | 96.9 | poor |
| Giannini et al. (2021) | Giannini | 2021-01-10 | Italy | 91 | Hospital | 74^ (61-87) | 45.0 | 23.1 | - | - | - | - | - | - | - | - | - | - | - | 76.9 | poor |
| Shade et al. (2021) | Shade | 2021-01-10 | USA | 3,779 | Community and Hospital | NA | 47.2 | 3.3 | - | - | - | 15.7 | - | - | - | - | - | - | - | 80.9 | poor |
| Park et al. (2021) | Park | 2021-01-11 | South Korea | 2,269 | Hospital | 55.5^ (35-75) | 64.1 | 4.1 | - | - | - | - | - | - | - | - | - | - | - | 95.9 | poor |
| Ferrari et al. (2021) | Ferrari | 2021-01-12 | Brazil | 198 | Community | 61 (19-91) | 65.0 | - | - | - | - | - | - | - | 20.7 | 79.3 | - | - | - | 0.0 | poor |
| Y. Zhang et al. (2021) | Zhang, Yang | 2021-01-12 | UK | 1,485 | Community and Hospital | 68.2^ (59-77) | 47.2 | 48.5 | - | - | - | 39.2 | - | - | - | 11.3 | - | - | - | 1.0 | fair |
| Ebrahimian et al. (2021) | Ebrahimian | 2021-01-13 | USA | 226 | Hospital | NA | - | - | - | - | - | - | - | - | 10.6 | - | - | - | 89.4 | 0.0 | poor |
| Vahidy et al. (2021) | Vahidy | 2021-01-13 | USA | 96,473 | Hospital | 51.2^ (32-69) | 59.6 | - | - | - | - | - | - | - | 26.2 | 73.8 | - | - | - | 0.0 | poor |
| Mendes et al. (2021) | Mendes | 2021-01-14 | Switzerland | 265 | Hospital | 85.9^ (79-92) | 57.0 | 5.7 | - | - | - | - | - | - | - | - | - | - | - | 94.3 | poor |
| Saurabh et al. (2021) | Saurabh | 2021-01-14 | India | 911 | Community | 43.1^ (23-62) | 35.2 | 7.0 | - | - | - | 0.6 | - | - | - | 79.1 | - | - | - | 0.0 | fair |
| Ayoubkhani et al. (2021) | Ayoubkhani | 2021-01-15 | UK | 47,780 | Hospital | NA | 45.1 | 8.4 | - | - | - | 40.9 | - | - | - | 42.5 | - | - | - | 8.2 | fair |
| Thakur et al. (2021) | Thakar | 2021-01-18 | India | 250 | Hospital | NA | 42.4 | - | - | - | - | - | - | - | 49.2 | - | - | - | 50.8 | 0.0 | poor |
| Zhong et al. (2020) | Zhong | 2021-01-18 | China | 91 | Hospital | 47.3^ (30-64) | 49.5 | - | - | - | - | - | - | - | 18.7 | - | - | - | - | 81.3 | poor |
| Cummins et al. (2021) | Cummins | 2021-01-20 | UK | 1,781 | Community and Hospital | NA | 44.8 | 10.2 | - | - | - | - | - | - | - | - | - | - | - | 89.8 | poor |
| Sun et al. (2021) | Sun | 2021-01-21 | USA | 323 | Community and Hospital | NA | 57.6 | - | - | - | - | - | - | - | 39.3 | - | - | - | 60.7 | 0.0 | poor |
| Lowe et al. (2021) | Lowe | 2021-01-25 | USA | 7,102 | Hospital | 50.3^ (NA) | 61.2 | 2.4 | - | - | - | 12.8 | - | - | - | 84.8 | - | - | - | 0.0 | fair |
| Caglar & Kacer (2021) | Caglar | 2021-01-25 | Turkey | 120 | Hospital | 57 (47-67) | 51.7 | - | - | - | - | - | - | - | 37.5 | - | - | - | 62.5 | 0.0 | poor |
| De Santi et al. (2021) | De, Santi | 2021-01-25 | Italy | 341 | Community | 47 (20-82) | 51.6 | 25.8 | - | - | - | - | - | - | - | - | - | - | - | 74.2 | poor |
| Quan et al. (2021) | Quan | 2021-01-27 | USA | 2,038 | Hospital | 64^ (47-80) | 50.4 | - | - | - | - | - | - | - | 39.7 | - | - | - | - | 60.3 | poor |
| Strangfeld et al. (2021) | Strangfeld | 2021-01-27 | Multiple | 3,729 | Community and Hospital | 57^ (41-72) | 68.0 | - | - | - | - | - | - | - | 20.8 | 64.0 | - | - | - | 15.2 | poor |
| Tardif et al. (2021) | Tardif | 2021-01-27 | Canada | 4,488 | Community and Hospital | NA | 53.9 | 9.6 | - | - | - | 33.6 | - | - | - | 56.8 | - | - | - | 0.0 | fair |
| Jafari et al. (2021) | Jafari | 2021-01-28 | USA | 1,979 | Hospital | 66 (57-74) | 32.0 | 12.1 | - | - | - | - | - | - | - | - | - | - | - | 87.9 | poor |
| Prats-Uribe, Tobed, et al. (2021) | Prats-Uribe | 2021-01-30 | Spain | 696 | Hospital | 63^ (52-73) | 30.9 | - | - | - | - | - | - | - | 16.1 | 74.6 | - | - | - | 9.3 | poor |
| Nuño et al. (2021) | Nuno | 2021-02-01 | USA | 4,730 | Hospital | 61 (46-73) | 43.6 | 10.1 | - | - | - | - | - | - | - | - | - | - | - | 89.8 | poor |
| Abajo et al. (2021) | de Abajo | 2021-02-03 | Spain | 625 | Hospital | NA | 39.4 | 4.6 | - | - | - | 29.3 | - | - | - | 39.2 | - | - | - | 26.9 | poor |
| Mora et al. (2021) | Mora | 2021-02-03 | USA | 1,058 | Community | 39.7^ (27-52) | 52.5 | 4.5 | - | - | - | 14.6 | - | - | - | 80.8 | - | - | - | 0.1 | fair |
| Molenaar et al. (2021) | Molenaar | 2021-02-03 | USA | 696 | Community and Hospital | 33.1^ (NA) | 100.0 | 4.5 | - | - | - | - | - | - | - | - | - | - | - | 95.5 | poor |
| Leister et al. (2021) | Leister | 2021-02-03 | Austria | 3,301 | Community and Hospital | 43.6^ (33-54) | 68.0 | 23.3 | - | - | - | - | - | - | - | - | - | - | - | 76.7 | poor |
| Didikoglu et al. (2021) | Didikoglu | 2021-02-04 | UK | 384,816 | Community and Hospital | 68.3^ (60-76) | 54.9 | 9.8 | - | - | - | 35.2 | - | - | - | 55.0 | - | - | - | 0.0 | fair |
| Estiri et al. (2021) | Estiri | 2021-02-04 | USA | 16,709 | Hospital | NA | 57.2 | - | - | - | - | - | - | - | 8.6 | - | - | - | - | 91.4 | poor |
| Tavakol et al. (2021) | Tavakol | 2021-02-04 | Iran | 206 | Community and Hospital | 40.9^ (29-52) | 57.8 | - | - | - | - | - | - | - | 12.6 | - | - | - | 87.4 | 0.0 | poor |
| Cai et al. (2021) | Cai, Yang | 2021-02-05 | China | 455 | Hospital | NA | 52.6 | 7.5 | - | - | - | - | - | - | - | - | - | - | - | 92.5 | poor |
| Lohia et al. (2021) | Lohia | 2021-02-05 | USA | 1,871 | Hospital | 64.1^ (48-80) | 48.4 | - | - | - | - | - | - | - | 37.6 | - | - | - | - | 62.4 | poor |
| Vila-Corcoles et al. (2021) | Vila-Corcoles, Satue-Gracia, Vila-Rovira | 2021-02-05 | Spain | 79,083 | Community | 65.8^ (54-77) | 52.4 | 16.1 | - | - | - | - | - | - | - | - | - | - | - | 83.9 | poor |
| Gégout petit et al. (2021) | Gegout Petit | 2021-02-12 | France | 2,006 | Community | NA | 55.0 | 16.8 | - | - | - | - | - | - | - | - | - | - | 78.9 | 4.2 | poor |
| Q. Zhang et al. (2021) | Zhang, Wang | 2021-02-13 | China | 172 | Hospital | 47.9^ (29-66) | 46.5 | 7.0 | - | - | - | 1.2 | - | - | 91.9 | - | - | - | - | 0.0 | poor |
| Dambha-Miller et al. (2021) | Dambha, Miller | 2021-02-19 | UK | 5,451 | Community and Hospital | 59^ (37-80) | 100.0 | 8.9 | - | - | - | 49.8 | - | - | - | 39.0 | - | - | - | 2.3 | fair |
| Badr et al. (2021a) | Ibrahim, Badr | 2021-02-19 | Saudi Arabia | 159 | Hospital | NA | 30.0 | - | - | - | - | - | - | - | 38.4 | - | - | - | - | 61.6 | poor |
| Badr et al. (2021b) | Ibrahim, Badr | 2021-02-19 | Saudi Arabia | 159 | Hospital | NA | 30.0 | - | - | - | - | - | - | - | 38.4 | - | - | - | - | 61.6 | poor |
| Hoertel et al. (2021) | Hoertel, A | 2021-02-20 | France | 545 | Community and Hospital | NA | 46.0 | 21.7 | - | - | - | - | - | - | - | - | - | - | - | 78.3 | poor |
| Lombardi et al. (2021) | Lombardi | 2021-02-22 | Italy | 4,055 | Community | 44.8^ (NA) | 69.6 | 20.8 | - | - | - | 13.6 | - | - | - | 61.5 | - | - | - | 4.1 | fair |
| Gharebaghi et al. (2021) | Gharebaghi | 2021-02-24 | Iran | 215 | Hospital | 50.9^ (33-68) | 42.3 | 20.5 | - | - | - | - | - | - | - | - | - | - | - | 79.5 | poor |
| Shields et al. (2021) | Shields | 2021-02-26 | UK | 1,507 | Community | 37 (29-47) | 75.4 | 10.4 | - | - | - | 16.6 | - | - | - | 73.0 | - | - | - | 0.0 | fair |
| Voruz et al. (2021) | Voruz | 2021-02-26 | Switzerland | 45 | Community and Hospital | NA | 42.0 | - | - | - | - | - | - | - | 6.7 | - | - | - | 93.3 | 0.0 | poor |
| The OpenSAFELY Collaborative et al. (2021) | Williamson, Tazare | 2021-03-01 | UK | 11,972,947 | Community | NA | 52.1 | 18.8 | - | - | - | 32.7 | - | - | - | 46.3 | - | - | - | 2.1 | good |
| González, Vielot, et al. (2021) | Gonzalez, Vielot | 2021-03-01 | Nicaragua | 1,351 | Community | NA | 59.0 | - | - | - | - | - | - | - | 7.6 | 50.3 | - | - | - | 42.1 | poor |
| Lucar et al. (2021) | Lucar | 2021-03-01 | USA | 100 | Hospital | 59 (44-70) | 53.0 | - | - | - | - | - | - | - | 22.0 | - | - | - | - | 78.0 | poor |
| Drozd et al. (2021) | Drozd | 2021-03-01 | UK | 493,295 | Community | NA | 54.5 | 10.6 | - | - | - | 34.7 | - | - | - | 54.8 | - | - | - | 0.0 | fair |
| Printza et al. (2021) | Printza | 2021-03-02 | Greece | 150 | Hospital | 51.6^ (34-68) | 38.0 | 14.0 | - | - | - | - | - | - | - | - | - | - | - | 86.0 | poor |
| Dashti et al. (2021) | Dashti | 2021-03-02 | USA | 12,347 | Hospital | 47 (32-62) | 53.3 | 4.6 | - | - | - | 15.9 | - | - | - | 57.1 | - | - | - | 22.4 | poor |
| Nielsen et al. (2021) | Nielsen | 2021-03-03 | Denmark | 840 | Community | NA | 84.0 | 4.6 | - | - | - | 31.4 | - | - | - | 63.9 | - | - | - | 0.0 | fair |
| Peng et al. (2021) | Peng, Lei | 2021-03-03 | China | 622 | Hospital | NA | 48.9 | 10.0 | - | - | - | - | - | - | - | - | - | - | - | 90.0 | poor |
| Dayem Ullah et al. (2021) | Dayem, Ullah | 2021-03-04 | UK | 15,440 | Community | 57.2 (44.9-69.4) | 56.2 | 21.2 | - | - | - | 33.8 | - | - | - | 42.2 | - | - | - | 2.8 | fair |
| Velasco-Rodríguez et al. (2021) | Velasco, Rodriguez | 2021-03-04 | Spain | 2,070 | Hospital | 67 (54-79) | 42.7 | 4.1 | - | - | - | - | - | - | - | - | - | - | - | 0.7 | poor |
| Action to beat coronavirus/Action pour battre le coronavirus (Ab-C) Study Investigators & Jha (2021) | Jha | 2021-03-05 | Canada | 8,967 | Community | NA | 57.0 | - | - | - | - | - | - | - | 46.7 | 51.9 | - | - | - | 1.3 | poor |
| Guzmán et al. (2021) | Macias, Guzman | 2021-03-08 | Mexico | 196 | Hospital | 58.1^ (42-73) | 62.0 | - | - | - | - | - | - | - | 36.2 | - | - | - | - | 63.8 | poor |
| García-Abellán et al. (2021) | Garcia, Abellan | 2021-03-08 | Spain | 146 | Hospital | 64 (54-76) | 39.7 | 8.2 | - | - | - | - | - | - | - | - | - | - | - | 91.8 | poor |
| Martin-Vicente et al. (2021) | Martin, Vicente | 2021-03-08 | Spain | 92 | Hospital | 66 (50-71.5) | 34.8 | 5.4 | - | - | - | - | - | - | - | - | - | - | - | 94.6 | poor |
| Rogier et al. (2021) | Rogier | 2021-03-08 | France | 374 | Hospital | NA | 48.4 | 9.6 | - | - | - | - | - | - | - | - | - | - | - | 90.4 | poor |
| Greenbaum et al. (2021) | Greenbaum | 2021-03-10 | USA | 44 | Hospital | 60 (37-84) | 43.2 | 4.5 | - | - | - | 20.5 | - | - | - | 75.0 | - | - | - | 0.0 | fair |
| Grint et al. (2021) | Grint | 2021-03-10 | UK | 184,786 | Community and Hospital | 38 (24-52) | 53.1 | 10.5 | - | - | - | 27.0 | - | - | - | 47.3 | - | - | - | 15.2 | good |
| Kline et al. (2021) | Kline | 2021-03-10 | USA | 19,850 | Hospital | NA | 52.5 | 17.9 | - | - | - | - | - | - | - | - | - | - | - | 82.1 | poor |
| Hausfater et al. (2021) | Hausfater | 2021-03-12 | France | 1,062 | Community | 33 (28-42) | 71.4 | 17.8 | - | - | - | - | - | - | - | - | - | - | 48.5 | 33.7 | poor |
| Daugherty et al. (2021) | Daugherty | 2021-03-12 | USA | 266,586 | Community and Hospital | 41.7^ (27-55) | 52.4 | 3.0 | - | - | - | - | - | - | - | - | - | - | - | 97.0 | poor |
| Vanegas-Cedillo et al. (2021) | Vanegas, Cedillo | 2021-03-14 | Mexico | 551 | Community and Hospital | NA | 35.6 | 4.9 | - | - | - | - | - | - | - | - | - | - | - | 95.1 | poor |
| Amanat et al. (2021) | Amanat | 2021-03-16 | Iran | 873 | Hospital | 60.7^ (42-78) | 36.3 | 15.7 | - | - | - | - | - | - | - | - | - | - | - | 84.3 | poor |
| Yamei Zheng et al. (2021) | Zheng, Gao, Wu | 2021-03-19 | China | 70 | Hospital | 51.2^ (37-64) | 41.4 | 7.1 | - | - | - | - | - | - | - | - | - | - | - | 92.9 | poor |
| Melotti et al. (2021) | Melotti | 2021-03-20 | Italy | 2,244 | Community | NA | 51.0 | 14.5 | - | - | - | 15.1 | - | - | - | 70.5 | - | - | - | 0.0 | fair |
| HPG23 Covid-19 Study Group et al. (2021) | Raimondi | 2021-03-20 | Italy | 431 | Hospital | 67.6^ (54-80) | 27.6 | 4.2 | - | - | - | 22.0 | - | - | - | 47.8 | - | - | - | 26.0 | poor |
| Martinez-Lacalzada, Viteri-Noël, et al. (2020) | Martinez-Lacalzada | 2021-03-21 | Spain | 10,433 | Hospital | NA | 56.5 | 5.2 | - | - | - | 23.8 | - | - | - | 66.1 | - | - | - | 5.0 | fair |
| Martinez-Lacalzada, Adrián Viteri-Noël, et al. (2020) | Martinez-Lacalzada | 2021-03-21 | Spain | 10,433 | Hospital | NA | 56.5 | 5.2 | - | - | - | 23.8 | - | - | - | 66.1 | - | - | - | 5.0 | fair |
| Q. Wang et al. (2021) | Wang, Codd | 2021-03-22 | UK | 6,775 | Community and Hospital | NA | 52.0 | 11.0 | - | - | - | 35.6 | - | - | - | 53.0 | - | - | - | 0.3 | fair |
| Rachmawati et al. (2021a) | Rachmawati | 2021-03-23 | Indonesia | 490 | Hospital | NA | 53.1 | 17.1 | - | - | - | 13.1 | - | - | - | 69.8 | - | - | - | 0.0 | fair |
| Rachmawati et al. (2021b) | Rachmawati | 2021-03-23 | Indonesia | 490 | Hospital | NA | 53.1 | 17.1 | - | - | - | 13.1 | - | - | - | 69.8 | - | - | - | 0.0 | fair |
| Fernandez-Fuertes et al. (2021) | Fernandez, Fuertes | 2021-03-24 | Spain | 710 | Community | 52 (43-57) | 19.3 | 100.0 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
| Menges et al. (2021) | Menges | 2021-03-24 | Switzerland | 431 | Community | 47 (33-58) | 50.0 | 14.2 | - | - | - | 28.3 | - | - | - | 56.8 | - | - | - | 0.7 | fair |
| Dev et al. (2021) | Dev | 2021-03-24 | India | 506 | Community | 32^ (23-41) | 44.0 | 16.0 | - | - | - | - | - | - | - | - | - | - | - | 84.0 | poor |
| PHOSP-COVID Collaborative Group et al. (2021) | P-HOSP-COVID Collaborative | 2021-03-25 | UK | 1,077 | Community and Hospital | 58^ (45-71) | 35.7 | 1.5 | - | - | - | 34.4 | - | - | - | 46.9 | - | - | - | 17.3 | fair |
| Asem et al. (2021) | Asem | 2021-03-25 | Egypt | 8,162 | Quarantine Centre | NA | 45.5 | 16.6 | - | - | - | - | - | - | - | - | - | - | - | 83.4 | poor |
| S. F. Lee et al. (2021) | Lee, Niksic | 2021-03-25 | UK | 89 | Community | 74 (68-78) | 47.0 | 13.5 | - | - | - | 48.3 | - | - | - | 37.1 | - | - | - | 1.1 | fair |
| Avouac et al. (2021) | Avouac | 2021-03-25 | France | 1,090 | Hospital | NA | 67.0 | 9.7 | - | - | - | - | - | - | - | - | - | - | 90.3 | 0.0 | poor |
| (**schaad\_point?**)–care\_2021 | Schaad | 2021-03-26 | Switzerland | 134 | Community and Hospital | 35 (29-46) | 63.0 | 29.1 | - | - | - | - | - | - | - | - | - | - | - | 70.9 | poor |
| Mok et al. (2021) | Mok | 2021-03-26 | USA | 211 | Hospital | 70.4^ (57-83) | 43.6 | - | - | - | - | - | - | - | 37.0 | - | - | - | - | 63.0 | poor |
| Faverio et al. (2021) | Faverio | 2021-03-30 | Italy | 312 | Community and Hospital | NA | 26.6 | 4.8 | - | - | - | 20.8 | - | - | - | 58.0 | - | - | - | 16.4 | fair |
| Bell et al. (2021) | Bell | 2021-03-31 | USA | 303 | Community | 43.6 (27-60) | 70.0 | - | - | 13.2 | - | - | - | - | - | - | - | - | - | 86.8 | poor |
| Gil et al. (2021) | Gil | 2021-03-31 | Brazil | 186 | Hospital | NA | 93.0 | 24.7 | - | - | - | - | - | - | - | - | - | - | 75.3 | 0.0 | poor |
| Galluzzi et al. (2021) | Galluzzi | 2021-04-01 | Italy | 376 | Community and Hospital | 60.8^ (48-73) | 37.0 | 2.1 | - | - | - | 17.3 | - | - | - | 77.7 | - | - | - | 2.9 | fair |
| Wagner et al. (2021) | Wagner | 2021-04-04 | Germany | 4,203 | Community | 52 (35-64) | 51.7 | 20.3 | - | - | - | 24.5 | - | - | - | 54.7 | - | - | - | 0.6 | good |
| Mady et al. (2021) | Mady | 2021-04-07 | Saudi Arabia | 415 | Hospital | NA | 31.8 | - | - | - | - | - | - | - | 34.0 | - | - | - | - | 66.0 | poor |
| Rubina et al. (2021) | Rubina | 2021-04-07 | Russia | 52 | Hospital | NA | 46.0 | 3.8 | - | - | - | - | - | - | - | - | - | - | - | 17.3 | poor |
| Scully et al. (2021) | Scully | 2021-04-07 | USA | 2,608 | Hospital | NA | 48.7 | 6.0 | - | - | - | 20.7 | - | - | - | 62.9 | - | - | - | 10.3 | fair |
| Manohar et al. (2021) | Manohar | 2021-04-07 | USA | 11,930 | Community and Hospital | 57.3^ (NA) | 50.7 | 2.0 | - | - | - | 11.6 | - | - | - | 11.8 | - | - | - | 74.6 | poor |
| Durstenfeld et al. (2021) | Durstenfeld | 2021-04-07 | USA | 21,528 | Hospital | NA | 45.9 | 6.5 | - | - | - | - | - | - | - | - | - | - | - | 93.5 | poor |
| R. A. Rashid et al. (2021) | Rashid, Zgair | 2021-04-07 | Iraq | 276 | Community | 29 (23-37) | 71.7 | 11.6 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
| J. Wang et al. (2021) | Wang, Su | 2021-04-08 | China | 185 | Hospital | 41 (32-57) | 48.6 | - | - | - | - | - | - | - | 10.8 | - | - | - | - | 89.2 | poor |
| Thomas et al. (2021) | Rhys, Thomas | 2021-04-09 | UK | 2,820 | Community | NA | - | - | - | 16.5 | - | - | - | - | - | - | - | - | - | 83.5 | poor |
| S. Li, Jun, et al. (2021) | Li, Jun | 2021-04-11 | USA | 2,627 | Hospital | NA | - | 5.2 | - | - | - | 25.7 | - | - | - | 46.6 | - | - | - | 22.5 | poor |
| Atergeleh et al. (2021) | Atergeleh | 2021-04-13 | Iran | 4,394 | Community | 61^ (NA) | 59.0 | - | - | - | - | - | - | - | 9.0 | 91.0 | - | - | - | 0.0 | poor |
| Boscolo-Rizzo et al. (2021) | Boscolo-Rizzo | 2021-04-13 | Italy | 304 | Community and Hospital | NA | 60.9 | 16.8 | - | - | - | 24.3 | - | - | - | 58.9 | - | - | - | 0.0 | fair |
| Chalkias et al. (2021) | Chalkias | 2021-04-15 | Multiple | 81 | Hospital | NA | 65.0 | - | - | - | - | - | - | - | 30.9 | 69.1 | - | - | - | 0.0 | poor |
| Byttebier et al. (2021) | Byttebier | 2021-04-15 | Belgium | 959 | Hospital | 73 (0-98) | 45.5 | - | - | - | - | - | - | - | 14.9 | - | - | - | - | 85.1 | poor |
| Husain et al. (2021) | Husain | 2021-04-19 | USA | 2,892 | Community and Hospital | NA | 40.7 | 4.2 | - | - | - | 16.8 | - | - | - | 68.3 | - | - | - | 10.8 | fair |
| Reese et al. (2021) | Reese | 2021-04-20 | USA | 24,788 | Community and Hospital | NA | 60.0 | - | - | - | - | - | - | - | 11.7 | 88.3 | - | - | - | 0.0 | poor |
| Desgranges et al. (2021) | Desgranges | 2021-04-20 | Switzerland | 507 | Community | NA | 62.7 | 14.4 | - | - | - | - | - | - | - | - | - | - | - | 85.6 | poor |
| S. Li, Sarangarajan, et al. (2021) | Li, Sarangarajan | 2021-04-22 | USA | 6,218 | Hospital | NA | 46.1 | 4.3 | - | - | - | 19.0 | - | - | - | 54.2 | - | - | - | 22.4 | poor |
| Tarifi et al. (2021) | Tarifi | 2021-04-22 | Jordan | 97 | Hospital | NA | 47.4 | - | - | - | - | - | - | - | 41.2 | 58.8 | - | - | - | 0.0 | poor |
| Zell et al. (2021) | Zell | 2021-04-23 | USA | 995 | Community | NA | 20.8 | 7.7 | 6.6 | - | - | 28.0 | - | - | - | 63.4 | - | - | - | 0.8 | fair |
| S. C. Lee et al. (2021) | Lee, Son | 2021-04-23 | South Korea | 4,167 | Community | NA | 65.3 | 6.7 | - | - | - | 14.8 | - | - | - | 78.4 | - | - | - | 0.0 | fair |
| Joubert et al. (2021) | Joubert, Andry | 2021-04-26 | Reunion | 1,013 | Community | NA | 60.0 | 16.0 | - | - | - | - | - | - | - | - | - | - | - | 84.0 | poor |
| Halabi et al. (2021) | El, Halabi | 2021-04-26 | USA | 5,859 | Community and Hospital | 60.5^ (43-78) | 44.0 | - | - | - | - | - | - | - | 21.9 | 53.6 | - | - | - | 24.5 | poor |
| Shiri et al. (2021) | Shiri | 2021-04-28 | Iran | 78 | Hospital | NA | 46.2 | 2.8 | - | - | - | - | - | - | - | - | - | - | - | 97.2 | poor |
| Gerhards et al. (2021) | Gerhards | 2021-04-28 | Germany | 61 | Community | 46.4^ (18-76) | 59.0 | 6.6 | - | - | - | - | - | - | - | - | - | - | - | 93.4 | poor |
| Radon et al. (2021) | Radon | 2021-04-29 | Germany | 4,433 | Community | NA | 52.0 | 16.4 | - | - | - | 27.8 | - | - | - | 50.0 | - | - | - | 5.7 | good |
| González, Zepeda, et al. (2021) | Gonzalez, Zepeda | 2021-04-29 | Nicaragua | 157 | Community | NA | 39.5 | 11.5 | - | - | - | - | - | - | - | - | - | - | - | 88.5 | poor |
| Ahmadi et al. (2021) | Ahmadi | 2021-05-01 | UK | 468,569 | Community | 56.5^ (48-64) | 54.6 | 10.2 | - | - | - | 30.8 | - | - | - | 35.3 | - | - | - | 23.6 | poor |
| Ravindra et al. (2021) | Ravindra | 2021-05-05 | India | 1,035 | Hospital | 46.7^ (29-63) | 36.8 | 0.2 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
| Mann et al. (2021) | Mann | 2021-05-06 | USA | 1,769 | Hospital | 64.4^ (47-80) | 47.0 | - | - | - | - | - | - | - | 36.5 | 56.7 | - | - | - | 6.8 | poor |
| Noh et al. (2021) | Noh | 2021-05-07 | South Korea | 265 | Hospital | 46 (30-60) | 52.1 | 10.2 | - | - | - | - | - | - | - | - | - | - | - | 89.8 | poor |
| Bhaskaran et al. (2021) | Bhaskaran | 2021-05-08 | UK | 17,456,515 | Community | NA | 50.1 | 17.0 | - | - | - | 32.9 | - | - | - | 50.1 | - | - | - | 0.0 | fair |
| Chetboun et al. (2021) | Chetboun | 2021-05-09 | Multiple | 1,461 | Hospital | 64 (56-73) | 26.8 | 5.7 | - | - | - | - | - | - | - | - | - | - | - | 94.3 | poor |
| Fogh et al. (2021) | Fogh | 2021-05-10 | Denmark | 3,236 | Community | NA | - | - | - | - | - | - | - | - | 26.2 | - | - | - | - | 73.8 | poor |
| Madakkatel et al. (2021) | Madakkatel | 2021-05-11 | UK | 421,111 | Community and Hospital | NA | 55.1 | 9.9 | - | - | - | 34.3 | - | - | - | 55.3 | - | - | - | 0.6 | fair |
| Bertuzzi et al. (2021) | Bertuzzi | 2021-05-11 | Italy | 557 | Hospital | 65^ (NA) | 32.7 | 9.0 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
| Röthlin Eriksen et al. (2021) | Rothlin, Eriksen | 2021-05-12 | Denmark | 819 | Community | NA | 43.8 | - | - | - | - | - | - | - | 71.7 | - | - | - | - | 28.3 | poor |
| Gornyk et al. (2021a) | Gornyk | 2021-05-13 | Germany | 13,045 | Community | 50.9^ (33-68) | 55.2 | 19.4 | - | - | - | 30.9 | - | - | - | 49.6 | - | - | - | 0.1 | good |
| Gornyk et al. (2021b) | Gornyk | 2021-05-13 | Germany | 13,045 | Community | 50.9^ (33-68) | 55.2 | 19.4 | - | - | - | 30.9 | - | - | - | 49.6 | - | - | - | 0.1 | good |
| Campbell et al. (2021) | Campbell | 2021-05-14 | Canada | 2,128 | Community | 48 (37-57) | 38.0 | 15.6 | - | - | - | 6.1 | - | - | - | 78.4 | - | - | - | 0.0 | fair |
| Marimuthu et al. (2021) | Marimuthu | 2021-05-17 | India | 854 | Hospital | 45.3^ (28-62) | 47.4 | - | - | - | - | - | - | - | 1.2 | - | - | - | - | 98.8 | poor |
| Bruce et al. (2021) | Bruce | 2021-05-17 | Multiple | 1,584 | Hospital | 74 (61.5-83) | 42.7 | 7.1 | - | - | - | 38.2 | - | - | - | 52.0 | - | - | - | 2.7 | fair |
| Bark et al. (2021) | Bark | 2021-05-18 | Canada | 157 | Community | 39^ (18-73) | 66.0 | - | - | 17.2 | - | - | - | - | - | - | - | - | - | 82.8 | poor |
| Jha et al. (2021) | Jha, Shrestha | 2021-05-18 | Nepal | 198 | Hospital | 40.8 (29.8-51.3) | 26.3 | 11.6 | - | - | - | 12.6 | - | - | - | 75.8 | - | - | - | 0.0 | fair |
| Lekoubou et al. (2021) | Lekoubou | 2021-05-18 | USA | 8,815 | Hospital | 51^ (33-69) | 57.0 | 2.9 | - | - | - | 6.6 | - | - | - | 18.1 | - | - | - | 72.3 | poor |
| Kahlert et al. (2021) | Kahlert | 2021-05-18 | Switzerland | 4,664 | Community | 38.3 (29.7-49.5) | 78.3 | 17.6 | - | - | - | 20.4 | - | - | - | 62.0 | - | - | - | 0.0 | fair |
| Hirschtick et al. (2021) | Hirschtick | 2021-05-19 | USA | 593 | Community | 51.5^ (35-67) | 56.0 | 6.2 | - | - | - | - | - | - | - | - | - | - | - | 93.8 | poor |
| Y. Li et al. (2021) | Li, Tong | 2021-05-19 | USA | 18,148 | Community | 47 (37-56) | 67.1 | 12.3 | - | - | - | - | - | - | - | - | - | - | - | 0.1 | poor |
| AlSafar et al. (2021) | Alsafar | 2021-05-19 | United Arab Emirates | 464 | Community and Hospital | 47^ (32-62) | 40.0 | 10.8 | - | - | - | - | - | - | - | - | - | - | 89.2 | 0.0 | poor |
| Wallis et al. (2021) | Wallis | 2021-05-21 | UK | 101 | Hospital | 53 (45-63) | 46.5 | - | - | - | - | - | - | - | 34.7 | - | - | - | - | 65.3 | poor |
| Ayhan et al. (2021) | Ayhan | 2021-05-21 | Turkey | 92 | Hospital | 67 (55-73) | 44.6 | 17.4 | - | - | - | - | - | - | - | - | - | - | 43.5 | 39.1 | poor |
| Nanda et al. (2021) | Nanda | 2021-05-24 | USA | 1,169 | Hospital | 28.6 (NA) | 50.7 | 12.8 | - | - | - | 14.9 | - | - | - | 72.3 | - | - | - | 0.0 | fair |
| Prats-Uribe, Xie, et al. (2021) | Prats-Uribe, Xie | 2021-05-25 | UK | 1,591 | Community and Hospital | NA | 47.5 | 12.1 | - | - | - | 39.5 | - | - | - | 48.5 | - | - | - | 0.0 | fair |
| Egede et al. (2021) | Egede | 2021-05-26 | USA | 30,976 | Community and Hospital | 52.8^ (33-71) | 60.0 | 13.9 | - | - | - | 32.3 | - | - | - | - | - | - | 53.8 | 0.0 | poor |
| Kleynhans et al. (2021) | Kleynhans | 2021-05-29 | South Africa | 350 | Community | NA | 65.0 | 10.3 | - | - | - | - | - | - | - | - | - | - | - | 35.4 | poor |
| Puebla Neira et al. (2021) | Puebla, Neira | 2021-06-01 | USA | 10,216 | Community and Hospital | 45.8^ (27-63) | 64.9 | 3.9 | - | - | - | 9.0 | - | - | - | 87.1 | - | - | - | 0.0 | fair |
| Lassen et al. (2021) | Hojbjerg, Lassen | 2021-06-01 | Denmark | 171 | Hospital | NA | 55.0 | 5.8 | - | - | - | 53.8 | - | - | - | 38.6 | - | - | - | 1.8 | fair |
| S. Chen et al. (2021) | Chen, Zheng | 2021-06-06 | China | 1,030 | Hospital | 55 (44-65) | 44.1 | - | - | - | - | - | - | - | 10.5 | 89.5 | - | - | - | 0.0 | poor |
| Fisher et al. (2021) | Fisher | 2021-06-09 | UK | 146 | Hospital | NA | 24.0 | - | - | - | - | - | - | - | 41.1 | - | - | - | - | 58.9 | poor |
| Ghani et al. (2021) | Ghani | 2021-06-09 | UK | 2,366 | Hospital | NA | - | - | - | - | - | - | - | - | 33.1 | - | - | - | - | 66.9 | poor |
| Andrade Barreto et al. (2021) | Andrade, Barreto | 2021-06-09 | Brazil | 602 | Community | 51.8^ (37-66) | 59.0 | - | - | - | - | - | - | - | 25.6 | - | - | - | - | 74.4 | poor |
| Aabakke et al. (2021) | Aabakke | 2021-06-10 | Denmark | 420 | Community | 29 (27-33) | 100.0 | 2.4 | - | - | - | - | - | - | - | - | - | - | - | 51.0 | poor |
| Yozgat et al. (2021) | Yozgat | 2021-06-10 | Turkey | 382 | Hospital | NA | 37.4 | 29.6 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
| Sandri et al. (2021) | Sandri | 2021-06-10 | Italy | 3,985 | Community | NA | 66.8 | 23.9 | - | - | - | - | - | - | - | - | - | - | - | 76.1 | poor |
| Jose et al. (2021) | Jose | 2021-06-10 | USA | 69,264 | Community and Hospital | NA | 62.1 | 8.8 | - | 1.5 | 0.7 | 25.8 | 0.9 | 1.3 | - | 60.3 | 0.3 | 0.3 | - | 0.0 | fair |
| Herzberg et al. (2021) | Herzberg | 2021-06-13 | Germany | 52 | Community | 39.7^ (27-52) | 75.0 | - | - | - | - | - | - | - | 19.2 | - | - | - | - | 80.8 | poor |
| Han et al. (2021) | Han, Peng | 2021-06-15 | China | 160 | Hospital | 62.3^ (51-73) | 42.8 | - | - | - | - | - | - | - | 16.9 | - | - | - | - | 83.1 | poor |
| Abdulamir et al. (2021) | Abdulamir | 2021-06-17 | Iraq | 150 | Hospital | 49.3^ (33-65) | 46.7 | 27.3 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
| L. Chauhan et al. (2021) | Chauhan | 2021-06-18 | USA | 376 | Hospital | 58.9^ (42-75) | 43.1 | 6.1 | - | - | - | - | - | - | - | - | - | - | - | 93.9 | poor |
| Barchuk et al. (2021) | Barchuk | 2021-06-21 | Russia | 962 | Community | NA | 62.8 | 20.3 | - | - | - | 27.8 | - | - | - | 48.5 | - | - | - | 3.4 | good |
| Patone et al. (2021) | Patone | 2021-06-22 | UK | 429,926 | Community and Hospital | 37.7^ (19-55) | 52.7 | 11.2 | - | - | - | 17.6 | - | - | - | 56.3 | - | - | - | 15.0 | fair |
| Mollan et al. (2021) | Mollan | 2021-06-25 | USA | 204 | Community | 40 (27-52) | 51.0 | - | - | 14.7 | - | - | 16.7 | - | - | - | 68.1 | - | - | 0.5 | fair |
| Sonnweber et al. (2021) | Sonnweber | 2021-06-25 | Austria | 108 | Hospital | 57^ (43-71) | 45.4 | 3.7 | - | - | - | 42.6 | - | - | - | - | - | - | - | 53.7 | poor |
| Nassar et al. (2021) | Nassar | 2021-06-25 | Egypt | 160 | Hospital | 60^ (46-74) | 32.5 | 10.6 | - | - | - | - | - | - | - | - | - | - | - | 89.4 | poor |
| Ali et al. (2021) | Ali, Hasan | 2021-06-25 | Bangladesh | 326 | Hospital | NA | 39.9 | 20.9 | - | - | - | - | - | - | - | - | - | - | 79.1 | 0.0 | poor |
| Demichev et al. (2021) | Demichev | 2021-06-26 | Multiple | 50 | Hospital | 62 (54-73) | 30.0 | 2.0 | - | - | - | 16.0 | - | - | - | 82.0 | - | - | - | 0.0 | fair |
| Mostafa et al. (2021) | Mostafa | 2021-06-28 | Egypt | 4,040 | Community | NA | 61.5 | 11.9 | - | - | - | 2.0 | - | - | - | 86.2 | - | - | - | 0.0 | fair |
| Tehrani et al. (2021a) | Tehrani | 2021-06-30 | USA | 8,222 | Hospital | NA | 44.0 | - | - | - | - | - | - | - | 6.3 | - | - | - | - | 93.7 | poor |
| Tehrani et al. (2021b) | Tehrani | 2021-06-30 | USA | 8,222 | Hospital | NA | 44.0 | - | - | - | - | - | - | - | 6.3 | - | - | - | - | 93.7 | poor |
| Amer et al. (2021) | Amer | 2021-07-01 | Multiple | 860 | Hospital | NA | 34.0 | 4.9 | 0.1 | - | - | 20.1 | - | - | - | - | - | - | - | 74.9 | poor |
| X. Wu et al. (2021) | Wu, Liu | 2021-07-01 | China | 83 | Hospital | 60 (52-66) | 43.0 | - | - | - | - | - | - | - | - | 100.0 | - | - | - | 0.0 | poor |
| N. K. Chauhan et al. (2021) | Chauhan, Shadrach | 2021-07-01 | India | 125 | Hospital | 49.9^ (32-67) | 25.6 | 20.0 | - | - | - | - | - | - | - | - | - | - | - | 80.0 | poor |
| Mendez-Dominguez et al. (2021) | Mendez, Dominguez | 2021-07-02 | Mexico | 7,064 | Community | NA | 100.0 | 1.9 | - | - | - | - | - | - | - | - | - | - | - | 98.1 | poor |
| The CONCOR-1 Study Group et al. (2021) | CONCOR-1 Study-group | 2021-07-03 | Canada | 921 | Hospital | 69 (58-79) | 41.9 | 2.7 | - | - | - | 31.7 | - | - | - | 52.4 | - | - | - | 13.1 | fair |
| Gebhard et al. (2021) | Gebhard | 2021-07-06 | Switzerland | 2,799 | Hospital | 43.6^ (27-60) | 45.9 | - | - | - | - | - | - | - | 27.6 | - | - | - | - | 72.4 | poor |
| Genecand et al. (2021) | Genecand | 2021-07-06 | Switzerland | 51,706 | Community | NA | 53.3 | 9.0 | - | - | - | - | - | - | - | - | - | - | - | 91.0 | poor |
| Qureshi et al. (2021) | Qureshi | 2021-07-06 | USA | 85,645 | Hospital | NA | 54.4 | 15.8 | - | - | - | - | - | - | - | - | - | - | - | 84.2 | poor |
| Y. I. Wan et al. (2021) | Wan, Apea | 2021-07-07 | UK | 5,533 | Hospital | NA | 46.8 | 13.3 | - | - | - | - | - | - | - | - | - | - | - | 86.7 | poor |
| Gaitán-Duarte et al. (2021) | Gaitan, Duarte | 2021-07-10 | Colombia | 633 | Hospital | NA | 32.4 | 16.4 | - | - | - | - | - | - | - | - | - | - | - | 83.6 | poor |
| Chuo et al. (2021) | Chuo | 2021-07-12 | USA | 138,792 | Community and Hospital | 44 (30-60) | 54.9 | 6.7 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
| Sholzberg et al. (2021) | Sholzberg | 2021-07-12 | Canada | 465 | Hospital | NA | 43.2 | 2.6 | - | - | - | - | - | - | - | - | - | - | - | 97.4 | poor |
| Riyahi et al. (2021) | Riyahi | 2021-07-13 | USA | 413 | Hospital | 60^ (44-76) | 44.3 | - | - | - | - | - | - | - | 12.8 | - | - | - | - | 87.2 | poor |
| International Severe Acute Respiratory and emerging Infections Consortium, Escher, et al. (2020) | Isaric, 11 | 2021-07-14 | Multiple | 442,643 | Hospital | 60 (NA) | 50.0 | 11.4 | - | - | - | - | - | - | - | - | - | - | - | 65.6 | poor |
| International Severe Acute Respiratory and emerging Infections Consortium, Hall, et al. (2020) | Isaric, 11 | 2021-07-14 | Multiple | 442,643 | Hospital | 60 (NA) | 50.0 | 11.4 | - | - | - | - | - | - | - | - | - | - | - | 65.6 | poor |
| Pritchard et al. (2020) | Isaric, 11 | 2021-07-14 | Multiple | 442,643 | Hospital | 60 (NA) | 50.0 | 11.4 | - | - | - | - | - | - | - | - | - | - | - | 65.6 | poor |
| ISARIC Clinical Characterisation Group et al. (2020) | Isaric, 11 | 2021-07-14 | Multiple | 442,643 | Hospital | 60 (NA) | 50.0 | 11.4 | - | - | - | - | - | - | - | - | - | - | - | 65.6 | poor |
| Aboueshia et al. (2021) | Aboueshia | 2021-07-15 | USA | 260 | Hospital | 58.6^ (18-93) | 52.3 | 21.5 | - | - | - | 8.8 | - | - | - | 60.4 | - | - | - | 9.2 | fair |
| Matli et al. (2021) | Matli | 2021-07-16 | Lebanon | 242 | Hospital | NA | 31.0 | 21.9 | - | - | - | - | - | - | - | - | - | - | - | 78.1 | poor |
| Alhamlan et al. (2021) | Alhamlan | 2021-07-16 | Saudi Arabia | 492 | Hospital | NA | 45.9 | 8.7 | - | - | - | - | - | - | - | - | - | - | - | 23.6 | poor |

### Smoking prevalence by country

Unadjusted smoking prevalence compared with overall estimates for national adult smoking prevalence split by country and study setting is presented in [Figure 2](#fig-2). Lower than expected current smoking prevalence was generally observed, especially in studies with hospitalised samples. Former smoking prevalence was more similar to expected prevalence when reported; however, study-based prevalence was typically higher than national estimates. National smoking prevalence estimates used for comparison are presented in [Supplementary table 3](#supplementary-t3).



*Figure 2.* Weighted mean prevalence of current (left panel) and former (right panel) smoking in included studies, split by country. The circles represent individual studies, with colour corresponding to study setting (i.e. hospital, community and hospital, community) and size corresponding to relative study sample size. For comparison, national current and former smoking prevalence are indicated by the red lines. Countries with three or more eligible studies are shown.

### SARS-CoV-2 testing by smoking status


Four studies provided data on access to SARS-CoV-2 diagnostic testing for those meeting local testing criteria by smoking status. In a cohort study of US military veterans aged 54-75 (C. Rentsch et al., 2020), current smokers were more likely to receive a test: 42.3% (1,603/3,789) of the sample were current smokers compared with 23.8% of all veterans aged 50+ years using any tobacco product between 2010-2015 (Odani, 2018). In the UK Biobank cohort (Niedzwiedz et al., 2020), a multivariable analysis showed former (RR = 1.29, 95% CI = 1.14-1.45, *p* < .001) and current (RR = 1.44, 95% CI = 1.20-1.71, *p* < .001) compared with never smokers to be more likely to receive a test. In an Australian rapid assessment screening clinic for COVID-19 (Trubiano et al., 2020), 9.4% (397/4,226) of the self-referred sample (subsequently assessed by a healthcare professional to decide on testing) were current smokers. Of these self-referrals, healthcare professionals decided that current compared with former or never smokers were less likely to require a test (RR = 0.93, 95% CI = 0.86-1.0, *p* = 0.045). In a further study using the UK Biobank cohort (Didikoglu et al., 2021), current (RR = 1.23, 95% CI = 1.19-1.26, *p* < 0.001) and former smokers (RR = 1.20, 95% CI = 1.18-1.23, *p* < 0.001) were more likely to receive a test compared with never smokers.

### SARS-CoV-2 infection by smoking status


108 studies provided data on SARS-CoV-2 infection for people meeting local testing criteria by smoking status (see [Table 2](#table-2)). Meta-analyses were performed for 6 ‘good’ and 33 ‘fair’ quality studies (see [Figure 3](#fig-3) and [4](#fig-4)). Current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.67, 95% Credible Interval (CrI) = 0.6-0.75, τ = 0.27). The six good quality studies each reported point estimates less than 1, although the CrI for two of the six studies crossed 1. The probability of current smokers being at reduced risk of infection compared with never smokers (RR ≤0.9) was >99%. Former compared with never smokers were at increased risk of testing positive, but data were inconclusive (RR = 0.99, 95% CrI = 0.94-1.05, τ = 0.12) and favoured there being no important association. The probability of former smokers being at increased risk of infection (RR ≥1.1) compared with never smokers was < 1%. Results were materially unchanged in sensitivity analyses.

#### *Table 2* SARS-CoV-2 infection by smoking status

|  | | SARS-CoV-2 negative | | | | | | | | SARS-CoV-2 positive | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author | Total population tested | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Current vaper (%) | Current vaper and smoker (%) | Not stated (%) | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Current vaper (%) | Current vaper and smoker (%) | Not stated (%) |
| Rentsch | 3,528 | 2974 (84.30%) | 1444 (48.55%) | 704 (23.67%) | - | 826 (27.77%) | - | - | - | 554 (15.70%) | 159 (28.70%) | 179 (32.31%) | - | 216 (38.99%) | - | - | - |
| Fontanet | 661 | 490 (74.13%) | 64 (13.06%) | - | - | 426 (86.94%) | - | - | - | 171 (25.87%) | 5 (2.92%) | - | - | 166 (97.08%) | - | - | - |
| Cho | 1,331 | 793 (59.58%) | 142 (17.91%) | 214 (26.99%) | - | 437 (55.11%) | - | - | - | 538 (40.42%) | 111 (20.63%) | 145 (26.95%) | - | 282 (52.42%) | - | - | - |
| Shah | 243 | 212 (87.24%) | 52 (24.53%) | 47 (22.17%) | - | 113 (53.30%) | - | - | - | 29 (11.93%) | 0 (0.00%) | 9 (31.03%) | - | 20 (68.97%) | - | - | - |
| Kolin | 1,474 | 805 (54.61%) | 141 (17.52%) | 307 (38.14%) | - | 354 (43.98%) | - | - | 3 (0.37%) | 669 (45.39%) | 72 (10.76%) | 285 (42.60%) | - | 303 (45.29%) | - | - | 9 (1.35%) |
| de Lusignan | 3,291 | 2740 (83.26%) | 366 (13.36%) | 1450 (52.92%) | - | 924 (33.72%) | - | - | - | 551 (16.74%) | 47 (8.53%) | 303 (54.99%) | - | 201 (36.48%) | - | - | - |
| Valenti | 789 | 689 (87.33%) | 197 (28.59%) | - | - | - | - | - | 492 (71.41%) | 40 (5.07%) | 7 (17.50%) | - | - | - | - | - | 33 (82.50%) |
| Parrotta | 76 | 39 (51.32%) | 1 (2.56%) | 10 (25.64%) | - | 27 (69.23%) | - | - | 1 (2.56%) | 37 (48.68%) | 1 (2.70%) | 10 (27.03%) | - | 25 (67.57%) | - | - | 1 (2.70%) |
| Berumen | 102,875 | 71353 (69.36%) | - | - | 7173 (10.05%) | 64180 (89.95%) | - | - | - | 31522 (30.64%) | - | - | 2748 (8.72%) | 28774 (91.28%) | - | - | - |
| Israel | 24,906 | 20755 (83.33%) | 3783 (18.23%) | 2671 (12.87%) | - | 14301 (68.90%) | - | - | - | 4151 (16.67%) | 406 (9.78%) | 483 (11.64%) | - | 3262 (78.58%) | - | - | - |
| del Valle | 1,108 | 143 (12.91%) | 27 (18.88%) | 53 (37.06%) | - | - | - | - | 63 (44.06%) | 965 (87.09%) | 55 (5.70%) | 293 (30.36%) | - | - | - | - | 617 (63.94%) |
| Romao | 34 | 20 (58.82%) | - | - | 5 (25.00%) | - | - | - | 15 (75.00%) | 14 (41.18%) | - | - | 4 (28.57%) | - | - | - | 10 (71.43%) |
| Ramlall | 11,116 | 4723 (42.49%) | - | - | - | - | - | - | - | 6393 (57.51%) | - | - | 1643.001 (25.70%) | 4749.999 (74.30%) | - | - | - |
| Sharma | 501 | 267 (53.29%) | - | - | 1 (0.37%) | - | - | - | 266 (99.63%) | 234 (46.71%) | - | - | 20 (8.55%) | - | - | - | 214 (91.45%) |
| Eugen-Olsen | 407 | 290 (71.25%) | 76 (26.21%) | 104 (35.86%) | - | 102 (35.17%) | - | - | - | 117 (28.75%) | 8 (6.84%) | 46 (39.32%) | - | 59 (50.43%) | - | - | - |
| Raisi-Estabragh | 4,510 | 3184 (70.60%) | - | - | 1653 (51.92%) | - | - | - | 1531 (48.08%) | 1326 (29.40%) | - | - | 683 (51.51%) | - | - | - | 643 (48.49%) |
| Houlihan | 177 | 97 (54.80%) | 14 (14.43%) | 14 (14.43%) | - | 69 (71.13%) | - | - | - | 80 (45.20%) | 7 (8.75%) | 19 (23.75%) | - | 54 (67.50%) | - | - | - |
| McQueenie | 428,199 | 424355 (99.10%) | - | - | 189299 (44.61%) | 235056 (55.39%) | - | - | - | 1311 (0.31%) | - | - | 669 (51.03%) | 642 (48.97%) | - | - | - |
| Woolford | 4,474 | 3161 (70.65%) | 441 (13.95%) | 1194 (37.77%) | - | 1526 (48.28%) | - | - | - | 1313 (29.35%) | 145 (11.04%) | 525 (39.98%) | - | 643 (48.97%) | - | - | - |
| Lan | 104 | 83 (79.81%) | - | - | 24 (28.92%) | - | - | - | 59 (71.08%) | 21 (20.19%) | - | - | 1 (4.76%) | - | - | - | 20 (95.24%) |
| Hernandez, Garduno | 32,583 | 20279 (62.24%) | - | - | 2399 (11.83%) | 17861 (88.08%) | - | - | - | 12304 (37.76%) | - | - | 1191 (9.68%) | 11083 (90.08%) | - | - | - |
| Govind | 6,215 | 6207 (99.87%) | 4104 (66.12%) | 1669 (26.89%) | - | 342 (5.51%) | - | - | - | 102 (1.64%) | 78 (76.47%) | 20 (19.61%) | - | 2 (1.96%) | - | - | - |
| Gu | 4,699 | 3815 (81.19%) | 360 (9.44%) | 1142 (29.93%) | - | 2313 (60.63%) | - | - | - | 884 (18.81%) | 40 (4.52%) | 264 (29.86%) | - | 580 (65.61%) | - | - | - |
| Kibler | 702 | 680 (96.87%) | 25 (3.68%) | - | - | - | - | - | 655 (96.32%) | 22 (3.13%) | 1 (4.55%) | - | - | - | - | - | 21 (95.45%) |
| Auvinen | 61 | 33 (54.10%) | 10 (30.30%) | 8 (24.24%) | - | 15 (45.45%) | - | - | - | 28 (45.90%) | 1 (3.57%) | 9 (32.14%) | - | 18 (64.29%) | - | - | - |
| Antonio-Villa | 34,263 | 23338 (68.11%) | 2293 (9.83%) | - | - | - | - | - | 21045 (90.17%) | 10925 (31.89%) | 1023 (9.36%) | - | - | - | - | - | 9902 (90.64%) |
| Merzon | 7,807 | 7025 (89.98%) | - | - | 1136 (16.17%) | - | - | - | 5889 (83.83%) | 782 (10.02%) | - | - | 127 (16.24%) | - | - | - | 655 (83.76%) |
| Trubiano | 2,935 | 2827 (96.32%) | - | - | 256 (9.06%) | - | - | - | 2586 (91.48%) | 108 (3.68%) | - | - | 3 (2.78%) | - | - | - | 105 (97.22%) |
| Shi, Resurreccion | 1,521 | 1265 (83.17%) | - | - | 681 (53.83%) | - | - | - | 584 (46.17%) | 256 (16.83%) | - | - | 154 (60.16%) | - | - | - | 102 (39.84%) |
| Riley | 120,620 | 120461 (99.87%) | 2594 (2.15%) | - | - | 19914 (16.53%) | - | - | 97953 (81.32%) | 159 (0.13%) | 3 (1.89%) | - | - | 17 (10.69%) | - | - | 139 (87.42%) |
| Alizadehsani | 319 | 196 (61.44%) | - | - | - | - | - | - | 196 (100.00%) | 123 (38.56%) | - | - | 1 (0.81%) | - | - | - | 122 (99.19%) |
| Merkely | 10,474 | 10336 (98.68%) | 2904 (28.10%) | 2107 (20.39%) | - | 5310 (51.37%) | - | - | 15 (0.15%) | 70 (0.67%) | 16 (22.86%) | 15 (21.43%) | - | 38 (54.29%) | - | - | 1 (1.43%) |
| Edwards | 209 | 118 (56.46%) | - | - | 31 (26.27%) | - | - | - | 87 (73.73%) | 91 (43.54%) | - | - | 8 (8.79%) | - | - | - | 83 (91.21%) |
| Reiter | 235 | 175 (74.47%) | - | - | 93 (53.14%) | 82 (46.86%) | - | - | - | 60 (25.53%) | - | - | 13 (21.67%) | 47 (78.33%) | - | - | - |
| Izquierdo | 71,192 | NA ( NA%) | - | - | - | - | - | - | - | 1006 (1.41%) | 111 (11.03%) | - | - | - | - | - | 895 (88.97%) |
| Ward | 99,908 | 94416 (94.50%) | 10202 (10.81%) | - | - | - | - | - | 84214 (89.19%) | 5492 (5.50%) | 433 (7.88%) | - | - | - | - | - | 5059 (92.12%) |
| Ebinger | 6,062 | 5850 (96.50%) | 99 (1.69%) | - | - | - | 83 (1.42%) | - | 5668 (96.89%) | 212 (3.50%) | 3 (1.42%) | - | - | - | 4 (1.89%) | - | 205 (96.70%) |
| Salerno | 15,920 | 14753 (92.67%) | - | - | 5517 (37.40%) | 8278 (56.11%) | - | - | 958 (6.49%) | 1167 (7.33%) | - | - | 339 (29.05%) | 626 (53.64%) | - | - | 202 (17.31%) |
| Iversen | 28,792 | 27629 (95.96%) | 4430 (16.03%) | 1799 (6.51%) | - | 21217 (76.79%) | - | - | 246 (0.89%) | 1163 (4.04%) | 177 (15.22%) | 78 (6.71%) | - | 898 (77.21%) | - | - | 10 (0.86%) |
| Hippisley-Cox | 8,275,949 | NA ( NA%) | - | - | - | - | - | - | - | 19486 (0.24%) | 1354 (6.95%) | 5715 (29.33%) | - | 12036 (61.77%) | - | - | 381 (1.96%) |
| Fillmore | 22,914 | 21120 (92.17%) | 8137 (38.53%) | 8416 (39.85%) | - | 3227 (15.28%) | - | - | 1340 (6.34%) | 1794 (7.83%) | 452 (25.20%) | 899 (50.11%) | - | 322 (17.95%) | - | - | 121 (6.74%) |
| Alkurt | 119 | NA ( NA%) | - | - | - | - | - | - | - | 119 (100.00%) | 14 (11.76%) | - | - | - | - | - | 105 (88.24%) |
| Petrilli | 10,620 | 5341 (50.29%) | 541 (10.13%) | 816 (15.28%) | - | 3454 (64.67%) | - | - | 530 (9.92%) | 5279 (49.71%) | 288 (5.46%) | 902 (17.09%) | - | 3268 (61.91%) | - | - | 821 (15.55%) |
| Bello-Chavolla | 150,200 | 98567 (65.62%) | - | - | 9624 (9.76%) | - | - | - | 88943 (90.24%) | 51633 (34.38%) | - | - | 4366 (8.46%) | - | - | - | 47267 (91.54%) |
| Ariza | 351 | 322 (91.74%) | 21 (6.52%) | - | - | - | - | - | 301 (93.48%) | 29 (8.26%) | 3 (10.34%) | - | - | - | - | - | 26 (89.66%) |
| Carrat | 14,393 | 13426 (93.28%) | 1652 (12.30%) | 5620 (41.86%) | - | 6154 (45.84%) | - | - | - | 967 (6.72%) | 98 (10.13%) | 353 (36.50%) | - | 516 (53.36%) | - | - | - |
| Meini | 461 | 243 (52.71%) | 39 (16.05%) | 66 (27.16%) | - | 138 (56.79%) | - | - | - | 218 (47.29%) | 9 (4.13%) | 53 (24.31%) | - | 156 (71.56%) | - | - | - |
| Favara | 434 | 354 (81.57%) | 28 (7.91%) | - | - | - | - | - | 326 (92.09%) | 80 (18.43%) | 9 (11.25%) | - | - | - | - | - | 71 (88.75%) |
| Erber | 4,554 | 4446 (97.63%) | - | - | 806 (18.13%) | - | - | - | 3640 (81.87%) | 108 (2.37%) | - | - | 11 (10.19%) | - | - | - | 97 (89.81%) |
| Roederer | 815 | 390 (47.85%) | 175 (44.87%) | 32 (8.21%) | - | 183 (46.92%) | - | - | - | 425 (52.15%) | 127 (29.88%) | 40 (9.41%) | - | 258 (60.71%) | - | - | - |
| Makaronidis | 567 | 127 (22.40%) | 16 (12.60%) | - | - | - | - | - | 111 (87.40%) | 440 (77.60%) | 37 (8.41%) | - | - | - | - | - | 403 (91.59%) |
| Ioannou | 88,747 | 78616 (88.58%) | 17138 (21.80%) | 29245 (37.20%) | - | 22327 (28.40%) | - | - | 9906 (12.60%) | 10131 (11.42%) | 1135 (11.20%) | 4073 (40.20%) | - | 3647 (36.00%) | - | - | 1277 (12.60%) |
| Perico | 423 | 260 (61.47%) | 69 (26.54%) | 35 (13.46%) | - | 156 (60.00%) | - | - | - | 163 (38.53%) | 23 (14.11%) | 41 (25.15%) | - | 99 (60.74%) | - | - | - |
| Vila-Corcoles | 2,324 | 1944 (83.65%) | - | - | - | - | - | - | - | 380 (16.35%) | - | - | 27 (7.11%) | - | - | - | 353 (92.89%) |
| O'Reilly | 1,334 | 1284 (96.25%) | - | - | 376 (29.28%) | - | - | - | 908 (70.72%) | 50 (3.75%) | - | - | 4 (8.00%) | - | - | - | 46 (92.00%) |
| Ghinai | 1,435 | 1004 (69.97%) | 412 (41.04%) | 155 (15.44%) | - | 341 (33.96%) | - | - | 96 (9.56%) | 431 (30.03%) | 113 (26.22%) | 96 (22.27%) | - | 135 (31.32%) | - | - | 87 (20.19%) |
| Kortela | 2,993 | 2419 (80.82%) | 300 (12.40%) | 340 (14.06%) | - | 636 (26.29%) | - | - | 1143 (47.25%) | 574 (19.18%) | 26 (4.53%) | 80 (13.94%) | - | 232 (40.42%) | - | - | 236 (41.11%) |
| Gallichotte | 239 | 190 (79.50%) | 40 (21.05%) | 28 (14.74%) | - | 110 (57.89%) | 12 (6.32%) | - | - | 49 (20.50%) | 8 (16.33%) | 12 (24.49%) | - | 27 (55.10%) | 2 (4.08%) | - | - |
| Saeed | 173 | 69 (39.88%) | 2 (2.90%) | - | - | - | - | - | 67 (97.10%) | 104 (60.12%) | 9 (8.65%) | - | - | - | - | - | 95 (91.35%) |
| Woolcott | 1,636,050 | 878840 (53.72%) | - | - | 85816 (9.76%) | - | - | - | 793024 (90.24%) | 757210 (46.28%) | - | - | 57451 (7.59%) | - | - | - | 699759 (92.41%) |
| Barasa | 394 | 277 (70.30%) | 49 (17.69%) | 105 (37.91%) | - | 110 (39.71%) | - | - | 13 (4.69%) | 117 (29.70%) | 9 (7.69%) | 37 (31.62%) | - | 54 (46.15%) | - | - | 17 (14.53%) |
| Paleiron | 1,688 | 409 (24.23%) | 236 (57.70%) | 77 (18.83%) | - | 96 (23.47%) | - | - | - | 1279 (75.77%) | 579 (45.27%) | 309 (24.16%) | - | 391 (30.57%) | - | - | - |
| Didikoglu | 43,428 | 35695 (82.19%) | 3919 (10.98%) | 13841 (38.78%) | - | 17939 (50.26%) | - | - | - | 7733 (17.81%) | 867 (11.21%) | 2966 (38.36%) | - | 3901 (50.45%) | - | - | - |
| Kantele | 1,095 | 1059 (96.71%) | 176 (16.62%) | 272 (25.68%) | - | 611 (57.70%) | - | - | - | 36 (3.29%) | 3 (8.33%) | 11 (30.56%) | - | 21 (58.33%) | - | - | 1 (2.78%) |
| Polat | 1,322 | NA ( NA%) | - | - | - | - | - | - | - | 23 (1.74%) | 4 (17.39%) | 2 (8.70%) | - | 17 (73.91%) | - | - | - |
| Richard | 8,344 | 6798 (81.47%) | 1065 (15.67%) | 1171 (17.23%) | - | 4456 (65.55%) | - | - | 106 (1.56%) | 531 (6.36%) | 47 (8.85%) | 83 (15.63%) | - | 396 (74.58%) | - | - | 5 (0.94%) |
| Schubl | 1,557 | 1392 (89.40%) | 33 (2.37%) | - | - | - | - | - | 1359 (97.63%) | 165 (10.60%) | 4 (2.42%) | - | - | - | - | - | 161 (97.58%) |
| Nezhadmoghadam | 33,325 | 19958 (59.89%) | 2151 (10.78%) | - | - | - | - | - | 17807 (89.22%) | 13367 (40.11%) | 1251 (9.36%) | - | - | - | - | - | 12116 (90.64%) |
| Mora | 1,058 | 857 (81.00%) | 40 (4.67%) | 118 (13.77%) | - | 698 (81.45%) | - | - | 1 (0.12%) | 201 (19.00%) | 8 (3.98%) | 36 (17.91%) | - | 157 (78.11%) | - | - | - |
| Molenaar | 696 | 591 (84.91%) | 29 (4.91%) | - | - | - | - | - | 562 (95.09%) | 105 (15.09%) | 2 (1.90%) | - | - | - | - | - | 103 (98.10%) |
| Vila-Corcoles, Satue-Gracia, Vila-Rovira | 4,113 | 3577 (86.97%) | 591 (16.52%) | - | - | - | - | - | 2986 (83.48%) | 536 (13.03%) | 41 (7.65%) | - | - | - | - | - | 495 (92.35%) |
| Gegout Petit | 2,006 | 1964 (97.91%) | 334 (17.01%) | - | - | 1545 (78.67%) | - | - | 85 (4.33%) | 42 (2.09%) | 4 (9.52%) | - | - | 38 (90.48%) | - | - | - |
| Leister | 3,301 | 3269 (99.03%) | 764 (23.37%) | - | - | - | - | - | 2505 (76.63%) | 32 (0.97%) | 5 (15.62%) | - | - | - | - | - | 27 (84.38%) |
| Bell | 303 | NA ( NA%) | - | - | - | - | - | - | - | 303 (100.00%) | - | - | - | - | - | 40 (13.20%) | 263 (86.80%) |
| Rhys, Thomas | 2,820 | 2621 (92.94%) | - | - | - | - | - | 422 (16.10%) | 2199 (83.90%) | 199 (7.06%) | - | - | - | - | - | 44 (22.11%) | 155 (77.89%) |
| Radon | 4,433 | 4292 (96.82%) | 711 (16.57%) | 1194 (27.82%) | - | 2144 (49.95%) | - | - | 243 (5.66%) | 141 (3.18%) | 18 (12.77%) | 40 (28.37%) | - | 73 (51.77%) | - | - | 10 (7.09%) |
| Hausfater | 1,062 | 999 (94.07%) | 246 (24.62%) | - | - | - | - | - | 753 (75.38%) | 61 (5.74%) | 4 (6.56%) | - | - | - | - | - | 57 (93.44%) |
| Fernandez, Fuertes | 710 | 664 (93.52%) | 358 (53.92%) | - | - | - | - | - | 306 (46.08%) | 46 (6.48%) | 12 (26.09%) | - | - | - | - | - | 34 (73.91%) |
| Shields | 1,507 | 1261 (83.68%) | 145 (11.50%) | 206 (16.34%) | - | 907 (71.93%) | - | - | - | 246 (16.32%) | 12 (4.88%) | 41 (16.67%) | - | 193 (78.46%) | - | - | - |
| Gonzalez, Vielot | 782 | 540 (69.05%) | - | - | 75 (13.89%) | 465 (86.11%) | - | - | - | 242 (30.95%) | - | - | 28 (11.57%) | 214 (88.43%) | - | - | - |
| Nielsen | 840 | 630 (75.00%) | 29 (4.60%) | 204 (32.38%) | - | 397 (63.02%) | - | - | - | 210 (25.00%) | 10 (4.76%) | 60 (28.57%) | - | 140 (66.67%) | - | - | - |
| Jha | 8,967 | 8799 (98.13%) | - | - | 4120 (46.82%) | 4563 (51.86%) | - | - | 116 (1.32%) | 168 (1.87%) | - | - | 71 (42.26%) | 95 (56.55%) | - | - | 2 (1.19%) |
| Joubert, Andry | 1,013 | 933 (92.10%) | 158 (16.93%) | - | - | - | - | - | 775 (83.07%) | 80 (7.90%) | 4 (5.00%) | - | - | - | - | - | 76 (95.00%) |
| Daugherty | 266,586 | NA ( NA%) | - | - | - | - | - | - | - | 266586 (100.00%) | 8113 (3.04%) | - | - | - | - | - | 258473 (96.96%) |
| Vanegas, Cedillo | 551 | NA ( NA%) | - | - | - | - | - | - | - | 551 (100.00%) | 27 (4.90%) | - | - | - | - | - | 524 (95.10%) |
| Schaad | 134 | 103 (76.87%) | 32 (31.07%) | - | - | - | - | - | 71 (68.93%) | 31 (23.13%) | 7 (22.58%) | - | - | - | - | - | 24 (77.42%) |
| Mok | 211 | NA ( NA%) | - | - | - | - | - | - | - | 211 (100.00%) | - | - | 78 (36.97%) | - | - | - | 133 (63.03%) |
| Desgranges | 507 | 89 (17.55%) | 27 (30.34%) | - | - | - | - | - | 62 (69.66%) | 418 (82.45%) | 46 (11.00%) | - | - | - | - | - | 372 (89.00%) |
| Gonzalez, Zepeda | 157 | 97 (61.78%) | 13 (13.40%) | - | - | - | - | - | 84 (86.60%) | 60 (38.22%) | 5 (8.33%) | - | - | - | - | - | 55 (91.67%) |
| Fogh | 3,236 | 2632 (81.33%) | - | - | 727 (27.62%) | - | - | - | 1905 (72.38%) | 604 (18.67%) | - | - | 121 (20.03%) | - | - | - | 483 (79.97%) |
| Rothlin, Eriksen | 819 | 764 (93.28%) | - | - | 554 (72.51%) | - | - | - | 210 (27.49%) | 55 (6.72%) | - | - | 33 (60.00%) | - | - | - | 22 (40.00%) |
| Gornyk | 13,045 | 12791 (98.05%) | 2496 (19.51%) | 3947 (30.86%) | - | 6335 (49.53%) | - | - | 13 (0.10%) | 254 (1.95%) | 35 (13.78%) | 84 (33.07%) | - | 135 (53.15%) | - | - | - |
| Campbell | 2,128 | 2075 (97.51%) | 326 (15.71%) | 127 (6.12%) | - | 1622 (78.17%) | - | - | - | 53 (2.49%) | 5 (9.43%) | 2 (3.77%) | - | 46 (86.79%) | - | - | - |
| Kleynhans | 226 | 129 (57.08%) | 20 (15.50%) | - | - | - | - | - | 109 (84.50%) | 97 (42.92%) | 16 (16.49%) | - | - | - | - | - | 81 (83.51%) |
| Rogier | 374 | 152 (40.64%) | 28 (18.42%) | - | - | - | - | - | 124 (81.58%) | 222 (59.36%) | 8 (3.60%) | - | - | - | - | - | 214 (96.40%) |
| Mostafa | 4,040 | 3770 (93.32%) | 456 (12.10%) | 75 (1.99%) | - | 3239 (85.92%) | - | - | - | 270 (6.68%) | 23 (8.52%) | 4 (1.48%) | - | 243 (90.00%) | - | - | - |
| Lombardi | 4,055 | 3746 (92.38%) | 808 (21.57%) | 503 (13.43%) | - | 2283 (60.95%) | - | - | - | 309 (7.62%) | 34 (11.00%) | 49 (15.86%) | - | 210 (67.96%) | - | - | - |
| Li, Tong | 18,148 | 17248 (95.04%) | 2164 (12.55%) | - | - | - | - | - | 15069 (87.37%) | 900 (4.96%) | 74 (8.22%) | - | - | - | - | - | 826 (91.78%) |
| Kahlert | 4,664 | 4525 (97.02%) | 806 (17.81%) | 924 (20.42%) | - | 2795 (61.77%) | - | - | - | 139 (2.98%) | 16 (11.51%) | 27 (19.42%) | - | 96 (69.06%) | - | - | - |
| Egede | 30,976 | 28873 (93.21%) | 4148 (14.37%) | 9433 (32.67%) | - | 15292 (52.96%) | - | - | - | 2103 (6.79%) | 158 (7.51%) | 572 (27.20%) | - | 1373 (65.29%) | - | - | - |
| De, Santi | 341 | 292 (85.63%) | 81 (27.74%) | - | - | - | - | - | 211 (72.26%) | 49 (14.37%) | 7 (14.29%) | - | - | - | - | - | 42 (85.71%) |
| Dashti | 15,440 | 15214 (98.54%) | 3243 (21.32%) | 5110 (33.59%) | - | 6425 (42.23%) | - | - | 436 (2.87%) | 226 (1.46%) | 26 (11.50%) | 114 (50.44%) | - | 84 (37.17%) | - | - | 2 (0.88%) |
| Chetboun | 1,447 | 1283 (88.67%) | 229 (17.85%) | 105 (8.18%) | - | 608 (47.39%) | - | - | 341 (26.58%) | 164 (11.33%) | 18 (10.98%) | 33 (20.12%) | - | 113 (68.90%) | - | - | - |
| Barchuk | 962 | 868 (90.23%) | 183 (21.08%) | 241 (27.76%) | - | 412 (47.47%) | - | - | 32 (3.69%) | 94 (9.77%) | 12 (12.77%) | 26 (27.66%) | - | 55 (58.51%) | - | - | 1 (1.06%) |



*Figure 3.* Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers. \* Indicates ‘good’ quality studies. The prior from the previous review version (v11) was RR = 0.71.




*Figure 4.* Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers. \* Indicates ‘good’ quality studies. The prior from the previous review version (v11) was RR = 1.03.

### Hospitalisation for COVID-19 by smoking status


55 studies examined hospitalisation for COVID-19 disease, stratified by smoking status (see [Table 3](#table-3)). Meta-analyses were performed for 19 ‘fair’ quality studies (see [Figure 5](#fig-5) and [6](#fig-6)). Current (RR = 1.1, 95% CrI = 0.97-1.24, τ = 0.23) and former (RR = 1.27, CrI = 1.15-1.4, τ = 0.2) compared with never smokers were at increased risk of hospitalisation with COVID-19. However, data for current smokers were inconclusive and favoured there being no important association. The probability of current and former smokers being at increased risk of hospitalisation (RR ≥1.1) compared with never smokers was 50% and >99%, respectively. Results were materially unchanged in two sensitivity analyses.

#### *Table 3* COVID-19 hospitalisation by smoking status

|  | | Community | | | | | | | Hospitalised | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author | Population with outcome | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) |
| Rentsch | 554 | 269 (48%) | 69 (25.65%) | 90 (33.46%) | - | 110 (40.89%) | - | - | 285 (51%) | 90 (31.58%) | 89 (31.23%) | - | 106 (37.19%) | - | - |
| Chow (US CDC) | 6,637 | 5143 (77%) | 61 (1.19%) | 80 (1.56%) | - | - | - | 5002 (97.26%) | 1494 (22%) | 27 (1.81%) | 78 (5.22%) | - | - | - | 1389 (92.97%) |
| Argenziano | 1,000 | 151 (15%) | 14 (9.27%) | 18 (11.92%) | - | 119 (78.81%) | - | - | 849 (84%) | 35 (4.12%) | 161 (18.96%) | - | 653 (76.91%) | - | - |
| Lubetzky | 54 | 15 (27%) | - | - | 4 (26.67%) | - | - | 11 (73.33%) | 39 (72%) | - | - | 8 (20.51%) | - | - | 31 (79.49%) |
| Carillo-Vega | 9,946 | 3922 (39%) | 408 (10.40%) | - | - | - | - | 3514 (89.60%) | 6024 (60%) | 486 (8.07%) | - | - | - | - | 5538 (91.93%) |
| Yanover | 4,353 | 4180 (96%) | 484 (11.58%) | 118 (2.82%) | - | 3578 (85.60%) | - | - | 173 (3%) | 30 (17.34%) | 11 (6.36%) | - | 132 (76.30%) | - | - |
| Hamer | 387,109 | 386349 (99%) | 37333 (9.66%) | 134542 (34.82%) | - | 214474 (55.51%) | - | - | 760 (0%) | 93 (12.24%) | 313 (41.18%) | - | 354 (46.58%) | - | - |
| Heili-Frades | 4,712 | 1973 (41%) | 121 (6.13%) | 222 (11.25%) | - | - | 1630 (82.62%) | 1630 (82.62%) | 2739 (58%) | 112 (4.09%) | 598 (21.83%) | - | - | 2029 (74.08%) | - |
| Freites | 123 | 69 (56%) | 1 (1.45%) | - | - | - | - | 68 (98.55%) | 54 (43%) | 3 (5.56%) | - | - | - | - | 51 (94.44%) |
| Berumen | 31,522 | 18832 (59%) | - | - | 1546 (8.21%) | - | 17286 (91.79%) | - | 12690 (40%) | - | - | 1202 (9.47%) | - | 11488 (90.53%) | - |
| Gianfrancesco | 600 | 323 (53%) | - | - | 61 (18.89%) | - | - | 262 (81.11%) | 277 (46%) | - | - | 68 (24.55%) | - | - | 209 (75.45%) |
| Chaudhry | 40 | 19 (47%) | - | - | 0 (0.00%) | - | - | 19 (100.00%) | 21 (52%) | - | - | 6 (28.57%) | - | - | 15 (71.43%) |
| Giannouchos | 89,756 | 58485 (65%) | 4679 (8.00%) | - | - | - | 53806 (92.00%) | - | 31271 (34%) | 2721 (8.70%) | - | - | - | 28550 (91.30%) | - |
| Wang, Oekelen | 57 | 22 (38%) | - | - | 6 (27.27%) | - | - | 16 (72.73%) | 36 (63%) | - | - | 15 (41.67%) | - | - | 20 (55.56%) |
| Miyara | 470 | 132 (28%) | 14 (10.61%) | 41 (31.06%) | - | 77 (58.33%) | - | - | 338 (71%) | 18 (5.33%) | 111 (32.84%) | - | 209 (61.83%) | - | - |
| Suleyman | 463 | 108 (23%) | - | - | 23 (21.30%) | - | - | 85 (78.70%) | 355 (76%) | - | - | 137 (38.59%) | - | - | 218 (61.41%) |
| Garassino | 196 | 48 (24%) | 10 (20.83%) | 27 (56.25%) | - | 11 (22.92%) | - | - | 152 (77%) | 38 (25.00%) | 84 (55.26%) | - | 26 (17.11%) | - | - |
| Siso-Almirall | 260 | 119 (45%) | - | - | 31 (26.05%) | - | - | 88 (73.95%) | 141 (54%) | - | - | 50 (35.46%) | - | - | 91 (64.54%) |
| Gu | 884 | 511 (57%) | 30 (5.87%) | 126 (24.66%) | - | 355 (69.47%) | - | - | 373 (42%) | 10 (2.68%) | 138 (37.00%) | - | 225 (60.32%) | - | - |
| Killerby | 531 | 311 (58%) | - | - | 37 (11.90%) | 222 (71.38%) | - | 52 (16.72%) | 220 (41%) | - | - | 54 (24.55%) | 157 (71.36%) | - | 9 (4.09%) |
| Nguyen | 689 | 333 (48%) | - | - | 57 (17.12%) | - | - | 276 (82.88%) | 356 (51%) | - | - | 114 (32.02%) | - | - | 242 (67.98%) |
| Mendy | 689 | 473 (68%) | - | - | 84 (17.76%) | - | - | 389 (82.24%) | 216 (31%) | - | - | 86 (39.81%) | - | - | 130 (60.19%) |
| Soares | 10,713 | 9561 (89%) | 132 (1.38%) | - | - | - | 9429 (98.62%) | - | 1152 (10%) | 77 (6.68%) | - | - | - | 1075 (93.32%) | - |
| Zobairy | 203 | 65 (32%) | 1 (1.54%) | - | - | - | 64 (98.46%) | - | 138 (67%) | 11 (7.97%) | - | - | - | 127 (92.03%) | - |
| Izquierdo | 1,006 | 743 (73%) | 52 (7.00%) | - | - | - | 691 (93.00%) | - | 263 (26%) | 16 (6.08%) | - | - | - | 247 (93.92%) | - |
| Rizzo | 76,819 | 60039 (78%) | 3931 (6.55%) | 11379 (18.95%) | - | 30042 (50.04%) | - | 14687 (24.46%) | 16780 (21%) | 1254 (7.47%) | 4585 (27.32%) | - | 8693 (51.81%) | - | 2248 (13.40%) |
| Pan | 12,084 | 8548 (70%) | - | - | 1263 (14.78%) | - | - | 7285 (85.22%) | 3536 (29%) | - | - | 874 (24.72%) | - | - | 2662 (75.28%) |
| Petrilli | 5,279 | 2538 (48%) | 147 (5.79%) | 337 (13.28%) | - | 1678 (66.12%) | - | 376 (14.81%) | 2741 (51%) | 141 (5.14%) | 565 (20.61%) | - | 1590 (58.01%) | - | 445 (16.23%) |
| Vilar-Garcia | 328,892 | 291254 (88%) | 64792 (22.25%) | - | - | - | - | 226462 (77.75%) | 37638 (11%) | 9526 (25.31%) | - | - | - | - | 28112 (74.69%) |
| Ibarra-Nava | 416,546 | 302693 (72%) | 26773 (8.84%) | - | - | - | - | 275920 (91.16%) | 113853 (27%) | 8875 (7.80%) | - | - | - | - | 104978 (92.20%) |
| da Silva Neto | 91 | 44 (48%) | - | - | 4 (9.09%) | - | 40 (90.91%) | - | 47 (51%) | - | - | 14 (29.79%) | - | 33 (70.21%) | - |
| Israel, Schaffer | 26,676 | 13706 (51%) | 944 (6.89%) | 2166 (15.80%) | - | 10596 (77.31%) | - | - | 12970 (48%) | 880 (6.78%) | 1936 (14.93%) | - | 10154 (78.29%) | - | - |
| Ioannou | 10,131 | 6624 (65%) | 716 (10.81%) | 2484 (37.50%) | - | 2542 (38.38%) | - | 882 (13.32%) | 3507 (34%) | 419 (11.95%) | 1593 (45.42%) | - | 1102 (31.42%) | - | 393 (11.21%) |
| Zhang, Li | 1,596 | 576 (36%) | 63 (10.94%) | 190 (32.99%) | - | 318 (55.21%) | - | 5 (0.87%) | 1020 (63%) | 116 (11.37%) | 429 (42.06%) | - | 462 (45.29%) | - | 13 (1.27%) |
| Parra-Bracamonte | 331,298 | 235840 (71%) | - | - | 16676 (7.07%) | - | - | 219164 (92.93%) | 95458 (28%) | - | - | 7517 (7.87%) | - | - | 87941 (92.13%) |
| Jehi | 4,536 | 3578 (78%) | 247 (6.90%) | 943 (26.36%) | - | 1795 (50.17%) | - | 593 (16.57%) | 958 (21%) | 82 (8.56%) | 349 (36.43%) | - | 467 (48.75%) | - | 60 (6.26%) |
| Arleo | 70 | 36 (51%) | 1 (2.78%) | 10 (27.78%) | - | 25 (69.44%) | - | - | 34 (48%) | 0 (0.00%) | 10 (29.41%) | - | 24 (70.59%) | - | - |
| Kortela | 604 | 246 (40%) | 12 (4.88%) | 14 (5.69%) | - | 55 (22.36%) | - | 165 (67.07%) | 328 (54%) | 14 (4.27%) | 66 (20.12%) | - | 177 (53.96%) | - | 71 (21.65%) |
| Didikoglu | 7,733 | 5239 (67%) | 554 (10.57%) | 1845 (35.22%) | - | 2841 (54.23%) | - | - | 2494 (32%) | 313 (12.55%) | 1121 (44.95%) | - | 1060 (42.50%) | - | - |
| Ho, Narasimhan | 9,991 | 5082 (50%) | 189 (3.72%) | 744 (14.64%) | - | 4148 (81.62%) | - | - | 4909 (49%) | 217 (4.42%) | 1062 (21.63%) | - | 3630 (73.95%) | - | - |
| Saurabh | 911 | 69 (7%) | 6 (8.70%) | 0 (0.00%) | - | 63 (91.30%) | - | - | 842 (92%) | 68 (8.08%) | 6 (0.71%) | - | 768 (91.21%) | - | - |
| Munoz | 314 | 294 (93%) | 20 (6.80%) | - | - | - | - | 274 (93.20%) | 20 (6%) | 1 (5.00%) | - | - | - | - | 19 (95.00%) |
| Cummins | 1,781 | 586 (32%) | 77 (13.14%) | - | - | - | - | 509 (86.86%) | 1195 (67%) | 104 (8.70%) | - | - | - | - | 1091 (91.30%) |
| Fernandez, Fuertes | 46 | 41 (89%) | 12 (29.27%) | - | - | - | - | 29 (70.73%) | 5 (10%) | 0 (0.00%) | - | - | - | - | 5 (100.00%) |
| Patone | 429,926 | 381887 (88%) | 45230 (11.84%) | 66378 (17.38%) | - | 213519 (55.91%) | - | 56760 (14.86%) | 48039 (11%) | 5488 (11.42%) | 12593 (26.21%) | - | 27255 (56.74%) | - | 2703 (5.63%) |
| Wang, Codd | 6,775 | 5861 (86%) | 606 (10.34%) | 2001 (34.14%) | - | 3236 (55.21%) | - | 17 (0.29%) | 914 (13%) | 142 (15.54%) | 408 (44.64%) | - | 358 (39.17%) | - | 6 (0.66%) |
| Manohar | 11,930 | 7035 (58%) | 185 (2.63%) | 951 (13.52%) | - | 534 (7.59%) | - | 2755 (39.16%) | 4895 (41%) | 54 (1.10%) | 431 (8.80%) | - | 873 (17.83%) | - | 3537 (72.26%) |
| Puebla, Neira | 10,216 | 9066 (88%) | 369 (4.07%) | 723 (7.97%) | - | 7974 (87.95%) | - | - | 1150 (11%) | 29 (2.52%) | 194 (16.87%) | - | 927 (80.61%) | - | - |
| Colaneri | 12,347 | 8946 (72%) | 353 (3.95%) | 1099 (12.28%) | - | 5133 (57.38%) | - | 2361 (26.39%) | 3401 (27%) | 210 (6.17%) | 171 (5.03%) | - | 1920 (56.45%) | - | 411 (12.08%) |



*Figure 5.* Forest plot for risk of hospitalisation in current vs. never smokers. The prior from the previous review version (v11) was RR = 1.1.




*Figure 6.* Forest plot for risk of hospitalisation in former vs. never smokers. The prior from the previous version (v11) was RR = 1.19.

### Disease severity by smoking status


91 studies reported disease severity in hospitalised patients stratified by smoking status (see [Table 4](#table-4)). Severe (as opposed to non-severe) disease was broadly defined as requiring intensive treatment unit (ITU) admission, requiring oxygen as a hospital inpatient or in-hospital death. Meta-analyses were performed for 16 ‘fair’ quality studies (see [Figure 7](#fig-7) and [8](#fig-8)). Current (RR = 1.3, 95% CrI = 1.01-1.71, τ = 0.32) and former (RR = 1.69, 95% CrI = 1.3-2.22, τ = 0.43) compared with never smokers were at increased risk of greater disease severity. The probability of current and former smokers having increased risk of greater disease severity (RR ≥1.1) compared with never smokers was 92% and 100%, respectively. Results were materially unchanged in two sensitivity analyses.

#### *Table 4* COVID-19 disease severity by smoking status

|  | | Non severe disease | | | | | | | Severe disease | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author | Population with severity | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) |
| Guan, Ni | 1,085 | 913 (84%) | 108 (11.83%) | 12 (1.31%) | - | 793 (86.86%) | - | - | 172 (15%) | 29 (16.86%) | 9 (5.23%) | - | 134 (77.91%) | - | - |
| Zhang, Dong | 9 | 3 (33%) | 0 (0.00%) | 3 (100.00%) | - | 0 (0.00%) | - | - | 6 (66%) | 2 (33.33%) | 4 (66.67%) | - | 0 (0.00%) | - | - |
| Wan | 9 | 8 (88%) | 8 (100.00%) | 0 (0.00%) | - | 0 (0.00%) | - | - | 1 (11%) | 1 (100.00%) | 0 (0.00%) | - | 0 (0.00%) | - | - |
| Huang, Wang | 3 | 3 (100%) | 3 (100.00%) | 0 (0.00%) | - | 0 (0.00%) | - | - | 0 (0%) | 0 (NaN%) | 0 (NaN%) | - | 0 (NaN%) | - | - |
| Rentsch | 285 | 168 (58%) | 47 (27.98%) | 53 (31.55%) | - | 68 (40.48%) | - | - | 117 (41%) | 43 (36.75%) | 36 (30.77%) | - | 38 (32.48%) | - | - |
| Hu | 323 | 151 (46%) | - | - | 12 (7.95%) | - | 139 (92.05%) | - | 172 (53%) | - | - | 26 (15.12%) | - | 146 (84.88%) | - |
| Wang, Pan | 125 | 100 (80%) | - | - | 9 (9.00%) | - | 91 (91.00%) | - | 25 (20%) | - | - | 7 (28.00%) | - | 18 (72.00%) | - |
| Kim | 27 | 21 (77%) | 3 (14.29%) | - | - | - | 18 (85.71%) | - | 6 (22%) | 2 (33.33%) | 0 (0.00%) | - | - | 4 (66.67%) | - |
| Shi, Yu | 474 | 425 (89%) | - | - | 34 (8.00%) | - | 391 (92.00%) | - | 49 (10%) | - | - | 6 (12.24%) | - | 43 (87.76%) | - |
| Liao, Feng | 148 | 92 (62%) | - | - | 5 (5.43%) | - | - | 87 (94.57%) | 56 (37%) | 3 (5.36%) | - | - | - | - | 53 (94.64%) |
| Shi, Ren | 134 | 88 (65%) | - | - | 8 (9.09%) | - | - | 80 (90.91%) | 46 (34%) | - | - | 6 (13.04%) | - | - | 40 (86.96%) |
| Hadjadj | 50 | 15 (30%) | 1 (6.67%) | 2 (13.33%) | - | 12 (80.00%) | - | - | 35 (70%) | 0 (0.00%) | 7 (20.00%) | - | 28 (80.00%) | - | - |
| Zheng, Xiong | 73 | 43 (58%) | - | - | 6 (13.95%) | 37 (86.05%) | - | - | 30 (41%) | - | - | 2 (6.67%) | 28 (93.33%) | - | - |
| de la Rica | 48 | 26 (54%) | - | - | 6 (23.08%) | - | - | 20 (76.92%) | 20 (41%) | - | - | 4 (20.00%) | - | - | 16 (80.00%) |
| Yin, Yang | 106 | 47 (44%) | - | - | 6 (12.77%) | - | - | 41 (87.23%) | 59 (55%) | - | - | 12 (20.34%) | - | - | 47 (79.66%) |
| Allenbach | 147 | 100 (68%) | - | - | 9 (9.00%) | - | - | 91 (91.00%) | 47 (31%) | - | - | 0 (0.00%) | - | - | 47 (100.00%) |
| Goyal | 393 | 263 (66%) | 14 (5.32%) | - | - | - | - | 249 (94.68%) | 130 (33%) | 6 (4.62%) | - | - | - | - | 124 (95.38%) |
| Feng | 454 | 333 (73%) | 27 (8.11%) | - | - | - | - | 306 (91.89%) | 121 (26%) | 17 (14.05%) | - | - | - | - | 104 (85.95%) |
| Yao | 108 | 83 (76%) | 1 (1.20%) | - | - | - | - | 82 (98.80%) | 25 (23%) | 3 (12.00%) | - | - | - | - | 22 (88.00%) |
| Regina | 200 | 163 (81%) | 9 (5.52%) | - | - | - | - | 154 (94.48%) | 37 (18%) | 0 (0.00%) | - | - | - | - | 37 (100.00%) |
| Feuth | 28 | 21 (75%) | 1 (4.76%) | 7 (33.33%) | - | 13 (61.90%) | - | - | 7 (25%) | 2 (28.57%) | 1 (14.29%) | - | 4 (57.14%) | - | - |
| Mejia-Vilet | 329 | 214 (65%) | - | - | 13 (6.07%) | - | - | 201 (93.93%) | 115 (34%) | - | - | 10 (8.70%) | - | - | 105 (91.30%) |
| Chen, Jiang | 135 | 54 (40%) | - | - | 4 (7.41%) | - | - | 50 (92.59%) | 81 (60%) | - | - | 9 (11.11%) | - | - | 72 (88.89%) |
| Vaquero-Roncero | 146 | 75 (51%) | - | - | 4 (5.33%) | - | - | 71 (94.67%) | 71 (48%) | - | - | 6 (8.45%) | - | - | 65 (91.55%) |
| Kim, Garg | 2,490 | 1692 (67%) | 112 (6.62%) | 395 (23.35%) | - | - | 1185 (70.04%) | - | 798 (32%) | 38 (4.76%) | 247 (30.95%) | - | - | 512 (64.16%) | - |
| Wu | 174 | 92 (52%) | - | - | 47 (51.09%) | - | 45 (48.91%) | - | 82 (47%) | 11 (13.41%) | - | - | - | 71 (86.59%) | - |
| Chaudhry | 40 | 34 (85%) | - | - | 5 (14.71%) | - | - | 29 (85.29%) | 6 (15%) | - | - | 1 (16.67%) | - | - | 5 (83.33%) |
| Garibaldi | 832 | 532 (63%) | 25 (4.70%) | 107 (20.11%) | - | - | - | 400 (75.19%) | 300 (36%) | 21 (7.00%) | 81 (27.00%) | - | - | - | 198 (66.00%) |
| Kuderer | 928 | 686 (73%) | 35 (5.10%) | 210 (30.61%) | - | 370 (53.94%) | - | 29 (4.23%) | 242 (26%) | 8 (3.31%) | 116 (47.93%) | - | 99 (40.91%) | 15 (6.20%) | 4 (1.65%) |
| Romao | 14 | 14 (100%) | - | - | 4 (28.57%) | - | - | 10 (71.43%) | 0 (0%) | - | - | - | - | - | - |
| Giannouchos | 89,756 | 78050 (86%) | 6322 (8.10%) | - | - | - | 71728 (91.90%) | - | 11706 (13%) | 1089 (9.30%) | - | - | - | 10617 (90.70%) | - |
| Cen | 1,007 | 720 (71%) | - | - | 70 (9.72%) | - | - | 650 (90.28%) | 287 (28%) | - | - | 18 (6.27%) | - | - | 269 (93.73%) |
| Maraschini | 132 | 89 (67%) | - | 11 (12.36%) | - | 78 (87.64%) | - | - | 43 (32%) | - | 3 (6.98%) | - | 40 (93.02%) | - | - |
| Russell | 156 | 128 (82%) | 9 (7.03%) | 31 (24.22%) | - | 51 (39.84%) | - | 37 (28.91%) | 28 (17%) | 2 (7.14%) | 8 (28.57%) | - | 8 (28.57%) | - | 10 (35.71%) |
| Siso-Almirall | 260 | 212 (81%) | - | - | 60 (28.30%) | - | - | 152 (71.70%) | 48 (18%) | - | - | 21 (43.75%) | - | - | 27 (56.25%) |
| Gu | 645 | 511 (79%) | 30 (5.87%) | 126 (24.66%) | - | 355 (69.47%) | - | - | 134 (20%) | 3 (2.24%) | 61 (45.52%) | - | 70 (52.24%) | - | - |
| Mendy | 689 | 598 (86%) | - | - | 133 (22.24%) | - | - | 465 (77.76%) | 91 (13%) | - | - | 37 (40.66%) | - | - | 54 (59.34%) |
| Jin, Gu | 6 | 2 (33%) | - | - | 0 (0.00%) | - | - | 2 (100.00%) | 4 (66%) | - | - | 2 (50.00%) | - | - | 2 (50.00%) |
| Senkal | 611 | 446 (73%) | 48 (10.76%) | - | - | - | - | 398 (89.24%) | 165 (27%) | 21 (12.73%) | - | - | - | - | 144 (87.27%) |
| Patel | 129 | 89 (68%) | 26 (29.21%) | - | - | - | 58 (65.17%) | 5 (5.62%) | 40 (31%) | 22 (55.00%) | - | - | - | 14 (35.00%) | 4 (10.00%) |
| Maucourant | 27 | 10 (37%) | 1 (10.00%) | 2 (20.00%) | - | 2 (20.00%) | - | 5 (50.00%) | 17 (62%) | 2 (11.76%) | 5 (29.41%) | - | 9 (52.94%) | - | 1 (5.88%) |
| Xie | 619 | 469 (75%) | - | - | 32 (6.82%) | - | - | 437 (93.18%) | 150 (24%) | - | - | 19 (12.67%) | - | - | 131 (87.33%) |
| Fox | 55 | 30 (54%) | 1 (3.33%) | 4 (13.33%) | - | 17 (56.67%) | - | 8 (26.67%) | 25 (45%) | 0 (0.00%) | 2 (8.00%) | - | 14 (56.00%) | - | 9 (36.00%) |
| Zhang, Cao | 240 | 162 (67%) | 2 (1.23%) | 6 (3.70%) | - | - | - | 154 (95.06%) | 78 (32%) | 4 (5.13%) | 4 (5.13%) | - | - | - | 70 (89.74%) |
| Kurashima | 53 | 10 (18%) | - | - | 3 (30.00%) | - | - | 7 (70.00%) | 43 (81%) | - | - | 24 (55.81%) | - | - | 19 (44.19%) |
| Zhan | 75 | NA (NA%) | - | - | - | - | - | - | 75 (100%) | - | - | 9 (12.00%) | - | - | 66 (88.00%) |
| Omrani | 858 | 806 (93%) | - | - | 121 (15.01%) | - | - | 685 (84.99%) | 52 (6%) | - | - | 9 (17.31%) | - | - | 43 (82.69%) |
| Marcos | 918 | 555 (60%) | 38 (6.85%) | - | 69 (12.43%) | - | - | 448 (80.72%) | 363 (39%) | 18 (4.96%) | - | 71 (19.56%) | - | - | 292 (80.44%) |
| Hoertel, Sanchez, Rico | 7,345 | 6014 (81%) | 433 (7.20%) | - | - | - | - | 5581 (92.80%) | 1331 (18%) | 190 (14.27%) | - | - | - | - | 1141 (85.73%) |
| Qi | 267 | 217 (81%) | 22 (10.14%) | - | - | - | 195 (89.86%) | - | 50 (18%) | 31 (62.00%) | - | - | - | 19 (38.00%) | - |
| Monteiro | 112 | 84 (75%) | 3 (3.57%) | 14 (16.67%) | - | 63 (75.00%) | - | 4 (4.76%) | 28 (25%) | 4 (14.29%) | 6 (21.43%) | - | 14 (50.00%) | - | 4 (14.29%) |
| Morshed | 103 | 87 (84%) | 28 (32.18%) | - | - | - | 59 (67.82%) | - | 16 (15%) | 4 (25.00%) | - | - | - | 12 (75.00%) | - |
| Zhou, Sun | 144 | 108 (75%) | 11 (10.19%) | - | - | - | - | 97 (89.81%) | 36 (25%) | 2 (5.56%) | - | - | - | - | 34 (94.44%) |
| Zhao, Chen | 641 | 398 (62%) | 87 (21.86%) | - | - | - | - | 311 (78.14%) | 195 (30%) | 52 (26.67%) | - | - | - | - | 143 (73.33%) |
| Qu | 246 | 226 (91%) | 90 (39.82%) | - | - | - | - | 136 (60.18%) | 20 (8%) | 14 (70.00%) | - | - | - | - | 6 (30.00%) |
| Petrilli | 2,729 | 1739 (63%) | 97 (5.58%) | 325 (18.69%) | - | 1067 (61.36%) | - | 250 (14.38%) | 990 (36%) | 44 (4.44%) | 236 (23.84%) | - | 517 (52.22%) | - | 193 (19.49%) |
| Ren | 432 | 314 (72%) | 26 (8.28%) | - | - | 288 (91.72%) | - | - | 118 (27%) | 17 (14.41%) | - | - | 101 (85.59%) | - | - |
| Yan | 578 | 450 (77%) | 31 (6.89%) | - | - | - | - | 419 (93.11%) | 128 (22%) | 20 (15.62%) | - | - | - | - | 108 (84.38%) |
| Nicholson | 1,042 | 550 (52%) | 37 (6.73%) | 106 (19.27%) | - | 211 (38.36%) | - | 196 (35.64%) | 401 (38%) | 41 (10.22%) | 92 (22.94%) | - | 155 (38.65%) | - | 113 (28.18%) |
| Zhu | 432 | 285 (65%) | 46 (16.14%) | - | - | - | - | 239 (83.86%) | 147 (34%) | 16 (10.88%) | - | - | - | - | 147 (100.00%) |
| Kalan | 193 | 122 (63%) | 9 (7.38%) | - | - | 102 (83.61%) | - | 11 (9.02%) | 71 (36%) | 5 (7.04%) | - | - | 62 (87.32%) | - | 4 (5.63%) |
| Burrell | 204 | 85 (41%) | - | - | 7 (8.24%) | - | 75 (88.24%) | 3 (3.53%) | 119 (58%) | - | - | 20 (16.81%) | - | 94 (78.99%) | 5 (4.20%) |
| Zhou, He, Yang | 1,087 | 990 (91%) | - | - | 849 (85.76%) | 141 (14.24%) | - | - | 97 (8%) | - | - | 75 (77.32%) | 22 (22.68%) | - | - |
| Zhou, Qin | 51 | NA (NA%) | - | - | - | - | - | - | 51 (100%) | - | - | 40 (78.43%) | 11 (21.57%) | - | - |
| Zhan, Liu | 405 | 257 (63%) | - | - | 21 (8.17%) | 236 (91.83%) | - | - | 148 (36%) | - | - | 25 (16.89%) | 123 (83.11%) | - | - |
| Li, Long, Zhang | 954 | 838 (87%) | - | - | 34 (4.06%) | 804 (95.94%) | - | - | 116 (12%) | - | - | 22 (18.97%) | 94 (81.03%) | - | - |
| Jakob | 2,155 | 1400 (64%) | - | - | 92 (6.57%) | 99 (7.07%) | - | 669 (47.79%) | 755 (35%) | 51 (6.75%) | 58 (7.68%) | - | 200 (26.49%) | - | 446 (59.07%) |
| Aksu | 123 | 34 (27%) | 3 (8.82%) | - | - | - | 31 (91.18%) | - | 89 (72%) | 11 (12.36%) | - | - | - | 78 (87.64%) | - |
| Hoertel, Sanchez, Vernet | 12,210 | 11018 (90%) | 921 (8.36%) | - | - | - | - | 10097 (91.64%) | 1192 (9%) | 181 (15.18%) | - | - | - | - | 1011 (84.82%) |
| Vila-Corcoles, Satue-Gracia | 282 | 218 (77%) | - | - | 21 (9.63%) | - | - | 197 (90.37%) | 64 (22%) | - | - | 4 (6.25%) | - | - | 60 (93.75%) |
| Boyd | 38 | 0 (0%) | - | - | - | - | - | - | 38 (100%) | - | - | 2 (5.26%) | - | - | 36 (94.74%) |
| Caliskan | 565 | 474 (83%) | 96 (20.25%) | 45 (9.49%) | - | 333 (70.25%) | - | - | 91 (16%) | 22 (24.18%) | 34 (37.36%) | - | 35 (38.46%) | - | - |
| Ebrahimian | 226 | 134 (59%) | - | - | 12 (8.96%) | - | 122 (91.04%) | - | 92 (40%) | - | - | 12 (13.04%) | - | 80 (86.96%) | - |
| Ho, Narasimhan | 4,909 | 3859 (78%) | 169 (4.38%) | 833 (21.59%) | - | - | 2857 (74.03%) | - | 1050 (21%) | 48 (4.57%) | 229 (21.81%) | - | 773 (73.62%) | - | - |
| Quan | 2,038 | 1452 (71%) | - | 549 (37.81%) | - | - | - | 903 (62.19%) | 586 (28%) | - | - | 261 (44.54%) | - | - | 325 (55.46%) |
| Saurabh | 911 | 783 (85%) | 65 (8.30%) | 3 (0.38%) | - | 715 (91.32%) | - | - | 128 (14%) | 9 (7.03%) | 3 (2.34%) | - | 116 (90.62%) | - | - |
| Chousein | 114 | 94 (82%) | 17 (18.09%) | 17 (18.09%) | - | 60 (63.83%) | - | - | 20 (17%) | 2 (10.00%) | 6 (30.00%) | - | 12 (60.00%) | - | - |
| Tavakol | 206 | 182 (88%) | - | - | 24 (13.19%) | - | 158 (86.81%) | - | 24 (11%) | - | - | 2 (8.33%) | - | 22 (91.67%) | - |
| Yao, Hasegawa | 101 | 78 (77%) | - | - | 17 (21.79%) | - | 71 (91.03%) | - | 23 (22%) | - | - | 12 (52.17%) | - | 11 (47.83%) | - |
| Cummins | 1,195 | 1043 (87%) | 96 (9.20%) | - | - | - | - | 947 (90.80%) | 152 (12%) | 9 (5.92%) | - | - | - | - | 143 (94.08%) |
| Nuno | 4,730 | 3536 (74%) | 333 (9.42%) | - | - | - | - | 3203 (90.58%) | 1194 (25%) | 147 (12.31%) | - | - | - | - | 1047 (87.69%) |
| P-HOSP-COVID Collaborative | 1,077 | 604 (56%) | 11 (1.82%) | 205 (33.94%) | - | 277 (45.86%) | - | 111 (18.38%) | 473 (43%) | 5 (1.06%) | 165 (34.88%) | - | 228 (48.20%) | - | 75 (15.86%) |
| Faverio | 312 | 71 (22%) | 1 (1.41%) | 8 (11.27%) | - | 47 (66.20%) | - | 15 (21.13%) | 241 (77%) | 14 (5.81%) | 57 (23.65%) | - | 134 (55.60%) | - | 36 (14.94%) |
| Manohar | 4,895 | 3825 (78%) | 41 (1.07%) | 288 (7.53%) | - | 647 (16.92%) | - | 2849 (74.48%) | 1070 (21%) | 13 (1.21%) | 143 (13.36%) | - | 226 (21.12%) | - | 688 (64.30%) |
| Jha, Shrestha | 198 | 165 (83%) | 17 (10.30%) | 19 (11.52%) | - | 129 (78.18%) | - | - | 33 (16%) | 6 (18.18%) | 6 (18.18%) | - | 21 (63.64%) | - | - |
| Riou | 124 | 90 (72%) | - | - | 34 (37.78%) | - | - | 56 (62.22%) | 34 (27%) | - | - | 17 (50.00%) | - | - | 17 (50.00%) |
| Rachmawati | 490 | 472 (96%) | 76 (16.10%) | 61 (12.92%) | - | 335 (70.97%) | - | - | 18 (3%) | 8 (44.44%) | 3 (16.67%) | - | 7 (38.89%) | - | - |
| Peng, Lei | 622 | 254 (40%) | 19 (7.48%) | - | - | - | - | 235 (92.52%) | 368 (59%) | 43 (11.68%) | - | - | - | - | 325 (88.32%) |
| Hojbjerg, Lassen | 171 | 127 (74%) | 10 (7.87%) | 58 (45.67%) | - | 56 (44.09%) | - | 3 (2.36%) | 44 (25%) | 0 (0.00%) | 34 (77.27%) | - | 10 (22.73%) | - | - |
| Alsafar | 873 | 574 (65%) | 77 (13.41%) | - | - | - | - | 497 (86.59%) | 299 (34%) | 60 (20.07%) | - | - | - | - | 239 (79.93%) |
| Ali, Hasan | 464 | 319 (68%) | 47 (14.73%) | - | - | - | 272 (85.27%) | - | 145 (31%) | 3 (2.07%) | - | - | - | 142 (97.93%) | - |



*Figure 7.* Forest plot for the risk of severe disease in current vs. never smokers. The prior from the previous review version (v11) was RR = 1.26.



*Figure 8.* Forest plot for the risk of severe disease in former vs. never smokers. The prior from the previous review version (v11) was RR = 1.8.

### Mortality by smoking status

115 studies reported mortality from COVID-19 by smoking status (see [Table 5](#table-5)), with 28 ‘fair’ quality studies included in meta-analyses (see [Figure 9](#fig-9) and [10](#fig-10)). Current (RR = 1.13, 95% CrI = 0.9-1.4, τ = 0.41) and former (RR = 1.59, 95% CrI = 1.34-1.89, τ = 0.37) compared with never smokers were at increased risk of in-hospital mortality from COVID-19. However, data for current smokers were inconclusive and favoured there being no important association. The probability of current and former smokers being at greater risk of in-hospital mortality (RR ≥1.1) compared with never smokers was 60% and >99%, respectively. Results were materially unchanged in two sensitivity analyses.

#### *Table 5* COVID-19 attributed mortality by smoking status

|  | | Recovered | | | | | | | Died | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author | Population with mortality | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) |
| Chen | 274 | 161 (58%) | 5 (3.11%) | 5 (3.11%) | - | - | - | 151 (93.79%) | 113 (41%) | 7 (6.19%) | 2 (1.77%) | - | - | - | 104 (92.04%) |
| Zhou, Yu | 191 | 137 (71%) | 6 (4.38%) | - | - | - | - | 131 (95.62%) | 54 (28%) | 5 (9.26%) | - | - | - | - | 49 (90.74%) |
| Yang, Yu | 52 | 20 (38%) | 2 (10.00%) | - | - | - | 18 (90.00%) | - | 32 (61%) | - | - | - | - | 32 (100.00%) | - |
| Borobia | 2,226 | 1766 (79%) | 113 (6.40%) | - | - | - | - | 1653 (93.60%) | 460 (20%) | 44 (9.57%) | - | - | - | - | 416 (90.43%) |
| Giacomelli | 233 | 185 (79%) | - | - | 53 (28.65%) | 132 (71.35%) | - | - | 48 (20%) | - | - | 17 (35.42%) | 31 (64.58%) | - | 0 (0.00%) |
| Yao | 108 | 96 (88%) | 1 (1.04%) | - | - | - | - | 95 (98.96%) | 12 (11%) | 3 (25.00%) | - | - | - | - | 9 (75.00%) |
| Carillo-Vega | 9,946 | 8983 (90%) | 795 (8.85%) | - | - | - | - | 8188 (91.15%) | 963 (9%) | 99 (10.28%) | - | - | - | - | 864 (89.72%) |
| Ge | 51 | 39 (76%) | 6 (15.38%) | - | - | - | - | 33 (84.62%) | 12 (23%) | 1 (8.33%) | - | - | - | - | 11 (91.67%) |
| Chen, Jiang | 135 | NA (NA%) | - | - | - | - | - | - | 31 (22%) | - | - | 4 (12.90%) | - | - | 27 (87.10%) |
| Heili-Frades | 4,712 | 4086 (86%) | 210 (5.14%) | 659 (16.13%) | - | - | 3217 (78.73%) | - | 626 (13%) | 23 (3.67%) | 161 (25.72%) | - | - | 442 (70.61%) | - |
| Kim, Garg | 2,490 | 2070 (83%) | 128 (6.18%) | 481 (23.24%) | - | - | 1461 (70.58%) | - | 420 (16%) | 22 (5.24%) | 161 (38.33%) | - | - | 236 (56.19%) | - |
| Al-Hindawi | 31 | 15 (48%) | 0 (0.00%) | 10 (66.67%) | - | 5 (33.33%) | - | - | 16 (51%) | 1 (6.25%) | 12 (75.00%) | - | 3 (18.75%) | - | - |
| Louis | 22 | 16 (72%) | - | - | 7 (43.75%) | - | - | 9 (56.25%) | 6 (27%) | - | - | 3 (50.00%) | - | - | 3 (50.00%) |
| Soto-Mota | 400 | 200 (50%) | - | - | 23 (11.50%) | - | - | 177 (88.50%) | 200 (50%) | - | - | 25 (12.50%) | - | - | 175 (87.50%) |
| Garibaldi | 747 | 634 (84%) | 36 (5.68%) | 129 (20.35%) | - | - | - | 469 (73.97%) | 113 (15%) | 6 (5.31%) | 36 (31.86%) | - | - | - | 71 (62.83%) |
| Docherty | 13,364 | 8199 (61%) | 370 (4.51%) | 1832 (22.34%) | - | 4179 (50.97%) | - | 1818 (22.17%) | 5165 (38%) | 214 (4.14%) | 1350 (26.14%) | - | 2105 (40.76%) | - | 1496 (28.96%) |
| Kuderer | 928 | 807 (86%) | 38 (4.71%) | 262 (32.47%) | - | 425 (52.66%) | - | 31 (3.84%) | 121 (13%) | 5 (4.13%) | 64 (52.89%) | - | 44 (36.36%) | - | 2 (1.65%) |
| Ramlall | 11,116 | 10498 (94%) | - | - | 2771 (26.40%) | 7727 (73.60%) | - | - | 618 (5%) | - | - | 208 (33.66%) | 410 (66.34%) | - | - |
| Wang, Oekelen | 57 | 43 (75%) | - | - | 14 (32.56%) | - | - | 29 (67.44%) | 14 (24%) | - | - | 7 (50.00%) | - | - | 7 (50.00%) |
| Martinez-Portilla | 224 | 217 (96%) | - | - | 7 (3.23%) | - | - | 210 (96.77%) | 7 (3%) | - | - | 0 (0.00%) | - | - | 7 (100.00%) |
| Cen | 1,007 | 964 (95%) | - | - | 87 (9.02%) | - | - | 877 (90.98%) | 43 (4%) | - | - | 1 (2.33%) | - | - | 42 (97.67%) |
| Klang | 3,406 | 2270 (66%) | - | - | 492 (21.67%) | - | - | 1778 (78.33%) | 1136 (33%) | - | - | 301 (26.50%) | - | - | 835 (73.50%) |
| Wang, Zhong | 5,510 | 4874 (88%) | 247 (5.07%) | 1083 (22.22%) | - | 3544 (72.71%) | - | - | 636 (11%) | 28 (4.40%) | 214 (33.65%) | - | 394 (61.95%) | - | - |
| Miyara | 338 | 211 (62%) | 13 (6.16%) | 58 (27.49%) | - | 141 (66.82%) | - | - | 46 (13%) | 1 (2.17%) | 23 (50.00%) | - | 21 (45.65%) | - | - |
| Rajter | 255 | 209 (81%) | - | - | 28 (13.40%) | 181 (86.60%) | - | - | 53 (20%) | - | - | 18 (33.96%) | 28 (52.83%) | - | - |
| Zeng | 1,031 | 866 (84%) | - | - | 69 (7.97%) | - | - | 797 (92.03%) | 165 (16%) | - | - | 36 (21.82%) | - | - | 129 (78.18%) |
| Chen, Yu | 1,859 | 1651 (88%) | 32 (1.94%) | 54 (3.27%) | - | 1565 (94.79%) | - | - | 208 (11%) | 13 (6.25%) | 12 (5.77%) | - | 183 (87.98%) | - | - |
| Garassino | 190 | 124 (65%) | - | - | 92 (74.19%) | 32 (25.81%) | - | - | 66 (34%) | - | 61 (92.42%) | - | 5 (7.58%) | - | - |
| Gu | 884 | 864 (97%) | 40 (4.63%) | 250 (28.94%) | - | 219 (25.35%) | - | - | 20 (2%) | 0 (0.00%) | 14 (70.00%) | - | 6 (30.00%) | - | - |
| Sigel | 88 | 70 (79%) | - | - | 37 (52.86%) | - | - | 33 (47.14%) | 18 (20%) | - | - | 11 (61.11%) | - | - | 7 (38.89%) |
| Nguyen | 356 | 308 (86%) | - | - | 91 (29.55%) | - | - | 217 (70.45%) | 45 (12%) | - | - | 23 (51.11%) | - | - | 22 (48.89%) |
| de Souza | 8,443 | 7826 (92%) | - | - | 95 (1.21%) | - | 7571 (96.74%) | 160 (2.04%) | 617 (7%) | - | - | 47 (7.62%) | - | 560 (90.76%) | 10 (1.62%) |
| Mendy | 689 | 663 (96%) | - | - | 160 (24.13%) | - | - | 502 (75.72%) | 26 (3%) | - | - | 10 (38.46%) | - | - | 16 (61.54%) |
| Shi, Resurreccion | 256 | 210 (82%) | - | - | 128 (60.95%) | - | - | 82 (39.05%) | 46 (17%) | - | - | 26 (56.52%) | - | - | 20 (43.48%) |
| Xie | 619 | 591 (95%) | - | - | 43 (7.28%) | - | - | 548 (92.72%) | 28 (4%) | - | - | 8 (28.57%) | - | - | 20 (71.43%) |
| Fox | 54 | 35 (64%) | 1 (2.86%) | 4 (11.43%) | - | 18 (51.43%) | - | 12 (34.29%) | 19 (35%) | 0 (0.00%) | 2 (10.53%) | - | 12 (63.16%) | - | 5 (26.32%) |
| Zhang, Cao | 289 | 240 (83%) | 10 (4.17%) | 6 (2.50%) | - | - | - | 224 (93.33%) | 49 (16%) | 4 (8.16%) | 8 (16.33%) | - | - | - | 37 (75.51%) |
| Gupta | 496 | 255 (51%) | - | - | 15 (5.88%) | - | 80 (31.37%) | 160 (62.75%) | 241 (48%) | - | - | 21 (8.71%) | 77 (31.95%) | - | 143 (59.34%) |
| Soares | 1,152 | 696 (60%) | 38 (5.46%) | - | - | - | 658 (94.54%) | - | 456 (39%) | 39 (8.55%) | - | - | - | 417 (91.45%) | - |
| Thompson | 470 | 301 (64%) | 39 (12.96%) | 79 (26.25%) | - | 183 (60.80%) | - | - | 169 (35%) | 27 (15.98%) | 49 (28.99%) | - | 93 (55.03%) | - | - |
| Bernaola | 1,645 | 1382 (84%) | 35 (2.53%) | 146 (10.56%) | - | 1201 (86.90%) | - | - | 263 (15%) | 6 (2.28%) | 33 (12.55%) | - | 218 (82.89%) | - | - |
| Islam | 654 | 631 (96%) | 103 (16.32%) | - | - | - | - | 507 (80.35%) | 23 (3%) | 3 (13.04%) | - | - | - | - | - |
| Philipose | 466 | 267 (57%) | 19 (7.12%) | 204 (76.40%) | - | 44 (16.48%) | - | - | 199 (42%) | 9 (4.52%) | 137 (68.84%) | - | 33 (16.58%) | - | 20 (10.05%) |
| Fillmore | 1,794 | 1566 (87%) | 408 (26.05%) | 758 (48.40%) | - | 279 (17.82%) | - | 98 (6.26%) | 228 (12%) | 44 (19.30%) | 141 (61.84%) | - | 43 (18.86%) | - | 23 (10.09%) |
| Pan | 3,536 | 3302 (93%) | - | - | 862 (26.11%) | - | - | 2440 (73.89%) | 234 (6%) | - | - | 82 (35.04%) | - | - | 152 (64.96%) |
| Zhao, Chen | 474 | 398 (83%) | 87 (21.86%) | - | - | - | - | 311 (78.14%) | 82 (17%) | 36 (43.90%) | - | - | - | - | 46 (56.10%) |
| Holman | 10,989 | NA (NA%) | - | - | - | - | - | - | 10989 (100%) | 609 (5.54%) | 4684 (42.62%) | - | 5386 (49.01%) | - | 310 (2.82%) |
| Chand | 300 | 143 (47%) | 23 (16.08%) | - | - | - | - | 120 (83.92%) | 157 (52%) | 44 (28.03%) | - | - | - | - | 113 (71.97%) |
| Oliveira | 131 | 105 (80%) | - | - | 16 (15.24%) | - | 83 (79.05%) | 6 (5.71%) | 26 (19%) | - | - | 7 (26.92%) | - | 17 (65.38%) | - |
| Vilar-Garcia | 328,892 | 316605 (96%) | 71215 (22.49%) | - | - | - | - | 245390 (77.51%) | 12287 (3%) | 3103 (25.25%) | - | - | - | - | 9184 (74.75%) |
| Ibarra-Nava | 416,546 | 370038 (88%) | 27001 (7.30%) | - | - | - | - | 343037 (92.70%) | 46508 (11%) | 3817 (8.21%) | - | - | - | - | 426791 (917.67%) |
| Rubio-Rivas | 186 | 147 (79%) | 7 (4.76%) | 32 (21.77%) | - | 108 (73.47%) | - | - | 39 (20%) | 1 (2.56%) | 6 (15.38%) | - | 32 (82.05%) | - | - |
| Ren | 432 | 289 (66%) | 25 (8.65%) | - | - | 264 (91.35%) | - | - | 143 (33%) | 18 (12.59%) | - | 125 (87.41%) | - | - | - |
| Ullah | 212 | 158 (74%) | 22 (13.92%) | 67 (42.41%) | - | 63 (39.87%) | - | 6 (3.80%) | 54 (25%) | 2 (3.70%) | 35 (64.81%) | - | 17 (31.48%) | - | 0 (0.00%) |
| Nicholson | 1,040 | 829 (79%) | 70 (8.44%) | 163 (19.66%) | - | 320 (38.60%) | - | 276 (33.29%) | 211 (20%) | 16 (7.58%) | 68 (32.23%) | - | 65 (30.81%) | - | 62 (29.38%) |
| Kalan | 193 | 188 (97%) | 14 (7.45%) | - | - | 162 (86.17%) | - | 12 (6.38%) | 5 (2%) | 0 (0.00%) | - | - | 2 (40.00%) | - | 3 (60.00%) |
| Incerti | 13,658 | 11495 (84%) | 785 (6.83%) | 2450 (21.31%) | - | 5450 (47.41%) | 2810 (24.45%) | - | 2163 (15%) | 81 (3.74%) | 642 (29.68%) | - | 757 (35.00%) | 683 (31.58%) | - |
| Ioannou | 10,131 | 9033 (89%) | 1054 (11.67%) | 3549 (39.29%) | - | 3339 (36.96%) | - | 1091 (12.08%) | 1098 (10%) | 81 (7.38%) | 528 (48.09%) | - | 305 (27.78%) | - | 184 (16.76%) |
| Lamure | 89 | 59 (66%) | 4 (6.78%) | 16 (27.12%) | - | 31 (52.54%) | - | 8 (13.56%) | 30 (33%) | 1 (3.33%) | 13 (43.33%) | - | 12 (40.00%) | - | 4 (13.33%) |
| Yadaw | 5,051 | 4635 (91%) | 162 (3.50%) | 709 (15.30%) | - | 2394 (51.65%) | - | 1370 (29.56%) | 416 (8%) | 17 (4.09%) | 105 (25.24%) | - | 196 (47.12%) | - | 98 (23.56%) |
| Zinellu | 105 | 77 (73%) | 24 (31.17%) | 8 (10.39%) | - | 45 (58.44%) | - | - | 28 (26%) | 8 (28.57%) | 3 (10.71%) | - | 17 (60.71%) | - | - |
| Zhang, Li | 399 | NA (NA%) | - | - | - | - | - | - | 399 (100%) | 60 (15.04%) | 186 (46.62%) | - | 148 (37.09%) | - | - |
| Wang, Shu | 59 | 18 (30%) | - | - | 0 (0.00%) | - | - | 18 (100.00%) | 41 (69%) | - | - | 9 (21.95%) | - | - | 32 (78.05%) |
| Wang, Zheutlin | 2,448 | 1706 (69%) | 57 (3.34%) | 315 (18.46%) | - | 954 (55.92%) | - | 380 (22.27%) | 742 (30%) | 25 (3.37%) | 197 (26.55%) | - | 354 (47.71%) | - | 166 (22.37%) |
| Torres-Macho | 1,968 | 1643 (83%) | - | - | 335 (20.39%) | - | - | 1308 (79.61%) | 325 (16%) | - | - | 125 (38.46%) | - | - | 200 (61.54%) |
| Raines | 440 | 408 (92%) | - | - | 222 (54.41%) | 186 (45.59%) | - | - | 32 (7%) | - | - | 28 (87.50%) | 4 (12.50%) | - | - |
| Parra-Bracamonte | 331,298 | 292988 (88%) | - | - | 21269 (7.26%) | - | - | 271719 (92.74%) | 38310 (11%) | - | - | 3215 (8.39%) | - | - | 35095 (91.61%) |
| Li, Long, Zhang | 954 | 876 (91%) | - | - | 48 (5.48%) | 828 (94.52%) | - | - | 78 (8%) | - | - | 8 (10.26%) | 70 (89.74%) | - | - |
| Bellan | 407 | 285 (70%) | 30 (10.53%) | - | - | - | 191 (67.02%) | 64 (22.46%) | 122 (29%) | 24 (19.67%) | - | - | - | 67 (54.92%) | 31 (25.41%) |
| Alharthy | 352 | 239 (67%) | 109 (45.61%) | - | - | - | 130 (54.39%) | - | 113 (32%) | 65 (57.52%) | - | - | - | 48 (42.48%) | - |
| Adrish | 1,173 | 783 (66%) | - | - | 205 (26.18%) | 578 (73.82%) | - | - | 390 (33%) | - | - | 131 (33.59%) | 259 (66.41%) | - | - |
| Hoertel, Sanchez, Vernet | 12,210 | 10802 (88%) | 898 (8.31%) | - | - | - | - | 9904 (91.69%) | 1408 (11%) | 204 (14.49%) | - | - | - | - | 1204 (85.51%) |
| Sourij | 238 | 180 (75%) | 4 (2.22%) | 26 (14.44%) | - | 150 (83.33%) | - | - | 58 (24%) | 0 (0.00%) | 12 (20.69%) | - | 46 (79.31%) | - | - |
| Simons | 446 | 318 (71%) | 30 (9.43%) | 109 (34.28%) | - | 179 (56.29%) | - | - | 128 (28%) | 12 (9.38%) | 63 (49.22%) | - | 53 (41.41%) | - | - |
| Bisso | 168 | 122 (72%) | 13 (10.66%) | - | - | - | - | 109 (89.34%) | 46 (27%) | 5 (10.87%) | - | - | - | - | 39 (84.78%) |
| Caliskan | 565 | 490 (86%) | 97 (19.80%) | 48 (9.80%) | - | 345 (70.41%) | - | - | 75 (13%) | 21 (28.00%) | 31 (41.33%) | - | 23 (30.67%) | - | - |
| Ebrahimian | 226 | 128 (56%) | - | - | 9 (7.03%) | - | 119 (92.97%) | - | 98 (43%) | - | - | 15 (15.31%) | - | 83 (84.69%) | - |
| Estiri | 16,709 | 15879 (95%) | - | - | 1304 (8.21%) | - | - | 14575 (91.79%) | 830 (4%) | - | - | 137 (16.51%) | - | - | 693 (83.49%) |
| Ferrari | 198 | 165 (83%) | - | - | 27 (16.36%) | 138 (83.64%) | - | - | 33 (16%) | - | - | 14 (42.42%) | 19 (57.58%) | - | - |
| Ho, Narasimhan | 4,909 | 3553 (72%) | 163 (4.59%) | 743 (20.91%) | - | 2647 (74.50%) | - | - | 1356 (27%) | 54 (3.98%) | 319 (23.53%) | - | 983 (72.49%) | - | - |
| Mansour | 111 | 83 (74%) | 5 (6.02%) | - | - | - | - | 78 (93.98%) | 28 (25%) | 6 (21.43%) | - | - | - | - | 22 (78.57%) |
| Park | 2,269 | 2105 (92%) | 92 (4.37%) | - | - | - | - | 2013 (95.63%) | 164 (7%) | 2 (1.22%) | - | - | - | - | 162 (98.78%) |
| Quan | 2,038 | 1587 (77%) | - | - | 589 (37.11%) | - | - | 998 (62.89%) | 442 (21%) | - | - | 218 (49.32%) | - | - | 224 (50.68%) |
| Saurabh | 911 | 870 (95%) | 70 (8.05%) | 4 (0.46%) | - | 796 (91.49%) | - | - | 41 (4%) | 4 (9.76%) | 2 (4.88%) | - | 35 (85.37%) | - | - |
| Strangfeld | 3,729 | 3339 (89%) | - | - | 664 (19.89%) | 2190 (65.59%) | - | 485 (14.53%) | 390 (10%) | - | - | 112 (28.72%) | 198 (50.77%) | - | 80 (20.51%) |
| Nezhadmoghadam | 13,367 | 7757 (58%) | 686 (8.84%) | - | - | - | - | 7071 (91.16%) | 5610 (41%) | 565 (10.07%) | - | - | - | - | 5045 (89.93%) |
| Nuno | 4,730 | 4401 (93%) | 427 (9.70%) | - | - | - | - | 3974 (90.30%) | 329 (6%) | 53 (16.11%) | - | - | - | - | 276 (83.89%) |
| Fernandez, Fuertes | 46 | 45 (97%) | 12 (26.67%) | - | - | - | - | 33 (73.33%) | 1 (2%) | 0 (0.00%) | - | - | - | - | 1 (100.00%) |
| Dambha, Miller | 5,328 | 4684 (87%) | 447 (9.54%) | 2326 (49.66%) | - | 1912 (40.82%) | - | - | 664 (12%) | 40 (6.02%) | 388 (58.43%) | - | 216 (32.53%) | - | - |
| Williamson, Tazare | 7,999 | NA (NA%) | - | - | - | - | - | - | 7999 (100%) | 737 (9.21%) | 4745 (59.32%) | - | 2499 (31.24%) | - | 18 (0.23%) |
| Dayem, Ullah | 217 | 164 (75%) | 23 (14.02%) | 72 (43.90%) | - | 67 (40.85%) | - | 2 (1.22%) | 53 (24%) | 2 (3.77%) | 37 (69.81%) | - | 14 (26.42%) | - | - |
| Macias, Guzman | 196 | 109 (55%) | - | - | 37 (33.94%) | - | - | 72 (66.06%) | 87 (44%) | - | - | 34 (39.08%) | - | - | 53 (60.92%) |
| Martin, Vicente | 92 | 38 (41%) | 3 (7.89%) | - | - | - | - | 35 (92.11%) | 54 (58%) | 2 (3.70%) | - | - | - | - | 52 (96.30%) |
| Greenbaum | 44 | 32 (72%) | 2 (6.25%) | 6 (18.75%) | - | 24 (75.00%) | - | - | 12 (27%) | 0 (0.00%) | 3 (25.00%) | - | 9 (75.00%) | - | - |
| Asem | 8,162 | 7573 (92%) | 1147 (15.15%) | - | - | - | - | 6426 (84.85%) | 589 (7%) | 208 (35.31%) | - | - | - | - | 381 (64.69%) |
| Gil | 186 | 174 (93%) | 42 (24.14%) | - | - | - | 132 (75.86%) | - | 12 (6%) | 4 (33.33%) | - | - | - | 8 (66.67%) | - |
| Rubina | 52 | 41 (78%) | 2 (4.88%) | - | - | - | 35 (85.37%) | 4 (9.76%) | 11 (21%) | 0 (0.00%) | - | - | - | 6 (54.55%) | 5 (45.45%) |
| Mann | 1,769 | 1422 (80%) | - | - | 515 (36.22%) | 840 (59.07%) | - | 67 (4.71%) | 347 (19%) | - | - | 130 (37.46%) | 163 (46.97%) | - | 54 (15.56%) |
| Madakkatel | 1,953 | 1577 (80%) | 184 (11.67%) | 586 (37.16%) | - | 789 (50.03%) | - | 18 (1.14%) | 376 (19%) | 54 (14.36%) | 176 (46.81%) | - | 140 (37.23%) | - | 6 (1.60%) |
| Demichev | 50 | 35 (70%) | 1 (2.86%) | 6 (17.14%) | - | 28 (80.00%) | - | - | 15 (30%) | 0 (0.00%) | 2 (13.33%) | - | 13 (86.67%) | - | - |
| Velasco, Rodriguez | 2,070 | 1677 (81%) | 68 (4.05%) | - | - | - | - | 1599 (95.35%) | 393 (18%) | 17 (4.33%) | - | - | - | - | 376 (95.67%) |
| Puebla, Neira | 10,216 | 10028 (98%) | 395 (3.94%) | 870 (8.68%) | - | 8763 (87.39%) | - | - | 188 (1%) | 3 (1.60%) | 47 (25.00%) | - | 138 (73.40%) | - | - |
| Prats-Uribe, Xie | 1,591 | 1219 (76%) | 136 (11.16%) | 453 (37.16%) | - | 630 (51.68%) | - | - | 372 (23%) | 56 (15.05%) | 175 (47.04%) | - | 141 (37.90%) | - | - |
| Peng, Lei | 622 | 547 (87%) | 48 (8.78%) | - | - | - | - | 499 (91.22%) | 75 (12%) | 14 (18.67%) | - | - | - | - | 61 (81.33%) |
| Nassar | 160 | 121 (75%) | 9 (7.44%) | - | - | - | - | 112 (92.56%) | 39 (24%) | 8 (20.51%) | - | - | - | - | 31 (79.49%) |
| Mendez, Dominguez | 7,064 | 6867 (97%) | 132 (1.92%) | - | - | - | - | 6735 (98.08%) | 197 (2%) | 2 (1.02%) | - | - | - | - | 195 (98.98%) |
| Marimuthu | 854 | 767 (89%) | 4 (0.52%) | - | - | - | - | 763 (99.48%) | 87 (10%) | 6 (6.90%) | - | - | - | - | 81 (93.10%) |
| Chetboun | 3,401 | 2892 (85%) | 190 (6.57%) | 689 (23.82%) | - | 1756 (60.72%) | - | 257 (8.89%) | 509 (14%) | 20 (3.93%) | 171 (33.60%) | - | 164 (32.22%) | - | 154 (30.26%) |
| Bruce | 125 | 101 (80%) | 13 (12.87%) | - | - | - | - | 88 (87.13%) | 24 (19%) | 12 (50.00%) | - | - | - | - | 12 (50.00%) |
| Bhaskaran | 1,584 | 1082 (68%) | 85 (7.86%) | 381 (35.21%) | - | 587 (54.25%) | - | 29 (2.68%) | 502 (31%) | 27 (5.38%) | 224 (44.62%) | - | 237 (47.21%) | - | 14 (2.79%) |
| Bertuzzi | 17,456,515 | NA (NA%) | - | - | - | - | - | - | 17063 (0%) | 1109 (6.50%) | 10276 (60.22%) | - | 5678 (33.28%) | - | - |
| Avouac | 92 | 70 (76%) | 10 (14.29%) | - | - | - | 35 (50.00%) | 25 (35.71%) | 22 (23%) | 6 (27.27%) | - | - | - | 5 (22.73%) | 11 (50.00%) |
| Alsafar | 873 | 751 (86%) | 101 (13.45%) | - | - | - | - | 650 (86.55%) | 122 (13%) | 36 (29.51%) | - | - | - | - | 86 (70.49%) |
| Ahmadi | 464 | 438 (94%) | 50 (11.42%) | - | - | - | 388 (88.58%) | - | 26 (5%) | 0 (0.00%) | - | - | - | 26 (100.00%) | - |
| Aboueshia | 468,443 | 468056 (99%) | 48522 (10.37%) | 162807 (34.78%) | - | 256727 (54.85%) | - | - | 387 (0%) | 59 (15.25%) | 183 (47.29%) | - | 145 (37.47%) | - | - |




Figure 9. Forest plot for the risk of mortality in current vs. never smokers. The prior from the previous review version (v11) was RR = 1.12.




Figure 10. Forest plot for the risk of mortality in former smokers vs. never smokers. The prior from the previous version (v11) was RR = 1.56.


## Discussion

This living rapid review found uncertainty in the majority of 547 studies arising from the recording of smoking status. Notwithstanding this uncertainty, compared with overall adult national prevalence estimates, recorded current smoking rates in most studies were lower than expected. In a subset of good and fair quality studies (n = 39), current but not former smokers had a reduced risk of testing positive for SARS-CoV-2 but current smokers appeared somewhat more likely to present for testing and/or receive a test. Current compared with never smokers had an increased risk of greater disease severity. Data for current smokers on the risk of hospitalisation and mortality were inconclusive, and favoured there being no important associations. Former smokers were at increased risk of hospitalisation, disease severity and mortality compared with never smokers.

### Issues complicating interpretation

Interpretation of results from studies conducted during the first phase of the SARS-CoV-2 pandemic is complicated by several factors (see [Figure 11](#fig-11)):

1. *Exposure to SARS-CoV-2*  
   1. Exposure to the SARS-CoV-2 virus is heterogeneous with different subgroups at heightened risk of infection at different stages of the pandemic, at least partly due to differential contact matrices by age, sex and socioeconomic position (CMMID COVID-19 working group et al., 2020), which are associated with smoking status.  
   2. The probability of viral exposure depends largely on local prevalence, which varies over time. This likely introduces bias in studies assessing the rate of infection by smoking status conducted in the early phase of the pandemic.
2. *Infection with SARS-CoV-2*  
   1. Infection following viral exposure depends on individual differences in, for example, genetic susceptibility or immunocompetence, which are poorly understood at present and may be confounded with smoking. For example, the household secondary attack rate for COVID-19 is estimated at 17% (Fung et al., 2020).  
   2. Heated and humidified air may act to disrupt the ability of the virus to persist in the airway mucosa of smokers. There is some evidence that transient localised hyperthermia can inhibit replication of rhinoviruses, a non-enveloped virus that causes the common cold (Conti et al., 1999). However, as SARS-CoV-2 is an enveloped virus (Schoeman & Fielding, 2019), it is unclear whether a similar protective effect against viral replication or invasion by heated and humidified air may occur.
3. *Symptomatic COVID-19*  
   1. An estimated 20% (95% CI = 17-25%) of COVID-19 cases are asymptomatic (Buitrago-Garcia et al., 2020), with some evidence suggesting younger people are more likely to be asymptomatic (Kronbichler et al., 2020). Testing is hence likely limited in some subgroups, with the potential for these groups to include an overrepresentation of current smokers.  
   2. On the other hand, current and former smokers may be more likely to meet local criteria for community testing due to increased prevalence of symptoms consistent with SARS-CoV-2 infection, such as cough, increased sputum production or altered sense of smell or taste (Hopkinson et al., 2020). Evidence from a small number of studies indicates that current smokers may be more likely to present for testing, hence increasing the denominator in comparisons with never smokers and potentially inflating the rate of negative tests in current smokers. Infection positivity rates estimated among random samples are more informative. We identified nine random/population studies reporting on seroprevalence and smoking status. However, response rates were suboptimal where reported (e.g. 58.8%-64.3%; (Merkely et al., 2020) and (Wagner et al., 2021)) and the current smoking rate was often several percentage points below national prevalence estimates (e.g. 12% vs. 25% and 15% vs. 27% daily smoking prevalence, respectively; (Andler, 2019) and (OFS, 2020)), which raises doubt about the representativeness of the final samples.
4. *Testing positive for SARS-CoV-2*  
   1. Smokers with COVID-19 may be less likely to receive a SARS-CoV-2 test or present to hospital due to lack of access to healthcare and may be more likely to die in the community from sudden complications (i.e. self-selection bias) and thus not be recorded (Brown, 2020).  
   2. Diagnostic criteria for SARS-CoV-2 infection and COVID-19 have changed during the course of the pandemic (Organisation, n.d.). It was not possible to extract details on the specific RT-PCR or antibody-based techniques or platforms used across the included studies due to reporting gaps. Different platforms have varying sensitivity and specificity to detect SARS-CoV-2 infection. In addition, testing for acute infection requires swabbing of the mucosal epithelium, which may be disrupted in current smokers, potentially altering the sensitivity of assays (Lusignan et al., 2020).
5. *Hospitalisation with COVID-19*  
   1. Reasons for hospitalisation vary by country and time in the pandemic. For example, early cases may have been hospitalised for isolation and quarantine reasons and not due to medical necessity. It is plausible this may have skewed early data towards less severe cases. In addition, the observed association between former smoking and greater disease severity may be explained by collider bias (Griffith et al., 2020), where conditioning on a collider (e.g. testing or hospitalisation) by design or analysis may introduce a spurious association between current or former smoking (a potential cause of testing or hospitalisation) and SARS-CoV-2 infection/adverse outcomes from COVID-19 (potentially exacerbated by smoking) (Murray, 2020).  
   2. The majority of included studies relied on EHRs as the source of information on smoking status. Research shows large discrepancies between EHRs and actual behaviour (Polubriaginof et al., 2018). Known failings of EHRs include implausible longitudinal changes, such as former smokers being recorded as never smokers at subsequent hospital visits (Polubriaginof et al., 2018). A recent study conducted in a UK hospital setting found a large discrepancy between smoking status recorded on the EHR and within the contemporaneous clinical notes (Simons, Perski, et al., 2020). Known failings of EHRs include implausible longitudinal changes, such as former smokers being recorded as never smokers at subsequent hospital visits (Polubriaginof et al., 2018). Misreporting on the part of the patient (perhaps due to perceived stigma) has also been observed, with biochemical measures showing higher rates of smoking compared with self-report in hospitalised patients in the US (Benowitz et al., 2009). It is hence likely that under-reporting of current and former smoking status in hospitals occurred across the included studies.  
   3. The majority of included studies were conducted in hospital settings. It is plausible that a non-trivial proportion of patients were infected with SARS-CoV-2 while being an inpatient for a different medical reason. If so, this may have biased the hospitalised populations towards older and more frail groups, who are less likely to be smokers (Mangera et al., 2017).  
   4. Individuals with severe COVID-19 symptoms may have stopped smoking immediately before admission to hospital and may therefore not have been recorded as current smokers (i.e. reverse causality).
6. *COVID-19 disease severity and death*  
   1. Given lack of knowledge of the disease progression and long-term outcomes of COVID-19, it is unclear whether studies conducted thus far in the pandemic have monitored patients for a sufficient time period to report complete survival outcomes or whether they are subject to early censoring. Adding to this, COVID-19 related mortality has been differentially defined across countries and epidemic phases. For example, in some UK reporting, death within 28 days of a COVID-19 diagnosis is required for attributing the cause of death to the virus. However, according to the UK Office for National Statistics, COVID-19 deaths are recorded only if this was stated on the death certificate.  
   2. If there is a protective effect of nicotine on COVID-19 disease outcomes, abrupt nicotine withdrawal upon hospitalisation may lead to worse disease outcomes including death (Farsalinos, Niaura, et al., 2020).  
   3. During periods of heightened demand of limited healthcare resources, current and former smokers with extensive comorbidities may have reduced priority for intensive care admission, thus leading to higher in-hospital mortality.  
   4. COVID-19 outcomes are currently limited to in-hospital death or survival to discharge. This binary outcome does not capture potential long-term morbidity attributed to COVID-19, such as stroke, amputation, acute cardiac events, or long COVID (i.e. symptoms that persist for weeks or months beyond infection), which may be moderated by smoking status.



*Figure 11.* A schematic of some of the interpretation issues for the association of smoking status and COVID-19 infection, hospitalisation, disease severity and mortality. Numbers refer to the issues listed in-text in the above section. Issues presented on the right-hand side relate directly to smoking status.

### Limitations

This living rapid evidence review was limited by having a single reviewer extracting data with a second independently verifying the data extracted to minimise errors, restricting the search to one electronic database and one pre-print server and by not including at least three large population surveys due to their reliance on self-reported suspected or confirmed SARS-CoV-2 infection (which means they do not meet our eligibility criteria) (Bowyer et al., 2020; Hopkinson et al., 2020; Jackson et al., 2020). We also did not include a large, UK-based, representative seroprevalence study (Ward et al., 2020) in our meta-analyses as the odds of testing positive in former smokers was not reported. However, the odds of infection for current smokers (OR = 0.64, 95% CI = 0.58-0.71) was in concordance with the pooled estimate in our meta-analysis. Population surveys – particularly with linked data on confirmed infection or antibodies – will be included in future review versions to help mitigate some of the limitations of healthcare based observational studies. The comparisons of current and former smoking prevalence in the included studies with national prevalence estimates did not adjust observed prevalence for the demographic profile of those tested/admitted to hospital. Other reviews focused on this comparison have applied adjustments for sex and age, and continue to find lower than expected prevalence – notwithstanding the issues complicating interpretation described above (Farsalinos, Barbouni, et al., 2020).

### Implications for research, policy and practice

Further scientific research is needed to resolve the mixed findings summarised in our review. First, clinical trials of the posited therapeutic effect of nicotine could have important implications both for smokers and for improved understanding of how the SARS-CoV-2 virus causes disease in humans. Such trials should focus on medicinal nicotine (as smoked tobacco is a dirty delivery mechanism that could mask beneficial effects) and potentially differentiate between different modes of delivery (i.e. inhaled vs. ingested) since this can affect pharmacokinetics (Shahab et al., 2013) and potential therapeutic effects. A second research priority would be a large, representative (randomly sampled) population survey with a validated assessment of smoking status which distinguishes between recent and long-term ex-smokers – ideally biochemically verified – and assesses seroprevalence and links to health records.

In the meantime, public-facing messages about the possible protective effect of smoking or nicotine are premature. In our view, until there is further research, the quality of the evidence does not justify the huge risk associated with a message likely to reach millions of people that a lethal activity, such as smoking, may protect against COVID-19. It continues to be appropriate to recommend smoking cessation and emphasise the role of alternative nicotine products to support smokers to stop as part of public health efforts during COVID-19. At the very least, smoking cessation reduces acute risks from cardiovascular disease and could reduce demands on the healthcare system (Stead et al., 2013). GPs and other healthcare providers can play a crucial role – brief, high-quality and free online training is available at [National Centre for Smoking Cessation and Training](https://www.ncsct.co.uk/).

## Conclusion

Across 547 studies, recorded current but not past smoking prevalence was generally lower than national prevalence estimates. Current smokers were at reduced risk of testing positive for SARS-CoV-2 and at increased risk of greater disease severity. Former smokers were at increased risk of hospitalisation, disease severity and mortality compared with never smokers.

## Acknowledgements

An original short review for the Royal College of Physicians was converted to an extended living review after a request by Martin Dockrell, Tobacco Control Lead, Public Health England. All scientific decisions were made by the authors independently of funders and external organisations. The authors would like to thank Rosemary Koper for her assistance in running the electronic searches and data extraction up until v7, and all authors who responded to requests for additional data.

## Declaration of conflicts of interest

DS and OP have no conflicts of interest to declare. LS has received a research grant and honoraria for a talk and travel expenses from manufacturers of smoking cessation medications (Pfizer and Johnson & Johnson). JB has received unrestricted research funding to study smoking cessation from companies who manufacture smoking cessation medications. All authors declare no financial links with tobacco companies or e-cigarette manufacturers or their representatives.

## Funding statement

DS is supported by a PhD studentship from the UK Biotechnology and Biological Sciences Research Council [BB/M009513/1]. OP receives salary support from Cancer Research UK (C1417/A22962). JB, LS, & OP are members of SPECTRUM, a UK Prevention Research Partnership Consortium (MR/S037519/1). UKPRP is an initiative funded by the UK Research and Innovation Councils, the Department of Health and Social Care (England) and the UK devolved administrations, and leading health research charities.

## Review versions

The most up-to-date review version is available [here](https://www.qeios.com/read/latest-UJR2AW)

### Previous review versions

* [Version 1](https://doi.org/10.32388/UJR2AW)
* [Version 2](https://doi.org/10.32388/UJR2AW.3)
* [Version 3](https://doi.org/10.32388/UJR2AW.4)
* [Version 4](https://doi.org/10.32388/UJR2AW.5)
* [Version 5](https://doi.org/10.32388/UJR2AW.6)
* [Version 6](https://doi.org/10.32388/UJR2AW.7)
* [Version 7](https://doi.org/10.1111/add.15276)
* [Version 8](https://doi.org/10.32388/UJR2AW.9)
* [Version 9](https://doi.org/10.32388/UJR2AW.10)
* [Version 10](https://doi.org/10.32388/UJR2AW.11)
* [Version 11](https://doi.org/10.32388/UJR2AW.13)

## Data availability

All data contributing to the current and future review versions are available [here](https://doi.org/10.6084/m9.figshare.12756020)

All code required to reproduce the current and future analyses are available [here](https://doi.org/10.5281/zenodo.4002046)

#### To delete

C. Huang et al. (2020), Jie Li et al. (2020), Jin-jin Zhang et al. (2020), Yang et al. (2020), Guan, Ni, et al. (2020), W. Liu et al. (2020), Qi et al. (2020), Y. Huang et al. (2020), Xu et al. (2020), F. Zhou et al. (2020), R. Liu et al. (2020), Mo et al. (n.d.), Y. Shi et al. (2020), Xiaoli Zhang et al. (2020), Dong et al. (2020), S. Wan et al. (2020), X. Jin et al. (2020), R. Wang et al. (2020), Lian et al. (n.d.), Hu et al. (2020), Guan, Liang, et al. (2020), T. Chen et al. (2020), Guo et al. (2020), CDCMMWR (2020), E. S. Kim et al. (2020), Feng et al. (2020), C. Rentsch et al. (2020), Goyal et al. (2020), K. I. Zheng et al. (2020), Gold et al. (2020), Argenziano et al. (2020), Richardson et al. (2020), Fontanet et al. (2020), P. Shi et al. (2020), Hadjadj et al. (2020), Liao et al. (2020), Gil-Agudo et al. (2020), Q. Yao et al. (n.d.), Zuo, Yalavarthi, et al. (2020), Solís & Carreño (2020), Yu et al. (2020), Ziehr et al. (2020), Yi Zheng et al. (2020), Kalan et al. (2020), Kolin et al. (2020), Borobia et al. (2020), Giacomelli et al. (2020), Shah et al. (2020), Williamson et al. (2020), Allenbach et al. (2020), Robilotti et al. (2020), Lubetzky et al. (2020), Yin et al. (2020), Rica et al. (2020), Cho et al. (2020), Yanover et al. (2020), Hamer et al. (2020), Targher et al. (2020), Carrillo-Vega et al. (2020), Regina et al. (2020), Almazeedi et al. (2020), Lusignan et al. (2020), Palaiodimos et al. (2020), Mejia-Vilet et al. (2020), C. Chen et al. (2020), Jiong Li et al. (2020), Valenti et al. (2020), Feuth et al. (2020), Ge et al. (2020), Parrotta et al. (2020), Shekhar et al. (2020), Rimland et al. (2020), Basse et al. (2020), Freites et al. (2020), Alshami et al. (2020), Q. Shi et al. (2020), Al-Hindawi et al. (2020), M. A. Wu et al. (2020), L. Kim et al. (2020), Docherty et al. (2020), Petrilli et al. (2020), Klang et al. (n.d.), Vaquero et al. (2020), Ip et al. (2020), Heili-Frades (n.d.), Berumen et al. (2020), Garibaldi et al. (2020), Soto-Mota et al. (2020), Jingwen Li et al. (n.d.), Louis et al. (2020), Kuderer et al. (2020), M. Gianfrancesco et al. (2020), Chaudhry et al. (2020), Niedzwiedz et al. (2020), Valle et al. (2020), Bello-Chavolla, Bahena-López, et al. (2020), Batty et al. (2020), Israel, Feldhamer, et al. (2020), Hao et al. (2020), Lassale et al. (2020), Eugen-Olsen et al. (2020), Martinez-Portilla et al. (2020), Raisi-Estabragh et al. (n.d.), H. Luo et al. (2020), Boulware et al. (2020), Ikitimur et al. (n.d.), Sierpiński et al. (2020), B. Wang et al. (2020), Perrone et al. (2020), Sharma et al. (2020), Magagnoli et al. (2020), Ramlall et al. (2020), Giannouchos et al. (2020), Romão et al. (2020), Cen et al. (2020), Houlihan et al. (2020), Lan et al. (2020), Russell et al. (2020), Veras et al. (2020), Rossi et al. (2020), Martin-Jimenez et al. (2020), Rajter et al. (2020), Yaya Zhou et al. (2020), Woolford et al. (2020), Hultcrantz et al. (2020), Hernández-Garduño (2020), Sterlin et al. (2020), Maraschini et al. (2020), A.-L. Wang et al. (2020), McQueenie et al. (2020), Miyara et al. (2020), Apea et al. (2021), Garassino et al. (2020), Zeng et al. (2020), Suleyman et al. (2020), L. Chen et al. (2020), Kibler et al. (2020), Olivares et al. (2020), Elezkurtaj et al. (2020), Zuo, Estes, et al. (2020), Killerby (2020), Gu et al. (2020), Wei et al. (2020), Crovetto et al. (2020), Govind et al. (2020), Sisó-Almirall et al. (2020), Salton et al. (2020), Duan et al. (2020), Lenka et al. (2020), Fisman et al. (2020), Madariaga et al. (2020), C. Jin et al. (2020), Mendy et al. (2020), Sigel et al. (n.d.), Souza et al. (2020), Nguyen et al. (2020), Melo et al. (2020), Auvinen et al. (2020), Magleby et al. (n.d.), Hewitt et al. (2020), Mohamud et al. (2020), Trubiano et al. (2020), Patel et al. (2020), Merzon et al. (2020), Bello-Chavolla, Antonio-Villa, et al. (2020), Zacharioudakis et al. (2020), Antonio-Villa et al. (2020), Kimmig et al. (2020), Senkal (2020), Xie et al. (2020), Elmunzer et al. (2020), Alizadehsani et al. (2020), Maucourant et al. (2020), Fan et al. (2020), Z. Shi et al. (2020), Riley et al. (2020), Hippisley-Cox et al. (2020), Jin‐jin Zhang et al. (2020), Eiros et al. (2020), Marcos et al. (2020), Hoertel, Rico, Vernet, Beeker, et al. (2020), H. Shi et al. (2020), Hussein et al. (2020), Bian et al. (2020), Z. Zhan et al. (2020), Omrani et al. (2020), Gupta et al. (2020), Soares et al. (2020), Abolghasemi et al. (n.d.), Merkely et al. (2020), Fox et al. (n.d.), Pandolfi et al. (2020), Girardeau et al. (2020), Kurashima et al. (2020), McGrail & Edwards (2020), Martinez-Resendez et al. (2020), Hoertel, Rico, Vernet, Jannot, et al. (2020), Z.-H. Wang et al. (2020), Bernaola et al. (2020), Schneeweiss et al. (2020), Concha-Mejia & Rincon-Sanchez (2020), Izquierdo et al. (2020), Santos et al. (2020), Reiter et al. (2020), Motta et al. (2020), Altamimi et al. (2020), Thompson et al. (2020), Zobairy et al. (2020), K. Zhou et al. (2020), Kumar et al. (2020), Qu et al. (2020), Higuchi et al. (2020), Zhao et al. (2020), Fond et al. (2020), Jun et al. (2020), Morshed et al. (2020), Iversen et al. (2020), Ebinger et al. (2020), Hadi et al. (2020), Tao et al. (2020), Klang et al. (2020), J. Zhou et al. (2021), Altibi et al. (2020), Izzi-Engbeaya et al. (2020), Rizzo et al. (2020), Jehi et al. (2020), Holman et al. (2020), Ouyang et al. (2020), Valenzuela et al. (2020), Monteiro et al. (2020), Philipose et al. (2020), Weerahandi et al. (2020), Parra-Bracamonte et al. (2020), Peters et al. (2020), Islam et al. (2020), Chand et al. (2020), Aksu et al. (2020), Alkurt et al. (2020), Ward et al. (2020), Salerno et al. (2020), M. Rashid et al. (2020), Pan et al. (2020), Fillmore et al. (2020), Wei Zhou et al. (2020), Ibrahim et al. (2020), Oliveira et al. (2020), Yoo et al. (2020), T. Zhan et al. (2020), Mohamed-Hussein et al. (2020), Villar-Garcia et al. (2020), Ibarra-Nava et al. (2020), Rubio-Rivas et al. (2020), Mamtani et al. (2020), Ren, Guo, Blighe, et al. (2020), Mutambudzi et al. (2020), Yan et al. (2020), Mancilla-Galindo et al. (2020), Ullah et al. (2020), Hamadah et al. (2020), Sami et al. (2020), Pongpirul et al. (2020), Burrell et al. (2020), Nicholson et al. (2020), Ariza et al. (2020), Carrat et al. (2020), Favara et al. (2020a), Favara et al. (2020b), Invernizzi et al. (2020), Zhu et al. (2020), O’Reilly et al. (2020), Meini et al. (n.d.), Silva Neto et al. (2020), Ioannou et al. (2020), Torres-Macho et al. (2020), F. Li et al. (2020), J. G. Wang et al. (2020), Lopez-Medrano et al. (2020), Collard et al. (2020), Makaronidis et al. (2020), Yadaw et al. (2020), Talavera et al. (2020), Jakob et al. (2020), Incerti et al. (2020), J. Luo et al. (2020), Alharthy et al. (2020), Robinson et al. (2021), Adrish et al. (2020), Erber et al. (2020), Chaudhary et al. (2020), Raines et al. (2021), Roederer et al. (2021), Zinellu et al. (2021), Ramachandran et al. (2020), Lamure et al. (2020), Ghinai et al. (2020), Best et al. (2020), Savarraj et al. (n.d.), Israel, Schäffer, et al. (2020), El-Solh et al. (2020), Perico et al. (2020), Wenqian Zhou et al. (2020), Chudasama et al. (2020), Salama et al. (2021), Z. Wang et al. (2020), Yiwu Zhou et al. (2020), Hoertel, Sánchez, et al. (2020), Arleo et al. (2020), Bermejo-Martin et al. (2020), Joubert et al. (2020), Kortela et al. (2020), M. A. Gianfrancesco et al. (2020), Colaneri et al. (2021), Gallichotte et al. (2020), Lin et al. (2020), (**kim\_easy?**)–use\_2020, Galal et al. (2020), Riou et al. (2021), Sourij et al. (2020), Clavario et al. (2020), Saeed et al. (2020), Mansour et al. (2020), Cadegiani et al. (2020), Ilic et al. (2021), Benaim et al. (2020), F. K. Ho et al. (2020), Singh et al. (2020), Márquez-Salinas et al. (2020), Díez-Manglano et al. (2020), Bellan et al. (2020), Woolcott & Castilla-Bancayán (2021a), Woolcott & Castilla-Bancayán (2021b), K. Yao et al. (2021), H. Chen et al. (2020), Serling-Boyd et al. (2020), Simons, Perski, et al. (2020), Dupraz et al. (2020), Barasa et al. (2020), Ren, Guo, Tu, et al. (2020), J. Li et al. (2020), Martini et al. (2020), O’Gallagher et al. (2020), Alguwaihes et al. (2020), Zuo, Warnock, et al. (2020), Xiaomeng Zhang et al. (2020), Dai et al. (2020), Vila-Córcoles et al. (2020), Bisso et al. (2020), C. T. Rentsch et al. (2020), Thiabaud et al. (2020), Vila-Corcoles et al. (2020), Lévy et al. (2020), Kantele et al. (2020), Iftime et al. (2020), K. S. Ho et al. (2020), Caliskan & Saylan (2020), Muñoz et al. (2020), Crooks et al. (2020), Nunez-Gil et al. (2020), Núñez-Gil et al. (2021), Gori et al. (2020), Rowlands et al. (2020), Richard et al. (2020), Schubl et al. (2020), Ugur Chousein et al. (2020), Modrák et al. (2020), Kara Polat et al. (2020), Kjetland et al. (2020), Lewnard et al. (2021), Nezhadmoghadam & Tamez-Peña (2021), Covid-19 in pregnancy et al. (2021), Boyd & Martin-Loeches (2021), Paleiron et al. (2021), Ader et al. (2021), Giannini et al. (2021), Shade et al. (2021), Park et al. (2021), Ferrari et al. (2021), Y. Zhang et al. (2021), Ebrahimian et al. (2021), Vahidy et al. (2021), Mendes et al. (2021), Saurabh et al. (2021), Ayoubkhani et al. (2021), Thakur et al. (2021), Zhong et al. (2020), Cummins et al. (2021), Sun et al. (2021), Lowe et al. (2021), Caglar & Kacer (2021), De Santi et al. (2021), Quan et al. (2021), Strangfeld et al. (2021), Tardif et al. (2021), Jafari et al. (2021), Prats-Uribe, Tobed, et al. (2021), Nuño et al. (2021), Abajo et al. (2021), Mora et al. (2021), Molenaar et al. (2021), Leister et al. (2021), Didikoglu et al. (2021), Estiri et al. (2021), Tavakol et al. (2021), H. Cai et al. (2021), Lohia et al. (2021), Vila-Corcoles et al. (2021), Gégout petit et al. (2021), Q. Zhang et al. (2021), Dambha-Miller et al. (2021), Badr et al. (2021a), Badr et al. (2021b), Hoertel et al. (2021), Lombardi et al. (2021), Gharebaghi et al. (2021), Shields et al. (2021), Voruz et al. (2021), The OpenSAFELY Collaborative et al. (2021), González, Vielot, et al. (2021), Lucar et al. (2021), Drozd et al. (2021), Printza et al. (2021), Dashti et al. (2021), Nielsen et al. (2021), Peng et al. (2021), Dayem Ullah et al. (2021), Velasco-Rodríguez et al. (2021), Action to beat coronavirus/Action pour battre le coronavirus (Ab-C) Study Investigators & Jha (2021), Guzmán et al. (2021), García-Abellán et al. (2021), Martin-Vicente et al. (2021), Rogier et al. (2021), Greenbaum et al. (2021), Grint et al. (2021), Kline et al. (2021), Hausfater et al. (2021), Daugherty et al. (2021), Vanegas-Cedillo et al. (2021), Amanat et al. (2021), Yamei Zheng et al. (2021), Melotti et al. (2021), HPG23 Covid-19 Study Group et al. (2021), Martinez-Lacalzada, Viteri-Noël, et al. (2020), Martinez-Lacalzada, Adrián Viteri-Noël, et al. (2020), Q. Wang et al. (2021), Rachmawati et al. (2021a), Rachmawati et al. (2021b), Fernandez-Fuertes et al. (2021), Menges et al. (2021), Dev et al. (2021), PHOSP-COVID Collaborative Group et al. (2021), Asem et al. (2021), S. F. Lee et al. (2021), Avouac et al. (2021), (**schaad\_point?**)–care\_2021, Mok et al. (2021), Faverio et al. (2021), Bell et al. (2021), Gil et al. (2021), Galluzzi et al. (2021), Wagner et al. (2021), Mady et al. (2021), Rubina et al. (2021), Scully et al. (2021), Manohar et al. (2021), Durstenfeld et al. (2021), R. A. Rashid et al. (2021), J. Wang et al. (2021), Thomas et al. (2021), S. Li, Jun, et al. (2021), Atergeleh et al. (2021), Boscolo-Rizzo et al. (2021), Chalkias et al. (2021), Byttebier et al. (2021), Husain et al. (2021), Reese et al. (2021), Desgranges et al. (2021), S. Li, Sarangarajan, et al. (2021), Tarifi et al. (2021), Zell et al. (2021), S. C. Lee et al. (2021), Joubert et al. (2021), Halabi et al. (2021), Shiri et al. (2021), Gerhards et al. (2021), Radon et al. (2021), González, Zepeda, et al. (2021), Ahmadi et al. (2021), Ravindra et al. (2021), Mann et al. (2021), Noh et al. (2021), Bhaskaran et al. (2021), Chetboun et al. (2021), Fogh et al. (2021), Madakkatel et al. (2021), Bertuzzi et al. (2021), Röthlin Eriksen et al. (2021), Gornyk et al. (2021a), Gornyk et al. (2021b), Campbell et al. (2021), Marimuthu et al. (2021), Bruce et al. (2021), Bark et al. (2021), Jha et al. (2021), Lekoubou et al. (2021), Kahlert et al. (2021), Hirschtick et al. (2021), Y. Li et al. (2021), AlSafar et al. (2021), Wallis et al. (2021), Ayhan et al. (2021), Nanda et al. (2021), Prats-Uribe, Xie, et al. (2021), Egede et al. (2021), Kleynhans et al. (2021), Puebla Neira et al. (2021), Lassen et al. (2021), S. Chen et al. (2021), Fisher et al. (2021), Ghani et al. (2021), Andrade Barreto et al. (2021), Aabakke et al. (2021), Yozgat et al. (2021), Sandri et al. (2021), Jose et al. (2021), Herzberg et al. (2021), Han et al. (2021), Abdulamir et al. (2021), L. Chauhan et al. (2021), Barchuk et al. (2021), Patone et al. (2021), Mollan et al. (2021), Sonnweber et al. (2021), Nassar et al. (2021), Ali et al. (2021), Demichev et al. (2021), Mostafa et al. (2021), Tehrani et al. (2021a), Tehrani et al. (2021b), Amer et al. (2021), X. Wu et al. (2021), N. K. Chauhan et al. (2021), Mendez-Dominguez et al. (2021), The CONCOR-1 Study Group et al. (2021), Gebhard et al. (2021), Genecand et al. (2021), Qureshi et al. (2021), Y. I. Wan et al. (2021), Gaitán-Duarte et al. (2021), Chuo et al. (2021), Sholzberg et al. (2021), Riyahi et al. (2021), International Severe Acute Respiratory and emerging Infections Consortium, Escher, et al. (2020), International Severe Acute Respiratory and emerging Infections Consortium, Hall, et al. (2020), Pritchard et al. (2020), ISARIC Clinical Characterisation Group et al. (2020), Aboueshia et al. (2021), Matli et al. (2021), Alhamlan et al. (2021)

## References

Aabakke, A. J., Krebs, L., Petersen, T. G., Kjeldsen, F. S., Corn, G., Wøjdemann, K., Ibsen, M. H., Jonsdottir, F., Rønneberg, E., Andersen, C. S., Sundtoft, I., Clausen, T., Milbak, J., Burmester, L., Lindved, B., Thorsen-Meyer, A., Khalil, M. R., Henriksen, B., Jønsson, L., … Bliddal, M. (2021). *SARS-CoV-2 infection in pregnancy in Denmark – characteristics and outcomes after confirmed infection in pregnancy: A nationwide, prospective, population-based cohort study* [Preprint]. Obstetrics; Gynecology. <https://doi.org/10.1101/2021.06.08.21258480>

Abadom, T. R., Smith, A. D., Tempia, S., Madhi, S. A., Cohen, C., & Cohen, A. L. (2016). Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: A case-population study. *Vaccine*, *34*(46), 5649–5655. <https://doi.org/10.1016/j.vaccine.2016.09.011>

Abajo, F. J. de, Rodríguez-Miguel, A., Rodríguez-Martín, S., Lerma, V., & García-Lledó, A. (2021). *IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS: A RETROSPECTIVE COHORT STUDY*. <https://doi.org/10.1101/2021.02.01.21250853>

Abdulamir, A. S., Gorial, F. I., Saadi, S. J., Maulood, M. F., Hashim, H. A., & abdulrrazaq, M. K. (2021). *Effectiveness and Safety of Niclosamaide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management: Randomized controlled clinical trial* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.06.10.21258709>

Abolghasemi, S., Mardani, M., Sali, S., Honarvar, N., & Baziboroun, M. (n.d.). COVID-19 and Kidney Transplant Recipients. *Transplant Infectious Disease*, *n/a*(n/a), e13413. <https://doi.org/10.1111/tid.13413>

Aboueshia, M., Hussein, M. H., Attia, A. S., Swinford, A., Miller, P., Omar, M., Toraih, E. A., Saba, N., Safah, H., Duchesne, J., & Kandil, E. (2021). Cancer and COVID-19: Analysis of patient outcomes. *Future Oncology*, fon-2021-0121. <https://doi.org/10.2217/fon-2021-0121>

Action to beat coronavirus/Action pour battre le coronavirus (Ab-C) Study Investigators, & Jha, P. (2021). *COVID Seroprevalence, Symptoms and Mortality During the First Wave of SARS-CoV-2 in Canada* [Preprint]. Public; Global Health. <https://doi.org/10.1101/2021.03.04.21252540>

Ader, F., Peiffer-Smadja, N., Poissy, J., Bouscambert-Duchamp, M., Belhadi, D., Diallo, A., Delmas, C., Saillard, J., Dechanet, A., Mercier, N., Dupont, A., Alfaiate, T., Lescure, F.-X., Raffi, F., Goehringer, F., Kimmoun, A., Jaureguiberry, S., Reignier, J., Nseir, S., … Mentre, F. (2021). *Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial*. <https://doi.org/10.1101/2021.01.08.20248149>

Adrish, M., Chilimuri, S., Mantri, N., Sun, H., Zahid, M., Gongati, S., Fortuzi, K., Jog, A. P., Purmessur, P., & Singhal, R. (2020). Association of smoking status with outcomes in hospitalised patients with COVID-19. *BMJ Open Respiratory Research*, *7*(1), e000716. <https://doi.org/10.1136/bmjresp-2020-000716>

Ahmadi, M. N., Huang, B.-H., Inan-Eroglu, E., Hamer, M., & Stamatakis, E. (2021). Lifestyle risk factors and infectious disease mortality, including COVID-19, among middle aged and older adults: Evidence from a community-based cohort study in the United Kingdom. *Brain, Behavior, and Immunity*, *96*, 18–27. <https://doi.org/10.1016/j.bbi.2021.04.022>

Aksu, K., Naziroğlu, T., & Özkan, P. (2020). Factors determining COVID‐19 pneumonia severity in a country with routine BCG vaccination. *Clinical & Experimental Immunology*, *202*(2), 220–225. <https://doi.org/10.1111/cei.13507>

Alguwaihes, A. M., Al-Sofiani, M. E., Megdad, M., Albader, S. S., Alsari, M. H., Alelayan, A., Alzahrani, S. H., Sabico, S., Al-Daghri, N. M., & Jammah, A. A. (2020). Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: A single-centre retrospective study. *Cardiovascular Diabetology*, *19*(1), 205. <https://doi.org/10.1186/s12933-020-01184-4>

Alhamlan, F. S., Almaghrabi, R. S., Devol, E. B., Alotaibi, A. B., Alageel, S. M., Obeid, D. A., Alraddadi, B. M., Althawadi, S. I., Mutabagani, M. S., & Al-Qahtani, A. A. (2021). *Epidemiology and Clinical Characteristics in Individuals with Confirmed SARS-CoV-2 Infection During the Early COVID-19 Pandemic in Saudi Arabia* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.07.13.21260428>

Alharthy, A., Aletreby, W., Faqihi, F., Balhamar, A., Alaklobi, F., Alanezi, K., Jaganathan, P., Tamim, H., Alqahtani, S. A., Karakitsos, D., & Memish, Z. A. (2020). Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study: *Journal of Epidemiology and Global Health*. <https://doi.org/10.2991/jegh.k.200928.001>

Al-Hindawi, A., Sokhi, J., Cuddihy, J., Lockie, C., Christie, L., Davies, R., Singh, S., Vizcaychipi, M., Hayes, M., Sisson, A., & Keays, R. (2020). COVID-19 in London, a Case Series Demonstrating Late Improvement in Survivors. *medRxiv*, 2020.05.16.20103853. <https://doi.org/10.1101/2020.05.16.20103853>

Ali, M. R., Hasan, Md. A., Rahman, Md. S., Billah, M., Karmakar, S., Shimu, A. S., Hossain, Md. F., Maruf, Md. M. H., Rahman, Md. S., Saju, Md. S. R., Hasan, M. R., Acharjee, U. K., & Hasan, Md. F. (2021). Clinical manifestations and socio-demographic status of COVID-19 patients during the second-wave of pandemic: A Bangladeshi experience. *Journal of Infection and Public Health*, S1876034121001775. <https://doi.org/10.1016/j.jiph.2021.06.011>

Alizadehsani, R., Sani, Z. A., Behjati, M., Roshanzamir, Z., Hussain, S., Abedini, N., Hasanzadeh, F., Khosravi, A., Shoeibi, A., Roshanzamir, M., Moradnejad, P., Nahavandi, S., Khozeimeh, F., Zare, A., Panahiazar, M., Acharya, U. R., & Islam, S. M. S. (2020). Risk Factors Prediction, Clinical Outcomes, and Mortality of COVID-19 Patients. *medRxiv*, 2020.07.07.20148569. <https://doi.org/10.1101/2020.07.07.20148569>

Alkurt, G., Murt, A., Aydin, Z., Tatli, O., Agaoglu, N. B., Irvem, A., Aydin, M., Karaali, R., Gunes, M., Yesilyurt, B., Turkez, H., Mardinoglu, A., Doganay, M., Basinoglu, F., Seyahi, N., Doganay, G. D., & Doganay, L. (2020). Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey. *medRxiv*, 2020.08.19.20178095. <https://doi.org/10.1101/2020.08.19.20178095>

Allenbach, Y., Saadoun, D., Maalouf, G., Vieira, M., Hellio, A., Boddaert, J., Gros, H., Salem, J. E., Resche Rigon, M., Menyssa, C., Biard, L., Benveniste, O., Cacoub, P., & on behalf of DIMICOVID. (2020). Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. *PLOS ONE*, *15*(10), e0240711. <https://doi.org/10.1371/journal.pone.0240711>

Almazeedi, S., Al-Youha, S., Jamal, M. H., Al-Haddad, M., Al-Muhaini, A., Al-Ghimlas, F., & Al-Sabah, S. (2020). Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. *EClinicalMedicine*, *24*, 100448. <https://doi.org/10.1016/j.eclinm.2020.100448>

Almirall, J., González, C. A., Balanzó, X., & Bolíbar, I. (1999). Proportion of community-acquired pneumonia cases attributable to tobacco smoking. *Chest*, *116*, 375–379. <https://doi.org/10.1378/chest.116.2.375>

Alqahtani, J. S., Oyelade, T., Aldhahir, A. M., Alghamdi, S. M., Almehmadi, M., Alqahtani, A. S., Quaderi, S., Mandal, S., & Hurst, J. (2020). Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. *medRxiv*, 2020.03.25.20043745. <https://doi.org/10.1101/2020.03.25.20043745>

AlSafar, H., Grant, W. B., Hijazi, R., Uddin, M., Alkaabi, N., Tay, G., Mahboub, B., & Al Anouti, F. (2021). COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents. *Nutrients*, *13*(5), 1714. <https://doi.org/10.3390/nu13051714>

Alshami, A. A., Alattas, R. A., Anan, H. F., Qahtani, H. S. A., Mulhim, M. A. A., Alahilmi, A. A., & Alfaraj, A. H. (2020). Silent Disease and Loss of Taste and Smell are Common Manifestations of SARS-COV-2 Infection in a Quarantine Facility: First report from Saudi Arabia. *medRxiv*, 2020.05.13.20100222. <https://doi.org/10.1101/2020.05.13.20100222>

Altamimi, H., Alahmad, Y., Khazal, F., Elhassan, M., AlBinali, H., Arabi, A., AlQahtani, A., Asaad, N., Al-Hijji, M., Hamid, T., Rafie, I., Omrani, A. S., AlKaabi, S., Alkhal, A., AlMalslmani, M., Ali, M., Alkhani, M., AlNesf, M., Jalala, S. A., … Suwaidi, J. A. (2020). The Outcome of COVID-19 Patients with Acute Myocardial Infarction. *medRxiv*, 2020.07.21.20156349. <https://doi.org/10.1101/2020.07.21.20156349>

Altibi, A. M., Bhargava, P., Liaqat, H., Slota, A. A., Sheth, R., Jebbawi, L. A., George, M. E., LeDuc, A., Abdallah, E., Russell, L. R., Jain, S., Shirvanian, N., Masri, A., & Kak, V. (2020). Comparative Clinical Outcomes and Mortality in Prisoner and Non-Prisoner Populations Hospitalized with COVID-19: A Cohort from Michigan. *medRxiv*, 2020.08.08.20170787. <https://doi.org/10.1101/2020.08.08.20170787>

Amanat, M., Rezaei, N., Roozbeh, M., Shojaei, M., Tafakhori, A., Zoghi, A., Darazam, I. A., Salehi, M., Karimialavijeh, E., Lima, B. S., Garakani, A., Vaccaro, A., & Ramezani, M. (2021). Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: A multicenter prospective clinical study. *BMC Neurology*, *21*(1), 116. <https://doi.org/10.1186/s12883-021-02152-5>

Amer, M., Bawazeer, M., Maghrabi, K., Kamel, A. M., Butt, A., Dahhan, T., Kseibi, E., Khurshid, S. M., Abujazar, M., Alghunaim, R., Rabee, M., Abualkhair, M., Al-Janoubi, A., AlFirm, A. T., Gajic, O., Walkey, A. J., Mosier, J. M., Zabolotskikh, I. B., Gavidia, O. Y., … Kashyap, R. (2021). *Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and Corticosteroid Therapy: A Multicenter International Observational Study* [Preprint]. Intensive Care; Critical Care Medicine. <https://doi.org/10.1101/2021.04.12.21255323>

Andler, R. (2019). *BAISSE DE LA PRÉVALENCE DU TABAGISME QUOTIDIEN PARMI LES ADULTES : RÉSULTATS DU BAROMÈTRE DE SANTÉ PUBLIQUE FRANCE 2018 / REDUCTION OF DAILY SMOKING RATE AMONG ADULTS: RESULTS FROM THE 2018 SANTÉ PUBLIQUE FRANCE HEALTH BAROMETER*. 7.

Andrade Barreto, A. P., Duarte, L. C., Cerqueira-Silva, T., Barreto Filho, M. A., Camelier, A., Tavares, N. M., Barral-Netto, M., Boaventura, V., & Coelho Lima, M. C. (2021). *Post-Acute COVID Syndrome, the Aftermath of Mild to Severe COVID-19 in Brazilian Patients* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.06.07.21258520>

Antonio-Villa, N. E., Bello-Chavolla, O. Y., Vargas-Vazquez, A., Fermin-Martinez, C. A., Marquez-Salinas, A., & Bahena-Lopez, J. P. (2020). Health-care workers with COVID-19 living in Mexico City: Clinical characterization and related outcomes. *medRxiv*, 2020.07.02.20145169. <https://doi.org/10.1101/2020.07.02.20145169>

Apea, V. J., Wan, Y. I., Dhairyawan, R., Puthucheary, Z. A., Pearse, R. M., Orkin, C. M., & Prowle, J. R. (2021). Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: An observational cohort study. *BMJ Open*, *11*. <https://doi.org/10.1136/bmjopen-2020-042140>

Argenziano, M. G., Bruce, S. L., Slater, C. L., Tiao, J. R., Baldwin, M. R., Barr, R. G., Chang, B. P., Chau, K. H., Choi, J. J., Gavin, N., Goyal, P., Mills, A. M., Patel, A. A., Romney, M.-L. S., Safford, M. M., Schluger, N. W., Sengupta, S., Sobieszczyk, M. E., Zucker, J. E., … Chen, R. (2020). Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series. *BMJ*, m1996. <https://doi.org/10.1136/bmj.m1996>

Ariza, B. E., Torres, Y. X., Salgado, D., Cepeda, M., Gomez, C., Castellanos, J. C., Suarez, F., Cuellar, A., Cardozo, C. C., Angel, J., & Franco, M. A. (2020). Seroprevalence and seroconversion rates to SARS-CoV-2 in interns, residents, and medical doctors in a University Hospital in Bogota, Colombia. *medRxiv*, 2020.09.15.20195313. <https://doi.org/10.1101/2020.09.15.20195313>

Arleo, T., Tong, D., Shabto, J., O’Keefe, G., & Khosroshahi, A. (2020). *Clinical Course and Outcomes of coronavirus disease 2019 (COVID-19) in Rheumatic Disease Patients on Immunosuppression: A case Cohort Study at a Single Center with a Significantly Diverse Population* [Preprint]. Epidemiology. <https://doi.org/10.1101/2020.10.26.20219154>

Asem, N., Hassany, M., Taema, K., Masoud, H., Elassal, G., Kamal, E., Amin, W., Abdelbary, A., Baki, A. A., Zaky, S., Abdalmohsen, A., Ibrahim, H., Elnady, M., Mohamed, A., Atteia, E., & Zaid, H. (2021). *Demographic and clinical features associated with in-hospital mortality in Egyptian COVID-19 patients: A retrospective cohort study* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.03.22.21253577>

Atergeleh, H. J., Emamian, M. H., Goli, S., Rohani-Rasaf, M., Hashemi, H., & Fotouhi, A. (2021). *The risk factors of COVID-19 in a longitudinal population-based study* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.04.12.21255369>

Auvinen, R., Nohynek, H., Syrjänen, R., Ollgren, J., Kerttula, T., Mäntylä, J., Ikonen, N., Loginov, R., Haveri, A., Kurkela, S., & Skogberg, K. (2020). Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients: A prospective observational study. *medRxiv*, 2020.06.29.20140632. <https://doi.org/10.1101/2020.06.29.20140632>

Avouac, J., Drumez, E., Hachulla, E., Seror, R., Georgin-Lavialle, S., El Mahou, S., Pertuiset, E., Pham, T., Marotte, H., Servettaz, A., Domont, F., Chazerain, P., Devaux, M., Claudepierre, P., Langlois, V., Mekinian, A., Maria, A. T. J., Banneville, B., Fautrel, B., … Xerri-Campano, B. (2021). COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. *The Lancet Rheumatology*, *3*(6), e419–e426. <https://doi.org/10.1016/S2665-9913(21)00059-X>

Ayhan, M., Odabas, H., Turan, N., Ozyukseler, D. T., Kostek, O., Alkan, G., Abamor, E., & Yildirim, M. E. (2021). Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: A single center’s experience. *Journal of Chemotherapy*, 1–10. <https://doi.org/10.1080/1120009X.2021.1923153>

Ayoubkhani, D., Khunti, K., Nafilyan, V., Maddox, T., Humberstone, B., Diamond, S. I., & Banerjee, A. (2021). *Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: A retrospective cohort study*. <https://doi.org/10.1101/2021.01.15.21249885>

Badr, O. I., Alwafi, H., Elrefaey, W. A., Naser, A. Y., & Shabrawishi, M. (2021a). *“Incidence and Outcomes of Pulmonary embolism among hospitalized COVID-19 patients”* [Preprint]. Respiratory Medicine. <https://doi.org/10.1101/2021.02.16.21251676>

Badr, O. I., Alwafi, H., Elrefaey, W. A., Naser, A. Y., & Shabrawishi, M. (2021b). *“Incidence and Outcomes of Pulmonary embolism among hospitalized COVID-19 patients”* [Preprint]. Respiratory Medicine. <https://doi.org/10.1101/2021.02.16.21251676>

Barasa, S., Kiage-Mokaya, J., Cruz-Madrid, K., & Friedlander, M. (2020). *Smoking increases the risk of COVID-19 positivity, while Never-smoking reduces the risk* [Preprint]. Respiratory Medicine. <https://doi.org/10.1101/2020.11.30.20241380>

Barchuk, A., Skougarevskiy, D., Titaev, K., Shirokov, D., Raskina, Y., Novkunkskaya, A., Talantov, P., Isaev, A., Pomerantseva, E., Zhikrivetskaya, S., Barabanova, L., & Volkov, V. (2021). Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: A population-based study. *Scientific Reports*, *11*(1), 12930. <https://doi.org/10.1038/s41598-021-92206-y>

Bark, D., Dhillon, N., St-Jean, M., Kinniburgh, B., McKee, G., & Choi, A. (2021). *SARS-CoV-2 transmission in K-12 schools in the Vancouver Coastal Health Region: A descriptive epidemiologic study* [Preprint]. Public; Global Health. <https://doi.org/10.1101/2021.05.15.21257271>

Basse, C., Diakite, S., Servois, V., Frelaut, M., Noret, A., Bellesoeur, A., Moreau, P., Massiani, M.-A., Bouyer, A.-S., Vuagnat, P., Malak, Sa., Bidard, F.-C., Vanjak, D., Kriegel, I., Burnod, A., Bilger, G., Ramtohul, T., Dhonneur, G., Bouleuc, C., … Cottu, P. (2020). Characteristics and outcome of SARS-CoV-2 infection in cancer patients. *medRxiv*, 2020.05.14.20101576. <https://doi.org/10.1101/2020.05.14.20101576>

Batty, G. D., Deary, I., Luciano, M., Altschul, D., Kivimaki, M., & Gale, C. (2020). Psychosocial factors and hospitalisations for COVID-19: Prospective cohort study of the general population. *medRxiv*, 2020.05.29.20100735. <https://doi.org/10.1101/2020.05.29.20100735>

Bell, M. L., Catalfamo, C. J., Farland, L. V., Ernst, K. C., Jacobs, E. T., Klimentidis, Y. C., Jehn, M., & Pogreba-Brown, K. (2021). *Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT* [Preprint]. Public; Global Health. <https://doi.org/10.1101/2021.03.29.21254588>

Bellan, M., Patti, G., Hayden, E., Azzolina, D., Pirisi, M., Acquaviva, A., Aimaretti, G., Aluffi Valletti, P., Angilletta, R., Arioli, R., Avanzi, G. C., Avino, G., Balbo, P. E., Baldon, G., Baorda, F., Barbero, E., Baricich, A., Barini, M., Barone-Adesi, F., … Sainaghi, P. P. (2020). Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. *Scientific Reports*, *10*(1), 20731. <https://doi.org/10.1038/s41598-020-77698-4>

Bello-Chavolla, O. Y., Antonio-Villa, N. E., Vargas-Vázquez, A., Fermín-Martínez, C. A., Márquez-Salinas, A., & Bahena-López, J. P. (2020). Profiling pre-symptomatic and asymptomatic cases with confirmed SARS-CoV-2 infection in Mexico City. *medRxiv*, 2020.07.02.20145516. <https://doi.org/10.1101/2020.07.02.20145516>

Bello-Chavolla, O. Y., Bahena-López, J. P., Antonio-Villa, N. E., Vargas-Vázquez, A., González-Díaz, A., Márquez-Salinas, A., Fermín-Martínez, C. A., Naveja, J. J., & Aguilar-Salinas, C. A. (2020). Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. *The Journal of Clinical Endocrinology & Metabolism*, *105*(8). <https://doi.org/10.1210/clinem/dgaa346>

Benaim, A. R., Sobel, J. A., Almog, R., Lugassy, S., Shabbat, T. B., Johnson, A., Eytan, D., & Behar, J. A. (2020). *At the dawn of winter: Comparing COVID-19 and influenza presentation and trajectory* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.11.19.20235077>

Benowitz, N. L., Schultz, K. E., Haller, C. A., Wu, A. H. B., Dains, K. M., & Jacob, P. (2009). Prevalence of smoking assessed biochemically in an urban public hospital: A rationale for routine cotinine screening. *American Journal of Epidemiology*, *170*(7), 885–891. <https://doi.org/10.1093/aje/kwp215>

Berlin, I., Thomas, D., Le Faou, A.-L., & Cornuz, J. (2020). COVID-19 and Smoking. *Nicotine & Tobacco Research*. <https://doi.org/10.1093/NTR/NTAA059>

Bermejo-Martin, J. F., González-Rivera, M., Almansa, R., Micheloud, D., Tedim, A. P., Domínguez-Gil, M., Resino, S., Martín-Fernández, M., Ryan Murua, P., Pérez-García, F., Tamayo, L., Lopez-Izquierdo, R., Bustamante, E., Aldecoa, C., Gómez, J. M., Rico-Feijoo, J., Orduña, A., Méndez, R., Fernández Natal, I., … Kelvin, D. J. (2020). Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. *Critical Care*, *24*(1), 691. <https://doi.org/10.1186/s13054-020-03398-0>

Bernaola, N., Mena, R., Bernaola, A., Lara, A., Carballo, C., Larranaga, P., & Bielza, C. (2020). Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid. *medRxiv*, 2020.07.17.20155960. <https://doi.org/10.1101/2020.07.17.20155960>

Bertuzzi, A. F., Ciccarelli, M., Marrari, A., Gennaro, N., Dipasquale, A., Giordano, L., Cariboni, U., Quagliuolo, V. L., Alloisio, M., & Santoro, A. (2021). Impact of active cancer on COVID-19 survival: A matched-analysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy. *British Journal of Cancer*. <https://doi.org/10.1038/s41416-021-01396-9>

Berumen, J., Schmulson, M., Alegre, J., Guerrero, G., Olaiz, G., Wong-Chew, R. M., Larriva-Sahd, J., Cantu-Brito, C., Ochoa-Guzman, A., Garcilazo-Avila, A., Gonzalez-Carballo, C., & Chiquete, E. (2020). Risk of infection and hospitalization by Covid-19 in Mexico: A case-control study. *medRxiv*, 2020.05.24.20104414. <https://doi.org/10.1101/2020.05.24.20104414>

Best, J. H., Mohan, S. V., Kong, A. M., Patel, K., Pagel, J. M., Ivanov, B., Brawley, O. W., Jariwala-Parikh, K., Zazzali, J. L., & Pauk, J. (2020). Baseline Demographics and Clinical Characteristics Among 3471 US Patients Hospitalized with COVID-19 and Pulmonary Involvement: A Retrospective Study. *Advances in Therapy*, *37*(12), 4981–4995. <https://doi.org/10.1007/s12325-020-01510-y>

Bhaskaran, K., Bacon, S., Evans, S. J., Bates, C. J., Rentsch, C. T., MacKenna, B., Tomlinson, L., Walker, A. J., Schultze, A., Morton, C. E., Grint, D., Mehrkar, A., Eggo, R. M., Inglesby, P., Douglas, I. J., McDonald, H. I., Cockburn, J., Williamson, E. J., Evans, D., … Goldacre, B. (2021). Factors associated with deaths due to COVID-19 versus other causes: Population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. *The Lancet Regional Health - Europe*, *6*, 100109. <https://doi.org/10.1016/j.lanepe.2021.100109>

Bian, H., Zheng, Z.-H., Wei, D., Zhang, Z., Kang, W.-Z., Hao, C.-Q., Dong, K., Kang, W., Xia, J.-L., Miao, J.-L., Xie, R.-H., Wang, B., Sun, X.-X., Yang, X.-M., Lin, P., Geng, J.-J., Wang, K., Cui, H.-Y., Zhang, K., … Zhu, P. (2020). Meplazumab treats COVID-19 pneumonia: An open-labelled, concurrent controlled add-on clinical trial. *medRxiv*, 2020.03.21.20040691. <https://doi.org/10.1101/2020.03.21.20040691>

Bisso, I. C., Huespe, I., Lockhart, C., Massó, A., González Anaya, J., Hornos, M., Famiglietti, R., Di Grazia, M., Coria, P., Román, E. S., & Heras, M. L. (2020). *Clinical characteristics of critically ill patients with COVID-19* [Preprint]. Intensive Care; Critical Care Medicine. <https://doi.org/10.1101/2020.12.09.20246413>

Borobia, A. M., Carcas, A. J., Arnalich, F., Álvarez-Sala, R., Monserrat-Villatoro, J., Quintana, M., Figueira, J. C., Torres Santos-Olmo, R. M., García-Rodríguez, J., Martín-Vega, A., Buño, A., Ramírez, E., Martínez-Alés, G., García-Arenzana, N., Núñez, M. C., Martí-de-Gracia, M., Moreno Ramos, F., Reinoso-Barbero, F., Martin-Quiros, A., … COVID@HULP Working Group, on behalf of the. (2020). A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. *Journal of Clinical Medicine*, *9*(6), 1733. <https://doi.org/10.3390/jcm9061733>

Boscolo-Rizzo, P., Guida, F., Polesel, J., Marcuzzo, A. V., Capriotti, V., D’Alessandro, A., Zanelli, E., Marzolino, R., Lazzarin, C., Antonucci, P., Sacchet, E., Tofanelli, M., Borsetto, D., Gardenal, N., Pengo, M., & Tirelli, G. (2021). *Long COVID In Adults at 12 Months After Mild-to-Moderate SARS-CoV-2 Infection* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.04.12.21255343>

Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., Engen, N. W., Cheng, M. P., LaBar, D., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Zarychanski, R., Kelly, L. E., … Hullsiek, K. H. (2020). A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *New England Journal of Medicine*. <https://doi.org/10.1056/NEJMoa2016638>

Bowyer, R. C. E., Varsavsky, T., Sudre, C. H., Murray, B. A. K., Freidin, M. B., Yarand, D., Ganesh, S., Capdevila, J., Thompson, E. J., Bakker, E., Cardoso, M. J., Davies, R., Wolf, J., Spector, T. D., Ourselin, S., Steves, C. J., & Menni, C. (2020). *Geo-social gradients in predicted COVID-19 prevalence and severity in Great Britain: Results from 2,266,235 users of the COVID-19 Symptoms Tracker app*. <https://doi.org/10.1101/2020.04.23.20076521>

Boyd, S., & Martin-Loeches, I. (2021). The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients. *Ir J Med Sci*, *NA*. <https://doi.org/10.1007/s11845-020-02503-0>

Brake, S. J., Barnsley, K., Lu, W., McAlinden, K. D., Eapen, M. S., & Sohal, S. S. (2020). Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). *J Clin Med*, *9, Page 841*, 841. <https://doi.org/10.3390/jcm9030841>

Brown, J. (2020). *The Smoking Toolkit Study, 2020*. <https://docs.google.com/presentation/d/e/2PACX-1vQmMeD0wPM7iEawo39m2QZnVBOo2e8YIQPjm2R0OgYBvKhBbYqnarSn5vxyk3-56w/embed?start=false&loop=false&delayms=3000&usp=embed_facebook>

Bruce, E., Carter, B., Quinn, T. J., Verduri, A., Pearson, O., Vilches-Moraga, A., Price, A., McGovern, A., Evans, L., McCarthy, K., Hewitt, J., Moug, S., Myint, P. K., behalf of COPE Study Team, Einarsson, A., Fleck, A., Bisset, C., Alexander, R., Guaraldi, G., … Stechman, M. (2021). Multiple House Occupancy is Associated with Mortality in Hospitalised Patients with Covid-19. *European Journal of Public Health*, ckab085. <https://doi.org/10.1093/eurpub/ckab085>

Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Ipekci, A. M., Salanti, G., & Low, N. (2020). Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLOS Medicine*, *17*(9), e1003346. <https://doi.org/10.1371/journal.pmed.1003346>

Burrell, A. J., Pellegrini, B., Salimi, F., Begum, H., Broadley, T., Campbell, L. T., Cheng, A. C., Cheung, W., Cooper, D. J., Earnest, A., Erickson, S. J., French, C. J., Kaldor, J. M., Litton, E., Murthy, S., McAllister, R., Nichol, A., Palermo, A., Plummer, M., … Udy, A. (2020). Outcomes of COVID-19 patients admitted to Australian intensive care units during the early phase of the pandemic. *The Medical Journal of Australia*, 1. <https://doi.org/10.5694/mja2.50883>

Bürkner, P.-C. (2017). Advanced Bayesian Multilevel Modeling with the R Package brms. *arXiv:1705.11123 [Stat]*. <http://arxiv.org/abs/1705.11123>

Byttebier, G., Belmans, L., Alexander, M., Saxberg, B. E. H., De Spiegeleer, B., De Spiegeleer, A., Devreker, N., Van Praet, J. T., Vanhove, K., Reybrouck, R., Wynendaele, E., & Fedson, D. S. (2021). Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. *Human Vaccines & Immunotherapeutics*, 1–10. <https://doi.org/10.1080/21645515.2021.1920271>

Cadegiani, F. A., McCoy, J., Wambier, C. G., & Goren, A. (2020). *5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.11.16.20232512>

Caglar, A., & Kacer, I. (2021). Anxiety levels in patients admitted to the emergency department with myocardial infarction or COVID-19 pneumonia. *PSYCHOL HEALTH MED*, *NA*, 1–9. <https://doi.org/10.1080/13548506.2021.1876893>

Cai, G. (2020). *Bulk and Single-Cell Transcriptomics Identify Tobacco-Use Disparity in Lung Gene Expression of ACE2, the Receptor of 2019-nCov*. https://doi.org/<10.20944/preprints202002.0051.v3; http://web.archive.org/web/20200925104805/https://www.preprints.org/manuscript/202002.0051/v3>

Cai, H., Yang, L., Lu, Y., Zhang, S., Ye, C., Zhang, X., Yu, G., Gu, J., Lian, J., Hao, S., Hu, J., Zhang, Y., Jin, C., Sheng, J., Yang, Y., & Jia, H. (2021). High body mass index is a significant risk factor for the progression and prognosis of imported COVID-19: A multicenter, retrospective cohort study. *BMC Infect Dis*, *21*. <https://doi.org/10.1186/s12879-021-05818-0>

Caliskan, T., & Saylan, B. (2020). Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: A retrospective observational study. *Rev Assoc Med Bras*, *66*, 1679–1684. <https://doi.org/10.1590/1806-9282.66.12.1679>

Campbell, J. R., Dion, C., Uppal, A., Yansouni, C. P., & Menzies, D. (2021). *Systematic Testing for SARS-CoV-2 Infection Among Essential Workers in Montréal, Canada: A Prospective Observational and Cost Assessment Study* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.05.12.21256956>

Carrat, F., Lamballerie, X. de, Rahib, D., Blanche, H., Lapidus, N., Artaud, F., Kab, S., Renuy, A., Edelenyi, F. S. de, Meyer, L., Lydie, N., Charles, M.-A., Ancel, P.-Y., Jusot, F., Rouquette, A., Priet, S., Villaroel, P. M. S., Fourie, T., Lusivika-Nzinga, C., … Zins, M. (2020). Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: A multicohort study. *medRxiv*, 2020.09.16.20195693. <https://doi.org/10.1101/2020.09.16.20195693>

Carrillo-Vega, M. F., Salinas-Escudero, G., Garcia-Peña, C., Gutierrez-Robledo, L. M., & Parra-Rodriguez, L. (2020). Early estimation of the risk factors for hospitalisation and mortality by COVID-19 in Mexico. *medRxiv*, 2020.05.11.20098145. <https://doi.org/10.1101/2020.05.11.20098145>

CDCMMWR. (2020). Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. *MMWR. Morbidity and Mortality Weekly Report*, *69*. <https://doi.org/10.15585/mmwr.mm6913e2>

Cen, Y., Chen, X., Shen, Y., Zhang, X.-H., Lei, Y., Xu, C., Jiang, W.-R., Xu, H.-T., Chen, Y., Zhu, J., Zhang, L.-L., & Liu, Y.-H. (2020). Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study. *Clinical Microbiology and Infection*, S1198743X20303414. <https://doi.org/10.1016/j.cmi.2020.05.041>

Chalkias, A., Pantazopoulos, I., Papagiannakis, N., Skoulakis, A., Laou, E., Kolonia, K., Ntalarizou, N., Ragias, D., Kampolis, C., García de Guadiana Romualdo, L., Tourlakopoulos, K., Pagonis, A., Hayek, S. S., Eugen-Olsen, J., Gourgoulianis, K., & Arnaoutoglou, E. (2021). *Clinical course and outcomes of critically ill COVID-19 patients in two successive pandemic waves* [Preprint]. Intensive Care; Critical Care Medicine. <https://doi.org/10.1101/2021.02.26.21251848>

Chand, S., Kapoor, S., Orsi, D., Fazzari, M. J., Tanner, T. G., Umeh, G. C., Islam, M., & Dicpinigaitis, P. V. (2020). COVID-19-Associated Critical Illness—Report of the First 300 Patients Admitted to Intensive Care Units at a New York City Medical Center: *Journal of Intensive Care Medicine*. <https://doi.org/10.1177/0885066620946692>

Chaudhary, A., Singh, U. N., Paudel, P., Thapa, N., Khadka, K., Sah, P. K., Kamar, S. B., Joshi, J., Ansari, K. H., Tiwari, S. R., Sharma, S., Jaiswal, S. K., Joshi, R., Baskota, S., Tiwari, A. P., & Pandey, H. R. (2020). Characteristics and outcomes of hospitalized adults with COVID-19 in Nepal: A multicenter, prospective cohort study. *medRxiv*, 2020.10.03.20206128. <https://doi.org/10.1101/2020.10.03.20206128>

Chaudhry, F., Bulka, H., Rathnam, A. S., Said, O. M., Lin, J., Lorigan, H., Bernitsas, E., Rube, J., Korzeniewski, S. J., Memon, A. B., Levy, P. D., Javed, A., Lisak, R., & Cerghet, M. (2020). COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection. *medRxiv*, 2020.05.27.20114827. <https://doi.org/10.1101/2020.05.27.20114827>

Chauhan, L., Pattee, J., Ford, J., Thomas, C., Lesteberg, K., Richards, E., Loi, M., Dumont, L., Annen, K., Berg, M., Zirbes, M., Miller, A., Jenkins, T. C., Bennett, T. D., Monkowski, D., Boxer, R. S., & Beckham, J. D. (2021). *A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.06.14.21258910>

Chauhan, N. K., Shadrach, B. J., Garg, M. K., Bhatia, P., Bhardwaj, P., Gupta, M. K., Dutt, N., Jalandra, R. N., Garg, P., Nag, V. L., Sharma, P., Bohra, G. K., Kumar, D., Elhence, P. A., Banerjee, M., Mathur, D., Purohit, A. H., Gadepalli, R., Sureka, B., & Misra, S. (2021). Predictors of Clinical Outcomes in Adult COVID-19 Patients Admitted to a Tertiary Care Hospital in India: An analytical cross-sectional study: Predictors of clinical outcomes in COVID-19. *Acta Biomedica Atenei Parmensis*, *92*(3), e2021024. <https://doi.org/10.23750/abm.v92i3.10630>

Chen, C., Jiang, J., Xu, X., Hu, Y., Hu, Y., & Zhao, Y. (2020). Dynamic liver function indexes monitoring and clinical characteristics in three types of COVID-19 patients. *medRxiv*, 2020.05.13.20099614. <https://doi.org/10.1101/2020.05.13.20099614>

Chen, H., Varatharajah, Y., Ramirez, S. S. de, Arnold, P., Frankenberger, C., Hota, B., & Iyer, R. (2020). *A Retrospective Longitudinal Study of COVID-19 as Seen by a Large Urban Hospital in Chicago* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.11.29.20240606>

Chen, L., Yu, J., He, W., Chen, L., Yuan, G., Dong, F., Chen, W., Cao, Y., Yang, J., Cai, L., Wu, D., Ran, Q., Li, L., Liu, Q., Ren, W., Gao, F., Wang, H., Chen, Z., Gale, R. P., … Hu, Y. (2020). Risk factors for death in 1859 subjects with COVID-19. *Leukemia*, 1–11. <https://doi.org/10.1038/s41375-020-0911-0>

Chen, S., Zheng, T., Wang, S., Yu, Y., Wang, P., Song, Y., & Jiang, J. (2021). Association between risk of venous thromboembolism and mortality in patients with COVID-19. *International Journal of Infectious Diseases*, *108*, 543–549. <https://doi.org/10.1016/j.ijid.2021.06.005>

Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., Wang, T., Guo, W., Chen, J., Ding, C., Zhang, X., Huang, J., Han, M., Li, S., Luo, X., … Ning, Q. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. *BMJ*, *368*. <https://doi.org/10.1136/bmj.m1091>

Chetboun, M., Raverdy, V., Labreuche, J., Simonnet, A., Wallet, F., Caussy, C., Antonelli, M., Artigas, A., Goma, G., Meziani, F., Helms, J., Mylonakis, E., Levy, M. M., Kalligeros, M., Latronico, N., Piva, S., Cerf, C., Neuville, M., Klouche, K., … The "LICORNE Lille Intensive Care COVID‐19, Obesity Study Group", the "COVID‐19 Toulouse ICU Network", the "Hasharon Hospital‐Rabin Medical Center Covid‐19, Obesity Study Group", the "ID, ICU Covid‐19 Study Group", the "Rouen Covid‐19, Obesity Study", the "COVID‐O‐HCL Consortium", the "MICU Lapeyronie", the "Bronx COVID‐19, Obesity Study Group", the "MIR Amiens Covid19", the "Strasbourg NHC", the "Foch COVID‐19 Study Group". (2021). BMI and pneumonia outcomes in critically ill COVID‐19 patients: An international multicenter study. *Obesity*, oby.23223. <https://doi.org/10.1002/oby.23223>

Cho, E. R., Slutsky, A. S., & Jha, P. (2020). Smoking and the risk of COVID-19 infection in the UK Biobank Prospective Study. *medRxiv*, 2020.05.05.20092445. <https://doi.org/10.1101/2020.05.05.20092445>

Chudasama, Y. V., Zaccardi, F., Gillies, C. L., Razieh, C., Yates, T., Kloecker, D. E., Rowlands, A. V., Davies, M. J., Islam, N., Seidu, S., Forouhi, N. G., & Khunti, K. (2020). *Patterns of Multimorbidity and Risk of Severe SARS-CoV-2 Infection: An observational study in the U.K* [Preprint]. Epidemiology. <https://doi.org/10.1101/2020.10.21.20216721>

Chuo, C.-Y., Yau, V., Madhavan, S., Tsai, L., & Chia, J. (2021). *Risk of Severe COVID–19 Outcomes Among Patients with Rheumatoid Arthritis in the United States* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.07.09.21260106>

Clavario, P., De Marzo, V., Lotti, R., Barbara, C., Porcile, A., Russo, C., Beccaria, F., Bonavia, M., Bottaro, L. C., Caltabellotta, M., Chioni, F., Santangelo, M., Hautala, A. J., Ameri, P., Canepa, M., & Porto, I. (2020). *Assessment of functional capacity with cardiopulmonary exercise testing in non-severe COVID-19 patients at three months follow-up* [Preprint]. Cardiovascular Medicine. <https://doi.org/10.1101/2020.11.15.20231985>

CMMID COVID-19 working group, Jarvis, C. I., Van Zandvoort, K., Gimma, A., Prem, K., Klepac, P., Rubin, G. J., & Edmunds, W. J. (2020). Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. *BMC Medicine*, *18*(1), 124. <https://doi.org/10.1186/s12916-020-01597-8>

Colaneri, M., Novelli, V., Cutti, S., Muzzi, A., Resani, G., Monti, M. C., Rona, C., Grugnetti, A. M., Rettani, M., Rovida, F., Zuccaro, V., Triarico, A., & Marena, C. (2021). The experience of the health care workers of a severely hit SARS-CoV-2 referral Hospital in Italy: Incidence, clinical course and modifiable risk factors for COVID-19 infection. *Journal of Public Health*, *43*(1), 26–34. <https://doi.org/10.1093/pubmed/fdaa195>

Collard, D., Nurmohamed, N. S., Kaiser, Y., Reeskamp, L. F., Dormans, T., Moeniralam, H., Simsek, S., Douma, R. A., Eerens, A., Reidinga, A. C., Elbers, P., Beudel, M., Vogt, L., Stroes, E. S. G., & Born, B.-J. H. van den. (2020). *Cardiovascular risk factors are independently associated with COVID-19 mortality: A prospective cohort study* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.10.01.20205229>

Concha-Mejia, A., & Rincon-Sanchez, R. A. (2020). CCOFEE-GI Study: Colombian COVID19 First Experience in Gastroentrology. Characterization of digestive manifestations in patients diagnosed with COVID-19 at a highly complex institution in Bogota D.C., Colombia. *medRxiv*, 2020.07.24.20161604. <https://doi.org/10.1101/2020.07.24.20161604>

Conti, C., Marco, A. de, Mastromarino, P., Tomao, P., & Santoro, M. G. (1999). Antiviral Effect of Hyperthermic Treatment in Rhinovirus Infection. *Antimicrobial Agents and Chemotherapy*, *43*(4), 822–829. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89212/>

Covid-19 in pregnancy, Vousden, N., Bunch, K., Morris, E., Simpson, N., Gale, C., O’Brien, P., Quigley, M., Brocklehurst, P., Kurinczuk, J. J., & Knight, M. (2021). *The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS)*. <https://doi.org/10.1101/2021.01.04.21249195>

Crooks, C. J., West, J., Fogarty, A., Morling, J. R., Grainge, M. J., Gonem, S., Simmonds, M., Race, A., Juurlink, I., Briggs, S., Cruikshank, S., Hammond-Pears, S., & Card, T. R. (2020). *Predicting the need for escalation of care or death from repeated daily clinical observations and laboratory results in patients with SARS-CoV-2 during 2020: A retrospective population-based cohort study from the United Kingdom*. <https://doi.org/10.1101/2020.12.14.20248181>

Crovetto, F., Crispi, F., Llurba, E., Figueras, F., Gomez-Roig, M. D., & Gratacos, E. (2020). SEROPREVALENCE AND CLINICAL SPECTRUM OF SARS-CoV-2 INFECTION IN THE FIRST VERSUS THIRD TRIMESTER OF PREGNANCY. *medRxiv*, 2020.06.17.20134098. <https://doi.org/10.1101/2020.06.17.20134098>

Cummins, L., Ebyarimpa, I., Cheetham, N., Brown, V. T., Brennan, K., & Panovska-Griffiths, J. (2021). *Factors associated with COVID-19 related hospitalisation, critical care admission and mortality using linked primary and secondary care data*. <https://doi.org/10.1101/2021.01.19.20241844>

Dai, M., Tao, L., Chen, Z., Tian, Z., Guo, X., Allen-Gipson, D. S., Tan, R., Li, R., Chai, L., Ai, F., & Liu, M. (2020). Influence of Cigarettes and Alcohol on the Severity and Death of COVID-19: A Multicenter Retrospective Study in Wuhan, China. *Front Physiol*, *11*. <https://doi.org/10.3389/fphys.2020.588553>

Dambha-Miller, H., Hinton, W., Joy, M., Feher, M., & Lusignan, S. de. (2021). *Mortality in COVID-19 amongst women on Hormone Replacement Therapy or Combined Oral Contraception: A cohort study* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.02.16.21251853>

Dashti, H., Roche, E. C., Bates, D. W., Mora, S., & Demler, O. (2021). SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19. *Scientific Reports*, *11*(1), 4945. <https://doi.org/10.1038/s41598-021-84603-0>

Daugherty, S. E., Guo, Y., Heath, K., Dasmariñas, M. C., Jubilo, K. G., Samranvedhya, J., Lipsitch, M., & Cohen, K. (2021). *SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: A retrospective cohort study* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.03.12.21253448>

Dayem Ullah, A. Z. M., Sivapalan, L., Kocher, H. M., & Chelala, C. (2021). COVID-19 in patients with hepatobiliary and pancreatic diseases: A single-centre cross-sectional study in East London. *BMJ Open*, *11*(4), e045077. <https://doi.org/10.1136/bmjopen-2020-045077>

De Santi, M., Diotallevi, A., & Brandi, G. (2021). Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy. *Acta Biomedica Atenei Parmensis*, *92*(1), e2021070. <https://doi.org/10.23750/abm.v92i1.10847>

Demichev, V., Tober-Lau, P., Nazarenko, T., Aulakh, S. K., Whitwell, H., Lemke, O., Röhl, A., Freiwald, A., Mittermaier, M., Szyrwiel, L., Ludwig, D., Correia-Melo, C., Lippert, L. J., Helbig, E. T., Stubbemann, P., Olk, N., Thibeault, C., Grüning, N.-M., Blyuss, O., … Ralser, M. (2021). *A proteomic survival predictor for COVID-19 patients in intensive care* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.06.24.21259374>

Denholm, J. T., Gordon, C. L., Johnson, P. D., Hewagama, S. S., Stuart, R. L., Aboltins, C., Jeremiah, C., Knox, J., Lane, G. P., Tramontana, A. R., Slavin, M. A., Schulz, T. R., Richards, M., Birch, C. J., & Cheng, A. C. (2010). Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. *Medical Journal of Australia*, *192*(2), 84–86. <https://doi.org/10.5694/j.1326-5377.2010.tb03424.x>

Desgranges, F., Tadini, E., Munting, A., Regina, J., Filippidis, P., Viala, B., Karachalias, E., Suttels, V., Haefliger, D., Kampouri, E., Van Singer, M., Tschopp, J., Stettler, L. R., Schaad, S., Brahier, T., Hugli, O., Chabloz, Y. M., Gouveia, A., Opota, O., … the RegCOVID research group. (2021). *Post-COVID-19 syndrome in outpatients: A cohort study* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.04.19.21255742>

Dev, N., Meena, R. C., Gupta, D. K., Gupta, N., & Sankar, J. (2021). Risk factors and frequency of COVID-19 among healthcare workers at a tertiary care centre in India: A case–control study. *Transactions of The Royal Society of Tropical Medicine and Hygiene*, *115*(5), 551–556. <https://doi.org/10.1093/trstmh/trab047>

Didikoglu, A., Maharani, A., Pendleton, N., Canal, M. M., & Payton, A. (2021). Early life factors and COVID-19 infection in England: A prospective analysis of UK Biobank participants. *Early Hum Dev*, *155*. <https://doi.org/10.1016/j.earlhumdev.2021.105326>

Díez-Manglano, J., Marquínez, M. N. S., García, A. Á., Alcalá-Rivera, N., Riesco, I. M., Aseguinolaza, M. G., Pérez, J. L. B., Bailon, M. M., Ruiz, A. E. L.-I., Gómez, M. G., Cilleros, C. M., Fontan, P. M. P., Vázquez, L. A., Encinar, J. C. B., Boixeda, R., Sánchez, R. G., Peña Fernández, A. de la, Amigo, J. L., Sevilla, J. E., … for the SEMI-COVID-19 Network. (2020). *Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.11.23.20236810>

Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., Merson, L., Lee, J., Plotkin, D., Sigfrid, L., Halpin, S., Jackson, C., Gamble, C., Horby, P. W., Nguyen-Van-Tam, J. S., … Semple, M. G. (2020). Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ*, *369*. <https://doi.org/10.1136/bmj.m1985>

Dong, X., Cao, Y., Lu, X., Zhang, J., Du, H., Yan, Y., Akdis, C. A., & Gao, Y. (2020). Eleven faces of coronavirus disease 2019. *Allergy*, *75*(7), 1699–1709. <https://doi.org/10.1111/all.14289>

Drozd, M., Pujades-Rodriguez, M., Lillie, P. J., Straw, S., Morgan, A. W., Kearney, M. T., Witte, K. K., & Cubbon, R. M. (2021). Non-communicable disease, sociodemographic factors, and risk of death from infection: A UK Biobank observational cohort study. *The Lancet Infectious Diseases*, S1473309920309786. <https://doi.org/10.1016/S1473-3099(20)30978-6>

Duan, L., Zhang, S., Guo, M., Zhou, E., Fan, J., Wang, X., Wang, L., Wu, F., & Jin, Y. (2020). Epidemiological and clinical characteristics in patients with SARS-CoV-2 antibody negative probable COVID-19 in Wuhan. *medRxiv*, 2020.06.18.20134619. <https://doi.org/10.1101/2020.06.18.20134619>

Dupraz, J., Butty, A., Duperrex, O., Estoppey, S., Faivre, V., Thabard, J., Zuppinger, C., Greub, G., Pantaleo, G., Pasquier, J., Rousson, V., Egger, M., Steiner-Dubuis, A., Vassaux, S., Masserey, E., Bochud, M., Nusslé, S. G., & D’Acremont, V. (2020). *Prevalence of SARS-CoV-2 in household members and other close contacts of COVID-19 cases: A serologic study in canton of Vaud, Switzerland* [Preprint]. Epidemiology. <https://doi.org/10.1101/2020.11.27.20239244>

Durstenfeld, M. S., Sun, K., Ma, Y., Rodriguez, F., Secemsky, E. A., Parikh, R. V., & Hsue, P. Y. (2021). *Impact of HIV Infection on COVID-19 Outcomes Among Hospitalized Adults in the U.S.* [Preprint]. HIV/AIDS. <https://doi.org/10.1101/2021.04.05.21254938>

Dye, J. A., & Adler, K. B. (1994). Occasional review Effects of cigarette smoke on epithelial cells of the respiratory tract. *Thorax*, *49*, 825–834. <https://doi.org/10.1136/thx.49.8.825>

Ebinger, J., Botwin, G. J., Albert, C. M., Alotaibi, M., Arditi, M., Berg, A. H., Binek, A., Botting, P. G., Fert-Bober, J., Figueiredo, J. C., Grein, J. D., Hasan, W., Henglin, M., Hussain, S. K., Jain, M., Joung, S., Karin, M., Kim, E. H., Li, D., … Cheng, S. (2020). SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers. *medRxiv*, 2020.07.31.20163055. <https://doi.org/10.1101/2020.07.31.20163055>

Ebrahimian, S., Homayounieh, F., Rockenbach, M. A. B. C., Putha, P., Raj, T., Dayan, I., Bizzo, B. C., Buch, V., Wu, D., Kim, K., Li, Q., Digumarthy, S. R., & Kalra, M. K. (2021). Artificial intelligence matches subjective severity assessment of pneumonia for prediction of patient outcome and need for mechanical ventilation: A cohort study. *Sci. Rep*, *11*. <https://doi.org/10.1038/s41598-020-79470-0>

Egede, C., Dawson, A. Z., Walker, R. J., Garacci, E., Campbell, J. A., & Egede, L. E. (2021). Relationship between mental health diagnoses and COVID-19 test positivity, hospitalization, and mortality in Southeast Wisconsin. *Psychological Medicine*, 1–9. <https://doi.org/10.1017/S0033291721002312>

Eiros, R., Barreiro-Perez, M., Martin-Garcia, A., Almeida, J., Villacorta, E., Perez-Pons, A., Merchan, S., Torres-Valle, A., Sanchez-Pablo, C., Gonzalez-Calle, D., Perez-Escurza, O., Toranzo, I., Diaz-Pelaez, E., Fuentes-Herrero, B., Macias-Alvarez, L., Oliva-Ariza, G., Lecrevisse, Q., Fluxa, R., Bravo-Grandez, J. L., … Sanchez, P. L. (2020). Pericarditis and myocarditis long after SARS-CoV-2 infection: A cross-sectional descriptive study in health-care workers. *medRxiv*, 2020.07.12.20151316. <https://doi.org/10.1101/2020.07.12.20151316>

Elezkurtaj, S., Greuel, S., Ihlow, J., Michaelis, E., Bischoff, P., Kunze, C. A., Sinn, B. V., Gerhold, M., Hauptmann, K., Ingold-Heppner, B., Miller, F., Herbst, H., Corman, V. M., Martin, H., Heppner, F. L., & Horst, D. (2020). Causes of Death and Comorbidities in Patients with COVID-19. *medRxiv*, 2020.06.15.20131540. <https://doi.org/10.1101/2020.06.15.20131540>

Elliott, J. H., Turner, T., Clavisi, O., Thomas, J., Higgins, J. P. T., Mavergames, C., & Gruen, R. L. (2014). Living Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap. *PLoS Medicine*, *11*(2). <https://doi.org/10.1371/journal.pmed.1001603>

Elmunzer, B. J., Spitzer, R. L., Foster, L. D., Merchant, A. A., Howard, E. F., Patel, V. A., West, M. K., Qayad, E., Nustas, R., Zakaria, A., Piper, M. S., Taylor, J. R., Jaza, L., Forbes, N., Chau, M., Lara, L. F., Papachristou, G. I., Volk, M. L., Hilson, L. G., … Nitchie, H. (2020). Digestive Manifestations in Patients Hospitalized with COVID-19. *medRxiv*, 2020.07.07.20143024. <https://doi.org/10.1101/2020.07.07.20143024>

El-Solh, A. A., Meduri, U. G., Lawson, Y., Carter, M., & Mergenhagen, K. A. (2020). CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY. *medRxiv*, 2020.10.16.20214130. <https://doi.org/10.1101/2020.10.16.20214130>

Emami, A., Javanmardi, F., Pirbonyeh, N., & Akbari, A. (2020). Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. *Archives of Academic Emergency Medicine*, *8*(1), e35.

Erber, J., Kappler, V., Haller, B., Mijočević, H., Galhoz, A., Costa, C. P. da, Gebhardt, F., Graf, N., Hoffmann, D., Thaler, M., Lorenz, E., Roggendorf, H., Kohlmayer, F., Henkel, A., Menden, M. P., Ruland, J., Spinner, C. D., Protzer, U., Knolle, P., … on behalf of the SeCoMRI Study Group. (2020). *Strategies for infection control and prevalence of anti-SARS-CoV-2 IgG in 4,554 employees of a university hospital in Munich, Germany* [Preprint]. Epidemiology. <https://doi.org/10.1101/2020.10.04.20206136>

Estiri, H., Strasser, Z. H., Klann, J. G., Naseri, P., Wagholikar, K. B., & Murphy, S. N. (2021). Predicting COVID-19 mortality with electronic medical records. *Npj Digit. Med*, *4*. <https://doi.org/10.1038/s41746-021-00383-x>

Eugen-Olsen, J., Altintas, I., Tingleff, J., Stauning, M., Gamst-Jensen, H., Lindstroem, M. B., Rasmussen, L. J. H., Kristiansen, K. T., Rasmussen, C., Nehlin, J., Kallemose, T., & Andersen, O. (2020). Low levels of the prognostic biomarker suPAR are predictive of mild outcome in patients with symptoms of COVID-19 - a prospective cohort study. *medRxiv*, 2020.05.27.20114678. <https://doi.org/10.1101/2020.05.27.20114678>

Fan, X., Yin, C., Wang, J., Yang, M., Ma, H., Jin, G., Song, M., Hu, Z., Shen, H., & Hang, D. (2020). Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: Results from UK Biobank. *medRxiv*, 2020.07.09.20149369. <https://doi.org/10.1101/2020.07.09.20149369>

Farsalinos, K., Barbouni, A., & Niaura, R. (2020). Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: Could nicotine be a therapeutic option? *Internal and Emergency Medicine*. <https://doi.org/10.1007/s11739-020-02355-7>

Farsalinos, K., Niaura, R., Le Houezec, J., Barbouni, A., Tsatsakis, A., Kouretas, D., Vantarakis, A., & Poulas, K. (2020). Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. *Toxicology Reports*. <https://doi.org/10.1016/j.toxrep.2020.04.012>

Favara, D. M., McAdam, K., Cooke, A., Bordessa-Kelly, A., Budriunaite, I., Bossingham, S., Houghton, S., Doffinger, R., Ainsworth, N., & Corrie, P. G. (2020a). *SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic* [Preprint]. Oncology. <https://doi.org/10.1101/2020.09.18.20197590>

Favara, D. M., McAdam, K., Cooke, A., Bordessa-Kelly, A., Budriunaite, I., Bossingham, S., Houghton, S., Doffinger, R., Ainsworth, N., & Corrie, P. G. (2020b). *SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic* [Preprint]. Oncology. <https://doi.org/10.1101/2020.09.18.20197590>

Faverio, P., Luppi, F., Rebora, P., Busnelli, S., Stainer, A., Catalano, M., Parachini, L., Monzani, A., Galimberti, S., Bini, F., Bodini, B. D., Betti, M., Giacomi, F. D., Scarpazza, P., Oggionni, E., Scartabellati, A., Bilucaglia, L., Ceruti, P., Modina, D., … Pesci, A. (2021). *Six-month pulmonary impairment after severe COVID-19: A prospective, multicenter follow-up study* [Preprint]. Respiratory Medicine. <https://doi.org/10.1101/2021.03.29.21254151>

Feldman, C., & Anderson, R. (2013). Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. *J. Infect*, *67*, 169–184. <https://doi.org/10.1016/j.jinf.2013.05.004>

Feng, Y., Ling, Y., Bai, T., Xie, Y., Huang, J., Li, J., Xiong, W., Yang, D., Chen, R., Lu, F., Lu, Y., Liu, X., Chen, Y., Li, X., Li, Y., Summah, H. D., Lin, H., Yan, J., Zhou, M., … Qu, J. (2020). COVID-19 with Different Severities: A Multicenter Study of Clinical Features. *American Journal of Respiratory and Critical Care Medicine*, *201*(11), 1380–1388. <https://doi.org/10.1164/rccm.202002-0445OC>

Fernandez-Fuertes, M., Corma-Gomez, A., Torres, E., Rodriguez-Pineda, E., Fuentes-Lopez, A., Rincon, P., Fernanddez, N., Garcia, F., Bernal, S., Real, L. M., Macias, J., & Pineda, J. A. (2021). *Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain* [Preprint]. HIV/AIDS. <https://doi.org/10.1101/2021.03.20.21253397>

Ferrari, B. L., Ferreira, C. G., Menezes, M., De Marchi, P., Canedo, J., Melo, A. C. de, Jacome, A. A., Reinert, T., Paes, R. D., Sodre, B., Barrios, C. H., & Dienstmann, R. (2021). Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. *JCO Glob Oncol*, *7*, 46–55. <https://doi.org/10.1200/GO.20.00444>

Feuth, T., Saaresranta, T., Karlsson, A., Valtonen, M., Peltola, V., Rintala, E., & Oksi, J. (2020). Is sleep apnoea a risk factor for Covid-19? Findings from a retrospective cohort study. *medRxiv*, 2020.05.14.20098319. <https://doi.org/10.1101/2020.05.14.20098319>

Fillmore, N. R., La, J., Szalat, R. E., Tuck, D. P., Nguyen, V., Yildirim, C., Do, N. V., Brophy, M. T., & Munshi, N. C. (2020). Prevalence and outcome of Covid-19 infection in cancer patients: A national VA study. *medRxiv*, 2020.08.21.20177923. <https://doi.org/10.1101/2020.08.21.20177923>

Fisher, B. A., Veenith, T., Slade, D., Gaskell, C., Rowland, M., Whitehouse, T., Scriven, J., Parekh, D., Balasubramaniam, M. S., Cooke, G., Morley, N., Gabriel, Z., Wise, M. P., Porter, J., McShane, H., Ho, L.-P., Newsome, P. N., Rowe, A., Sharpe, R., … Kearns, P. (2021). *Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): A phase 2 randomised adaptive trial* [Preprint]. Intensive Care; Critical Care Medicine. <https://doi.org/10.1101/2021.06.02.21258204>

Fisman, D., Greer, A. L., & Tuite, A. (2020). Derivation and Validation of Clinical Prediction Rule for COVID-19 Mortality in Ontario, Canada. *medRxiv*, 2020.06.21.20136929. <https://doi.org/10.1101/2020.06.21.20136929>

Fogh, K., Eriksen, A. R., Hasselbalch, R. B., Kristensen, E. S., Bundgaard, H., Nielsen, S. D., Jørgensen, C. S., Scharff, B. F., Erikstrup, C., Sækmose, S. G., Holm, D. K., Aagaard, B., Norsk, J., Nielsen, P. B., Kristensen, J. H., Østergaard, L., Ellermann-Eriksen, S., Andersen, B., Nielsen, H., … Iversen, K. (2021). *Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.05.07.21256725>

Fond, G., Pauly, V., Orleans, V., Antonini, F., Fabre, C., Sanz, M., Klay, S., Jimeno, M.-T., Leone, M., Lancon, C., Auquier, P., & Boyer, L. (2020). Increased in-hospital mortality from COVID-19 in patients with schizophrenia. *L’Encéphale*, S0013700620301883. <https://doi.org/10.1016/j.encep.2020.07.003>

Fontanet, A., Tondeur, L., Madec, Y., Grant, R., Besombes, C., Jolly, N., Pellerin, S. F., Ungeheuer, M.-N., Cailleau, I., Kuhmel, L., Temmam, S., Huon, C., Chen, K.-Y., Crescenzo, B., Munier, S., Demeret, C., Grzelak, L., Staropoli, I., Bruel, T., … Hoen, B. (2020). Cluster of COVID-19 in northern France: A retrospective closed cohort study. *medRxiv*, 2020.04.18.20071134. <https://doi.org/10.1101/2020.04.18.20071134>

Fox, T. A., Troy‐Barnes, E., Kirkwood, A. A., Chan, W. Y., Day, J., Chavda, S. J., Kumar, E. A., David, K., Tomkins, O., Sanchez, E., Scully, M., Khwaja, A., Lambert, J., Singer, M., Roddie, C., Morris, E. C., Yong, K. L., Thomson, K. J., & Ardeshna, K. M. (n.d.). Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy. *British Journal of Haematology*, *n/a*(n/a). <https://doi.org/10.1111/bjh.17027>

Freites, D., Leon, L., Mucientes, A., Rodriguez-Rodriguez, L., Font, J., Madrid, A., Colomer, J. I., Jover, J. A., Fernandez-Gutierrez, B., & Abasolo, L. (2020). Risk factors for hospital admission related to COVID-19 in inflammatory rheumatic diseases. *medRxiv*, 2020.05.14.20101584. <https://doi.org/10.1101/2020.05.14.20101584>

Fung, H. F., Martinez, L., Alarid-Escudero, F., Salomon, J. A., Studdert, D. M., Andrews, J. R., Goldhaber-Fiebert, J. D., & Group, S.-C. M. (2020). The household secondary attack rate of SARS-CoV-2: A rapid review. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa1558>

Gaitán-Duarte, H. G., Álvarez-Moreno, C., Rincón-Rodríguez, C. J., Yomayusa-González, N., Cortés, J. A., Villar, J. C., Bravo-Ojeda, J. S., García-Peña, Á., Adarme-Jaimes, W., Rodríguez-Romero, V. A., Villate-Soto, S. L., Buitrago, G., Chacón-Sarmiento, J., Macías-Quintero, M., Vaca, C. P., Gómez-Restrepo, C., & Rodríguez-Malagón, N. (2021). *Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.07.06.21260085>

Galal, I., Hussein, A. A. M., Amin, M. T., Saad, M. M., Zayan, H. E. E., Abdelsayed, M. Z., Moustafa, M. M., Ezzat, A. R., Helmy, R. E., Abd- Elaal, H. K., Massry, N. A. A., Soliman, M. A., Ismail, A. M., Kholief, K. M., Fathy, E., & Hashem, M. K. (2020). *Determinants of Persistent Post COVID-19 symptoms: Value of a Novel COVID-19 symptoms score*. <https://doi.org/10.1101/2020.11.11.20230052>

Gallichotte, E. N., Quicke, K. M., Sexton, N. R., Fitzmeyer, E., Young, M. C., Janich, A. J., Dobos, K., Pabilonia, K. L., Gahm, G., Carlton, E. J., Ebel, G. D., & Ehrhart, N. (2020). Longitudinal Surveillance for SARS-CoV-2 Among Staff in Six Colorado Long-Term Care Facilities: Epidemiologic, Virologic and Sequence Analysis. *medRxiv*, 2020.06.08.20125989. <https://doi.org/10.1101/2020.06.08.20125989>

Galluzzi, F., Rossi, V., Bosetti, C., & Garavello, W. (2021). Risk Factors for Olfactory and Gustatory Dysfunctions in Patients with SARS-CoV-2 Infection. *Neuroepidemiology*, *55*(2), 154–161. <https://doi.org/10.1159/000514888>

Garassino, M. C., Whisenant, J. G., Huang, L.-C., Trama, A., Torri, V., Agustoni, F., Baena, J., Banna, G., Berardi, R., Bettini, A. C., Bria, E., Brighenti, M., Cadranel, J., De Toma, A., Chini, C., Cortellini, A., Felip, E., Finocchiaro, G., Garrido, P., … Horn, L. (2020). COVID-19 in patients with thoracic malignancies (TERAVOLT): First results of an international, registry-based, cohort study. *The Lancet Oncology*, *21*(7), 914–922. <https://doi.org/10.1016/S1470-2045(20)30314-4>

García-Abellán, J., Padilla, S., Fernández-González, M., García, J. A., Agulló, V., Andreo, M., Ruiz, S., Galiana, A., Gutiérrez, F., & Masiá, M. (2021). *Long-term clinical, virological and immunological outcomes in patients hospitalized for COVID-19: Antibody response predicts long COVID* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.03.08.21253124>

Garibaldi, B. T., Fiksel, J., Muschelli, J., Robinson, M. L., Rouhizadeh, M., Nagy, P., Gray, J. H., Malapati, H., Ghobadi-Krueger, M., Niessen, T. M., Kim, B. S., Hill, P. M., Ahmed, M. S., Dobkin, E. D., Blanding, R., Abele, J., Woods, B., Harkness, K., Thiemann, D. R., … Gupta, A. (2020). Patient trajectories and risk factors for severe outcomes among persons hospitalized for COVID-19 in the Maryland/DC region. *medRxiv*, 2020.05.24.20111864. <https://doi.org/10.1101/2020.05.24.20111864>

Ge, H., Zhu, M., Du, J., Zhou, Y., Wang, W., Zhang, W., Jiang, H., Qiao, Z., Gu, Z., Li, F., & Pu, J. (2020). Cardiac Structural and Functional Characteristics in Patients with Coronavirus Disease 2019: A Serial Echocardiographic Study. *medRxiv*, 2020.05.12.20095885. <https://doi.org/10.1101/2020.05.12.20095885>

Gebhard, C. E., Sütsch, C., Bengs, S., Deforth, M., Buehler, K. P., Hamouda, N., Meisel, A., Schuepbach, R. A., Zinkernagel, A. S., Brugger, S. D., Acevedo, C., Patriki, D., Wiggli, B., Beer, J. H., Friedl, A., Twerenbold, R., Kuster, G. M., Pargger, H., Tschudin-Sutter, S., … Gebhard, C. (2021). *Sex- and Gender-specific Risk Factors of Post-COVID-19 Syndrome: A Population-based Cohort Study in Switzerland* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.06.30.21259757>

Genecand, C., Mongin, D., Koegler, F., Lebowitz, D., Regard, S., Nehme, M., Braillard, O., Grira, M., Joubert, D., Chopard, P., Delaporte, E., Stirnemann, J., Guessous, I., Tardin, A., & Courvoisier, D. S. (2021). *Cohort profile: Actionable Register of Geneva Out- and inpatients with SARS-CoV-2 (ARGOS)* [Preprint]. Public; Global Health. <https://doi.org/10.1101/2021.05.24.21256813>

Gerhards, C., Thiaucourt, M., Kittel, M., Becker, C., Ast, V., Hetjens, M., Neumaier, M., & Haselmann, V. (2021). Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. *International Journal of Infectious Diseases*, *107*, 221–227. <https://doi.org/10.1016/j.ijid.2021.04.080>

Gégout petit, A., Jeulin, H., Legrand, K., Bochnakian, A., Vallois, P., Schvoerer, E., & Guillemin, F. (2021). *Seroprevalence of SARS-CoV-2, symptom profiles and seroneutralization during the first COVID-19 wave in a suburban area, France*. <https://doi.org/10.1101/2021.02.10.21250862>

Ghani, H., Navarra, A., Pyae, P. K., Mitchell, H., Evans, W., Cama, R., Shaw, M., Critchlow, B., Vaghela, T., Schechter, M., Nordin, N., Barlow, A., & Vancheeswaran, R. (2021). *Relevance of prediction scores derived from the SARS-CoV-2 first wave, in the UK COVID-19 second wave, for early discharge, severity and mortality: A PREDICT COVID UK prospective observational cohort study* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.06.09.21258602>

Gharebaghi, N., Farshid, S., Boroofeh, B., Nejadrahim, R., Mousavi, J., Dindarian, S., & Mohammadi, S. (2021). Evaluation of epidemiology, clinical features, prognosis, diagnosis and treatment outcomes of patients with COVID‐19 in West Azerbaijan Province. *International Journal of Clinical Practice*, *75*(6). <https://doi.org/10.1111/ijcp.14108>

Ghinai, I., Davis, E. S., Mayer, S., Toews, K.-A., Huggett, T. D., Snow-Hill, N., Perez, O., Hayden, M. K., Tehrani, S., Landi, A. J., Crane, S., Bell, E., Hermes, J.-M., Desai, K., Godbee, M., Jhaveri, N., Borah, B., Cable, T., Sami, S., … Layden, J. E. (2020). Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Homeless Shelters in Chicago, Illinois—March–May, 2020. *Open Forum Infectious Diseases*, *7*(11), ofaa477. <https://doi.org/10.1093/ofid/ofaa477>

Giacomelli, A., Ridolfo, A. L., Milazzo, L., Oreni, L., Bernacchia, D., Siano, M., Bonazzetti, C., Covizzi, A., Schiuma, M., Passerini, M., Piscaglia, M., Coen, M., Gubertini, G., Rizzardini, G., Cogliati, C., Brambilla, A. M., Colombo, R., Castelli, A., Rech, R., … Galli, M. (2020). 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. *Pharmacological Research*, *158*, 104931. <https://doi.org/10.1016/j.phrs.2020.104931>

Gianfrancesco, M. A., Leykina, L. A., Izadi, Z., Taylor, T., Sparks, J. A., Harrison, C., Trupin, L., Rush, S., Schmajuk, G., Katz, P., Jacobsohn, L., Hsu, T. Y., D’Silva, K. M., Serling‐Boyd, N., Wallwork, R., Todd, D. J., Bhana, S., Costello, W., Grainger, R., … Zell, J. (2020). Race/ethnicity association with COVID‐19 outcomes in rheumatic disease: Data from the COVID‐19 Global Rheumatology Alliance Physician Registry. *Arthritis & Rheumatology*, art.41567. <https://doi.org/10.1002/art.41567>

Gianfrancesco, M., Hyrich, K. L., Al-Adely, S., Carmona, L., Danila, M. I., Gossec, L., Izadi, Z., Jacobsohn, L., Katz, P., Lawson-Tovey, S., Mateus, E. F., Rush, S., Schmajuk, G., Simard, J., Strangfeld, A., Trupin, L., Wysham, K. D., Bhana, S., Costello, W., … Robinson, P. C. (2020). Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Annals of the Rheumatic Diseases*, *79*(7), 859–866. <https://doi.org/10.1136/annrheumdis-2020-217871>

Giannini, S., Passeri, G., Tripepi, G., Sella, S., Fusaro, M., Arcidiacono, G., Torres, M. O., Michielin, A., Prandini, T., Baffa, V., Aghi, A., Egan, C. G., Brigo, M., Zaninotto, M., Plebani, M., Vettor, R., Fioretto, P., Rossini, M., Vignali, A., … Bertoldo, F. (2021). Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study. *Nutrients*, *13*. <https://doi.org/10.3390/nu13010219>

Giannouchos, T., Sussman, R., Mier, J. M., Poulas, K., & Farsalinos, K. (2020). Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: An analysis of 89,756 laboratory-confirmed COVID-19 cases. *medRxiv*, 2020.06.04.20122481. <https://doi.org/10.1101/2020.06.04.20122481>

Gil, S., Filho, W. J., Shinjo, S. K., Ferriolli, E., Busse, A. L., Avelino-Silva, T. J., Longobardi, I., Oliveira, G. N. de, Swinton, P., Gualano, B., Roschel, H., Bonfá, E., Utiyama, E., Segurado, A., Perondi, B., Morais, A. M., Montal, A., Letaif, L., Fusco, S., … Francisco, M. C. P. B. (2021). *Muscle Strength and Muscle Mass as Predictors of Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Prospective Observational Study* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.03.30.21254578>

Gil-Agudo, A., Rodriguez-Cola, M., Jimenez-Velasco, I., Gutierrez-Henares, F., Lopez-Dolado, E., Gambarrutta-Malfatti, C., & Vargas-Baquero, E. (2020). Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury. *medRxiv*, 2020.04.20.20072918. <https://doi.org/10.1101/2020.04.20.20072918>

Girardeau, Y., Gallois, Y., De Bonnecaze, G., Escudé, B., Lafont, C., Chattelier, G., & Marx, M. (2020). *Confirmed central olfactory system lesions on brain MRI in COVID-19 patients with anosmia: A case-series*. <https://doi.org/10.1101/2020.07.08.20148692>

Gold, J. A. W., Wong, K. K., Szablewski, C. M., Patel, P. R., Rossow, J., Silva, J. da, Natarajan, P., Morris, S. B., Fanfair, R. N., Rogers-Brown, J., Bruce, B. B., Browning, S. D., Hernandez-Romieu, A. C., Furukawa, N. W., Kang, M., Evans, M. E., Oosmanally, N., Tobin-D’Angelo, M., Drenzek, C., … Jackson, B. R. (2020). Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020. *MMWR. Morbidity and Mortality Weekly Report*, *69*(18), 545–550. <https://doi.org/10.15585/mmwr.mm6918e1>

González, F., Vielot, N. A., Sciaudone, M., Toval-Ruíz, C., Premkumar, L., Gutierrez, L., Cuadra, E. C., Blandón, P., Silva, A. M. de, Rubinstein, R., Bowman, N., Becker-Dreps, S., & Bucardo, F. (2021). *Seroepidemiology of SARS-CoV-2 infections in an urban Nicaraguan population* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.02.25.21252447>

González, F., Zepeda, O., Toval-Ruiz, C., Matute, A., Vanegas, H., Munguia, N., Centeno, E., Reyes, Y., Svensson, L., Nordgren, J., Silva, A. M. de, Becker-Dreps, S., Premkumar, L., & Bucardo, F. (2021). *Antibody response to SARS-CoV-2 infection over six months among Nicaraguan outpatients* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.04.28.21256122>

Gori, M., Berzuini, C., D’Elia, E., Ghirardi, A., Bernardinelli, L., Gavazzi, A., Balestrieri, G., Giammarresi, A., Trevisan, R., Di Marco, F., Bellasi, A., Amoroso, M., Raimondi, F., Novelli, L., Magro, B., Mangia, G., Lorini, F. L., Guagliumi, G., Fagiuoli, S., … Senni, M. (2020). *Exposure to Renin-Angiotensin System Inhibitors Is Associated with Reduced Mortality of Older Hypertensive Covid-19 Patients*. <https://doi.org/10.1101/2020.12.15.20247999>

Gornyk, D., Harries, M., Glöckner, S., Strengert, M., Kerrinnes, T., Bojara, G., Castell, S., Frank, K., Gubbe, K., Heise, J.-K., Hernandez, P., Kappert, O., Kern, W., Illig, T., Klopp, N., Maaß, H., Ortmann, J., Kessel, B., Roller, G., … Krause, G. (2021a). *SARS-CoV-2 seroprevalence in Germany - a population based sequential study in five regions* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.05.04.21256597>

Gornyk, D., Harries, M., Glöckner, S., Strengert, M., Kerrinnes, T., Bojara, G., Castell, S., Frank, K., Gubbe, K., Heise, J.-K., Hernandez, P., Kappert, O., Kern, W., Illig, T., Klopp, N., Maaß, H., Ortmann, J., Kessel, B., Roller, G., … Krause, G. (2021b). *SARS-CoV-2 seroprevalence in Germany - a population based sequential study in five regions* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.05.04.21256597>

Govind, R., Freitas, D. F. de, Pritchard, M. R., Hayes, R. D., & MacCabe, J. H. (2020). Clozapine treatment and risk of COVID-19. *medRxiv*, 2020.06.17.20133595. <https://doi.org/10.1101/2020.06.17.20133595>

Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., Satlin, M. J., Campion, T. R., Nahid, M., Ringel, J. B., Hoffman, K. L., Alshak, M. N., Li, H. A., Wehmeyer, G. T., Rajan, M., Reshetnyak, E., Hupert, N., Horn, E. M., Martinez, F. J., … Safford, M. M. (2020). Clinical Characteristics of Covid-19 in New York City. *New England Journal of Medicine*, *382*(24), 2372–2374. <https://doi.org/10.1056/NEJMc2010419>

Greenbaum, U., Klein, K., Martinez, F., Song, J., Thall, P. F., Ramdial, J. L., Knape, C., Aung, F. M., Scroggins, J., Knopfelmacher, A., Mulanovich, V., Borjan, J., Adachi, J., Muthu, M., Leung, C., Medina, M. C., Champlin, R., Olson, A., Alousi, A., … Shpall, E. J. (2021). High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. *Frontiers in Immunology*, *12*, 675679. <https://doi.org/10.3389/fimmu.2021.675679>

Griffith, G., Morris, T. T., Tudball, M., Herbert, A., Mancano, G., Pike, L., Sharp, G. C., Palmer, T. M., Smith, G. D., Tilling, K., Zuccolo, L., Davies, N. M., & Hemani, G. (2020). Collider bias undermines our understanding of COVID-19 disease risk and severity. *medRxiv*, 2020.05.04.20090506. <https://doi.org/10.1101/2020.05.04.20090506>

Grint, D. J., Wing, K., Williamson, E., McDonald, H. I., Bhaskaran, K., Evans, D., Evans, S. J., Walker, A. J., Hickman, G., Nightingale, E., Schultze, A., Rentsch, C. T., Bates, C., Cockburn, J., Curtis, H. J., Morton, C. E., Bacon, S., Davy, S., Wong, A. Y., … Eggo, R. M. (2021). *Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.03.04.21252528>

Grundy\*, E. J., Suddek\*, T., Filippidis, F. T., Majeed, A., & Coronini-Cronberg, S. (2020). Smoking, SARS-CoV-2 and COVID-19: A review of reviews considering implications for public health policy and practice. *Tobacco Induced Diseases*, *18*(July). <https://doi.org/10.18332/tid/124788>

Gu, T., Mack, J. A., Salvatore, M., Sankar, S. P., Valley, T. S., Singh, K., Nallamothu, B. K., Kheterpal, S., Lisabeth, L., Fritsche, L. G., & Mukherjee, B. G. (2020). COVID-19 outcomes, risk factors and associations by race: A comprehensive analysis using electronic health records data in Michigan Medicine. *medRxiv*, 2020.06.16.20133140. <https://doi.org/10.1101/2020.06.16.20133140>

Guan, W., Liang, W., Zhao, Y., Liang, H., Chen, Z., Li, Y., Liu, X., Chen, R., Tang, C., Wang, T., Ou, C., Li, L., Chen, P., Sang, L., Wang, W., Li, J., Li, C., Ou, L., Cheng, B., … He, J. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. *European Respiratory Journal*, *55*(5). <https://doi.org/10.1183/13993003.00547-2020>

Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K.-Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., … Zhong, N. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*. <https://doi.org/10.1056/NEJMoa2002032>

Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., & Lu, Z. (2020). Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*, *5*(7), 811–818. <https://doi.org/10.1001/jamacardio.2020.1017>

Gupta, R., Agrawal, R., Bukhari, Z., Jabbar, A., Wang, D., Diks, J., Alshal, M., Emechebe, D. Y., Brunicardi, F. C., Lazar, J. M., Chamberlain, R., Burza, A., & Haseeb, M. A. (2020). Higher Comorbidities and Early Death is Characteristic of Hospitalized African-American Patients with COVID-19. *medRxiv*, 2020.07.15.20154906. <https://doi.org/10.1101/2020.07.15.20154906>

Guzmán, M. J. M., Castillo-Gonzalez, A., Gonzalez, J. L. B., Gámez, M. G., Enciso, E. A. M., Robles, I. O., Díaz, A. L. G., Peña, C. M. G., Medina, L. M., Colin, V. A. M., & Jose Manuel, A. G. (2021). *Factors associated with increased mortality in critically ill COVID-19 patients in a Mexican public hospital: The other faces of health system oversaturation* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.03.04.21252084>

Hadi, Y. B., Naqvi, S. F. Z., Kupec, J. T., & Sarwari, A. R. (2020). Characteristics and outcomes of COVID-19 in patients with HIV: A multicentre research network study. *AIDS*, *34*(13), F3–F8. <https://doi.org/10.1097/QAD.0000000000002666>

Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Pere, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., Breillat, P., Carlier, N., Gauzit, R., Morbieu, C., Pene, F., Marin, N., Roche, N., Szwebel, T.-A., Smith, N., Merkling, S., … Terrier, B. (2020). Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. *medRxiv*, 2020.04.19.20068015. <https://doi.org/10.1101/2020.04.19.20068015>

Halabi, M. E., Feghali, J., Tallón de Lara, P., Narasimhan, B., Ho, K., Saabiye, J., Huang, J., Osorio, G., Mathew, J., Wisnivesky, J., & Steiger, D. (2021). *A Novel Evidence-Based Predictor Tool for Hospitalization and Length of Stay: Insights from COVID19 Patients in New York City* [Preprint]. Emergency Medicine. <https://doi.org/10.1101/2021.04.24.21256042>

Hamadah, H., Alahmad, B., Behbehani, M., Al-Youha, S., Almazeedi, S., Al-Haddad, M., Jamal, M. H., & Al-Sabah, S. (2020). COVID-19 clinical outcomes and nationality: Results from a Nationwide registry in Kuwait. *BMC Public Health*, *20*(1), 1384. <https://doi.org/10.1186/s12889-020-09490-y>

Hamer, M., Kivimäki, M., Gale, C. R., & Batty, G. D. (2020). Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. *Brain, Behavior, and Immunity*, *87*, 184–187. <https://doi.org/10.1016/j.bbi.2020.05.059>

Han, H., Peng, X., Zheng, F., Deng, G., Cheng, X., & Peng, L. (2021). Association of Gender With Outcomes in Hospitalized Patients With 2019-nCoV Infection in Wuhan. *Frontiers in Public Health*, *9*, 619482. <https://doi.org/10.3389/fpubh.2021.619482>

Hao, S.-R., Zhang, S.-Y., Lian, J.-S., Jin, X., Ye, C.-Y., Cai, H., Zhang, X.-L., Hu, J.-H., Zheng, L., Zhang, Y.-M., Jia, H.-Y., Yu, G.-D., Wang, X.-Y., Gu, J.-Q., Lu, Y.-F., Yu, X.-P., Yu, L., Xiang, D.-R., Ye, C.-Y., … Yang, Y.-D. (2020). Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study. *The American Journal of Gastroenterology*. <https://doi.org/10.14309/ajg.0000000000000717>

Hausfater, P., Boutolleau, D., Lacombe, K., Beurton, A., Dumont, M., Constantin, J.-M., Ghosn, J., Combes, A., Cury, N., Guedj, R., Djibré, M., Bompard, R., Mazerand, S., Pourcher, V., Gimeno, L., Marois, C., Teyssou, E., Marcelin, A.-G., Hajage, D., & Tubach, F. (2021). *Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris, France: The SEROCOV prospective cohort study* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.03.09.21253200>

Heili-Frades, S. (n.d.). COVID-19 Outcomes in 4712 consecutively confirmed SARS-CoV2 cases in the city of Madrid. *medRxiv*. <https://doi.org/10.1101/2020.05.22.20109850>

Hernández-Garduño, E. (2020). Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study. *Obesity Research & Clinical Practice*. <https://doi.org/10.1016/j.orcp.2020.06.001>

Herzberg, J., Vollmer, T., Fischer, B., Becher, H., Becker, A.-K., Honarpisheh, H., Guraya, S. Y., Strate, T., & Knabbe, C. (2021). *SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.06.09.21258648>

Hewitt, J., Carter, B., Vilches-Moraga, A., Quinn, T. J., Braude, P., Verduri, A., Pearce, L., Stechman, M., Short, R., Price, A., Collins, J. T., Bruce, E., Einarsson, A., Rickard, F., Mitchell, E., Holloway, M., Hesford, J., Barlow-Pay, F., Clini, E., … Guaraldi, G. (2020). The effect of frailty on survival in patients with COVID-19 (COPE): A multicentre, European, observational cohort study. *The Lancet Public Health*, *5*(8), e444–e451. <https://doi.org/10.1016/S2468-2667(20)30146-8>

Higuchi, T., Nishida, T., Iwahashi, H., Morimura, O., Otani, Y., Okauchi, Y., Yokoe, M., Suzuki, N., Inada, M., & Abe, K. (2020). Early Clinical Factors Predicting the Development of Critical Disease in Japanese Patients with COVID-19: A Single-Center Retrospective, Observational Study. *medRxiv*, 2020.07.29.20159442. <https://doi.org/10.1101/2020.07.29.20159442>

Hippisley-Cox, J., Young, D., Coupland, C., Channon, K. M., Tan, P. S., Harrison, D. A., Rowan, K., Aveyard, P., Pavord, I. D., & Watkinson, P. J. (2020). Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people. *Heart*, heartjnl-2020-317393. <https://doi.org/10.1136/heartjnl-2020-317393>

Hirschtick, J. L., Titus, A. R., Slocum, E., Power, L. E., Hirschtick, R. E., Elliott, M. R., McKane, P., & Fleischer, N. L. (2021). Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics. *Clinical Infectious Diseases*, ciab408. <https://doi.org/10.1093/cid/ciab408>

Ho, F. K., Celis-Morales, C. A., Gray, S. R., Katikireddi, S. V., Niedzwiedz, C. L., Hastie, C., Ferguson, L. D., Berry, C., Mackay, D. F., Gill, J. M., Pell, J. P., Sattar, N., & Welsh, P. (2020). Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: Results from a UK Biobank prospective cohort study. *BMJ Open*, *10*. <https://doi.org/10.1136/bmjopen-2020-040402>

Ho, K. S., Narasimhan, B., Sheehan, J., Wu, L., & Fung, J. Y. (2020). Controversy over Smoking in COVID-19 - A Real World Experience in New York City. *J Med Virol*, *NA*. <https://doi.org/10.1002/jmv.26738>

Hoertel, N., Rico, M. S., Vernet, R., Beeker, N., Jannot, A.-S., Neuraz, A., Salamanca, E., Paris, N., Daniel, C., Gramfort, A., Lemaitre, G., Bernaux, M., Bellamine, A., Lemogne, C., Airagnes, G., Burgun, A., & Limosin, F. (2020). Association between SSRI Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients with Coronavirus Disease 2019: A Multicenter Retrospective Observational Study. *medRxiv*, 2020.07.09.20143339. <https://doi.org/10.1101/2020.07.09.20143339>

Hoertel, N., Rico, M. S., Vernet, R., Jannot, A.-S., Neuraz, A., Blanco, C., Lemogne, C., Airagnes, G., Paris, N., Daniel, C., Gramfort, A., Lemaitre, G., Bernaux, M., Bellamine, A., Beeker, N., & Limosin, F. (2020). Observational Study of Haloperidol in Hospitalized Patients with Covid-19. *medRxiv*, 2020.07.15.20150490. <https://doi.org/10.1101/2020.07.15.20150490>

Hoertel, N., Sánchez, M., Vernet, R., Beeker, N., Neuraz, A., Alvarado, J., Daniel, C., Paris, N., Gramfort, A., Lemaitre, G., Salamanca, E., Bernaux, M., Bellamine, A., Burgun, A., & Limosin, F. (2020). *Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: A Multicenter Retrospective Observational Study* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.10.23.20218172>

Hoertel, N., Sánchez-Rico, M., Gulbins, E., Kornhuber, J., Carpinteiro, A., Abellán, M., Muela, P. de la, Vernet, R., Beeker, N., Neuraz, A., Delcuze, A., Alvarado, J. M., Meneton, P., & Limosin, F. (2021). *Association between Psychotropic Medications Functionally Inhibiting Acid Sphingomyelinase and reduced risk of Intubation or Death among Individuals with Mental Disorder and Severe COVID-19: An Observational Study* [Preprint]. Public; Global Health. <https://doi.org/10.1101/2021.02.18.21251997>

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, *181*(2), 271–280.e8. <https://doi.org/10.1016/j.cell.2020.02.052>

Holman, N., Knighton, P., Kar, P., O’Keefe, J., Curley, M., Weaver, A., Barron, E., Bakhai, C., Khunti, K., Wareham, N. J., Sattar, N., Young, B., & Valabhji, J. (2020). Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. *The Lancet Diabetes & Endocrinology*, *0*(0). <https://doi.org/10.1016/S2213-8587(20)30271-0>

Hopkinson, N. S., Rossi, N., Moustafa, J. E.-S., Laverty, A. A., Quint, J. K., Freydin, M. B., Visconti, A., Murray, B., Modat, M., Ourselin, S., Small, K., Davies, R., Wolf, J., Spector, T., Steves, C. J., & Falchi, M. (2020). Current tobacco smoking and risk from COVID-19: Results from a population symptom app in over 2.4 million people. *medRxiv*, 2020.05.18.20105288. <https://doi.org/10.1101/2020.05.18.20105288>

Houlihan, C. F., Vora, N., Byrne, T., Lewer, D., Kelly, G., Heaney, J., Gandhi, S., Spyer, M. J., Beale, R., Cherepanov, P., Moore, D., Gilson, R., Gamblin, S., Kassiotis, G., McCoy, L. E., Swanton, C., Hayward, A., Nastouli, E., Aitken, J., … Hatipoglu, E. (2020). Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. *The Lancet*, S0140673620314847. <https://doi.org/10.1016/S0140-6736(20)31484-7>

HPG23 Covid-19 Study Group, Raimondi, F., Novelli, L., Ghirardi, A., Russo, F. M., Pellegrini, D., Biza, R., Trapasso, R., Giuliani, L., Anelli, M., Amoroso, M., Allegri, C., Imeri, G., Sanfilippo, C., Comandini, S., Hila, E., Manesso, L., Gandini, L., Mandelli, P., … Di Marco, F. (2021). Covid-19 and gender: Lower rate but same mortality of severe disease in women—an observational study. *BMC Pulmonary Medicine*, *21*(1), 96. <https://doi.org/10.1186/s12890-021-01455-0>

Hu, L., Chen, S., Fu, Y., Gao, Z., Long, H., Ren, H., Zuo, Y., Li, H., Wang, J., Xv, Q., Yu, W., Liu, J., Shao, C., Hao, J., Wang, C., Ma, Y., Wang, Z., Yanagihara, R., Wang, J., & Deng, Y. (2020). Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China. *medRxiv*, 2020.03.25.20037721. <https://doi.org/10.1101/2020.03.25.20037721>

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, *395*(10223), 497–506. <https://doi.org/10.1016/S0140-6736(20)30183-5>

Huang, Y., Yang, R., Xu, Y., & Gong, P. (2020). Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. *medRxiv*, 2020.02.27.20029009. <https://doi.org/10.1101/2020.02.27.20029009>

Hultcrantz, M., Richter, J., Rosenbaum, C., Patel, D., Smith, E., Korde, N., Lu, S., Mailankody, S., Shah, U., Lesokhin, A., Hassoun, H., Tan, C., Maura, F., Derkach, A., Diamond, B., Rossi, A., Pearse, R. N., Madduri, D., Chari, A., … Landgren, O. (2020). COVID-19 infections and outcomes in patients with multiple myeloma in New York City: A cohort study from five academic centers. *medRxiv*, 2020.06.09.20126516. <https://doi.org/10.1101/2020.06.09.20126516>

Husain, Q., Kokinakos, K., Kuo, Y.-H., Zaidi, F., Houston, S., & Shargorodsky, J. (2021). Characteristics of COVID-19 smell and taste dysfunction in hospitalized patients. *American Journal of Otolaryngology*, *42*(6), 103068. <https://doi.org/10.1016/j.amjoto.2021.103068>

Hussein, M. H., Toraih, E. A., Attia, A. S., Youssef, M., Omar, M., Burley, N., Zhang, A. D., Roos, J., Houghton, A., Aniemeka, N., Shama, M. A., Duchesne, J., & Kandil, E. (2020). Asthma in COVID-19: An extra chain fitting around the neck? *medRxiv*, 2020.07.13.20153130. <https://doi.org/10.1101/2020.07.13.20153130>

Ibarra-Nava, I., Flores-Rodriguez, K. G., Ruiz-Herrera, V., Ochoa-Bayona, H. C., Salinas-Zertuche, A., Padilla-Orozco, M., & Salazar-Montalvo, R. G. (2020). Ethnic disparities in COVID-19 mortality in Mexico: A cross-sectional study based on national data. *medRxiv*, 2020.08.26.20182543. <https://doi.org/10.1101/2020.08.26.20182543>

Ibrahim, D., Dulipsingh, L., Zapatka, L., Eadie, R., Crowell, R., Williams, K., Wakefield, D., Cook, L., Puff, J., & Hussain, S. A. (2020). Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial. *medRxiv*, 2020.08.27.20183293. <https://doi.org/10.1101/2020.08.27.20183293>

Iftime, S., López-Azcona, A. F., Vallverdu, I., Hernandez-Flix, S., Febrer, G. de, Parra, S., Hernández-Aguilera, A., Riu, F., Joven, J., Camps, J., Castro, A., & REUSCOVID Study Group. (2020). *First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.12.10.20246959>

Ikitimur, H., Uysal, B. B., Cengiz, M., Ikitimur, B., Uysal, H., Ozcan, E., Islamoglu, M. S., Seyhan, S., Yavuzer, H., & Yavuzer, S. (n.d.). ”Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?”. *Journal of Medical Virology*, *n/a*(n/a). <https://doi.org/10.1002/jmv.26106>

Ilic, I., Zdravkovic, M., Timcic, S., Unic Stojanovic, D., Bojic, M., & Loncar, G. (2021). Pneumonia in healthcare workers during a COVID-19 outbreak at a cardiovascular hospitals. *International Journal of Infectious Diseases*, *103*, 188–193. <https://doi.org/10.1016/j.ijid.2020.11.156>

Incerti, D., Rizzo, S., Li, X., Lindsay, L., Yau, V., Keebler, D., Chia, J., & Tsai, L. (2020). *Risk factors for mortality among hospitalized patients with COVID-19* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.09.22.20196204>

International Severe Acute Respiratory and emerging Infections Consortium, Escher, M., Hall, M., Baillie, J. K., Baruch, J., Blumberg, L., Carson, G., Citarella, B. W., Dankwa, E. A., Docherty, A., Dryden, M., Donnelly, C. A., Dunning, J., Fraser, C., Hardwick, H., Harrison, E. M., Holden, K. A., Jassat, W., Kartsonaki, C., … Merson, L. (2020). *ISARIC Clinical Data Report 10 February 2021*. <https://doi.org/10.1101/2020.07.17.20155218>

International Severe Acute Respiratory and emerging Infections Consortium, Hall, M., Pritchard, M., Dankwa, E. A., Baillie, J. K., Carson, G., Citarella, B. W., Docherty, A., Donnelly, C. A., Dunning, J., Fraser, C., Hardwick, H., Harrison, E. M., Holden, K. A., Kartsonaki, C., Kennon, K., Lee, J., McLean, K., Openshaw, P. J. M., … Merson, L. (2020). *ISARIC Clinical Data Report 20 November 2020* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.07.17.20155218>

Invernizzi, A., Torre, A., Parrulli, S., Zicarelli, F., Schiuma, M., Colombo, V., Giacomelli, A., Cigada, M., Milazzo, L., Ridolfo, A., Faggion, I., Cordier, L., Oldani, M., Marini, S., Villa, P., Rizzardini, G., Galli, M., Antinori, S., Staurenghi, G., & Meroni, L. (2020). Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. *EClinicalMedicine*, *27*, 100550. <https://doi.org/10.1016/j.eclinm.2020.100550>

Ioannou, G. N., Locke, E., Green, P., Berry, K., O’Hare, A. M., Shah, J. A., Crothers, K., Eastment, M. C., Dominitz, J. A., & Fan, V. S. (2020). Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10131 US Veterans With SARS-CoV-2 Infection. *JAMA Network Open*, *3*(9), e2022310. <https://doi.org/10.1001/jamanetworkopen.2020.22310>

Ip, A., Berry, D. A., Hansen, E., Goy, A. H., Pecora, A. L., Sinclaire, B. A., Bednarz, U., Marafelias, M., Berry, S. M., Berry, N. S., Mathura, S., Sawczuk, I. S., Biran, N., Go, R. C., Sperber, S., Piwoz, J. A., Balani, B., Cicogna, C., Sebti, R., … Goldberg, S. L. (2020). Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study. *medRxiv*, 2020.05.21.20109207. <https://doi.org/10.1101/2020.05.21.20109207>

ISARIC Clinical Characterisation Group, Baillie, J. K., Baruch, J., Beane, A., Blumberg, L., Bozza, F., Broadley, T., Burrell, A., Carson, G., Citarella, B., Dagens, A., Elotmani, L., Escher, M., Farshait, N., Garcia Barrio, N., Goffard, J.-C., Hall, M., Hashmi, M., Horby, P., … Merson, L. (2020). *ISARIC Clinical Data Report issued: 14 July 2021* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.07.17.20155218>

Islam, M. Z., Riaz, B. K., Islam, A. S., Khanam, F., Akhter, J., Choudhury, R., Farhana, N., Uddin, M. J., & Efa, S. S. (2020). Risk factors associated with morbidity and mortality outcomes of COVID-19 patients on the 14th and 28th day of the disease course: A retrospective cohort study in Bangladesh. *medRxiv*, 2020.08.17.20176586. <https://doi.org/10.1101/2020.08.17.20176586>

Israel, A., Feldhamer, I., Lahad, A., Levin-Zamir, D., & Lavie, G. (2020). Smoking and the risk of COVID-19 in a large observational population study. *medRxiv*, 2020.06.01.20118877. <https://doi.org/10.1101/2020.06.01.20118877>

Israel, A., Schäffer, A. A., Cicurel, A., Feldhamer, I., Tal, A., Cheng, K., Sinha, S., Schiff, E., Lavie, G., & Ruppin, E. (2020). Large population study identifies drugs associated with reduced COVID-19 severity. *medRxiv*, 2020.10.13.20211953. <https://doi.org/10.1101/2020.10.13.20211953>

Iversen, K., Bundgaard, H., Hasselbalch, R. B., Kristensen, J. H., Nielsen, P. B., Pries-Heje, M., Knudsen, A. D., Christensen, C. E., Fogh, K., Norsk, J. B., Andersen, O., Fischer, T. K., Jensen, C. A. J., Larsen, M., Torp-Pedersen, C., Rungby, J., Ditlev, S. B., Hageman, I., Møgelvang, R., … Ullum, H. (2020). Risk of COVID-19 in health-care workers in Denmark: An observational cohort study. *The Lancet Infectious Diseases*, *0*(0). <https://doi.org/10.1016/S1473-3099(20)30589-2>

Izquierdo, J. L., Almonacid, C., Gonzalez, Y., Rio-Bermudez, C. D., Ancochea, J., Cardenas, R., & Soriano, J. B. (2020). The impact of COVID-19 on patients with asthma. *medRxiv*, 2020.07.24.20161596. <https://doi.org/10.1101/2020.07.24.20161596>

Izzi-Engbeaya, C., Distaso, W., Amin, A., Yang, W., Idowu, O., Kenkre, J. S., Shah, R. J., Woin, E., Shi, C., Alavi, N., Bedri, H., Brady, N., Blackburn, S., Leczycka, M., Patel, S., Sokol, E., Toke-Bjolgerud, E., Qayum, A., Abdel-Malek, M., … Salem, V. (2020). Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals. *medRxiv*, 2020.08.07.20160275. <https://doi.org/10.1101/2020.08.07.20160275>

Jackson, S. E., Brown, J., Shahab, L., Steptoe, A., & Fancourt, D. (2020). COVID-19, smoking and inequalities: A study of 53 002 adults in the UK. *Tobacco Control*, tobaccocontrol-2020-055933. <https://doi.org/10.1136/tobaccocontrol-2020-055933>

Jafari, D., Gandomi, A., Makhnevich, A., Qiu, M., Rolston, D. M., Gottesman, E. P., Tsegaye, A., Mayo, P. H., Stewart, M. E., Zhang, M., & Hajizadeh, N. (2021). *Trajectories of Hypoxemia & Respiratory System Mechanics of COVID-19 ARDS in the NorthCARDS dataset*. <https://doi.org/10.1101/2021.01.26.21250492>

Jakob, C. E. M., Borgmann, S., Duygu, F., Behrends, U., Hower, M., Merle, U., Friedrichs, A., Tometten, L., Hanses, F., Jung, N., Rieg, S., Wille, K., Grüner, B., Klinker, H., Gersbacher-Runge, N., Hellwig, K., Eberwein, L., Dolff, S., Rauschning, D., … Vehreschild, J. J. (2020). First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS).” *Infection*. <https://doi.org/10.1007/s15010-020-01499-0>

Jehi, L., Ji, X., Milinovich, A., Erzurum, S., Merlino, A., Gordon, S., Young, J. B., & Kattan, M. W. (2020). Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19. *PLOS ONE*, *15*(8), e0237419. <https://doi.org/10.1371/journal.pone.0237419>

Jha, R. K., Shrestha, A., Tamang, B., K. C., I., & Sah, S. K. (2021). *Predisposing factors associated with the severity of the illness in adults with Covid-19 in Nepal* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.05.16.21257280>

Jin, C., Gu, J., Yuan, Y., Long, Q., Zhang, Q., Zhou, H., Wu, W., & Zhang, W. (2020). Treatment of Six COVID-19 Patients with Convalescent Plasma. *medRxiv*, 2020.05.21.20109512. <https://doi.org/10.1101/2020.05.21.20109512>

Jin, X., Lian, J.-S., Hu, J.-H., Gao, J., Zheng, L., Zhang, Y.-M., Hao, S.-R., Jia, H.-Y., Cai, H., Zhang, X.-L., Yu, G.-D., Xu, K.-J., Wang, X.-Y., Gu, J.-Q., Zhang, S.-Y., Ye, C.-Y., Jin, C.-L., Lu, Y.-F., Yu, X., … Yang, Y. (2020). Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*, *69*(6), 1002–1009. <https://doi.org/10.1136/gutjnl-2020-320926>

Jose, T., Croghan, I. T., Hays, J. T., Schroeder, D. R., & Warner, D. O. (2021). Electronic Cigarette Use Is Not Associated with COVID-19 Diagnosis. *Journal of Primary Care & Community Health*, *12*, 215013272110243. <https://doi.org/10.1177/21501327211024391>

Joubert, A., Andry, F., Bertolotti, A., Accot, F., Koumar, Y., Legrand, F., Poubeau, P., Manaquin, R., Gérardin, P., & Levin, C. (2021). Distinguishing non severe cases of dengue from COVID-19 in the context of co-epidemics: A cohort study in a SARS-CoV-2 testing center on Reunion island. *PLOS Neglected Tropical Diseases*, *15*(4), e0008879. <https://doi.org/10.1371/journal.pntd.0008879>

Joubert, A., Andry, F., Bertolotti, A., Accot, F., Koumar, Y., Legrand, F., Poubeau, P., Manaquin, R., Gérardin, P., & Levin, C. (2020). *Distinguishing non severe cases of dengue from COVID-19 in the context of co-epidemics: A cohort study in a SARS-CoV-2 testing center on Reunion island* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.10.20.20214718>

Jun, T., Nirenberg, S., Kovatch, P., & Huang, K. (2020). Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: Prospective cohort study. *medRxiv*, 2020.07.29.20164640. <https://doi.org/10.1101/2020.07.29.20164640>

Kahlert, C. R., Persi, R., Güsewell, S., Egger, T., Leal-Neto, O. B., Sumer, J., Flury, D., Brucher, A., Lemmenmeier, E., Möller, J. C., Rieder, P., Stocker, R., Vuichard-Gysin, D., Wiggli, B., Albrich, W. C., Babouee Flury, B., Besold, U., Fehr, J., Kuster, S. P., … Kohler, P. (2021). Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers – A multicentre cross-sectional study. *Clinical Microbiology and Infection*, S1198743X21002366. <https://doi.org/10.1016/j.cmi.2021.05.014>

Kalan, M. E., Ghobadi, H., Taleb, Z. B., Ward, K. D., Adham, D., Matin, S., Fazlzadeh, M., & Narimani, S. (2020). Descriptive characteristics of hospitalized adult smokers and never-smokers with COVID-19. *Tobacco Induced Diseases*, *18*(May). <https://doi.org/10.18332/tid/122759>

Kantele, A., Laaveri, T., Kareinen, L., Pakkanen, S. H., Blomgren, K., Mero, S., Patjas, A., Virtanen, J., Uusitalo, R., Lappalainen, M., Jarvinen, A., Kurkela, S., Jaaskelainen, A. J., Vapalahti, O., & Sironen, T. (2020). SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: Serosurvey, symptoms and risk factors. *Travel Med Infect Dis*, *39*. <https://doi.org/10.1016/j.tmaid.2020.101949>

Kara Polat, A., Oguz Topal, I., Karadag, A. S., Aksoy, H., Koku Aksu, A. E., Ozkur, E., Ozkok Akbulut, T., Topaloglu Demir, F., Engin, B., Uzuncakmak, T. K., & Kivanc Altunay, I. (2020). The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. *Dermatol Ther*, *NA*. <https://doi.org/10.1111/dth.14691>

Kibler, M., Carmona, A., Marchandot, B., Matsushita, K., Trimaille, A., Kanso, M., Dietrich, L., How-Choong, C., Odier, A., Gennesseaux, G., Schramm, O., Reydel, A. C., Kindo, M., Hoang, M., Hess, S., Sato, C., Ohlmann, S., Jesel, L., Morel, O., & Ohlmann, P. (2020). Risk and severity of COVID-19 and ABO blood group in transcatheter aortic valve patients. *medRxiv*, 2020.06.13.20130211. <https://doi.org/10.1101/2020.06.13.20130211>

Killerby, M. E. (2020). Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020. *MMWR. Morbidity and Mortality Weekly Report*, *69*. <https://doi.org/10.15585/mmwr.mm6925e1>

Kim, E. S., Chin, B. S., Kang, C. K., Kim, N. J., Kang, Y. M., Choi, J.-P., Oh, D. H., Kim, J.-H., Koh, B., Kim, S. E., Yun, N. R., Lee, J.-H., Kim, J. Y., Kim, Y., Bang, J. H., Song, K.-H., Kim, H. B., Chung, K., Oh, M., & Covid-19, on behalf of the K. N. C. for C. M. of. (2020). Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. *Journal of Korean Medical Science*, *35*(13). <https://doi.org/10.3346/jkms.2020.35.e142>

Kim, L., Garg, S., O’Halloran, A., Whitaker, M., Pham, H., Anderson, E. J., Armistead, I., Bennett, N. M., Billing, L., Como-Sabetti, K., Hill, M., Kim, S., Monroe, M. L., Muse, A., Reingold, A., Schaffner, W., Sutton, M., Talbot, H. K., Torres, S. M., … Langley, G. E. (2020). Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). *medRxiv*, 2020.05.18.20103390. <https://doi.org/10.1101/2020.05.18.20103390>

Kimmig, L. M., Wu, D., Gold, M., Pettit, N. N., Pitrak, D., Mueller, J., Husain, A. N., Mutlu, E. A., & Mutlu, G. M. (2020). IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections. *Frontiers in Medicine*, *7*, 583897. <https://doi.org/10.3389/fmed.2020.583897>

Kjetland, E. F., Kalleberg, K. T., Søraas, C. L., Hammarström, B., Myklebust, T. Å., Jenum, S., Axelsen, E., Lind, A., Bævre-Jensen, R., Jørgensen, S. B., Pettersen, F. O., Solberg, L. B., Hadley, C. L., Istre, M. S., Liestøl, K., Dahl, J. A., Ursin, G., & Søraas, A. (2020). *Risk factors for community transmission of SARS-CoV-2. A cross-sectional study in 116,678 people*. <https://doi.org/10.1101/2020.12.23.20248514>

Klang, E., Kassim, G., Soffer, S., Freeman, R., Levin, M. A., & Reich, D. L. (n.d.). Morbid Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. *Obesity*, *n/a*(n/a). <https://doi.org/10.1002/oby.22913>

Klang, E., Soffer, S., Nadkarni, G., Glicksberg, B., Freeman, R., Horowitz, C., Reich, D. L., & Levin, M. A. (2020). Sex Differences in Age and Comorbidities for COVID-19 Mortality in Urban New York City. *SN Comprehensive Clinical Medicine*, *2*(9), 1319–1322. <https://doi.org/10.1007/s42399-020-00430-w>

Kleynhans, J., Tempia, S., Wolter, N., Gottberg, A. von, Bhiman, J. N., Buys, A., Moyes, J., McMorrow, M. L., Kahn, K., Gómez-Olivé, F. X., Tollman, S., Martinson, N. A., Wafawanaka, F., Lebina, L., Toit, J. du, Jassat, W., Neti, M., Brauer, M., Cohen, C., & for the PHIRST-C Group. (2021). *Longitudinal SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, during the first and second waves July 2020-March 2021* [Preprint]. Public; Global Health. <https://doi.org/10.1101/2021.05.26.21257849>

Kline, J. A., Camargo, C. A., Courtney, D. M., Kabrhel, C., Nordenholz, K. E., Aufderheide, T., Baugh, J. J., Beiser, D. G., Bennett, C. L., Bledsoe, J., Castillo, E., Chisolm-Straker, M., Goldberg, E. M., House, H., House, S., Jang, T., Lim, S. C., Madsen, T. E., McCarthy, D. M., … Wilburn, J. (2021). Clinical prediction rule for SARS-CoV-2 infection from 116 U.S. Emergency departments 2-22-2021. *PLOS ONE*, *16*(3), e0248438. <https://doi.org/10.1371/journal.pone.0248438>

Kolin, D. A., Kulm, S., & Elemento, O. (2020). Clinical and Genetic Characteristics of Covid-19 Patients from UK Biobank. *medRxiv*, 2020.05.05.20075507. <https://doi.org/10.1101/2020.05.05.20075507>

Kortela, E., Kirjavainen, V., Ahava, M. J., Jokiranta, S. T., But, A., Lindahl, A., Jääskeläinen, A. E., Jääskeläinen, A. J., Järvinen, A., Jokela, P., Kallio-Kokko, H., Loginov, R., Mannonen, L., Ruotsalainen, E., Sironen, T., Vapalahti, O., Lappalainen, M., Kreivi, H.-R., Jarva, H., … Kekäläinen, E. (2020). *Real-life clinical sensitivity of SARS-CoV-2 RT-PCR test in symptomatic patients* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.11.01.20223107>

Kronbichler, A., Kresse, D., Yoon, S., Lee, K. H., Effenberger, M., & Shin, J. I. (2020). Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. *International Journal of Infectious Diseases*, *98*, 180–186. <https://doi.org/10.1016/j.ijid.2020.06.052>

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., Lima Lopes, G. de, Grivas, P., Painter, C. A., Peters, S., Thompson, M. A., Bakouny, Z., Batist, G., Bekaii-Saab, T., Bilen, M. A., Bouganim, N., … West, J. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study. *The Lancet*, *395*(10241), 1907–1918. <https://doi.org/10.1016/S0140-6736(20)31187-9>

Kumar, A., Prasad, G., Srivastav, S., Gautam, V. K., & Sharma, N. (2020). A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients. *medRxiv*, 2020.07.23.20160424. <https://doi.org/10.1101/2020.07.23.20160424>

Kurashima, K., Kagiyama, N., Ishiguro, T., Takaku, Y., Nakajima, H., Shibata, S., Matsui, Y., Takano, K., Isono, T., Nishida, T., Kawate, E., Hosoda, C., Kobayashi, Y., Takayanagi, N., & Yanagisawa, T. (2020). *IgG antibody seroconversion and the clinical progression of COVID-19 pneumonia: A retrospective, cohort study*. <https://doi.org/10.1101/2020.07.16.20154088>

Lamure, S., Duléry, R., Blasi, R. D., Chauchet, A., Laureana, C., Deau-Fischer, B., Drenou, B., Soussain, C., Rossi, C., Noël, N., Choquet, S., Bologna, S., Joly, B., Kohn, M., Malak, S., Fouquet, G., Daguindau, E., Bernard, S., Thiéblemont, C., … Besson, C. (2020). Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. *EClinicalMedicine*, *27*. <https://doi.org/10.1016/j.eclinm.2020.100549>

Lan, F.-Y., Suharlim, C., Kales, S. N., & Yang, J. (2020). Association between SARS-CoV-2 infection, exposure risk and mental health among a cohort of essential retail workers in the United States. *medRxiv*, 2020.06.08.20125120. <https://doi.org/10.1101/2020.06.08.20125120>

Lassale, C., Gaye, B., Hamer, M., Gale, C. R., & Batty, G. D. (2020). Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. *Brain, Behavior, and Immunity*, *88*, 44–49. <https://doi.org/10.1016/j.bbi.2020.05.074>

Lassen, M. C. H., Skaarup, K. G., Sengeløv, M., Iversen, K., Ulrik, C. S., Jensen, J. U. S., & Biering-Sørensen, T. (2021). Alcohol Consumption and the Risk of Acute Respiratory Distress Syndrome in COVID-19. *Annals of the American Thoracic Society*, *18*(6), 1074–1076. <https://doi.org/10.1513/AnnalsATS.202008-988RL>

Lee, S. C., Son, K. J., Kim, D. W., Han, C. H., Choi, Y. J., Kim, S. W., & Park, S. C. (2021). Smoking and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *Nicotine & Tobacco Research*, ntab079. <https://doi.org/10.1093/ntr/ntab079>

Lee, S. F., Nikšić, M., Rachet, B., Sanchez, M.-J., & Luque-Fernandez, M. A. (2021). Socioeconomic Inequalities and Ethnicity Are Associated with a Positive COVID-19 Test among Cancer Patients in the UK Biobank Cohort. *Cancers*, *13*(7), 1514. <https://doi.org/10.3390/cancers13071514>

Leister, I., Ponocny-Seliger, E., Kollaritsch, H., Dungel, P., Holzer, B., Grillari, J., Redl, H., Ponocny, I., Wilfing, C., Aigner, L., Exner, M., Stainer, M., Hackl, M., Hausner, T., Mittermayr, R., & Schaden, W. (2021). *Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel*. <https://doi.org/10.1101/2021.02.01.21250898>

Lekoubou, A., Pelton, M., Ba, D. M., & Ssentongo, P. (2021). Racial Disparities in Ischemic Stroke Among Patients with COVID-19 in the United States. *Journal of Stroke and Cerebrovascular Diseases*, *30*(8), 105877. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105877>

Lenka, J., Chhabria, M. S., Sharma, N., Tan, B. E.-X., Boppana, L. K. T., Venugopal, S., & Sondhi, D. S. (2020). Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York. *medRxiv*, 2020.06.18.20135046. <https://doi.org/10.1101/2020.06.18.20135046>

Lewnard, J. A., Mora, A. M., Nkwocha, O., Kogut, K., Rauch, S. A., Morga, N., Hernandez, S., Wong, M. P., Huen, K., Andrejko, K., Jewell, N. P., Parra, K. L., Holland, N., Harris, E., Cuevas, M., & Eskenazi, B. (2021). *Prevalence and clinical profile of SARS-CoV-2 infection among farmworkers in Monterey County, California: June-November, 2020*. <https://doi.org/10.1101/2020.12.27.20248894>

Lévy, Y., Wiedemann, A., Hejblum, B. P., Durand, M., Lefebvre, C., Surénaud, M., Lacabaratz, C., Perreau, M., Foucat, E., Déchenaud, M., Tisserand, P., Blengio, F., Hivert, B., Gautier, M., Cervantes-Gonzalez, M., Bachelet, D., Laouénan, C., Bouadma, L., Timsit, J.-F., … the French COVID cohort study group. (2020). *CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and death* [Preprint]. Allergy; Immunology. <https://doi.org/10.1101/2020.12.12.20246934>

Li, F., Cai, Y., Gao, C., Zhou, L., Chen, R., Zhang, K., Li, W., Zhang, R., Zhang, X., Wang, D., Liu, Y., & Tao, L. (2020). *Clinical Course And Risk Factors For In-hospital Death In Critical COVID-19 In Wuhan, China* [Preprint]. Public; Global Health. <https://doi.org/10.1101/2020.09.26.20189522>

Li, Jiong, Chen, Y., Chen, S., Wang, S., Zhang, D., Wang, J., Postmus, D., Zeng, H., Qin, G., Shen, Y., Jiang, J., & Yu, Y. (2020). Derivation and validation of a prognostic model for predicting in-hospital mortality in patients admitted with COVID-19 in Wuhan, China: The PLANS (Platelet Lymphocyte Age Neutrophil Sex) model. *medRxiv*, 2020.05.13.20100370. <https://doi.org/10.1101/2020.05.13.20100370>

Li, Jie, Li, S., Cai, Y., Liu, Q., Li, X., Zeng, Z., Chu, Y., Zhu, F., & Zeng, F. (2020). Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China. *medRxiv*, 2020.02.11.20022053. <https://doi.org/10.1101/2020.02.11.20022053>

Li, J., Long, X., Zhang, Q., Fang, X., Li, N., Fedorova, B., Hu, S., Li, Jh., Xiong, N., & Lin, Z. (2020). Tobacco smoking confers risk for severe COVID‐19 unexplainable by pulmonary imaging. *Journal of Internal Medicine*, joim.13190. <https://doi.org/10.1111/joim.13190>

Li, Jingwen, Long, X., Zhu, C., Wang, H., Wang, T., Lin, Z., Li, J., & Xiong, N. (n.d.). Olfactory Dysfunction in Recovered Coronavirus Disease 2019 (COVID-19) Patients. *Movement Disorders*, *n/a*(n/a). <https://doi.org/10.1002/mds.28172>

Li, S., Jun, T., Wang, Z., Kao, Y.-H., Schadt, E., Konig, M. F., Bettegowda, C., Vogelstein, J. T., Papadopoulos, N., Parsons, R. E., Chen, R., Schadt, E. E., Li, L., & Oh, W. K. (2021). *COVID-19 outcomes among hospitalized men with or without exposure to alpha-1-adrenergic receptor blocking agents* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.04.08.21255148>

Li, S., Sarangarajan, R., Jun, T., Kao, Y.-H., Wang, Z., Schadt, E., Kiebish, M. A., Granger, E., Narain, N. R., Chen, R., Schadt, E. E., & Li, L. (2021). *Association of in-hospital use of ACE-I/ARB and COVID-19 outcomes in African American population* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.04.14.21255443>

Li, Y., Tong, C. H., Bare, L. A., & Devlin, J. J. (2021). Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults. *JAMA Network Open*, *4*(5), e2111634. <https://doi.org/10.1001/jamanetworkopen.2021.11634>

Lian, J., Jin, X., Hao, S., Cai, H., Zhang, S., Zheng, L., Jia, H., Hu, J., Gao, J., Zhang, Y., Zhang, X., Yu, G., Wang, X., Gu, J., Ye, C., Jin, C., Lu, Y., Yu, X., Yu, X., … Yang, Y. (n.d.). Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa242>

Liao, Y., Feng, Y., Wang, B., Wang, H., Huang, J., Wu, Y., Wu, Z., Chen, X., Yang, C., Fu, X., & Sun, H. (2020). Clinical Characteristics and Risk factors for developed COVID-19 patients transferring to designated hospital from Jianghan Fangcang shelter Hospital: A retrospective, observational study. *medRxiv*, 2020.04.21.20074724. <https://doi.org/10.1101/2020.04.21.20074724>

Lin, K. J., Schneeweiss, S., Tesfaye, H., D’Andrea, E., Liu, J., Lii, J., Murphy, S. N., & Gagne, J. J. (2020). Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. *Drugs*, *80*, 1961–1972. <https://doi.org/10.1007/s40265-020-01424-7>

Liu, R., Ming, X., Xu, O., Zhou, J., Peng, H., Xiang, N., Zhang, J., & Zhu, H. (2020). Association of Cardiovascular Manifestations with In-hospital Outcomes in Patients with COVID-19: A Hospital Staff Data. *medRxiv*, 2020.02.29.20029348. <https://doi.org/10.1101/2020.02.29.20029348>

Liu, W., Tao, Z.-W., Wang, L., Yuan, M.-L., Liu, K., Zhou, L., Wei, S., Deng, Y., Liu, J., Liu, H.-G., Yang, M., & Hu, Y. (2020). Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chinese Medical Journal*, *133*(9), 1032–1038. <https://doi.org/10.1097/CM9.0000000000000775>

Lohia, P., Sreeram, K., Nguyen, P., Choudhary, A., Khicher, S., Yarandi, H., Kapur, S., & Badr, M. S. (2021). Preexisting respiratory diseases and clinical outcomes in COVID-19: A multihospital cohort study on predominantly African American population. *Respir Res*, *22*. <https://doi.org/10.1186/s12931-021-01647-6>

Lombardi, A., Mangioni, D., Consonni, D., Cariani, L., Bono, P., Cantù, A. P., Tiso, B., Carugno, M., Muscatello, A., Lunghi, G., Pesatori, A. C., Riboldi, L., Ceriotti, F., Bandera, A., & Gori, A. (2021). Seroprevalence of anti-SARS-CoV-2 IgG among healthcare workers of a large university hospital in Milan, Lombardy, Italy: A cross-sectional study. *BMJ Open*, *11*(2), e047216. <https://doi.org/10.1136/bmjopen-2020-047216>

Lopez-Medrano, F., Perez-Jacoiste Asin, M. A., Fernandez-Ruiz, M., Carretero, O., Lalueza, A., Maestro de la Calle, G., Caro, J. M., Calle, C. de la, Catalan, M., Garcia Garcia, R., Martinez-Lopez, J., Origuen, J., Ripoll, M., San Juan, R., Trujillo, H., Sevillano, A., Gutierrez, E., Miguel, B. de, Aguilar, F., … Aguado, J. M. (2020). *Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study.* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.09.26.20202283>

Louis, S., Dhawan, A., Newey, C., Nair, D., Jehi, L., Hantus, S., & Punia, V. (2020). Continuous Electroencephalography (cEEG) Characteristics and Acute Symptomatic Seizures in COVID-19 Patients. *medRxiv*, 2020.05.26.20114033. <https://doi.org/10.1101/2020.05.26.20114033>

Lowe, K. E., Zein, J., Hatipoglu, U., & Attaway, A. (2021). Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. *JAMA Intern Med*, *NA*. <https://doi.org/10.1001/jamainternmed.2020.8360>

Lubetzky, M., Aull, M., Craig-Shapiro, R., Lee, J., Lee, J., Sultan, S., Marku-Podvorica, J., Gingras, L., Kodiyanplakkal, R. P., Hartono, C., Saal, S., Muthukumar, T., Kapur, S., Suthanthiran, M., & Dadhania, D. (2020). Kidney Allograft Recipients Diagnosed with Coronavirus Disease-2019: A Single Center Report. *medRxiv*, 2020.04.30.20086462. <https://doi.org/10.1101/2020.04.30.20086462>

Lucar, J., Wingler, M. J. B., Cretella, D. A., Ward, L. M., Sims Gomillia, C. E., Chamberlain, N., Shimose, L. A., Brock, J. B., Harvey, J., Wilhelm, A., Majors, L. T., Jeter, J. B., Bueno, M. X., Albrecht, S., Navalkele, B., Mena, L. A., & Parham, J. (2021). Epidemiology, Clinical Features, and Outcomes of Hospitalized Adults with COVID-19: Early Experience from an Academic Medical Center in Mississippi. *Southern Medical Journal*, *114*(3), 144–149. <https://doi.org/10.14423/SMJ.0000000000001222>

Luo, H., Liu, S., Wang, Y., Phillips-Howard, P. A., Yang, Y., Ju, S., & Wang, D. (2020). Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: A retrospective, multi-center cohort study. *medRxiv*, 2020.06.01.20086025. <https://doi.org/10.1101/2020.06.01.20086025>

Luo, J., Rizvi, H., Preeshagul, I. R., Egger, J. V., Hoyos, D., Bandlamudi, C., McCarthy, C. G., Falcon, C. J., Schoenfeld, A. J., Arbour, K. C., Chaft, J. E., Daly, R. M., Drilon, A., Eng, J., Iqbal, A., Lai, W. V., Li, B. T., Lito, P., Namakydoust, A., … Hellmann, M. D. (2020). COVID-19 in patients with lung cancer. *Annals of Oncology*, *31*(10), 1386–1396. <https://doi.org/10.1016/j.annonc.2020.06.007>

Lusignan, S. de, Dorward, J., Correa, A., Jones, N., Akinyemi, O., Amirthalingam, G., Andrews, N., Byford, R., Dabrera, G., Elliot, A., Ellis, J., Ferreira, F., Lopez Bernal, J., Okusi, C., Ramsay, M., Sherlock, J., Smith, G., Williams, J., Howsam, G., … Hobbs, F. D. R. (2020). Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: A cross-sectional study. *The Lancet Infectious Diseases*, S1473309920303716. <https://doi.org/10.1016/S1473-3099(20)30371-6>

Madakkatel, I., King, C., Zhou, A., Mulugeta, A., Lumsden, A., McDonnell, M., & Hyppönen, E. (2021). *Identifying risk factors for COVID-19 severity and mortality in the UK Biobank* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.05.10.21256935>

Madariaga, M. L. L., Guthmiller, J., Schrantz, S., Jansen, M., Christenson, C., Kumar, M., Prochaska, M., Wool, G., Durkin, A., Oh, W. H., Trockman, L., Vigneswaran, J., Keskey, R., Shaw, D. G., Dugan, H., Zheng, N., Cobb, M., Utset, H., Wang, J., … Donington, J. (2020). Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. *medRxiv*, 2020.06.21.20132944. <https://doi.org/10.1101/2020.06.21.20132944>

Mady, A. F., Abdulrahman, B., Ramadan, O. E., Mumtaz, S. A., Al-Odat, M. A., Kuhail, A., Altoraifi, R., Alshae, R., Alharthy, A. M., Karakitsos, D., & Aletreby, W. Th. (2021). *Effect of Tocilizumab on “ventilator free days” composite outcome in SARS-CoV-2 patients. A retrospective competing risk analysis* [Preprint]. Intensive Care; Critical Care Medicine. <https://doi.org/10.1101/2021.04.01.21254794>

Magagnoli, J., Narendran, S., Pereira, F., Cummings, T. H., Hardin, J. W., Sutton, S. S., & Ambati, J. (2020). Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. *Med*, S2666634020300064. <https://doi.org/10.1016/j.medj.2020.06.001>

Magleby, R., Westblade, L. F., Trzebucki, A., Simon, M. S., Rajan, M., Park, J., Goyal, P., Safford, M. M., & Satlin, M. J. (n.d.). Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa851>

Makaronidis, J., Mok, J., Balogun, N., Magee, C. G., Omar, R. Z., Carnemolla, A., & Batterham, R. L. (2020). Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study. *PLOS Medicine*, *17*(10), e1003358. <https://doi.org/10.1371/journal.pmed.1003358>

Mamtani, M., Athavale, A. M., Abraham, M., Vernik, J., Amarah, A., Ruiz, J., Joshi, A., Itteera, M., Zhukovsky, S., Madaiah, R. P., Hart, P., & Kulkarni, H. (2020). ASSOCIATION OF HYPERGLYCEMIA WITH HOSPITAL MORTALITY IN COVID-19 PATIENTS WITHOUT DIABETES: A COHORT STUDY. *medRxiv*, 2020.08.31.20185157. <https://doi.org/10.1101/2020.08.31.20185157>

Mancilla-Galindo, J., Vera-Zertuche, J. M., Navarro-Cruz, A. R., Segura-Badilla, O., Reyez-Velazquez, G., Tepepa-Lopez, F. J., Aguilar-Alonso, P., Vidal-Mayo, J. de J., & Kammar-Garcia, A. (2020). Development and Validation of the Patient History COVID-19 (PH-Covid19) Scoring System: A Multivariable Prediction Model of Death in Mexican Patients with COVID-19. *medRxiv*, 2020.09.05.20189142. <https://doi.org/10.1101/2020.09.05.20189142>

Mangera, Z., Lewis, A., Hutchinson, J., Searle, L., & Agrawal, S. (2017). Smoking prevalence in UK hospital admissions from a national observational study. *European Respiratory Journal*, *50*(suppl 61). <https://doi.org/10.1183/1393003.congress-2017.PA1268>

Mann, C. Z., Abshire, C., Yost, M., Kaatz, S., Swaminathan, L., Flanders, S. A., Prescott, H. C., & Gagnon-Bartsch, J. A. (2021). *Derivation and external validation of a simple risk score to predict in-hospital mortality in patients hospitalized for COVID-19* [Preprint]. Emergency Medicine. <https://doi.org/10.1101/2021.05.04.21256599>

Manohar, J., Abedian, S., Martini, R., Kulm, S., Salvatore, M., Ho, K., Christos, P., Campion, T., Imperato-McGinley, J., Ibrahim, S., Evering, T. H., Phillips, E., Tamimi, R., Bea, V., D. Balogun, O., Sboner, A., Elemento, O., & Davis, M. B. (2021). *Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.04.06.21254728>

Mansour, A., Sajjadi-Jazi, S. M., Kasaeian, A., Khosravi, B., Sorouri, M., Azizi, F., Rajabi, Z., Motamedi, F., Sirusbakht, A., Eslahi, M., Mojtabbavi, H., Sima, A. R., Radmard, A. R., Mohajeri-Tehrani, M. R., & Abdollahi, M. (2020). Clinical characteristics and outcomes of diabetics hospitalized for COVID-19 infection: A single-centered, retrospective, observational study. *EXCLI j*, *19*, 1533–1543. <https://doi.org/10.17179/excli2020-2988>

Maraschini, A., Corsi, E., Salvatore, M. A., & Donati, S. (2020). Coronavirus and birth in Italy: Results of a national population-based cohort study. *medRxiv*, 2020.06.11.20128652. <https://doi.org/10.1101/2020.06.11.20128652>

Marcos, M., Belhassen-Garcia, M., Puente, A. S.-., Sampedro-Gomez, J., Azibeiro, R., Dorado-Diaz, P. I., Marcano-Millan, E., Garcia-Vidal, C., Moreiro-Barroso, M. T., Cubino-Boveda, N., Perez-Garcia, M. L., Rodriguez-Alonso, B., Encinas-Sanchez, D., Pena-Balbuena, S., Sobejano, E., Diez-Campelo, M., Ines, S., Carbonell, C., Lopez-Parra, M., … Martin-Oterino, J. A. (2020). Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients. *medRxiv*, 2020.07.13.20150177. <https://doi.org/10.1101/2020.07.13.20150177>

Marimuthu, Y., Kunnavil, R., Anil, N., Nagaraja, S. B., Satyanarayana, N., Kumar, J., & Ramya, B. (2021). Clinical profile and risk factors for mortality among COVID-19 inpatients at a tertiary care centre in Bengaluru, India. *Monaldi Archives for Chest Disease*. <https://doi.org/10.4081/monaldi.2021.1724>

Martinez-Lacalzada, M., Adrián Viteri-Noël, L., Manzano, L., Fabregate-Fuente, M., Rubio-Rivas, M., Garcia, S. L., Fernández, F. A., Beato Pérez, J. L., Núñez, J. A. V., Manuel, E. C., Espiño Álvarez, A. C., Castro, S. J. F., Loureiro-Amigo, J., Fontan, P. M. P., Pina, A., María Álvarez Suárez, A., Asiain, A. S., García López, B., Pino, J. L. del, … for the SEMI-COVID-19 Network. (2020). *Predicting critical illness on initial diagnosis of COVID-19 based on easily-obtained clinical variables: Development and validation of the PRIORITY model* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.11.27.20237966>

Martinez-Lacalzada, M., Viteri-Noël, L. A., Manzano, L., Fabregate-Fuente, M., Rubio-Rivas, M., Garcia, S. L., Fernández, F. A., Pérez, J. L. B., Núñez, J. A. V., Manuel, E. C., Espiño, A.-C., Freire Castro, S. J., Loureiro-Amigo, J., Fontan, P. M. P., Artero, A., Suárez, A. M. Á., Asiain, A. S., López, B. G., Pino, J. L. del, … for the SEMI-COVID-19 Network. (2020). *Predicting critical illness on initial diagnosis of COVID-19: Development and validation of the PRIORITY model for outpatient applicability*. <https://doi.org/10.1101/2020.11.27.20237966>

Martinez-Portilla, R. J., Sotiriadis, A., Torres-Torres, J., Christos, C., Hawkins-Villarreal, A., Villafan-Bernal, J. R., Gurrola-Ochoa, R. A., & Figueras, F. (2020). Risk factors for mortality in pregnant women with SARS-CoV-2 infection. *medRxiv*, 2020.05.31.20107276. <https://doi.org/10.1101/2020.05.31.20107276>

Martinez-Resendez, M. F., Castilleja-Leal, F., Torres-Quintanilla, A., Rojas-Martinez, A., Garcia-Rivas, G., Ortiz-Lopez, R., Trevino, V., Lara-Medrano, R., Villanueva-Lozano, H., Ramirez-Elizondo, T., Sanchez-Nava, V., Moreno-Hoyos, F., Martinez-Thomae, A., Hernandez-Torre, M., Diaz-Olachea, C., Cardona-Huerta, S., Rosa-Pacheco, S. de la, Diaz-Garza, C., Reynoso-Lobo, P., … Torre-Amione, G. (2020). Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series. *medRxiv*, 2020.07.14.20144469. <https://doi.org/10.1101/2020.07.14.20144469>

Martini, F., D’Alessio, A., Bracchi, F., Di Mauro, D., Fargnoli, A., Motta, M., Giussani, C., Meazza Prina, M., Gobbin, G., & Taverna, M. (2020). On Cancer, COVID-19, and CT Scans: A Monocentric Retrospective Study. *Journal of Clinical Medicine*, *9*(12), 3935. <https://doi.org/10.3390/jcm9123935>

Martin-Jimenez, P., Munoz-Garcia, M. I., Seoane, D., Roca-Rodriguez, L., Garcia-Reyne, A., Lalueza, A., Maestro, G., Folgueira, D., Blanco-Palmero, V. A., Martin, A. H.-S., Llamas-Velasco, S., Perez-Martinez, D. A., Gonzalez-Sanchez, M., & Villarejo-Galende, A. (2020). Cognitive impairment is a common comorbidity in COVID-19 deceased patients. A hospital-based retrospective cohort study. *medRxiv*, 2020.06.08.20125872. <https://doi.org/10.1101/2020.06.08.20125872>

Martin-Vicente, M., Almansa, R., Martínez, I., Tedim, A. P., Bustamante, E., Tamayo, L., Aldecoa, C., Gómez, J. M., Renedo, G., Berezo, J. Á., Cedeño, J. A., Mamolar, N., Olivares, P. G., Herrán, R., Cicuendez, R., Enríquez, P., Ortega, A., Jorge, N., Fuente, A. de la, … Torres, A. (2021). *Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.03.08.21253121>

Matli, K., Chamoun, N., Fares, A., Zibara, V., Osta, S. A., Nasrallah, R., Salameh, P., Mokhbat, J., & Ghanem, G. (2021). *Combined Anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalized COVID-19 patients: A propensity matched cohort study* [Preprint]. Cardiovascular Medicine. <https://doi.org/10.1101/2021.07.13.21260467>

Maucourant, C., Filipovic, I., Ponzetta, A., Aleman, S., Cornillet, M., Hertwig, L., Strunz, B., Lentini, A., Reinius, B., Brownlie, D., Gomez, A. C., Ask, E. H., Hull, R. M., Haroun-Izquierdo, A., Schaffer, M., Klingstrom, J., Folkesson, E., Buggert, M., Sandberg, J. K., … Group, K. C. S. (2020). Natural killer cell activation related to clinical outcome of COVID-19. *medRxiv*, 2020.07.07.20148478. <https://doi.org/10.1101/2020.07.07.20148478>

Márquez-Salinas, A., Fermín-Martínez, C. A., Antonio-Villa, N. E., Vargas-Vázquez, A., Guerra, E. C., Campos-Muñoz, A., Zavala-Romero, L., Mehta, R., Bahena-López, J. P., Ortiz-Brizuela, E., González-Lara, M. F., Roman-Montes, C. M., Martinez-Guerra, B. A., Leon, A. P. de, Sifuentes-Osornio, J., Gutiérrez-Robledo, L. M., Aguilar-Salinas, C. A., & Bello-Chavolla, O. Y. (2020). *Adaptive metabolic and inflammatory responses identified using accelerated aging metrics are linked to adverse outcomes in severe SARS-CoV-2 infection* [Preprint]. Geriatric Medicine. <https://doi.org/10.1101/2020.11.03.20225375>

McGrail, D. E., & Edwards, D. (2020). COVID-19 Case Series at UnityPoint Health St. Lukes Hospital in Cedar Rapids, IA. *medRxiv*, 2020.07.17.20156521. <https://doi.org/10.1101/2020.07.17.20156521>

McQueenie, R., Foster, H., Jani, B. D., Katikireddi, S. V., Sattar, N., Pell, J. P., Ho, F. K., Niedzwiedz, C. L., Hastie, C. E., Anderson, J., Mark, P. B., Sullivan, M., ODonnell, C. A., Mair, F. S., & Nicholl, B. I. (2020). Multimorbidity, Polypharmacy, and COVID-19 infection within the UK Biobank cohort. *medRxiv*, 2020.06.10.20127563. <https://doi.org/10.1101/2020.06.10.20127563>

Meini, S., Fortini, A., Andreini, R., Sechi, L. A., & Tascini, C. (n.d.). The Paradox of the Low Prevalence of Current Smokers Among Covid-19 Patients Hospitalized in Non-Intensive Care Wards: Results From an Italian Multicenter Case-Control Study. *Nicotine & Tobacco Research*. <https://doi.org/10.1093/ntr/ntaa188>

Mejia-Vilet, J. M., Cordova-Sanchez, B. M., Fernandez-Camargo, D., Mendez-Perez, R. A., Morales-Buenrostro, L. E., & Hernandez-Gilsoul, T. (2020). A Risk Score to Predict Admission to Intensive Care Unit in Patients With COVID-19: The ABC-GOALS Score. *medRxiv*, 2020.05.12.20099416. <https://doi.org/10.1101/2020.05.12.20099416>

Melo, A. C. de, Thuler, L. C. S., Silva, J. L. da, Albuquerque, L. Z. de, Pecego, A. C., Rodrigues, L. O. R., Conceicao, M. S. da, Garrido, M. M., Mendes, G. L., Pereira, A. C. M., Soares, M. A., Viola, J. P. B., & Force, I. C. T. (2020). Cancer inpatient with COVID-19: A report from the Brazilian National Cancer Institute. *medRxiv*, 2020.06.27.20141499. <https://doi.org/10.1101/2020.06.27.20141499>

Melotti, R., Scaggiante, F., Falciani, M., Weichenberger, C. X., Foco, L., Lombardo, S., Grandi, A. D., Laer, D. von, Mahlknecht, A., Pramstaller, P. P., Pagani, E., Meier, H., Gaertner, T., Troi, C., Mascalzoni, D., Pattaro, C., & Mian, M. (2021). *Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley* [Preprint]. Public; Global Health. <https://doi.org/10.1101/2021.03.19.21253883>

Mendes, A., Herrmann, F. R., Genton, L., Serratrice, C., Carrera, E., Vargas, M. I., Gold, G., Graf, C. E., Zekry, D., & Scheffler, M. (2021). Incidence, characteristics and clinical relevance of acute stroke in old patients hospitalized with COVID-19. *BMC Geriatr*, *21*. <https://doi.org/10.1186/s12877-021-02006-2>

Mendez-Dominguez, N., Santos-Zaldívar, K., Gomez-Carro, S., Datta-Banik, S., & Carrillo, G. (2021). Maternal mortality during the COVID-19 pandemic in Mexico: A preliminary analysis during the first year. *BMC Public Health*, *21*(1), 1297. <https://doi.org/10.1186/s12889-021-11325-3>

Mendy, A., Apewokin, S., Wells, A. A., & Morrow, A. L. (2020). Factors Associated with Hospitalization and Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients. *medRxiv*, 2020.06.25.20137323. <https://doi.org/10.1101/2020.06.25.20137323>

Menges, D., Ballouz, T., Anagnostopoulos, A., Aschmann, H. E., Domenghino, A., Fehr, J. S., & Puhan, M. A. (2021). *Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.02.27.21252572>

Merkely, B., Szabó, A. J., Kosztin, A., Berényi, E., Sebestyén, A., Lengyel, C., Merkely, G., Karády, J., Várkonyi, I., Papp, C., Miseta, A., Betlehem, J., Burián, K., Csóka, I., Vásárhelyi, B., Ludwig, E., Prinz, G., Sinkó, J., Hankó, B., … for the HUNgarian COronaVirus-19 Epidemiological Research (H-UNCOVER) investigators. (2020). Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. *GeroScience*. <https://doi.org/10.1007/s11357-020-00226-9>

Merzon, E., Tworowski, D., Gorohovski, A., Vinker, S., Cohen, A. G., Green, I., & Morgenstern, M. F. (2020). Low plasma 25(OH) vitamin D3 level is associated with increased risk of COVID-19 infection: An Israeli population-based study. *medRxiv*, 2020.07.01.20144329. <https://doi.org/10.1101/2020.07.01.20144329>

Miyara, M., Tubach, F., Martinez, V., Morelot-Panzini, C., Pernet, J., Haroche, J., Lebbah, S., Morawiec, E., Gorochov, G., Caumes, E., Hausfater, P., Combes, A., Similowski, T., & Amoura, Z. (2020). Low rate of daily smokers in patients with symptomatic COVID-19. *medRxiv*, 2020.06.10.20127514. <https://doi.org/10.1101/2020.06.10.20127514>

Mo, P., Xing, Y., Xiao, Y., Deng, L., Zhao, Q., Wang, H., Xiong, Y., Cheng, Z., Gao, S., Liang, K., Luo, M., Chen, T., Song, S., Ma, Z., Chen, X., Zheng, R., Cao, Q., Wang, F., & Zhang, Y. (n.d.). Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa270>

Modrák, M., Bürkner, P.-C., Sieger, T., Slisz, T., Vašáková, M., Mesežnikov, G., Casas-Mendez, L. F., Vajter, J., Táborský, J., Kubricht, V., Suk, D., Horejsek, J., Jedlička, M., Mifková, A., Jaroš, A., Kubiska, M., Váchalová, J., Šín, R., Veverková, M., … Hyánek, T. (2020). *Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis*. <https://doi.org/10.1101/2020.12.03.20239863>

Mohamed-Hussein, A., Galal, I., Saad, M., Zayan, H. E., Abdelsayed, M., Moustafa, M., Ezzat, A. R., Helmy, R., Elaal, H. A., Aly, K., & Abderheem, S. (2020). Post-COVID-19 Functional Status: Relation to age, smoking, hospitalization and comorbidities. *medRxiv*, 2020.08.26.20182618. <https://doi.org/10.1101/2020.08.26.20182618>

Mohamud, A. Y., Griffith, B., Rehman, M., Miller, D., Chebl, A., Patel, S. C., Howell, B., Kole, M., & Marin, H. (2020). Intraluminal Carotid Artery Thrombus in COVID-19: Another Danger of Cytokine Storm? *American Journal of Neuroradiology*. <https://doi.org/10.3174/ajnr.A6674>

Mok, J., Malpartida, J. C., O’Dell, K., Davis, J., Gao, C., & Manyam, H. (2021). Vascular comorbidities worsen prognosis of patients with heart failure hospitalised with COVID-19. *Open Heart*, *8*(1), e001668. <https://doi.org/10.1136/openhrt-2021-001668>

Molenaar, N. M., Rommel, A.-S., Witte, L. de, Dolan, S. M., Lieb, W., Ibroci, E., Ohrn, S., Lynch, J., Capuano, C., Stadlbauer, D., Krammer, F., Zapata, L. B., Brody, R. I., Sperling, R. S., Afzal, O., Missall, M. R., Balbierz, A., Janevic, T., Stone, J., … Bergink, V. (2021). *Seroprevalence of SARS-CoV-2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort study, New York City*. <https://doi.org/10.1101/2021.02.01.21250943>

Mollan, K. R., Eron, J. J., Krajewski, T. J., Painter, W., Duke, E. R., Morse, C. G., Goecker, E. A., Premkumar, L., Wolfe, C. R., Szewczyk, L. J., Alabanza, P. L., Loftis, A. J., Degli-Angeli, E. J., Brown, A. J., Dragavon, J. A., Won, J. J., Keys, J., Hudgens, M. G., Fang, L., … Fischer, W. A. (2021). *Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.05.28.21258011>

Monteiro, A. C. C., Suri, R., Emeruwa, I. O., Stretch, R. J., Lopez, R. Y. C., Sherman, A., Lindsay, C. C., Fulcher, J. A., Goodman-Meza, D., Sapru, A., Buhr, R. G., Chang, S. Y., Wang, T., & Qadir, N. (2020). Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19: A Retrospective, Observational Cohort Study. *medRxiv*, 2020.08.12.20173849. <https://doi.org/10.1101/2020.08.12.20173849>

Mora, A. M., Lewnard, J. A., Kogut, K., Rauch, S. A., Morga, N., Hernandez, S., Wong, M. P., Huen, K., Chang, C., Jewell, N. P., Holland, N., Harris, E., Cuevas, M., & Eskenazi, B. (2021). *Risk factors for SARS-CoV-2 infection among farmworkers in Monterey County, California*. <https://doi.org/10.1101/2021.02.01.21250963>

Morshed, M. S., Mosabbir, A. A., Chowdhury, P., Ashadullah, S. M., & Hossain, M. S. (2020). Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh. *medRxiv*, 2020.07.30.20165100. <https://doi.org/10.1101/2020.07.30.20165100>

Mostafa, A., El-Sayed, M. H., El-Meteini, M., Saleh, A., Omar, A., Mansour, O., Girgis, S., Hafez, H., & Kandil, S. (2021). SARS-Co-V2 infection in never, former, and current tobacco/nicotine users: A cohort study of 4040 Egyptian healthcare workers. *BMC Public Health*, *21*(1), 1243. <https://doi.org/10.1186/s12889-021-11290-x>

Motta, J. K., Ogunnaike, R. O., Shah, R., Stroever, S., Cedeno, H. V., Thapa, S. K., Chronakos, J. J., Jimenez, E. J., Petrini, J., & Hegde, A. (2020). Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19. *medRxiv*, 2020.07.20.20147769. <https://doi.org/10.1101/2020.07.20.20147769>

Muñoz, F. J. T., García-Guijarro, E., García-Domingo, P., Pérez-Nieto, G., Rojas, F. R., García-Peña, M., Gallo, M. A. N., Bermejo, J. A. M., García-Monge, M. T. de G., & Granizo, J. J. (2020). A safe protocol to identify low risk patients with COVID-19 pneumonia for outpatient management. *medRxiv*, 2020.12.15.20229286. <https://doi.org/10.1101/2020.12.15.20229286>

Murray, E. (2020). *Causation in smoking and COVID-19*. <https://twitter.com/EpiEllie/status/1258607277357006849?s=20>

Mutambudzi, M., Niedzwiedz, C. L., Macdonald, E. B., Leyland, A. H., Mair, F. S., Anderson, J. J., Celis-Morales, C. A., Cleland, J., Forbes, J., Gill, J. M., Hastie, C., Ho, F. K., Jani, B. D., Mackay, D. F., Nicholl, B. I., O’Donnell, C. A., Sattar, N. I., Welsh, P. I., Pell, J. P., … Demou, E. (2020). Occupation and risk of severe COVID-19: Prospective cohort study of 120,075 UK Biobank participants. *medRxiv*, 2020.05.22.20109892. <https://doi.org/10.1101/2020.05.22.20109892>

Nanda, S., Chacin Suarez, A. S., Toussaint, L., Vincent, A., Fischer, K. M., Hurt, R., Schroeder, D. R., Medina Inojosa, J. R., O’Horo, J. C., DeJesus, R. S., Abu Lebdeh, H. S., Mundi, M. S., Iftikhar, S., & Croghan, I. T. (2021). Body Mass Index, Multi-Morbidity, and COVID-19 Risk Factors as Predictors of Severe COVID-19 Outcomes. *Journal of Primary Care & Community Health*, *12*, 215013272110185. <https://doi.org/10.1177/21501327211018559>

Nassar, Y., Mokhtar, A., Elhadidy, A., Elsayed, M., Mostafa, F., Rady, A., Eladawy, A., Elshazly, M., Saeed, M., Mokhtar, S., Buschbeck, S., & Sakr, Y. (2021). Outcomes and risk factors for death in patients with coronavirus disease-2019 (COVID-19) pneumonia admitted to the intensive care units of an Egyptian University Hospital. A retrospective cohort study. *Journal of Infection and Public Health*, S1876034121001787. <https://doi.org/10.1016/j.jiph.2021.06.012>

Nezhadmoghadam, F., & Tamez-Peña, J. (2021). *Unsupervised Discovery of Risk Profiles on Negative and Positive COVID-19 Hospitalized Patients*. <https://doi.org/10.1101/2020.12.30.20248908>

Nguyen, A. B., Upadhyay, G. A., Chung, B., Smith, B., Besser, S. A., Johnson, J. A., Blair, J., Ward, R. P., DeCara, J., Polonsky, T., Patel, A. R., Grinstein, J., Holzhauser, L., Kalathiya, R., Shah, A. P., Paul, J., Nathan, S., Liao, J., Lang, R. M., … Tung, R. (2020). Outcomes and Cardiovascular Comorbidities in a Predominantly African-American Population with COVID-19. *medRxiv*, 2020.06.28.20141929. <https://doi.org/10.1101/2020.06.28.20141929>

Nicholson, C. J., Wooster, L., Sigurslid, H. H., Li, R. F., Jiang, W., Tian, W., Cardenas, C. L., & Malhotra, R. (2020). Estimating Risk of Mechanical Ventilation and Mortality Among Adult COVID-19 patients Admitted to Mass General Brigham: The VICE and DICE Scores. *medRxiv*, 2020.09.14.20194670. <https://doi.org/10.1101/2020.09.14.20194670>

Niedzwiedz, C. L., O’Donnell, C. A., Jani, B. D., Demou, E., Ho, F. K., Celis-Morales, C., Nicholl, B. I., Mair, F. S., Welsh, P., Sattar, N., Pell, J. P., & Katikireddi, S. V. (2020). Ethnic and socioeconomic differences in SARS-CoV-2 infection: Prospective cohort study using UK Biobank. *BMC Medicine*, *18*(1), 160. <https://doi.org/10.1186/s12916-020-01640-8>

Nielsen, K. J., Vestergaard, J. M., Schlünssen, V., Bonde, J. P., Kaspersen, K. A., Biering, K., Carstensen, O., Greve, T., Hansen, K. K., Dalbøge, A., Flachs, E. M., Jespersen, S., Hansen, M. L., Mikkelsen, S., Thomsen, M. K., Redder, J. D., Würtz, E. T., Østergaard, L., Erikstrup, C., & Kolstad, H. A. (2021). Day-by-day symptoms following positive and negative PCR tests for SARS-CoV-2 in non-hospitalized healthcare workers: A 90-day follow-up study. *International Journal of Infectious Diseases*, *108*, 382–390. <https://doi.org/10.1016/j.ijid.2021.05.032>

Noh, C. S., Kim, W.-Y., & Baek, M. S. (2021). Risk factors associated with the need for oxygen therapy in patients with COVID-19. *Medicine*, *100*(18), e25819. <https://doi.org/10.1097/MD.0000000000025819>

Nunez-Gil, I. J. J., Fernandez-Ortiz, A., Maroud Eid, C., Huang, J., Romero, R., Becerra-Munoz, V. M., Uribarri, A., Feltes, G., Trabatoni, D., Fernandez-Rozas, I., Viana-Llamas, M. C., Pepe, M., Cerrato, E., Bertaina, M., Capel Astrua, T., Alfonso, E., Castro-Mejia, A. F., Raposeiras-Roubin, S., D’Ascenzo, F., … Macaya, C. (2020). Underlying heart diseases and acute COVID-19 outcomes. *Cardiol J*, *NA*. <https://doi.org/10.5603/CJ.a2020.0183>

Nuño, M., García, Y., Rajasekar, G., Pinheiro, D., & Schmidt, A. J. (2021). *COVID-19 Hospitalizations in Five California Hospitals*. <https://doi.org/10.1101/2021.01.29.21250788>

Núñez-Gil, I. J., Fernández-Ortiz, A., Maroud Eid, C., Huang, J., Romero, R., Becerra-Muñoz, V. M., Uribarri, A., Feltes, G., Trabatoni, D., Fernandez-Rozas, I., Viana-Llamas, M. C., Pepe, M., Cerrato, E., Bertaina, M., Capel Astrua, T., Alfonso, E., Castro-Mejía, A. F., Raposeiras-Roubin, S., D’Ascenzo, F., … Macaya, C. (2021). Underlying heart diseases and acute COVID-19 outcomes. *Cardiology Journal*, *28*(2), 202–214. <https://doi.org/10.5603/CJ.a2020.0183>

O’Gallagher, K., Shek, A., Bean, D. M., Bendayan, R., Teo, J. T. H., Dobson, R. J. B., Shah, A. M., & Zakeri, R. (2020). *Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19* [Preprint]. Cardiovascular Medicine. <https://doi.org/10.1101/2020.12.02.20242933>

O’Reilly, G. M., Mitchell, R. D., Mitra, B., Akhlaghi, H., Tran, V., Furyk, J. S., Buntine, P., Bannon‐Murphy, H., Amos, T., Udaya Kumar, M., Perkins, E., Prentice, A., Szwarcberg, O., Loughman, A., Lowry, N., Colwell, S., Noonan, M. P., Hiller, R., Paton, A., … the COVED Project Team. (2020). Epidemiology and clinical features of emergency department patients with suspected and confirmed <span style="font-variant:small-caps;">COVID</span> ‐19: A multisite report from the <span style="font-variant:small-caps;">COVID‐19 Emergency Department</span> Quality Improvement Project for July 2020 ( <span style="font-variant:small-caps;">COVED</span> ‐3). *Emergency Medicine Australasia*, 1742–6723.13651. <https://doi.org/10.1111/1742-6723.13651>

Oakes, J. M., Fuchs, R. M., Gardner, J. D., Lazartigues, E., & Yue, X. (2018). Nicotine and the renin-angiotensin system. *Am. J. Physiol. - Regul. Integr. Comp. Physiol*, *315*, 895–906. <https://doi.org/10.1152/ajpregu.00099.2018>

Odani, S. (2018). Tobacco Product Use Among Military Veterans — United States, 2010–2015. *MMWR. Morbidity and Mortality Weekly Report*, *67*. <https://doi.org/10.15585/mmwr.mm6701a2>

OFS. (2020). La part des gros fumeurs s’est réduite de moitié en 25 ans - Enquête suisse sur la santé 2017: Consommation de tabac Communiqué de presse. In *Office fédéral de la statistique*. [/content/bfs/fr/home/aktuell/neue-veroeffentlichungen.assetdetail.11907023.html](https:///content/bfs/fr/home/aktuell/neue-veroeffentlichungen.assetdetail.11907023.html)

Olivares, F., Munoz, D., Fica, A., Delama, I., Alvarez, I., Navarrete, M., Blackburn, E., Garrido, P., & Granjean, J. (2020). Covid-19 in Chile. The experience of a Regional reference Center. Preliminary report. *medRxiv*, 2020.06.14.20130898. <https://doi.org/10.1101/2020.06.14.20130898>

Oliveira, E., Parikh, A., Lopez-Ruiz, A., Carrillo, M., Goldberg, J., Cearras, M., Fernainy, K., Andersen, S., Mercado, L., Guan, J., Zafar, H., Louzon, P., Carr, A., Baloch, N., Pratley, R., Silvestry, S., Hsu, V., Sniffen, J., Herrera, V., & Finkler, N. (2020). ICU Outcomes and Survival in Patients with Severe COVID-19 in the Largest Health Care System in Central Florida. *medRxiv*, 2020.08.25.20181909. <https://doi.org/10.1101/2020.08.25.20181909>

Omrani, A. S., Almaslamani, M. A., Daghfal, J., Alattar, R. A., Elgara, M., Shaar, S. H., Ibrahim, T., Zaqout, A., Bakdach, D., Akkari, A., Baiou, A., Alhariri, B., Elajez, R., Husain, A., Badawi, M. N., Abid, F. B., Jarir, S. A., Abdalla, S., Kaleeckal, A., … Kuwari, H. M. A. (2020). The First Consecutive 5000 Patients with Coronavirus Disease 2019 from Qatar; a Nation-wide Cohort Study. *medRxiv*, 2020.07.15.20154690. <https://doi.org/10.1101/2020.07.15.20154690>

Organisation, W. H. (n.d.). *Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases*. <https://www.who.int/publications-detail-redirect/10665-331501>

Ouyang, J., Shan, X., Wang, X., Zhang, X., Chen, Y., Qi, M., Xia, C., Gu, D., Chen, Y., & Zhang, B. (2020). Clinical characteristics of COVID-19 and the model for predicting the occurrence of critically ill patients: A retrospective cohort study. *medRxiv*, 2020.08.13.20173799. <https://doi.org/10.1101/2020.08.13.20173799>

Palaiodimos, L., Kokkinidis, D. G., Li, W., Karamanis, D., Ognibene, J., Arora, S., Southern, W. N., & Mantzoros, C. S. (2020). Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. *Metabolism*, *108*, 154262. <https://doi.org/10.1016/j.metabol.2020.154262>

Paleiron, N., Mayet, A., Marbac, V., Perisse, A., Barazzutti, H., Brocq, F.-X., Janvier, F., Bertrand, D., & Bylicki, O. (2021). Impact of Tobacco Smoking on the risk of COVID-19.A large scale retrospective cohort study. *Nicotine Tob Res*, *NA*. <https://doi.org/10.1093/ntr/ntab004>

Pan, A., Khan, O., Meeks, J., Boom, M., Masud, F., Andrieni, J., Phillips, R., Tiruneh, Y., Kash, B., & Vahidy, F. (2020). Disparities in COVID-19 Hospitalizations and Mortality among Black and Hispanic Patients: Cross-Sectional Analysis from the Greater Houston Metropolitan Area. *medRxiv*, 2020.08.19.20177956. <https://doi.org/10.1101/2020.08.19.20177956>

Pandolfi, L., Fossali, T., Frangipane, V., Bozzini, S., Morosini, M., D’Amato, M., Lettieri, S., Urtis, M., Toro, A. D., Saracino, L., Percivalle, E., Tomaselli, S., Cavagna, L., Cova, E., Mojoli, F., Bergomi, P., Ottolina, D., Lilleri, D., Corsico, A. G., … Meloni, F. (2020). Broncho-alveolar inflammation in COVID-19 patients: A correlation with clinical outcome. *medRxiv*, 2020.07.17.20155978. <https://doi.org/10.1101/2020.07.17.20155978>

Park, B. E., Lee, J. H., Park, H. K., Kim, H. N., Jang, S. Y., Bae, M. H., Yang, D. H., Park, H. S., Cho, Y., Lee, B. Y., Nam, C. W., Lee, J. B., Kim, U., Chae, S. C., & Daegu COVID-19 Research Project. (2021). Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City. *J Korean Med Sci*, *36*. <https://doi.org/10.3346/jkms.2021.36.e15>

Parra-Bracamonte, G. M., Lopez-Villalobos, N., & Parra-Bracamonte, F. E. (2020). Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. *Annals of Epidemiology*, *52*, 93–98.e2. <https://doi.org/10.1016/j.annepidem.2020.08.005>

Parrotta, E., Kister, I., Charvet, L., Sammarco, C., Saha, V., Charlson, R. E., Howard, J., Gutman, J. M., Gottesman, M., Abou-Fayssal, N., Wolintz, R., Keilson, M., Fernandez-Carbonell, C., Krupp, L. B., & Zhovtis Ryerson, L. (2020). COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. *Neurology - Neuroimmunology Neuroinflammation*, *7*(5), e835. <https://doi.org/10.1212/NXI.0000000000000835>

Patanavanich, R., & Glantz, S. A. (2020). Smoking is Associated with COVID-19 Progression: A Meta-Analysis. *medRxiv*. <https://doi.org/10.14171/j.2095-5944.sg.2014.02.004>

Patel, M., Chowdhury, J., Mills, N., Marron, R., Gangemi, A., Dorey-Stein, Z., Yousef, I., Zheng, M., Tragesser, L., Giurintano, J., Gupta, R., Rali, P., D’Alonzo, G., Zhao, H., Patlakh, N., Marchetti, N., Criner, G., & Gordon, M. (2020). ROX Index Predicts Intubation in Patients with COVID-19 Pneumonia and Moderate to Severe Hypoxemic Respiratory Failure Receiving High Flow Nasal Therapy. *medRxiv*, 2020.06.30.20143867. <https://doi.org/10.1101/2020.06.30.20143867>

Patone, M., Thomas, K., Hatch, R., Tan, P. S., Coupland, C., Liao, W., Mouncey, P., Harrison, D., Rowan, K., Horby, P., Watkinson, P., & Hippisley-Cox, J. (2021). Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: An observational cohort study. *The Lancet Infectious Diseases*, S1473309921003182. <https://doi.org/10.1016/S1473-3099(21)00318-2>

Peng, F., Lei, S., Zhang, Q., Zhong, Y., & Wu, S. (2021). Smoking Is Correlated With the Prognosis of Coronavirus Disease 2019 (COVID-19) Patients: An Observational Study. *Frontiers in Physiology*, *12*, 634842. <https://doi.org/10.3389/fphys.2021.634842>

Perico, L., Tomasoni, S., Peracchi, T., Perna, A., Pezzotta, A., Remuzzi, G., & Benigni, A. (2020). COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic. *EBioMedicine*, *61*. <https://doi.org/10.1016/j.ebiom.2020.103069>

Perrone, F., Piccirillo, M. C., Ascierto, P. A., Salvarani, C., Parrella, R., Marata, A. M., Popoli, P., Ferraris, L., Trischitta, M. M. M., Ripamonti, D., Binda, F., Bonfanti, P., Squillace, N., Castelli, F., Muiesan, M. L., Lichtner, M., Calzetti, C., Salerno, N. D., Atripaldi, L., … Gallo, C. (2020). Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial. *medRxiv*, 2020.06.01.20119149. <https://doi.org/10.1101/2020.06.01.20119149>

Peters, E. J., Collard, D., Assen, S. van, Beudel, M., Bomers, M. K., Buijs, J., Haan, L. de, Ruijter, W. de, Douma, R., Elbers, P. W., Goorhuis, A., Oever, N. C. G. van den, Knarren, G. H., Moeniralam, H. S., Mostard, R. L., Quanjel, M. J., Reidinga, A. C., Renckens, R., Bergh, J. P. van den, … Sikkens, J. J. (2020). Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine. *medRxiv*, 2020.08.14.20173369. <https://doi.org/10.1101/2020.08.14.20173369>

Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020). Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. *BMJ*, *369*. <https://doi.org/10.1136/bmj.m1966>

Philipose, Z., Smati, N., Wong, C. S. J., Aspey, K., & Mendall, M. A. (2020). Obesity, old age and frailty are the true risk factors for COVID-19 mortality and not chronic disease or ethnicity in Croydon. *medRxiv*, 2020.08.12.20156257. <https://doi.org/10.1101/2020.08.12.20156257>

PHOSP-COVID Collaborative Group, Evans, R. A., McAuley, H., Harrison, E. M., Shikotra, A., Singapuri, A., Sereno, M., Elneima, O., Docherty, A. B., Lone, N. I., Leavy, O. C., Daines, L., Baillie, J. K., Brown, J. S., Chalder, T., De Soyza, A., Diar Bakerly, N., Easom, N., Geddes, J. R., … Brightling, C. E. (2021). *Physical, cognitive and mental health impacts of COVID-19 following hospitalisation – a multi-centre prospective cohort study* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.03.22.21254057>

Polubriaginof, F., Salmasian, H., Albert, D. A., & Vawdrey, D. K. (2018). Challenges with Collecting Smoking Status in Electronic Health Records. *AMIA Annual Symposium Proceedings*, *2017*, 1392–1400. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977725/>

Pongpirul, W. A., Wiboonchutikul, S., Charoenpong, L., Panitantum, N., Vachiraphan, A., Uttayamakul, S., Pongpirul, K., Manosuthi, W., & Prasithsirikul, W. (2020). Clinical course and potential predicting factors of pneumonia of adult patients with coronavirus disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand. *medRxiv*, 2020.06.24.20139642. <https://doi.org/10.1101/2020.06.24.20139642>

Prats-Uribe, A., Tobed, M., Villacampa, J. M., Agüero, A., García-Bastida, C., Tato, J. I., Rodrigáñez, L., Holguera, V. D., Hernández-García, E., Poletti, D., Simonetti, G., Villarraga, V., Meler-Claramonte, C., Barrueco, Á. S., Chiesa-Estomba, C., Casasayas, M., Parente-Arias, P., Castro, P., Prieto-Alhambra, D., … TraqueoCOVID SEORL Group. (2021). *Timing of elective tracheotomy and duration of mechanical ventilation amongst patients admitted to intensive care with severe COVID-19: A multicentre prospective cohort study*. <https://doi.org/10.1101/2021.01.22.21249651>

Prats-Uribe, A., Xie, J., Prieto-Alhambra, D., & Petersen, I. (2021). Smoking and COVID-19 Infection and Related Mortality: A Prospective Cohort Analysis of UK Biobank Data. *Clinical Epidemiology*, *Volume 13*, 357–365. <https://doi.org/10.2147/CLEP.S300597>

Printza, A., Katotomichelakis, M., Valsamidis, K., Metallidis, S., Panagopoulos, P., Panopoulou, M., Petrakis, V., & Constantinidis, J. (2021). Smell and Taste Loss Recovery Time in COVID-19 Patients and Disease Severity. *Journal of Clinical Medicine*, *10*(5), 966. <https://doi.org/10.3390/jcm10050966>

Pritchard, M., Dankwa, E. A., Hall, M., Baillie, J. K., Carson, G., Docherty, A., Donnelly, C. A., Dunning, J., Fraser, C., Hardwick, H., Harrison, E. M., Holden, K. A., Kartsonaki, C., Kennon, K., Lee, J., McLean, K., Openshaw, P. J. M., Plotkin, D., Rojek, A., … Partners, on behalf of the I. C. (2020). ISARIC Clinical Data Report 4 October 2020. *medRxiv*, 2020.07.17.20155218. <https://doi.org/10.1101/2020.07.17.20155218>

Puebla Neira, D., Watts, A., Seashore, J., Polychronopoulou, E., Kuo, Y.-F., & Sharma, G. (2021). Smoking and risk of COVID-19 hospitalization. *Respiratory Medicine*, *182*, 106414. <https://doi.org/10.1016/j.rmed.2021.106414>

Qi, D., Yan, X., Tang, X., Peng, J., Yu, Q., Feng, L., Yuan, G., Zhang, A., Chen, Y., Yuan, J., Huang, X., Zhang, X., Hu, P., Song, Y., Qian, C., Sun, Q., Wang, D., Tong, J., & Xiang, J. (2020). Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: A retrospective, descriptive, multiple-center study. *medRxiv*, 2020.03.01.20029397. <https://doi.org/10.1101/2020.03.01.20029397>

Qu, J., Chang, L. K., Tang, X., Du, Y., Yang, X., Liu, X., Han, P., & Xue, Y. (2020). Clinical characteristics of COVID-19 and its comparison with influenza pneumonia. *Acta Clinica Belgica*, *0*(0), 1–9. <https://doi.org/10.1080/17843286.2020.1798668>

Quan, D., Luna Wong, L., Shallal, A., Madan, R., Hamdan, A., Ahdi, H., Daneshvar, A., Mahajan, M., Nasereldin, M., Van Harn, M., Opara, I. N., & Zervos, M. (2021). Impact of Race and Socioeconomic Status on Outcomes in Patients Hospitalized with COVID-19. *J Gen Intern Med*, *NA*. <https://doi.org/10.1007/s11606-020-06527-1>

Qureshi, A. I., Baskett, W. I., Huang, W., Myers, D., Lobanova, I., Ishfaq, M. F., Naqvi, S. H., French, B. R., Chandrasekaran, P. N., Siddiq, F., Gomez, C. R., & Shyu, C.-R. (2021). Intracerebral Hemorrhage and Coronavirus Disease 2019 in a Cohort of 282,718 Hospitalized Patients. *Neurocritical Care*. <https://doi.org/10.1007/s12028-021-01297-y>

Rachmawati, E., Listiowati, E., Kurniawan, D. W., Suraya, I., Ahsan, A., & Nurmansyah, M. I. (2021a). Significance of Chronic Diseases and Smoking Behavior in the Development of Acute Respiratory Distress Syndrome Among Hospitalized COVID-19 Patients in Indonesia. *Asia Pacific Journal of Public Health*, *33*(4), 427–430. <https://doi.org/10.1177/10105395211002624>

Rachmawati, E., Listiowati, E., Kurniawan, D. W., Suraya, I., Ahsan, A., & Nurmansyah, M. I. (2021b). Significance of Chronic Diseases and Smoking Behavior in the Development of Acute Respiratory Distress Syndrome Among Hospitalized COVID-19 Patients in Indonesia. *Asia Pacific Journal of Public Health*, *33*(4), 427–430. <https://doi.org/10.1177/10105395211002624>

Radon, K., Bakuli, A., Pütz, P., Gleut, R. L., Guggenbuehl Noller, J. M., Olbrich, L., Saathoff, E., Garí, M., Schälte, Y., Frahnow, T., Wölfel, R., Pritsch, M., Rothe, C., Pletschette, M., Rubio-Acero, R., Beyerl, J., Metaxa, D., Forster, F., Thiel, V., … Fuchs, C. (2021). *From first to second wave: Follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany)* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.04.27.21256133>

Raines, A. M., Tock, J. L., McGrew, S. J., Ennis, C. R., Derania, J., Jardak, C. L., Lim, J. H., Boffa, J. W., Houtsma, C., Jones, K. R., Martin-Klinger, C., Widmer, K., Schapira, R., Zvolensky, M. J., Hoerger, M., Constans, J. I., & Franklin, C. L. (2021). Correlates of death among SARS-CoV-2 positive veterans: The contribution of lifetime tobacco use. *Addictive Behaviors*, *113*, 106692. <https://doi.org/10.1016/j.addbeh.2020.106692>

Raisi-Estabragh, Z., McCracken, C., Bethell, M. S., Cooper, J., Cooper, C., Caulfield, M. J., Munroe, P. B., Harvey, N. C., & Petersen, S. E. (n.d.). Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: Study of 1326 cases from the UK Biobank. *Journal of Public Health*. <https://doi.org/10.1093/pubmed/fdaa095>

Rajter, J. C., Sherman, M., Fatteh, N., Vogel, F., Sacks, J., & Rajter, J.-J. (2020). ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. *medRxiv*, 2020.06.06.20124461. <https://doi.org/10.1101/2020.06.06.20124461>

Ramachandran, P., Kathirvelu, B., Chakraborti, A., Gajendran, M., Zhahid, U., Ghanta, S., Onukogu, I., Narh, J. T., Wang, J. C., & Anwer, F. (2020). COVID-19 in Cancer Patients From New York City: A Comparative Single Center Retrospective Analysis. *Cancer Control*, *27*(1), 107327482096045. <https://doi.org/10.1177/1073274820960457>

Ramlall, V., Thangaraj, P., Meydan, C., Foox, J., Butler, D., May, B., Freitas, J. de, Glicksberg, B. S., Mason, C., Tatonetti, N. P., & Shapira, S. D. (2020). Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome. *medRxiv*, 2020.05.05.20092452. <https://doi.org/10.1101/2020.05.05.20092452>

Rashid, M., Wu, J., Timmis, A., Curzen, N., Zaman, A., Clarke, S., Nolan, J., Shoiab, A., Mohamed, M. O., Belder, M. D., Deanfield, J., Gale, C., & Mamas, M. (2020). Clinical Characteristics and Outcomes of COVID-19 Positive Acute Coronary Syndrome Patients; a multisource Electronic Healthcare Records Study from England. *medRxiv*, 2020.08.20.20175091. <https://doi.org/10.1101/2020.08.20.20175091>

Rashid, R. A., Zgair, A., & Al-Ani, R. M. (2021). Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study. *American Journal of Otolaryngology*, *42*(5), 103033. <https://doi.org/10.1016/j.amjoto.2021.103033>

Ravindra, G., Chitra, L., Madhur, M., Santosh, D., Venugopalan, P., Sundeep, S., Shreepad, B., Piyush, C., Pradeep, D., Ashwini, J., Abhay, M., Vikram, P., Chetan, P., & Urvi, S. (2021). *Retrospective Assessment of Treatments of Hospitalized Covid-19 Patients* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.04.20.21255792>

Reese, J. T., Coleman, B., Chan, L., Blau, H., Callahan, T. J., Cappelletti, L., Fontana, T., Bradwell, K. R., Harris, N. L., Casiraghi, E., Valentini, G., Karlebach, G., Deer, R., McMurry, J. A., Haendel, M. A., Chute, C. G., Pfaff, E., Moffitt, R., Spratt, H., … Robinson, P. N. (2021). *Cyclooxygenase inhibitor use is associated with increased COVID-19 severity* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.04.13.21255438>

Regina, J., Papadimitriou-Olivgeris, M., Burger, R., Filippidis, P., Tschopp, J., Desgranges, F., Viala, B., Kampouri, E., Rochat, L., Haefliger, D., Belkoniene, M., Fidalgo, C., Kritikos, A., Jaton, K., Senn, L., Bart, P.-A., Pagani, J.-L., Manuel, O., & Lhopitallier, L. (2020). Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: An observational retrospective study. *medRxiv*, 2020.05.11.20097741. <https://doi.org/10.1101/2020.05.11.20097741>

Reiter, T., Pajenda, S., Wagner, L., Gaggl, M., Atamaniuk, J., Holzer, B., Zimpernik, I., Gerges, D., Mayer, K., Aigner, C., Strassl, R., Jansen-Skoupy, S., Födinger, M., Sunder-Plassmann, G., & Schmidt, A. (2020). Covid-19 serology in nephrology health care workers. *medRxiv*, 2020.07.21.20136218. <https://doi.org/10.1101/2020.07.21.20136218>

Ren, H. G., Guo, X., Blighe, K., Zhu, F., Martin, J., Safdar, L. B., Yang, P., Wang, D. W., Hu, Q., Huo, N., Stebbing, J., & Cheng, D. (2020). Risk Factors for ICU Admission, Mechanical Ventilation and Mortality in Hospitalized Patients with COVID-19 in Hubei, China. *medRxiv*, 2020.08.31.20184952. <https://doi.org/10.1101/2020.08.31.20184952>

Ren, H. G., Guo, X., Tu, L., Hu, Q., Blighe, K., Safdar, L. B., Stebbing, J., Weiner, S. D., Willis, M. S., Rosendaal, F. R., Xu, G., Cao, F., & Wang, D. W. (2020). *Clinical Characteristics and Risk Factors for Myocardial Injury and Arrhythmia in COVID-19 patients* [Preprint]. Cardiovascular Medicine. <https://doi.org/10.1101/2020.11.30.20190926>

Rentsch, C., Kidwai-Khan, F., Tate, J. P., Park, L. S., King, J. T., Skanderson, M., Hauser, R. G., Schultze, A., Jarvis, C. I., Holodniy, M., Re, V. L., Akgun, K. M., Crothers, K., Taddei, T. H., Freiberg, M. S., & Justice, A. C. (2020). Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. *medRxiv*, 2020.04.09.20059964. <https://doi.org/10.1101/2020.04.09.20059964>

Rentsch, C. T., Beckman, J. A., Tomlinson, L., Gellad, W. F., Alcorn, C., Kidwai-Khan, F., Skanderson, M., Brittain, E., King, J. T., Ho, Y.-L., Eden, S., Kundu, S., Lann, M. F., Greevy, R. A., Ho, P. M., Heidenreich, P. A., Jacobson, D. A., Douglas, I. J., Tate, J. P., … Freiberg, M. S. (2020). *Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: A nationwide cohort study of hospitalized patients in the United States* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.12.09.20246579>

Rica, R. de la, Borges, M., Aranda, M., Castillo, A. del, Socias, A., Payeras, A., Rialp, G., Socias, L., Masmiquel, L., & Gonzalez-Freire, M. (2020). Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: A retrospective cohort study. *medRxiv*, 2020.05.07.20094987. <https://doi.org/10.1101/2020.05.07.20094987>

Richard, A., Wisniak, A., Perez-Saez, J., Garrison-Desany, H., Petrovic, D., Piumatti, G., Baysson, H., Picazio, A., Pennacchio, F., Ridder, D. D., Chappuis, F., Vuilleumier, N., Low, N., Hurst, S., Eckerle, I., Flahault, A., Kaiser, L., Azman, A. S., Guessous, I., … Group, F. the S.-P. study. (2020). Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: A population-based study. *medRxiv*, 2020.12.16.20248180. <https://doi.org/10.1101/2020.12.16.20248180>

Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., Barnaby, D. P., Becker, L. B., Chelico, J. D., Cohen, S. L., Cookingham, J., Coppa, K., Diefenbach, M. A., Dominello, A. J., Duer-Hefele, J., Falzon, L., Gitlin, J., Hajizadeh, N., Harvin, T. G., … Zanos, T. P. (2020). Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*, *323*(20), 2052–2059. <https://doi.org/10.1001/jama.2020.6775>

Riley, S., Ainslie, K. E. C., Eales, O., Jeffrey, B., Walters, C. E., Atchison, C. J., Diggle, P. J., Ashby, D., Donnelly, C. A., Cooke, G., Barclay, W., Ward, H., Taylor, G., Darzi, A., & Elliott, P. (2020). Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study. *medRxiv*, 2020.07.10.20150524. <https://doi.org/10.1101/2020.07.10.20150524>

Rimland, C. A., Morgan, C. E., Bell, G. J., Kim, M. K., Hedrick, T., Marx, A., Bramson, B., Swygard, H., Napravnik, S., Schmitz, J. L., Carson, S. S., Fischer, W. A., Eron, J. J., Gay, C. L., & Parr, J. B. (2020). Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. *medRxiv*, 2020.05.13.20100404. <https://doi.org/10.1101/2020.05.13.20100404>

Riou, M., Marcot, C., Canuet, M., Renaud-Picard, B., Chatron, E., Porzio, M., Dégot, T., Hirschi, S., Metz-Favre, C., Kassegne, L., Ederle, C., Khayath, N., Labani, A., Leyendecker, P., De Blay, F., & Kessler, R. (2021). Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study. *Respiratory Medicine and Research*, *79*, 100801. <https://doi.org/10.1016/j.resmer.2020.100801>

Riyahi, S., Dev, H., Behzadi, A., Kim, J., Attari, H., Raza, S. I., Margolis, D. J., Jonisch, A., Megahed, A., Bamashmos, A., Elfatairy, K., & Prince, M. R. (2021). Pulmonary Embolism in Hospitalized Patients with COVID-19: A Multicenter Study. *Radiology*, 210777. <https://doi.org/10.1148/radiol.2021210777>

Rizzo, S., Chawla, D., Zalocusky, K., Keebler, D., Chia, J., Lindsay, L., Yau, V., Kamath, T., & Tsai, L. (2020). Descriptive epidemiology of 16,780 hospitalized COVID-19 patients in the United States. *medRxiv*, 2020.07.17.20156265. <https://doi.org/10.1101/2020.07.17.20156265>

Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa-Ortiz, C., Glickman, M., Joanow, A., Kaltsas, A., Lee, Y. J., Bianchi, A. L., Mariano, A., Morjaria, S., Nawar, T., Papanicolaou, G. A., Predmore, J., … Kamboj, M. (2020). Determinants of Severity in Cancer Patients with COVID-19 Illness. *medRxiv*, 2020.05.04.20086322. <https://doi.org/10.1101/2020.05.04.20086322>

Robinson, L., Wang, L., Fu, X., Wallace, Z., Long, A., Zhang, Y., Camargo, C., & Blumenthal, K. (2021). COVID-19 severity in asthma patients: A multi-center matched cohort study. *Journal of Allergy and Clinical Immunology*, *147*(2), AB241. <https://doi.org/10.1016/j.jaci.2020.12.026>

Roederer, T., Mollo, B., Vincent, C., Nikolay, B., Llosa, A. E., Nesbitt, R., Vanhomwegen, J., Rose, T., Goyard, S., Anna, F., Torre, C., Fourrey, E., Simons, E., Hennequin, W., Mills, C., & Luquero, F. J. (2021). Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: A cross-sectional study. *The Lancet Public Health*, S2468266721000013. <https://doi.org/10.1016/S2468-2667(21)00001-3>

Rogier, T., Eberl, I., Moretto, F., Sixt, T., Catherine, F.-X., Estève, C., Abdallahoui, M., Behague, L., Coussement, A., Mathey, L., Mahy, S., Buisson, M., Salmon-Rousseau, A., Duong, M., Chavanet, P., Bernard, Q., Nicolas, B., Benguella, L., Bonnotte, B., … Piroth, L. (2021). COVID-19 or not COVID-19? Compared characteristics of patients hospitalized for suspected COVID-19. *European Journal of Clinical Microbiology & Infectious Diseases*. <https://doi.org/10.1007/s10096-021-04216-3>

Romão, V. C., Oliveira-Ramos, F., Cruz-Machado, A. R., Martins, P., Barreira, S., Silva-Dinis, J., Galaio, L., Proença, H., Cristino, J. M., Sacadura-Leite, E., Khmelinskii, N., Romeu, J. C., Fonseca, J. E., & Department, C. R. (2020). A COVID-19 outbreak in a rheumatology department upon the early days of the pandemic. *medRxiv*, 2020.06.05.20107011. <https://doi.org/10.1101/2020.06.05.20107011>

Rossi, B., Nguyen, L. S., Zimmermann, P., Boucenna, F., Baucher, L., Dubret, L., Guillot, H., Bouldouyre, M., Allenbach, Y., Salem, J.-E., Barsoum, P., Oufella, A., & Gros, H. (2020). Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: A cohort study. *medRxiv*, 2020.06.06.20122341. <https://doi.org/10.1101/2020.06.06.20122341>

Rowlands, A. V., Gillies, C., Chudasama, Y., Davies, M. J., Islam, N., Kloecker, D. E., Lawson, C., Pareek, M., Razieh, C., Zaccardi, F., Yates, T., & Khunti, K. (2020). *Association of working shifts, inside and outside of healthcare, with risk of severe COVID-19: An observational study*. <https://doi.org/10.1101/2020.12.16.20248243>

Röthlin Eriksen, A. R., Fogh, K., Hasselbalch, R. B., Bundgaard, H., Nielsen, S. D., Jørgensen, C. S., Scharff, B. F., Erikstrup, C., Sækmose, S. G., Holm, D. K., Aagaard, B., Kristensen, J. H., Bødker, C. A., Norsk, J., Nielsen, P. B., Østergaard, L., Ellermann-Eriksen, S., Andersen, B., Nielsen, H., … Iversen, K. (2021). *SARS-CoV-2 antibody prevalence among homeless people, sex workers and shelter workers in Denmark: A nationwide cross-sectional study* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.05.07.21256388>

Rubina, K., Shmakova, A., Shabanov, A., Andreev, Yu., Borovkova, N., Kulabukhov, V., Evseev, A., Popugaev, K., Petrikov, S., & Semina, E. (2021). *Novel prognostic determinants of COVID-19-related mortality: A pilot study on severely-ill patients in Russia* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.04.01.21254688>

Rubio-Rivas, M., Ronda, M., Padulles, A., Mitjavila, F., Riera-Mestre, A., Garcia-Forero, C., Iriarte, A., Mora, J. M., Padulles, N., Gonzalez, M., Solanich, X., Gasa, M., Suarez, G., Sabater, J., Perez-Fernandez, X. L., Santacana, E., Leiva, E., Ariza-Sole, A., Dallaglio, P. D., … Corbella, X. (2020). Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness. *medRxiv*, 2020.08.31.20182428. <https://doi.org/10.1101/2020.08.31.20182428>

Russell, B., Moss, C., Papa, S., Irshad, S., Ross, P., Spicer, J., Kordasti, S., Crawley, D., Wylie, H., Cahill, F., Haire, A., Zaki, K., Rahman, F., Sita-Lumsden, A., Josephs, D., Enting, D., Lei, M., Ghosh, S., Harrison, C., … Van Hemelrijck, M. (2020). Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy’s Cancer Center in London. *Frontiers in Oncology*, *10*, 1279. <https://doi.org/10.3389/fonc.2020.01279>

Saeed, G. A., Al Helali, A. A., Almazrouei, S., Shah, A., & Ahmed, L. A. (2020). *Chest CT features of COVID-19 in the region of Abu Dhabi, UAE- A single institute study* [Preprint]. Radiology; Imaging. <https://doi.org/10.1101/2020.11.14.20229096>

Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan-Lewis, E., Baden, R., Pandit, L., Cameron, M. L., Garcia-Diaz, J., Chávez, V., Mekebeb-Reuter, M., Lima de Menezes, F., Shah, R., González-Lara, M. F., Assman, B., Freedman, J., & Mohan, S. V. (2021). Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *New England Journal of Medicine*, *384*(1), 20–30. <https://doi.org/10.1056/NEJMoa2030340>

Salerno, S., Zhao, Z., Sankar, S. P., Salvatore, M., Gu, T., Fritsche, L. G., Lee, S., Lisabeth, L. D., Valley, T. S., & Mukherjee, B. (2020). Understanding the patterns of repeated testing for COVID-19: Association with patient characteristics and outcomes. *medRxiv*, 2020.07.26.20162453. <https://doi.org/10.1101/2020.07.26.20162453>

Salton, F., Confalonieri, P., Santus, P., Harari, S., Scala, R., Lanini, S., Vertui, V., Oggionni, T., Caminati, A., Patruno, V., Tamburrini, M., Scartabellati, A., Parati, M., Villani, M., Radovanovic, D., Tomassetti, S., Ravaglia, C., Poletti, V., Vianello, A., … Confalonieri, M. (2020). Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. *medRxiv*, 2020.06.17.20134031. <https://doi.org/10.1101/2020.06.17.20134031>

Sami, R., Soltaninejad, F., Amra, B., Naderi, Z., Javanmard, S. H., Iraj, B., Ahmadi, S. H., Shayganfar, A., Dehghan, M., Khademi, N., Hosseini, N. S., Mortazavi, M., Mansourian, M., Mananas, M. A., Marateb, H. R., & Adibi, P. (2020). A one-year hospital-based prospective COVID-19 open-cohort in the Eastern Mediterranean region: The Khorshid COVID Cohort (KCC) study. *medRxiv*, 2020.05.11.20096727. <https://doi.org/10.1101/2020.05.11.20096727>

Sandri, M. T., Azzolini, E., Torri, V., Carloni, S., Pozzi, C., Salvatici, M., Tedeschi, M., Castoldi, M., Mantovani, A., & Rescigno, M. (2021). SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy. *Scientific Reports*, *11*(1), 12312. <https://doi.org/10.1038/s41598-021-91773-4>

Santos, C., Rhee, Y., Hollinger, E., Olaitan, O., Schadde, E., Peev, V., Saltzberg, S., & Hertl, M. (2020). Comparative Incidence and Outcomes of COVID-19 in Kidney or Kidney-Pancreas Transplant Recipients Versus Kidney or Kidney-Pancreas Waitlisted Patients: A Pilot Study. *medRxiv*, 2020.07.20.20157990. <https://doi.org/10.1101/2020.07.20.20157990>

Saurabh, S., Verma, M. K., Gautam, V., Kumar, N., Jain, V., Goel, A. D., Gupta, M. K., Sharma, P. P., Bhardwaj, P., Singh, K., Nag, V. L., Garg, M. K., & Misra, S. (2021). Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: A case-control study from western Rajasthan, India. *Trans R Soc Trop Med Hyg*, *NA*. <https://doi.org/10.1093/trstmh/traa172>

Savarraj, J. P., Burkett, A. B., Hinds, S. N., Paz, A. S., Assing, A., Juneja, S., Colpo, G. D., Torres, L. F., Gusdon, A., McCullough, L., & Choi, H. A. (n.d.). *Three-month outcomes in hospitalized COVID-19 patients*. 7. <https://doi.org/10.1101/2020.10.16.20211029>

Schneeweiss, M. C., Leonard, S., Weckstein, A., Schneeweiss, S., & Rassen, J. (2020). Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: A cohort study in commercially insured patients in the US. *medRxiv*, 2020.07.22.20159855. <https://doi.org/10.1101/2020.07.22.20159855>

Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: Current knowledge. *Virology Journal*, *16*(1), 69. <https://doi.org/10.1186/s12985-019-1182-0>

Schubl, S. D., Figueroa, C., Palma, A. M., Assis, R. R. de, Jain, A., Nakajima, R., Jasinkas, A., Brabender, D., Naaseh, A., Dominguez, O. H., Runge, A., Skochko, S., Chinn, J., Kelsey, A. J., Lai, K. T., Zhao, W., Horvath, P., Tifrea, D., Grigorian, A., … Khan, S. (2020). *Risk Factors for SARS-CoV-2 Seropositivity in a Health Care Worker Population*. <https://doi.org/10.1101/2020.12.17.20248430>

Scully, E. P., Schumock, G., Fu, M., Massaccesi, G., Muschelli, J., Betz, J., Klein, E. Y., West, N. E., Robinson, M., Garibaldi, B. T., Bandeen-Roche, K., Zeger, S., Klein, S. L., Gupta, A., & for the JH-CROWN registry team. (2021). *Sex and gender differences in COVID testing, hospital admission, presentation, and drivers of severe outcomes in the DC/Maryland region* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.04.05.21253827>

Senkal, N. (2020). Chronic ACE Inhibitor use is Associated with Decreased Odds of Severe Disease in Patients with COVID-19. *The Anatolian Journal of Cardiology*. <https://doi.org/10.14744/AnatolJCardiol.2020.57431>

Serling-Boyd, N., D’Silva, K. M., Hsu, T. Y., Wallwork, R., Fu, X., Gravallese, E. M., Jorge, A. M., Zhang, Y., Choi, H., Sparks, J. A., & Wallace, Z. S. (2020). Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. *Annals of the Rheumatic Diseases*, annrheumdis-2020-219279. <https://doi.org/10.1136/annrheumdis-2020-219279>

Shade, J. K., Doshi, A. N., Sung, E., Popescu, D. M., Minhas, A. S., Gilotra, N. A., Aronis, K. N., Hays, A. G., & Trayanova, N. A. (2021). *COVID-HEART: Development and Validation of a Multi-Variable Model for Real-Time Prediction of Cardiovascular Complications in Hospitalized Patients with COVID-19*. <https://doi.org/10.1101/2021.01.03.21249182>

Shah, S. J., Barish, P. N., Prasad, P. A., Kistler, A. L., Neff, N., Kamm, J., Li, L. M., Chiu, C. Y., Babick, J. M., Fang, M. C., Abe-Jones, Y., Alipanah, N., Alvarez, F. N., Botvinnik, O. B., Davis, J. M., Castenada, G. D., Consortium, C., Dadasovich, R. M., Deng, X., … Langelier, C. (2020). Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A comparison of patients with and without COVID-19. *medRxiv*, 2020.05.02.20082461. <https://doi.org/10.1101/2020.05.02.20082461>

Shahab, L., Brose, L. S., & West, R. (2013). Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: Rationale, and evidence for advantages over existing systems. *CNS Drugs*, *27*(12), 1007–1019. <https://doi.org/10.1007/s40263-013-0116-4>

Sharma, A. K., Ahmed, A., Baig, V. N., Dhakad, P., Dalela, G., Kacker, S., Panwar, V. R., Panwar, R. B., & Gupta, R. (2020). Characteristics and Outcomes of Hospitalized Young Adults with Mild to Moderate Covid-19 at a University Hospital in India. *medRxiv*, 2020.06.02.20106310. <https://doi.org/10.1101/2020.06.02.20106310>

Shekhar, R., Sheikh, A. B., Upadhyay, S., Atencio, J., & Kapuria, D. (2020). Early experience with COVID-19 patients at academic hospital in Southwestern United States. *Infectious Diseases*, *52*(8), 596–599. <https://doi.org/10.1080/23744235.2020.1774645>

Shi, H., Zuo, Y., Yalavarthi, S., Gockman, K., Zuo, M., Madison, J. A., Blair, C. N., Woodard, W., Lezak, S. P., Lugogo, N. L., Woods, R. J., Lood, C., Knight, J. S., & Kanthi, Y. (2020). Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. *medRxiv*, 2020.05.06.20093070. <https://doi.org/10.1101/2020.05.06.20093070>

Shi, P., Ren, G., Yang, J., Li, Z., Deng, S., Li, M., Wang, S., Xu, X., Chen, F., Li, Y., Li, C., Yang, X., Xie, Z., Wu, Z., & Chen, M. (2020). Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study. *medRxiv*, 2020.04.19.20071472. <https://doi.org/10.1101/2020.04.19.20071472>

Shi, Q., Zhao, K., Yu, J., Jiang, F., Feng, J., Zhao, K., Zhang, X., Chen, X., Hu, P., Hong, Y., Li, M., Liu, F., Chen, C., & Wang, W. (2020). Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: A retrospective study. *medRxiv*, 2020.03.04.20031039. <https://doi.org/10.1101/2020.03.04.20031039>

Shi, Y., Yu, X., Zhao, H., Wang, H., Zhao, R., & Sheng, J. (2020). Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan. *Critical Care*, *24*(1), 108. <https://doi.org/10.1186/s13054-020-2833-7>

Shi, Z., Resurreccion, W. K., Wang, C.-H., Wei, J., Na, R., Zheng, S. L., Billings, L. K., Helfand, B. T., Khandekar, J., & Xu, J. (2020). Association of Cancer with Risk and Mortality of COVID-19: Results from the UK Biobank. *medRxiv*, 2020.07.10.20151076. <https://doi.org/10.1101/2020.07.10.20151076>

Shields, A. M., Faustini, S. E., Kristunas, C. A., Cook, A. M., Backhouse, C., Dunbar, L., Ebanks, D., Emmanuel, B., Crouch, E., Kroeger, A., Hirschfeld, J., Sharma, P., Jaffery, R., Nowak, S., Gee, S., Drayson, M. T., Richter, A. G., Dietrich, T., & Chapple, I. C. (2021). *Longitudinal protection following natural SARS-CoV-2 infection and early vaccine responses: Insights from a cohort of community based dental health care professionals* [Preprint]. Allergy; Immunology. <https://doi.org/10.1101/2021.02.24.21252368>

Shiri, A. H., Raiatdoost, E., Afkhami, H., Ravanshad, R., Hosseini, S. E., Kalani, N., & Raoufi, R. (2021). *The herbal combination of Sugarcane, Black Myrobalan, and mastic as a supplementary treatment for COVID-19: A randomized clinical trial* [Preprint]. Respiratory Medicine. <https://doi.org/10.1101/2021.04.27.21256221>

Sholzberg, M., Tang, G. H., Rahhal, H., AlHamzah, M., Kreuziger, L. B., Ní Áinle, F., Alomran, F., Alayed, K., Alsheef, M., AlSumait, F., Pompilio, C. E., Sperlich, C., Tangri, S., Tang, T., Jaksa, P., Suryanarayan, D., Almarshoodi, M., Castellucci, L., James, P. D., … the RAPID Trial investigators. (2021). *Heparin for Moderately Ill Patients with Covid-19* [Preprint]. Hematology. <https://doi.org/10.1101/2021.07.08.21259351>

Sierpiński, R., Pinkas, J., Jankowski, M., Zgliczyński, W. S., Wierzba, W., Gujski, M., & Szumowski, Ł. (2020). Sex differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders among 1,942 non-hospitalized patients with COVID-19. *Polish Archives of Internal Medicine*. <https://doi.org/10.20452/pamw.15414>

Sigel, K., Swartz, T., Golden, E., Paranjpe, I., Somani, S., Richter, F., De Freitas, J. K., Miotto, R., Zhao, S., Polak, P., Mutetwa, T., Factor, S., Mehandru, S., Mullen, M., Cossarini, F., Bottinger, E., Fayad, Z., Merad, M., Gnjatic, S., … Glicksberg, B. S. (n.d.). Covid-19 and People with HIV Infection: Outcomes for Hospitalized Patients in New York City. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa880>

Silva Neto, P. V. da, Carvalho, J. C. S. de, Pimentel, V. E., Perez, M. M., Carmona-Garcia, I., Neto, N. T., Toro, D. M., Oliveira, C. N. S., Fraga-Silva, T. F. C., Milanezi, C. M., Rodrigues, L. C., Dias, C. F. S. L., Xavier, A. C., Porcel, G. S., Guarneri, I. C., Zaparoli, K., Garbato, C. T., Argolo, J. G. M., Junior, A. A. F., … Sorgi, C. A. (2020). *Prognostic value of sTREM-1 in COVID-19 patients: A biomarker for disease severity and mortality* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.09.22.20199703>

Simons, D., Brown, J., Shahab, L., & Perski, O. (2020). Smoking and COVID-19: Rapid evidence review for the Royal College of Physicians, London (UK). *Qeios*. <https://doi.org/10.32388/VGJCUN>

Simons, D., Perski, O., Shahab, L., Brown, J., & Bailey, R. (2020). The association of smoking status with hospitalisation for COVID-19 compared with other respiratory viruses a year previous: A case-control study at a single UK National Health Service trust. *medRxiv*, 2020.11.26.20238469. <https://doi.org/10.1101/2020.11.26.20238469>

Simons, D., Shahab, L., Brown, J., & Perski, O. (2020). The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses (version 7). *Addiction*, *n/a*(n/a). <https://doi.org/10.1111/add.15276>

Singh, B. M., Bateman, J., Viswanath, A., Klaire, V., Mahmud, S., Nevill, A. M., & Dunmore, S. J. (2020). *The risk of COVID hospital admission and COVID mortality during the first COVID 19 wave with a special emphasis on Ethnic Minorities: An observational study of a single, deprived, multi ethnic UK health economy* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.11.20.20224691>

Sisó-Almirall, A., Kostov, B., Mas-Heredia, M., Vilanova-Rotllan, S., Sequeira-Aymar, E., Sans-Corrales, M., Sant-Arderiu, E., Cayuelas-Redondo, L., Martínez-Pérez, A., Plana, N. G., Anguita-Guimet, A., & Benavent-Àreu, J. (2020). PROGNOSTIC FACTORS IN SPANISH COVID-19 PATIENTS: A CASE SERIES FROM BARCELONA. *medRxiv*, 2020.06.18.20134510. <https://doi.org/10.1101/2020.06.18.20134510>

Soares, R. de C. M., Mattos, L. R., & Raposo, L. M. (2020). *Risk Factors for Hospitalization and Mortality due to COVID-19 in Espírito Santo State, Brazil*. tpmd200483. <https://doi.org/10.4269/ajtmh.20-0483>

Solís, P., & Carreño, H. (2020). *COVID-19 Fatality and Comorbidity Risk Factors among Diagnosed Patients in Mexico*. <https://doi.org/10.1101/2020.04.21.20074591>

Sonnweber, T., Tymoszuk, P., Sahanic, S., Boehm, A., Pizzini, A., Luger, A., Schwabl, C., Nairz, M., Kurz, K., Koppelstätter, S., Aichner, M., Puchner, B., Egger, A., Hoermann, G., Wöll, E., Weiss, G., Widmann, G., Tancevski, I., & Löffler-Ragg, J. (2021). *Investigating phenotypes of pulmonary COVID-19 recovery – a longitudinal observational prospective multicenter trial* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.06.22.21259316>

Soto-Mota, A., Garza, B. A. M., Rodriguez, E. M., Rodriguez, J. O. B., Romo, A. E. L., Minutti, P. A., Loya, J. V. A., Talavera, F. E. P., Avila-Cervera, F. J., Burciaga, A. N. V., Aramburo, O. M., Olguin, L. A. P., Soto-Rodriguez, A., Prado, A. C., Santillan-Doherty, P., Galindo, J. O. G., Gordillo, D. H., & Mejia, J. G. (2020). THE LOW-HARM SCORE FOR PREDICTING MORTALITY IN PATIENTS DIAGNOSED WITH COVID-19: A MULTICENTRIC VALIDATION STUDY. *medRxiv*, 2020.05.26.20111120. <https://doi.org/10.1101/2020.05.26.20111120>

Sourij, H., Aziz, F., Bräuer, A., Ciardi, C., Clodi, M., Fasching, P., Karolyi, M., Kautzky‐Willer, A., Klammer, C., Malle, O., Oulhaj, A., Pawelka, E., Peric, S., Ress, C., Sourij, C., Stechemesser, L., Stingl, H., Stulnig, T., Tripolt, N., … for the COVID‐19 in diabetes in Austria study group. (2020). COVID‐19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. *Diabetes, Obesity and Metabolism*, dom.14256. <https://doi.org/10.1111/dom.14256>

Souza, F. S. H., Hojo-Souza, N. S., Santos, E. B., Silva, C. M., & Guidoni, D. L. (2020). Predicting the disease outcome in COVID-19 positive patients through Machine Learning: A retrospective cohort study with Brazilian data. *medRxiv*, 2020.06.26.20140764. <https://doi.org/10.1101/2020.06.26.20140764>

Stead, L. F., Buitrago, D., Preciado, N., Sanchez, G., Hartmann-Boyce, J., & Lancaster, T. (2013). Physician advice for smoking cessation. *Cochrane Database of Systematic Reviews*, *2017*(12). <https://doi.org/10.1002/14651858.CD000165.pub4>

Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claer, L., Quentric, P., Fadlallah, J., Ghillani, P., Gunn, C., Hockett, R., Mudumba, S., Guihot, A., Luyt, C.-E., Mayaux, J., Beurton, A., Fourati, S., Lacorte, J.-M., Yssel, H., … Gorochov, G. (2020). IgA dominates the early neutralizing antibody response to SARS-CoV-2. *medRxiv*, 2020.06.10.20126532. <https://doi.org/10.1101/2020.06.10.20126532>

Strangfeld, A., Schafer, M., Gianfrancesco, M. A., Lawson-Tovey, S., Liew, J. W., Ljung, L., Mateus, E. F., Richez, C., Santos, M. J., Schmajuk, G., Scire, C. A., Sirotich, E., Sparks, J. A., Sufka, P., Thomas, T., Trupin, L., Wallace, Z. S., Al-Adely, S., Bachiller-Corral, J., … COVID-19 Global Rheumatology Alliance Consortium. (2021). Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis*, *NA*. <https://doi.org/10.1136/annrheumdis-2020-219498>

Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., Demertzis, Z., Hanna, Z., Failla, A., Dagher, C., Chaudhry, Z., Vahia, A., Lanfranco, O. A., Ramesh, M., Zervos, M. J., Alangaden, G., Miller, J., & Brar, I. (2020). Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. *JAMA Network Open*, *3*(6), e2012270–e2012270. <https://doi.org/10.1001/jamanetworkopen.2020.12270>

Sun, L., Surya, S., Le, A. N., Desai, H., Doucette, A., Gabriel, P., Ritchie, M. D., Rader, D., Maillard, I., Bange, E., Huang, A. C., Vonderheide, R. H., DeMichele, A., Verma, A., Mamtani, R., & Maxwell, K. N. (2021). Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. *JNCI Cancer Spectr*, *5*. <https://doi.org/10.1093/jncics/pkaa120>

Talavera, B., García-Azorín, D., Martínez-Pías, E., Trigo, J., Hernández-Pérez, I., Valle-Peñacoba, G., Simón-Campo, P., Lera, M. de, Chavarría-Miranda, A., López-Sanz, C., Gutiérrez-Sánchez, M., Martínez-Velasco, E., Pedraza, M., Sierra, Á., Gómez-Vicente, B., Guerrero, Á., & Arenillas, J. F. (2020). Anosmia is associated with lower in-hospital mortality in COVID-19. *Journal of the Neurological Sciences*, *419*, 117163. <https://doi.org/10.1016/j.jns.2020.117163>

Tao, P.-Y., Leng, L., Liu, K., Zhou, R.-H., Hu, Y.-C., Wu, S.-J., Xiao, Y.-D., & Liu, J. (2020). Determination of risk factors for predicting the onset of symptoms in asymptomatic COVID-19 infected patients. *International Journal of Medical Sciences*, *17*(14), 2187–2193. <https://doi.org/10.7150/ijms.47576>

Tardif, J.-C., Bouabdallaoui, N., L’Allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., Lopez-Sendon, J., Luz, P. da, Verret, L., Audet, S., Dupuis, J., Denault, A., Pelletier, M., Tessier, P. A., Samson, S., Fortin, D., Tardif, J.-D., Busseuil, D., Goulet, E., … for the COLCORONA Investigators. (2021). *Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19*. <https://doi.org/10.1101/2021.01.26.21250494>

Targher, G., Mantovani, A., Wang, X.-B., Yan, H.-D., Sun, Q.-F., Pan, K.-H., Byrne, C. D., Zheng, K. I., Chen, Y.-P., Eslam, M., George, J., & Zheng, M.-H. (2020). Patients with diabetes are at higher risk for severe illness from COVID-19. *Diabetes & Metabolism*. <https://doi.org/10.1016/j.diabet.2020.05.001>

Tarifi, A., Al Shdaifat, A. A., Al‐Shudifat, A. M., Azab, M., Ismail, J., Bashir, R., Amro, A., Altarifi, A., & Khader, Y. (2021). Clinical, sinonasal, and long‐term smell and taste outcomes in mildly symptomatic COVID‐19 patients. *International Journal of Clinical Practice*, *75*(7). <https://doi.org/10.1111/ijcp.14260>

Tavakol, Z., Ghannadi, S., Tabesh, M. R., Halabchi, F., Noormohammadpour, P., Akbarpour, S., Alizadeh, Z., Nezhad, M. H., & Reyhan, S. K. (2021). Relationship between physical activity, healthy lifestyle and COVID-19 disease severity; a cross-sectional study. *J. Public Health*, *NA*, 1–9. <https://doi.org/10.1007/s10389-020-01468-9>

Team, R. C. (2013). *The R Project for Statistical Computing*. 1–12.

Tehrani, D., Wang, X., Rafique, A. M., Hayek, S. S., Herrmann, J., Neilan, T. G., Desai, P., Morgans, A., Lopez-Mattei, J., Parikh, R. V., & Yang, E. H. (2021a). *Impact of Cancer and Cardiovascular Disease on In-Hospital Outcomes of COVID-19 Patients: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry* [Preprint]. In Review. <https://doi.org/10.21203/rs.3.rs-600795/v1>

Tehrani, D., Wang, X., Rafique, A. M., Hayek, S. S., Herrmann, J., Neilan, T. G., Desai, P., Morgans, A., Lopez-Mattei, J., Parikh, R. V., & Yang, E. H. (2021b). *Impact of Cancer and Cardiovascular Disease on In-Hospital Outcomes of COVID-19 Patients: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry* [Preprint]. In Review. <https://doi.org/10.21203/rs.3.rs-600795/v1>

Thakur, K., Sagayaraj, A., Prasad, K. C., & Gupta, A. (2021). Olfactory Dysfunction in COVID-19 Patients: Findings from a Tertiary Rural Centre. *Indian j. Otolaryngol. Head Neck Surg*, *NA*, 1–7. <https://doi.org/10.1007/s12070-021-02364-8>

The CONCOR-1 Study Group, CONCOR-1 writing committee, Bégin, P., Callum, J., Jamula, E., Cook, R., Heddle, N. M., Tinmouth, A., Zeller, M. P., Beaudoin-Bussières, G., Amorim, L., Bazin, R., Loftsgard, K. C., Carl, R., Chassé, M., Cushing, M. M., Daneman, N., Devine, D. V., Dumaresq, J., … for The CONCOR-1 Study Group. (2021). *Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: A randomized controlled, open-label trial* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.06.29.21259427>

The OpenSAFELY Collaborative, Williamson, E. J., Tazare, J., Bhaskaran, K., McDonald, H. I., Walker, A. J., Tomlinson, L., Wing, K., Bacon, S., Bates, C., Curtis, H. J., Forbes, H., Minassian, C., Morton, C. E., Nightingale, E., Mehrkar, A., Evans, D., Nicholson, B. D., Leon, D., … Goldacre, B. (2021). *Predicting COVID-19 related death using the OpenSAFELY platform* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.02.25.21252433>

Thiabaud, A., Iten, A., Balmelli, C., Senn, L., Troillet, N., Widmer, A., Flury, D., Schreiber, P. W., Vázquez, M., Damonti, L., Buettcher, M., Vuichard-Gysin, D., Kuhm, C., Cusini, A., Riedel, T., Nussbaumer, Y., Gaudenz, R., Heininger, U., Berger, C., … Keiser, O. (2020). *SARS-CoV-2/COVID-19 hospitalised patients in Switzerland: A prospective cohort profile* [Preprint]. Epidemiology. <https://doi.org/10.1101/2020.12.10.20246884>

Thomas, D. R., Fina, L. H., Adamson, J. P., Sawyer, C., Jones, A., Nnoaham, K., Barrasa, A., Shankar, A. G., & Williams, C. J. (2021). *Social, demographic and behavioural determinants of SARS-CoV-2 infection: A case-control study carried out during mass community testing of asymptomatic individuals in South Wales, December 2020* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.04.06.21253465>

Thompson, J. V., Meghani, N., Powell, B. M., Newell, I., Craven, R., Skilton, G., Bagg, L. J., Yaqoob, I., Dixon, M. J., Evans, E. J., Kambele, B., Rehman, A., & Kwong, G. N. M. (2020). Patient characteristics and predictors of mortality in 470 adults admitted to a district general hospital in England with Covid-19. *medRxiv*, 2020.07.21.20153650. <https://doi.org/10.1101/2020.07.21.20153650>

Torres-Macho, J., Ryan, P., Valencia, J., Pérez-Butragueño, M., Jiménez, E., Fontán-Vela, M., Izquierdo-García, E., Fernandez-Jimenez, I., Álvaro-Alonso, E., Lazaro, A., Alvarado, M., Notario, H., Resino, S., Velez-Serrano, D., & Meca, A. (2020). The PANDEMYC Score. An Easily Applicable and Interpretable Model for Predicting Mortality Associated With COVID-19. *Journal of Clinical Medicine*, *9*(10), 3066. <https://doi.org/10.3390/jcm9103066>

Tricco, A. C., Antony, J., Zarin, W., Strifler, L., Ghassemi, M., Ivory, J., Perrier, L., Hutton, B., Moher, D., & Straus, S. E. (2015). A scoping review of rapid review methods. *BMC Medicine*, *13*(1), 224. <https://doi.org/10.1186/s12916-015-0465-6>

Trubiano, J. A., Vogrin, S., Smibert, O. C., Marhoon, N., Alexander, A. A., Chua, K. Y., James, F. L., Jones, N. R., Grigg, S. E., Xu, C. L., Moini, N., Stanley, S. R., Birrell, M. T., Rose, M. T., Gordon, C. L., Kwong, J. C., & Holmes, N. E. (2020). COVID-MATCH65 - A prospectively derived clinical decision rule for severe acute respiratory syndrome coronavirus 2. *medRxiv*, 2020.06.30.20143818. <https://doi.org/10.1101/2020.06.30.20143818>

Ugur Chousein, E. G., Cortuk, M., Cinarka, H., Tanriverdi, E., Turan, D., Yildirim, B. Z., Sezen, C. B., & Ozgul, M. A. (2020). Is there any effect of smoking status on severity and mortality of hospitalized patients with COVID-19 pneumonia? *Tuberk. Toraks*, *68*, 371–378. <https://doi.org/10.5578/tt.70352>

Ullah, A. Z. M. D., Sivapalan, L., Chelala, C., & Kocher, H. M. (2020). COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: A single-centre cohort study. *medRxiv*, 2020.09.07.20189621. <https://doi.org/10.1101/2020.09.07.20189621>

Vahidy, F. S., Pan, A. P., Ahnstedt, H., Munshi, Y., Choi, H. A., Tiruneh, Y., Nasir, K., Kash, B. A., Andrieni, J. D., & McCullough, L. D. (2021). Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. *PloS One*, *16*. <https://doi.org/10.1371/journal.pone.0245556>

Valenti, L., Bergna, A., Pelusi, S., Facciotti, F., Lai, A., Tarkowski, M., Berzuini, A., Caprioli, F., Santoro, L., Baselli, G., Ventura, C. D., Erba, E., Bosari, S., Galli, M., Zehender, G., & Prati, D. (2020). SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. *medRxiv*, 2020.05.11.20098442. <https://doi.org/10.1101/2020.05.11.20098442>

Valenzuela, O., Ibanez, S. E., Poli, M., Roessler, P., Aylwin, M., Roizen, G., Iruretagoyena, M., Agar, V., Donoso, J., Fierro, M., & Montes, J. (2020). First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia. *medRxiv*, 2020.08.12.20173104. <https://doi.org/10.1101/2020.08.12.20173104>

Valle, D. M. D., Kim-schulze, S., Hsin-hui, H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T., Madduri, D., Stock, A., Marron, T., Xie, H., Patel, M. K., Oekelen, O. van, Rahman, A., Kovatch, P., Aberg, J., Schadt, E., Jagannath, S., … Gnjatic, S. (2020). An inflammatory cytokine signature helps predict COVID-19 severity and death. *medRxiv*, 2020.05.28.20115758. <https://doi.org/10.1101/2020.05.28.20115758>

Vanegas-Cedillo, P. E., Bello-Chavolla, O. Y., Ramírez-Pedraza, N., Rodríguez Encinas, B., Pérez Carrión, C. I., Jasso Ávila, M. I., Valladares García, J. C., Hernández-Juárez, D., Vargas-Vázquez, A., Antonio-Villa, N. E., Chapa-Ibarguengoitia, M., Leon, A. P. de, Sifuentes-Osornio, J., Aguilar-Salinas, C. A., & Mehta, R. (2021). *Serum Vitamin D levels are associated with increased COVID-19 severity and mortality independent of visceral adiposity* [Preprint]. Endocrinology (including Diabetes Mellitus; Metabolic Disease). <https://doi.org/10.1101/2021.03.12.21253490>

Vaquero, L. M., Barrado, M. E. S., Escobar, D., Arribas, P., Gonzalez, J. R., Bermejo, J. F., Doncel, C., Bastida, J. M., Hernandez, A., Jambrina, C., & Sanchez, M. V. (2020). C-Reactive protein and SOFA score as early predictors of critical care requirement in patients with COVID-19 pneumonia in Spain. *medRxiv*, 2020.05.22.20110429. <https://doi.org/10.1101/2020.05.22.20110429>

Vardavas, C. I., & Nikitara, K. (2020). COVID-19 and smoking: A systematic review of the evidence. *Tob Induc Dis*, *18*, 20. <https://doi.org/10.18332/tid/119324>

Velasco-Rodríguez, D., Alonso-Dominguez, J.-M., Vidal Laso, R., Lainez-González, D., García-Raso, A., Martín-Herrero, S., Herrero, A., Martínez Alfonzo, I., Serrano-López, J., Jiménez-Barral, E., Nistal, S., Pérez Márquez, M., Askari, E., Castillo Álvarez, J., Núñez, A., Jiménez Rodríguez, Á., Heili-Frades, S., Pérez-Calvo, C., Górgolas, M., … Llamas-Sillero, P. (2021). Development and validation of a predictive model of in-hospital mortality in COVID-19 patients. *PLOS ONE*, *16*(3), e0247676. <https://doi.org/10.1371/journal.pone.0247676>

Veras, F. P., Pontelli, M., Silva, C., Toller-Kawahisa, J., Lima, M. de, Nascimento, D., Schneider, A., Caetite, D., Rosales, R., Colon, D., Martins, R., Castro, I., Almeida, G., Lopes, M. I., Benatti, M., Bonjorno, L., Giannini, M., Luppino-Assad, R., Almeida, S., … Cunha, F. (2020). SARS-CoV-2 triggered neutrophil extracellular traps (NETs) mediate COVID-19 pathology. *medRxiv*, 2020.06.08.20125823. <https://doi.org/10.1101/2020.06.08.20125823>

Vila-Corcoles, A., Satue-Gracia, E., Vila-Rovira, A., Diego-Cabanes, C. de, Forcadell-Peris, M. J., Hospital-Guardiola, I., & Ochoa-Gondar, O. (2020). *COVID-19 TARRACO Cohort Study: Development of a predictive prognostic rule for early assessment of COVID-19 patients in primary care settings* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.12.11.20247932>

Vila-Corcoles, A., Satue-Gracia, E., Vila-Rovira, A., Diego-Cabanes, C. de, Forcadell-Peris, M. J., & Ochoa-Gondar, O. (2021). *COVID19-related and all-cause mortality among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection in the region of Tarragona, Spain: Results from the COVID19 TARRACO Cohort Study, March-June 2020*. <https://doi.org/10.1101/2021.02.02.21251028>

Vila-Córcoles, A., Ochoa-Gondar, O., Satué-Gracia, E. M., Torrente-Fraga, C., Gomez-Bertomeu, F., Vila-Rovira, A., Hospital-Guardiola, I., Diego-Cabanes, C. de, Bejarano-Romero, F., & Basora-Gallisà, J. (2020). Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: A population-based cohort study in Tarragona, Spain. *BMJ Open*, *10*(12), e041577. <https://doi.org/10.1136/bmjopen-2020-041577>

Villar-Garcia, J., Vivanco-Hidalgo, R. M., Cleries, M., Martinez, E., Monterde, D., Perez-Sust, P., Garcia-Eroles, L., Sais, C., Moharra, M., & Vela, E. (2020). Risk factors for SARS-CoV-2 infection, hospitalisation, and death in Catalonia, Spain: A population-based cross-sectional study. *medRxiv*, 2020.08.26.20182303. <https://doi.org/10.1101/2020.08.26.20182303>

Voruz, P., Allali, G., Benzakour, L., Nuber-Champier, A., Thomasson, M., Jacot, I., Pierce, J., Lalive, P., Lövblad, K.-O., Braillard, O., Coen, M., Serratrice, J., Pugin, J., Ptak, R., Guessous, I., Landis, B. N., Assal, F., & Péron, J. A. (2021). *Long COVID neuropsychological deficits after severe, moderate or mild infection* [Preprint]. Neurology. <https://doi.org/10.1101/2021.02.24.21252329>

Wagner, R., Peterhoff, D., Beileke, S., Günther, F., Berr, M., Einhauser, S., Schütz, A., Niller, H. H., Steininger, P., Knöll, A., Tenbusch, M., Maier, C., Korn, K., Stark, K. J., Gessner, A., Burkhardt, R., Kabesch, M., Schedl, H., Küchenhoff, H., … Überla, K. (2021). Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020. *Viruses*, *13*(6), 1118. <https://doi.org/10.3390/v13061118>

Wallis, T. J. M., Heiden, E., Horno, J., Welham, B., Burke, H., Freeman, A., Dexter, L., Fazleen, A., Kong, A., McQuitty, C., Watson, M., Poole, S., Brendish, N. J., Clark, T. W., Wilkinson, T. M. A., Jones, M. G., & Marshall, B. G. (2021). Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19. *Respiratory Research*, *22*(1), 157. <https://doi.org/10.1186/s12931-021-01750-8>

Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., Lang, C., Huang, D., Sun, Q., Xiong, Y., Huang, X., Lv, J., Luo, Y., Shen, L., Yang, H., Huang, G., & Yang, R. (2020). Clinical features and treatment of COVID-19 patients in northeast Chongqing. *Journal of Medical Virology*, *92*(7), 797–806. <https://doi.org/10.1002/jmv.25783>

Wan, Y. I., Apea, V. J., Dhairyawan, R., Puthucheary, Z. A., Pearse, R. M., Orkin, C. M., & Prowle, J. R. (2021). *Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London* [Preprint]. Epidemiology. <https://doi.org/10.1101/2021.07.05.21260026>

Wang, A.-L., Zhong, X., & Hurd, Y. (2020). Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System. *medRxiv*, 2020.06.11.20128926. <https://doi.org/10.1101/2020.06.11.20128926>

Wang, B., Oekelen, O. V., Mouhieddine, T., Valle, D. M. D., Richter, J., Cho, H. J., Richard, S., Chari, A., Gnjatic, S., Merad, M., Jagannath, S., Parekh, S., & Madduri, D. (2020). A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward. *medRxiv*, 2020.06.04.20122846. <https://doi.org/10.1101/2020.06.04.20122846>

Wang, J. G., Liu, B., Percha, B., Pan, S., Goel, N., Mathews, K., Gao, C., Tandon, P., Tomlinson, M., Yoo, E., Howell, D., Eisenberg, E., Naymagon, L., Tremblay, D., Chokshi, K., Dua, S., Dunn, A., Powell, C., & Bose, S. (2020). *Cardiovascular disease and severe hypoxemia associated with higher rates of non-invasive respiratory support failure in COVID-19*. <https://doi.org/10.1101/2020.09.27.20202747>

Wang, J., Su, Y., Wang, Q., Cao, Y., Wang, A., Ding, R., & Xie, W. (2021). Sex differences in clinical characteristics and risk factors for disease severity of hospitalized patients with COVID‐19. *MedComm*, *2*(2), 247–255. <https://doi.org/10.1002/mco2.66>

Wang, Q., Codd, V., Raisi-Estabragh, Z., Musicha, C., Bountziouka, V., Kaptoge, S., Allara, E., Angelantonio, E. D., Butterworth, A. S., Wood, A. M., Thompson, J. R., Petersen, S. E., Harvey, N. C., Danesh, J. N., Samani, N. J., & Nelson, C. P. (2021). *Older biological age is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2021.03.20.21254010>

Wang, R., Pan, M., Zhang, X., Han, M., Fan, X., Zhao, F., Miao, M., Xu, J., Guan, M., Deng, X., Chen, X., & Shen, L. (2020). Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. *International Journal of Infectious Diseases*, *95*, 421–428. <https://doi.org/10.1016/j.ijid.2020.03.070>

Wang, Z.-H., Shu, C., Ran, X., Xie, C.-H., & Zhang, L. (2020). Critically Ill Patients with Coronavirus Disease 2019 in a Designated ICU: Clinical Features and Predictors for Mortality. *Risk Management and Healthcare Policy*, *Volume 13*, 833–845. <https://doi.org/10.2147/RMHP.S263095>

Wang, Z., Zheutlin, A., Kao, Y.-H., Ayers, K., Gross, S., Kovatch, P., Nirenberg, S., Charney, A., Nadkarni, G., De Freitas, J. K., O’Reilly, P., Just, A., Horowitz, C., Martin, G., Branch, A., Glicksberg, B. S., Charney, D., Reich, D., Oh, W. K., … Li, L. (2020). Hospitalised COVID-19 patients of the Mount Sinai Health System: A retrospective observational study using the electronic medical records. *BMJ Open*, *10*(10), e040441. <https://doi.org/10.1136/bmjopen-2020-040441>

Ward, H., Atchison, C. J., Whitaker, M., Ainslie, K. E. C., Elliott, J., Okell, L. C., Redd, R., Ashby, D., Donnelly, C. A., Barclay, W., Darzi, A., Cooke, G., Riley, S., & Elliott, P. (2020). Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. *medRxiv*, 2020.08.12.20173690. <https://doi.org/10.1101/2020.08.12.20173690>

Weerahandi, H., Hochman, K. A., Simon, E., Blaum, C., Chodosh, J., Duan, E., Garry, K., Kahan, T., Karmen-Tuohy, S., Karpel, H., Mendoza, F., Prete, A. M., Quintana, L., Rutishauser, J., Martinez, L. S., Shah, K., Sharma, S., Simon, E., Stirniman, A., & Horwitz, L. (2020). Post-discharge health status and symptoms in patients with severe COVID-19. *medRxiv*, 2020.08.11.20172742. <https://doi.org/10.1101/2020.08.11.20172742>

Wei, W., Ortwine, J. K., Mang, N. S., Joseph, C., Hall, B. C., & Prokesch, B. C. (2020). Limited Role for Antibiotics in COVID-19: Scarce Evidence of Bacterial Coinfection. *medRxiv*, 2020.06.16.20133181. <https://doi.org/10.1101/2020.06.16.20133181>

Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., Cockburn, J., McDonald, H. I., MacKenna, B., Tomlinson, L., Douglas, I. J., Rentsch, C. T., Mathur, R., Wong, A. Y. S., Grieve, R., … Goldacre, B. (2020). Factors associated with COVID-19-related death using OpenSAFELY. *Nature*, *584*(7821), 430–436. <https://doi.org/10.1038/s41586-020-2521-4>

Woolcott, O. O., & Castilla-Bancayán, J. P. (2021a). The effect of age on the association between diabetes and mortality in adult patients with COVID-19 in Mexico. *Scientific Reports*, *11*(1), 8386. <https://doi.org/10.1038/s41598-021-88014-z>

Woolcott, O. O., & Castilla-Bancayán, J. P. (2021b). The effect of age on the association between diabetes and mortality in adult patients with COVID-19 in Mexico. *Scientific Reports*, *11*(1), 8386. <https://doi.org/10.1038/s41598-021-88014-z>

Woolford, S. J., D’Angelo, S., Curtis, E. M., Parsons, C. M., Ward, K. A., Dennison, E. M., Patel, H. P., Cooper, C., & Harvey, N. C. (2020). COVID-19 and associations with frailty and multimorbidity: A prospective analysis of UK Biobank participants. *Aging Clinical and Experimental Research*, *32*(9), 1897–1905. <https://doi.org/10.1007/s40520-020-01653-6>

Wu, M. A., Fossali, T., Pandolfi, L., Carsana, L., Ottolina, D., Frangipane, V., Rech, R., Tosoni, A., Agarossi, A., Cogliati, C., Meloni, F., Marchini, B., Nebuloni, M., Catena, E., & Colombo, R. (2020). COVID-19: The key role of pulmonary capillary leakage. An observational cohort study. *medRxiv*, 2020.05.17.20104877. <https://doi.org/10.1101/2020.05.17.20104877>

Wu, X., Liu, X., Zhou, Y., Yu, H., Li, R., Zhan, Q., Ni, F., Fang, S., Lu, Y., Ding, X., Liu, H., Ewing, R. M., Jones, M. G., Hu, Y., Nie, H., & Wang, Y. (2021). 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: A prospective study. *The Lancet Respiratory Medicine*, *9*(7), 747–754. <https://doi.org/10.1016/S2213-2600(21)00174-0>

Xie, Y., Chen, S., Wang, X., Li, B., Zhang, T., He, X., Sun, N., Wang, L., Zeng, H., & Shen, Y. (2020). Early Diagnosis and Clinical Significance of Acute Cardiac Injury - Under the Iceberg: A Retrospective Cohort Study of 619 Non-critically Ill Hospitalized COVID-19 Pneumonia Patients. *medRxiv*, 2020.07.06.20147256. <https://doi.org/10.1101/2020.07.06.20147256>

Xu, H., Hou, K., Xu, H., Li, Z., Chen, H., Zhang, N., Xu, R., Fu, H., Sun, R., Wen, L., Xie, L., Liu, H., Zhang, K., Selvanayagam, J. B., Fu, C., Zhao, S., Yang, Z., Yang, M., & Guo, Y. (2020). Acute Myocardial Injury of Patients with Coronavirus Disease 2019. *medRxiv*, 2020.03.05.20031591. <https://doi.org/10.1101/2020.03.05.20031591>

Yadaw, A. S., Li, Y., Bose, S., Iyengar, R., Bunyavanich, S., & Pandey, G. (2020). Clinical features of COVID-19 mortality: Development and validation of a clinical prediction model. *The Lancet Digital Health*, *2*(10), e516–e525. <https://doi.org/10.1016/S2589-7500(20)30217-X>

Yan, H., Valdes, A. M., Vijay, A., Wang, S., Liang, L., Yang, S., Wang, H., Tan, X., Du, J., Jin, S., Huang, K., Jiang, F., Zhang, S., Zheng, N., Hu, Y., Cai, T., & Aithal, G. P. (2020). Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. *medRxiv*, 2020.04.24.20077875. <https://doi.org/10.1101/2020.04.24.20077875>

Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., & Shang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*, *8*(5), 475–481. <https://doi.org/10.1016/S2213-2600(20)30079-5>

Yanover, C., Mizrahi, B., Kalkstein, N., Marcus, K., Akiva, P., Barer, Y., Shalev, V., & Chodick, G. (2020). What factors increase the risk of complications in SARS-CoV-2 positive patients? A cohort study in a nationwide Israeli health organization. *medRxiv*, 2020.05.07.20091652. <https://doi.org/10.1101/2020.05.07.20091652>

Yao, K., Hasegawa, S., Tagashira, Y., Takamatsu, A., Uenoyama, Y., Shimizu, K., Honda, H., & Tokyo Metropolitan Tama Medical Center COVID-19 treatment team. (2021). Experience of 101 patients with coronavirus infectious disease 2019 (COVID-19) at a tertiary care center in Japan. *J Infect Chemother*, *27*, 413–417. <https://doi.org/10.1016/j.jiac.2020.11.024>

Yao, Q., Wang, P., Wang, X., Qie, G., & Chu, Y. (n.d.). *A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients*. <https://doi.org/10.20452/pamw.15312>

Yin, R., Yang, Z., Wei, Y., Li, Y., Chen, H., Liu, Z., Zhao, B., Ma, D., Dan, M., Zhang, Y., Liu, X., Leng, H., & Xiang, D. (2020). Clinical characteristics of 106 patients with neurological diseases and co-morbid coronavirus disease 2019: A retrospective study. *medRxiv*, 2020.04.29.20085415. <https://doi.org/10.1101/2020.04.29.20085415>

Yoo, E., Percha, B., Tomlinson, M., Razuk, V., Pan, S., Basist, M., Tandon, P., Wang, J. G., Gao, C., Bose, S., & Gidwani, U. K. (2020). Development and calibration of a simple mortality risk score for hospitalized COVID-19 adults. *medRxiv*, 2020.08.31.20185363. <https://doi.org/10.1101/2020.08.31.20185363>

Yozgat, A., Kasapoğlu, B., Can, G., Tanoğlu, A., Sakin, Y. S., Yalçin, K. S., Gürler, M., Kaplan, M., Kaban, M. G., Kirsoy, M., Kara, U., & Kekilli, M. (2021). Long-Term Proton Pump Inhibitor Use is a Risk Factor for Mortality in Patients Hospitalized for COVID-19. *Turkish Journal of Medical Sciences*. <https://doi.org/10.3906/sag-2103-80>

Yu, T., Cai, S., Zheng, Z., Cai, X., Liu, Y., Yin, S., Peng, J., & Xu, X. (2020). Association Between Clinical Manifestations and Prognosis in Patients with COVID-19. *Clinical Therapeutics*, *42*(6), 964–972. <https://doi.org/10.1016/j.clinthera.2020.04.009>

Zacharioudakis, I. M., Prasad, P. J., Zervou, F. N., Basu, A., Inglima, K., Weisenberg, S. A., & Aguero-Rosenfeld, M. E. (2020). Association of SARS-CoV-2 Genomic Load with COVID-19 Patient Outcomes. *medRxiv*, 2020.07.02.20145151. <https://doi.org/10.1101/2020.07.02.20145151>

Zell, J., Klein, J., Lucas, C., Slade, M., Liu, J., Iwasaki, A., Wisnewski, A. V., & Redlich, C. A. (2021). *Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel* [Preprint]. Occupational; Environmental Health. <https://doi.org/10.1101/2021.04.21.21255881>

Zeng, H., Zhang, T., He, X., Du, Y., Tong, Y., Zhang, W., & Shen, Y. (2020). Impact of Chronic Comorbidities on Progression and Prognosis in Patients with COVID-19: A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China. *medRxiv*, 2020.06.14.20125997. <https://doi.org/10.1101/2020.06.14.20125997>

Zhan, T., Liu, M., Tang, Y., Han, Z., Cheng, X., Deng, J., Chen, X., Tian, X., & Huang, X. (2020). Retrospective analysis of clinical characteristics of 405 patients with COVID-19. *Journal of International Medical Research*, *48*(8), 030006052094903. <https://doi.org/10.1177/0300060520949039>

Zhan, Z., Yang, X., Du, H., Zhang, C., Song, Y., Ran, X., Zhang, A., & Yang, M. (2020). Early Improvement of Acute Respiratory Distress Syndrome in Patients with COVID-19: Insights from the Data of ICU Patients in Chongqing, China. *medRxiv*, 2020.07.15.20154047. <https://doi.org/10.1101/2020.07.15.20154047>

Zhang, Jin‐jin, Cao, Y., Tan, G., Dong, X., Wang, B., Lin, J., Yan, Y., Liu, G., Akdis, M., Akdis, C. A., & Gao, Y. (2020). Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID‐19 patients. *Allergy*, all.14496. <https://doi.org/10.1111/all.14496>

Zhang, Jin-jin, Dong, X., Cao, Y., Yuan, Y., Yang, Y., Yan, Y., Akdis, C. A., & Gao, Y. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*, *75*(7), 1730–1741. <https://doi.org/10.1111/all.14238>

Zhang, Q., Wang, Z., Lv, Y., Zhao, J., Dang, Q., Xu, D., Zhao, D., Liu, H., Wang, Z., Zhao, X., Xu, Z., & Zhang, X. (2021). Clinical features and prognostic factors of patients with COVID-19 in Henan Province, China. *Hum Cell*, *NA*. <https://doi.org/10.1007/s13577-021-00499-y>

Zhang, Xiaoli, Cai, H., Hu, J., Lian, J., Gu, J., Zhang, S., Ye, C., Lu, Y., Jin, C., Yu, G., Jia, H., Zhang, Y., Sheng, J., Li, L., & Yang, Y. (2020). Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. *International Journal of Infectious Diseases*, *94*, 81–87. <https://doi.org/10.1016/j.ijid.2020.03.040>

Zhang, Xiaomeng, Li, X., Sun, Z., He, Y., Xu, W., Campbell, H., Dunlop, M. G., Timofeeva, M., & Theodoratou, E. (2020). Physical activity and COVID-19: An observational and Mendelian randomisation study. *Journal of Global Health*, *10*(2), 020514. <https://doi.org/10.7189/jogh-10-020514>

Zhang, Y., Yang, H., Li, S., Li, W.-D., Wang, J., & Wang, Y. (2021). Association analysis framework of genetic and exposure risks for COVID-19 in middle-aged and elderly adults. *Mech Ageing Dev*, *194*. <https://doi.org/10.1016/j.mad.2021.111433>

Zhao, Z., Chen, A., Hou, W., Graham, J. M., Li, H., Richman, P. S., Thode, H. C., Singer, A. J., & Duong, T. Q. (2020). Prediction model and risk scores of ICU admission and mortality in COVID-19. *PLOS ONE*, *15*(7), e0236618. <https://doi.org/10.1371/journal.pone.0236618>

Zheng, K. I., Gao, F., Wang, X.-B., Sun, Q.-F., Pan, K.-H., Wang, T.-Y., Ma, H.-L., Chen, Y.-P., Liu, W.-Y., George, J., & Zheng, M.-H. (2020). Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. *Metabolism*, *108*, 154244. <https://doi.org/10.1016/j.metabol.2020.154244>

Zheng, Yamei, Gao, Y., Wu, B., Huang, L., Chen, Y., & Cai, X. (2021). Characteristics and outcomes of patients with COVID-19 in Hainan, South China. *Medicine*, *100*(11), e24771. <https://doi.org/10.1097/MD.0000000000024771>

Zheng, Yi, Xiong, C., Liu, Y., Qian, X., Tang, Y., Liu, L., Leung, E. L.-H., & Wang, M. (2020). Epidemiological and clinical characteristics analysis of COVID-19 in the surrounding areas of Wuhan, Hubei Province in 2020. *Pharmacological Research*, *157*, 104821. <https://doi.org/10.1016/j.phrs.2020.104821>

Zhong, R., Chen, L., Zhang, Q., Li, B., Qiu, Y., Wang, W., Tan, D., & Zou, Y. (2020). Which Factors, Smoking, Drinking Alcohol, Betel Quid Chewing, or Underlying Diseases, Are More Likely to Influence the Severity of COVID-19? *Front Physiol*, *11*. <https://doi.org/10.3389/fphys.2020.623498>

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *The Lancet*, *395*(10229), 1054–1062. <https://doi.org/10.1016/S0140-6736(20)30566-3>

Zhou, J., Ma, Y., Liu, Y., Xiang, Y., Tao, C., Yu, H., & Huang, J. (2021). A Correlation Analysis between the Nutritional Status and Prognosis of COVID-19 Patients. *J Nutr Health Aging*, *25*, 84–93. <https://doi.org/10.1007/s12603-020-1457-6>

Zhou, K., Sun, Y., Li, L., Zang, Z., Wang, J., Li, J., Liang, J., Zhang, F., Zhang, Q., Ge, W., Chen, H., Sun, X., Yue, L., Wu, X., Shen, B., Xu, J., Zhu, H., Chen, S., Yang, H., … Guo, T. (2020). Eleven Routine Clinical Features Predict COVID-19 Severity. *medRxiv*, 2020.07.28.20163022. <https://doi.org/10.1101/2020.07.28.20163022>

Zhou, Wei, Qin, X., Hu, X., Lu, Y., & Pan, J. (2020). Prognosis models for severe and critical COVID-19 based on the Charlson and Elixhauser comorbidity indices. *International Journal of Medical Sciences*, *17*(15), 2257–2263. <https://doi.org/10.7150/ijms.50007>

Zhou, Wenqian, Song, L., Wang, X., Xu, Z., Wang, S., Wang, J., Xu, H., Zheng, Y., & Wang, Y. (2020). Cardiac injury prediction and lymphocyte immunity and inflammation analysis in hospitalized patients with coronavirus disease 2019 (COVID-19). *International Journal of Cardiology*, S016752732034002X. <https://doi.org/10.1016/j.ijcard.2020.10.049>

Zhou, Yaya, He, X., Zhang, J., Xue, Y. e., Liang, M., Yang, B., Ma, W., Zhou, Q., Chen, L., & Wang, X. (2020). Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment: A retrospective cohort study. *medRxiv*, 2020.06.09.20076646. <https://doi.org/10.1101/2020.06.09.20076646>

Zhou, Yiwu, He, Y., Yang, H., Yu, H., Wang, T., Chen, Z., Yao, R., & Liang, Z. (2020). Exploiting an early warning Nomogram for predicting the risk of ICU admission in patients with COVID-19: A multi-center study in China. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*, *28*(1), 106. <https://doi.org/10.1186/s13049-020-00795-w>

Zhu, S., Gao, Q., Yang, L., Yang, Y., Xia, W., Cai, X., Hui, Y., Zhu, D., Zhang, Y., Zhang, G., Wu, S., Wang, Y., Zhou, Z., Liu, H., Zhang, C., Zhang, B., Yang, J., Feng, M., Ni, Z., … Reinhardt, J. D. (2020). Prevalence and risk factors of disability and anxiety in a retrospective cohort of 432 survivors of Coronavirus Disease-2019 (Covid-19) from China. *PloS One*, *15*. <https://doi.org/10.1371/journal.pone.0243883>

Ziehr, D. R., Alladina, J., Petri, C. R., Maley, J. H., Moskowitz, A., Medoff, B. D., Hibbert, K. A., Thompson, B. T., & Hardin, C. C. (2020). Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study. *American Journal of Respiratory and Critical Care Medicine*, *201*(12), 1560–1564. <https://doi.org/10.1164/rccm.202004-1163LE>

Zinellu, A., Arru, F., De Vito, A., Sassu, A., Valdes, G., Scano, V., Zinellu, E., Perra, R., Madeddu, G., Carru, C., Pirina, P., Mangoni, A. A., Babudieri, S., & Fois, A. G. (2021). The De Ritis ratio as prognostic biomarker of in‐hospital mortality in COVID‐19 patients. *European Journal of Clinical Investigation*, *51*(1). <https://doi.org/10.1111/eci.13427>

Zobairy, H., Shamsoddin, E., Rasouli, M. A., Khodlan, N. V., Moradi, G., Zareie, B., Teymori, S., Asadi, J., Sofi-Mahmudi, A., & Sedaghat, A. R. (2020). Association of olfactory dysfunction with hospitalization for COVID-19: A multicenter study in Kurdistan. *medRxiv*, 2020.07.26.20158550. <https://doi.org/10.1101/2020.07.26.20158550>

Zuo, Y., Estes, S. K., Gandhi, A. A., Yalavarthi, S., Ali, R. A., Shi, H., Sule, G., Gockman, K., Madison, J. A., Zuo, M., Woodard, W., Lezak, S. P., Lugogo, N. L., Kanthi, Y., & Knight, J. S. (2020). Prothrombotic antiphospholipid antibodies in COVID-19. *medRxiv*, 2020.06.15.20131607. <https://doi.org/10.1101/2020.06.15.20131607>

Zuo, Y., Warnock, M., Harbaugh, A., Yalavarthi, S., Gockman, K., Zuo, M., Madison, J. A., Knight, J. S., Kanthi, Y., & Lawrence, D. A. (2020). *Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients* [Preprint]. Infectious Diseases (except HIV/AIDS). <https://doi.org/10.1101/2020.08.29.20184358>

Zuo, Y., Yalavarthi, S., Shi, H., Gockman, K., Zuo, M., Madison, J. A., Blair, C. N., Weber, A., Barnes, B. J., Egeblad, M., Woods, R. J., Kanthi, Y., & Knight, J. S. (2020). Neutrophil extracellular traps in COVID-19. *JCI Insight*. <https://doi.org/10.1172/jci.insight.138999>